Date,open,close,Price Change %,Article_title,Textrank_summary
2023-12-28,14.59000015258789,14.520000457763672,,,
2023-12-27,14.170000076293944,13.800000190734863,-0.47977857499749654,,
2023-12-26,14.899999618530272,14.199999809265137,-2.611149495885189,,
2023-12-22,14.90999984741211,15.289999961853027,-4.697985417359242,,
2023-12-21,15.619999885559082,14.90999984741211,2.5486258774635306,,
2023-12-20,15.479999542236328,15.880000114440918,-4.545454822975882,,
2023-12-19,16.3700008392334,15.699999809265137,2.5839831009891845,,
2023-12-18,14.899999618530272,15.770000457763672,-4.092858861451577,,
2023-12-15,13.84000015258789,14.800000190734863,5.838931956423879,,
2023-12-14,14.0,13.600000381469728,6.936416384124574,,
2023-12-13,12.800000190734863,13.380000114440918,-2.8571401323590835,,
2023-12-12,12.5,12.850000381469728,4.531249336432675,,
2023-12-11,12.949999809265137,12.65999984741211,2.8000030517578267,,
2023-12-08,12.81999969482422,12.270000457763672,-2.239381977793896,,
2023-12-07,12.1899995803833,12.520000457763672,-4.290165757824457,,
2023-12-06,11.359999656677246,12.489999771118164,2.707144288269078,,
2023-12-05,10.84000015258789,10.56999969482422,9.947184406618534,,
2023-12-04,10.31999969482422,10.869999885559082,-2.490779095600026,,
2023-12-01,10.029999732971191,10.31999969482422,5.329459370146131,,
2023-11-30,9.979999542236328,9.800000190734863,2.8913257185812733,,
2023-11-29,10.4399995803833,10.079999923706056,-1.8036007991752916,,
2023-11-28,10.449999809265137,10.489999771118164,-3.448272712133836,,
2023-11-27,9.800000190734863,10.449999809265137,0.3827747615608829,,
2023-11-24,9.770000457763672,9.770000457763672,6.632649039586728,,
2023-11-22,9.800000190734863,9.800000190734863,0.0,,
2023-11-21,9.600000381469728,9.800000190734863,0.0,,
2023-11-20,9.630000114440918,9.800000190734863,2.083331263727675,,
2023-11-17,9.640000343322754,9.640000343322754,1.7653174898618875,,
2023-11-16,9.770000457763672,9.770000457763672,0.0,,
2023-11-15,9.859999656677246,10.0,0.0,,
2023-11-14,10.149999618530272,9.90999984741211,1.4198818275611693,,
2023-11-13,9.6899995803833,9.56999969482422,-2.364529853577615,,
2023-11-10,9.949999809265137,9.9399995803833,-1.2383889654857292,,
2023-11-09,9.68000030517578,9.720000267028809,-0.1005048148093835,,
2023-11-08,10.0,9.630000114440918,0.41322273338815524,,
2023-11-07,9.979999542236328,10.020000457763672,-3.6999988555908208,,
2023-11-06,10.25,10.25,0.40081079521152263,,
2023-11-03,10.25,10.25,0.0,,
2023-11-02,10.390000343322754,10.25,0.0,,
2023-11-01,9.529999732971191,9.800000190734863,-1.3474527304777872,,
2023-10-31,9.920000076293944,9.59000015258789,2.833163329790495,,
2023-10-30,10.460000038146973,10.010000228881836,-3.326612108548885,,
2023-10-27,9.899999618530272,9.5600004196167,-4.302101411319457,,
2023-10-26,10.199999809265137,9.9399995803833,-3.434335474894168,,
2023-10-25,9.9399995803833,10.279999732971191,-2.5490218994481313,,
2023-10-24,10.199999809265137,10.130000114440918,3.420524818319758,,
2023-10-23,9.8100004196167,9.869999885559082,-0.6862715307174295,,
2023-10-20,10.5,10.149999618530272,0.6116153249331577,,
2023-10-19,10.0600004196167,10.720000267028809,-3.3333369663783654,,
2023-10-18,10.489999771118164,10.289999961853027,6.5606343924710915,,
2023-10-17,9.920000076293944,10.199999809265137,-1.9065759163864888,,
2023-10-16,9.100000381469728,9.899999618530272,2.822577931630415,,
2023-10-13,10.25,10.0,8.791200038733807,,
2023-10-12,11.130000114440918,10.260000228881836,-2.4390243902439024,,
2023-10-11,10.31999969482422,10.75,-7.816710481703206,,
2023-10-10,10.039999961853027,11.300000190734863,4.166669747010139,,
2023-10-09,9.699999809265137,10.039999961853027,12.549803124195277,,
2023-10-06,10.979999542236328,10.279999732971191,3.5051562811695427,,
2023-10-05,13.0,10.600000381469728,-6.375226215378928,,
2023-10-04,12.699999809265137,11.600000381469728,-18.461535527155938,,
2023-10-03,13.81999969482422,12.510000228881836,-8.661412947368051,,
2023-10-02,15.300000190734863,14.119999885559082,-9.479012263893157,,
2023-09-29,15.029999732971191,14.989999771118164,-7.712420199120961,,
2023-09-28,14.390000343322754,14.520000457763672,-0.26613414879362735,,
2023-09-27,15.010000228881836,14.56999969482422,0.9034059161870736,,
2023-09-26,15.920000076293944,15.239999771118164,-2.9313825939254703,,
2023-09-25,15.699999809265137,15.960000038146973,-4.271358680383113,,
2023-09-22,15.5,15.619999885559082,1.6560524333790145,,
2023-09-21,15.6899995803833,16.0,0.7741928100585938,,
2023-09-20,15.359999656677246,15.609999656677246,1.9757834793334392,,
2023-09-19,16.200000762939453,15.800000190734863,1.6276042030464555,,
2023-09-18,15.899999618530272,16.18000030517578,-2.469139218312053,,
2023-09-15,16.200000762939453,15.350000381469728,1.761010650083221,,
2023-09-14,15.300000190734863,16.010000228881836,-5.24691568789466,,
2023-09-13,13.899999618530272,14.859999656677246,4.640523067293316,,
2023-09-12,13.6899995803833,13.399999618530272,6.906475284122927,,
2023-09-11,12.899999618530272,13.390000343322754,-2.1183343370483105,,
2023-09-08,13.600000381469728,12.920000076293944,3.7984553432747252,,
2023-09-07,13.0600004196167,12.609999656677246,-5.000002103693311,,
2023-09-06,13.0,13.109999656677246,-3.445641259425475,,
2023-09-05,11.829999923706056,12.600000381469728,0.8461512052095853,,
2023-09-01,12.550000190734863,12.25,6.508879651137386,,
2023-08-31,11.600000381469728,12.40999984741211,-2.3904397304817637,,
2023-08-30,11.34000015258789,11.550000190734863,6.982753787114561,,
2023-08-29,13.039999961853027,12.720000267028809,1.8518521633269003,,
2023-08-28,13.949999809265137,13.279999732971191,-2.453985396935122,,
2023-08-25,13.529999732971191,14.770000457763672,-4.802867996090961,,
2023-08-24,16.0,14.960000038146973,9.164824458722853,,
2023-08-23,16.290000915527344,16.18000030517578,-6.499999761581421,,
2023-08-22,16.239999771118164,16.299999237060547,-0.6752646050910398,,
2023-08-21,16.209999084472656,16.5,0.3694548447536813,,
2023-08-18,16.959999084472656,16.899999618530273,1.7890248729571603,,
2023-08-17,16.0,16.899999618530273,-0.35377045507811355,,
2023-08-16,16.75,16.59000015258789,5.624997615814209,,
2023-08-15,16.75,16.700000762939453,-0.9552229696245337,,
2023-08-14,16.549999237060547,16.639999389648438,-0.29850290782416045,,
2023-08-11,16.25,16.959999084472656,0.5438075935759112,,
2023-08-10,16.200000762939453,16.010000228881836,4.369225135216346,,
2023-08-09,16.1299991607666,16.700000762939453,-1.1728427475897354,,
2023-08-08,17.209999084472656,16.5,3.533798089458558,,
2023-08-07,15.5,17.600000381469727,-4.125503325059658,,
2023-08-04,16.079999923706055,15.359999656677246,13.548389557869204,,
2023-08-03,15.4399995803833,16.100000381469727,-4.477613622170129,,
2023-08-02,14.93000030517578,14.850000381469728,4.274616703519633,,
2023-08-01,15.0,14.65999984741211,-0.5358333695299228,,
2023-07-31,14.520000457763672,15.350000381469728,-2.266667683919271,,
2023-07-28,15.779999732971191,14.890000343322754,5.716252737872782,,
2023-07-27,14.729999542236328,14.5,-5.640046924645041,,
2023-07-26,14.970000267028809,14.949999809265137,-1.5614361804753274,,
2023-07-25,15.869999885559082,15.0600004196167,-0.1336035898925304,,
2023-07-24,16.600000381469727,16.200000762939453,-5.103966425856388,,
2023-07-21,16.239999771118164,16.770000457763672,-2.4096362008327756,,
2023-07-20,16.040000915527344,16.450000762939453,3.263551072137829,,
2023-07-19,16.309999465942383,16.350000381469727,2.556108628492743,,
2023-07-18,16.799999237060547,16.43000030517578,0.24525393523691644,,
2023-07-17,15.18000030517578,16.649999618530273,-2.202374694568756,,
2023-07-14,15.539999961853027,15.479999542236328,9.6837897483657,,
2023-07-13,15.149999618530272,15.600000381469728,-0.3861030872843363,,
2023-07-12,14.4399995803833,15.149999618530272,2.9703021403977568,,
2023-07-11,13.31999969482422,14.4399995803833,4.916897913982657,,
2023-07-10,13.260000228881836,13.979999542236328,8.408407741888169,,
2023-07-07,13.460000038146973,13.399999618530272,5.429858981346389,,
2023-07-06,12.800000190734863,13.260000228881836,-0.44576834655760667,,
2023-07-05,12.6899995803833,13.0,3.5937502444721723,,
2023-07-03,13.06999969482422,12.449999809265137,2.442871787765147,,
2023-06-30,12.539999961853027,13.010000228881836,-4.743687069897994,,
2023-06-29,12.619999885559082,12.8100004196167,3.7480085204031925,,
2023-06-28,11.84000015258789,12.59000015258789,1.5055509966765734,,
2023-06-27,12.56999969482422,11.90999984741211,6.334459377824173,,
2023-06-26,11.81999969482422,12.56999969482422,-5.250595572280487,,
2023-06-23,12.600000381469728,12.579999923706056,6.345177828798189,,
2023-06-22,12.75,12.989999771118164,-0.15873378696944865,,
2023-06-21,12.43000030517578,12.8100004196167,1.8823511460248161,,
2023-06-20,12.75,12.5600004196167,3.057120716905292,,
2023-06-16,11.399999618530272,12.90999984741211,-1.490192787320006,,
2023-06-15,11.369999885559082,11.899999618530272,13.24561648605136,,
2023-06-14,10.510000228881836,12.100000381469728,4.661387320191065,,
2023-06-13,9.869999885559082,10.329999923706056,15.128450218474004,,
2023-06-12,10.029999732971191,10.079999923706056,4.6605880798439125,,
2023-06-09,10.619999885559082,10.029999732971191,0.49850640145584013,,
2023-06-08,11.399999618530272,10.84000015258789,-5.555557052219596,,
2023-06-07,9.75,11.640000343322754,-4.912276181414278,,
2023-06-06,9.93000030517578,10.210000038146973,19.384618905874397,,
2023-06-05,9.220000267028809,10.220000267028809,2.819735391400239,,
2023-06-02,11.0,10.0,10.845986670695131,,
2023-06-01,10.399999618530272,11.0,-9.090909090909092,,
2023-05-31,12.199999809265137,12.0,5.769234648823193,,
2023-05-30,12.0,12.199999809265137,-1.639342724524056,,
2023-05-26,13.0,11.800000190734863,1.6666650772094727,,
2023-05-25,12.800000190734863,13.0,-9.230767763577976,,
2023-05-24,13.399999618530272,13.0,1.562498486600839,,
2023-05-23,14.800000190734863,13.800000190734863,-2.9850718650553523,,
2023-05-22,15.399999618530272,14.399999618530272,-6.756756669679118,,
2023-05-19,15.399999618530272,15.399999618530272,-6.493506654355599,,
2023-05-18,15.399999618530272,15.600000381469728,0.0,,
2023-05-17,15.800000190734863,16.200000762939453,1.2987062850235587,,
2023-05-16,12.600000381469728,16.0,2.53164916060666,,
2023-05-15,13.600000381469728,12.600000381469728,26.984123139635003,,
2023-05-12,16.799999237060547,14.0,-7.352940970226148,,
2023-05-11,16.0,16.799999237060547,-16.666662882244605,,
2023-05-10,17.200000762939453,17.0,4.999995231628418,,
2023-05-09,15.600000381469728,17.600000381469727,-1.162795081790876,Unusual Call Option Trade in Acorda Therapeutics (ACOR) Worth $8.34K,"On May 9, 2023 at 13:13:25 ET an unusually large $8.34K block of Call contracts in Acorda Therapeutics (ACOR) was bought, with a strike price of $1.00 / share, expiring in 10 day(s) (on May 19, 2023). There are 46 funds or institutions reporting positions in Acorda Therapeutics. Average portfolio weight of all funds dedicated to ACOR is 0.00%, an increase of 177.89%."
2023-05-08,11.199999809265137,17.600000381469727,12.82051250701041,,
2023-05-05,9.800000190734863,10.0,57.14286322496386,,
2023-05-04,10.0,9.399999618530272,2.040814340536656,,
2023-05-03,10.0,9.800000190734863,-6.000003814697283,,
2023-05-02,9.600000381469728,9.399999618530272,-1.9999980926513672,,
2023-05-01,9.0,9.399999618530272,-2.0833411978347987,,
2023-04-28,9.800000190734863,9.399999618530272,4.444440205891907,,
2023-04-27,9.199999809265137,9.399999618530272,-4.0816384124437155,,
2023-04-26,9.600000381469728,9.0,2.1739110153428385,,
2023-04-25,9.399999618530272,9.0,-6.250003725290168,,
2023-04-24,9.800000190734863,9.399999618530272,-4.25531526343629,,
2023-04-21,10.0,9.800000190734863,-4.0816384124437155,,
2023-04-20,10.199999809265137,9.600000381469728,-1.9999980926513672,,
2023-04-19,11.0,10.800000190734863,-5.882347441324468,,
2023-04-18,10.199999809265137,10.600000381469728,-1.8181800842285156,,
2023-04-17,10.800000190734863,10.399999618530272,3.9215743106313825,,
2023-04-14,11.0,10.600000381469728,-3.7037089364845137,,
2023-04-13,10.600000381469728,10.800000190734863,-3.6363601684570153,,
2023-04-12,11.199999809265137,10.600000381469728,1.8867905855433964,,
2023-04-11,10.800000190734863,11.0,-5.357137839404802,,
2023-04-10,10.399999618530272,11.0,1.8518500530834543,,
2023-04-06,10.199999809265137,10.800000190734863,5.769234648823193,,
2023-04-05,10.800000190734863,10.399999618530272,5.88235679107286,,
2023-04-04,11.0,11.199999809265137,-3.7037089364845137,,
2023-04-03,11.0,11.199999809265137,1.8181800842285156,,
2023-03-31,12.0,11.800000190734863,1.8181800842285156,,
2023-03-30,12.0,11.600000381469728,-1.6666650772094727,,
2023-03-29,11.800000190734863,12.0,-3.3333301544189307,,
2023-03-28,10.800000190734863,11.600000381469728,1.6949136104436064,,
2023-03-27,11.0,11.399999618530272,7.407409042651422,,
2023-03-24,11.0,11.0,3.6363601684570153,,
2023-03-23,12.0,11.399999618530272,0.0,,
2023-03-22,12.600000381469728,12.0,-5.000003178914403,,
2023-03-21,11.600000381469728,12.399999618530272,-4.761907645273747,,
2023-03-20,12.800000190734863,12.199999809265137,6.896544920278553,,
2023-03-17,12.199999809265137,12.800000190734863,-4.687502910383003,,
2023-03-16,12.399999618530272,12.600000381469728,4.918035990574884,,
2023-03-15,12.0,12.600000381469728,1.6129094281630476,,
2023-03-14,13.600000381469728,12.399999618530272,5.000003178914403,,
2023-03-13,13.0,13.600000381469728,-8.823534774120166,,
2023-03-10,15.800000190734863,13.600000381469728,4.61538754976714,,
2023-03-09,21.0,16.200000762939453,-13.924049257639993,,
2023-03-08,18.0,20.0,-22.857139224097843,,
2023-03-07,17.799999237060547,17.600000381469727,11.11111111111111,,
2023-03-06,18.39999961853028,17.799999237060547,-1.1235891245119385,,
2023-03-03,17.799999237060547,18.39999961853028,-3.2608717060270207,,
2023-03-02,18.200000762939453,18.200000762939453,3.3707888044202883,,
2023-03-01,17.799999237060547,18.0,0.0,,
2023-02-28,17.799999237060547,18.0,1.123599839954155,,
2023-02-27,18.200000762939453,18.600000381469727,1.123599839954155,,
2023-02-24,17.799999237060547,18.600000381469727,2.1978000096834616,,
2023-02-23,18.0,18.600000381469727,4.494388644374403,,
2023-02-22,17.399999618530273,18.600000381469727,3.333335452609592,,
2023-02-21,19.0,17.799999237060547,6.89655626004441,,
2023-02-17,18.0,18.200000762939453,-6.315793489155016,,
2023-02-16,17.799999237060547,18.200000762939453,1.1111153496636283,,
2023-02-15,17.799999237060547,18.39999961853028,2.24719967990831,,
2023-02-14,17.200000762939453,17.0,3.3707888044202883,,
2023-02-13,17.799999237060547,17.399999618530273,-1.162795081790876,Renaissance Technologies Updates Holdings in Acorda Therapeutics (ACOR),"Fintel reports that Renaissance Technologies has filed a 13G/A form with the SEC disclosing ownership of 0.87MM shares of Acorda Therapeutics Inc (ACOR). Analyst Price Forecast Suggests 1,020.88% Upside As of February 12, 2023, the average one-year price target for Acorda Therapeutics is $10.20. There are 49 funds or institutions reporting positions in Acorda Therapeutics."
2023-02-10,18.200000762939453,18.200000762939453,-2.2471889644660936,,
2023-02-09,19.39999961853028,18.200000762939453,0.0,,
2023-02-08,19.600000381469727,19.200000762939453,-6.185561232922013,,
2023-02-07,19.39999961853028,19.600000381469727,-2.040814340536656,,
2023-02-06,20.200000762939453,19.799999237060547,1.0309317880007145,,
2023-02-03,19.39999961853028,19.600000381469727,-1.980205498867016,,
2023-02-02,19.600000381469727,19.39999961853028,1.0309317880007145,,
2023-02-01,19.200000762939453,18.39999961853028,-1.020412035953485,,
2023-01-31,17.799999237060547,19.0,-4.1666724615624195,,
2023-01-30,18.600000381469727,17.799999237060547,6.7415776088404975,,
2023-01-27,18.600000381469727,18.799999237060547,-4.301081333343315,,
2023-01-26,19.799999237060547,19.0,1.0752626424140799,,
2023-01-25,19.0,19.600000381469727,-4.04040034286038,,
2023-01-24,19.0,18.799999237060547,3.157896744577508,,
2023-01-23,19.39999961853028,19.799999237060547,-1.0526355944181742,,
2023-01-20,20.0,19.600000381469727,2.061853744307289,,
2023-01-19,20.39999961853028,19.600000381469727,-1.9999980926513672,,
2023-01-18,17.600000381469727,20.0,-3.9215649608830234,,
2023-01-17,17.0,18.0,13.636361173361838,,
2023-01-13,18.600000381469727,16.799999237060547,5.88235294117647,,
2023-01-12,17.600000381469727,18.600000381469727,-9.677425309100709,,
2023-01-11,18.600000381469727,17.399999618530273,5.681818058668092,,
2023-01-10,15.600000381469728,17.600000381469727,-6.451616872733807,,
2023-01-09,15.399999618530272,16.0,12.82051250701041,,
2023-01-06,14.399999618530272,15.399999618530272,3.896106469689579,,
2023-01-05,16.0,14.199999809265137,6.9444446284094035,,
2023-01-04,15.800000190734863,16.0,-11.250001192092896,,
2023-01-03,15.600000381469728,15.800000190734863,1.265821562346669,,
2022-12-30,13.600000381469728,15.399999618530272,1.2820500280416807,,
2022-12-29,11.800000190734863,13.399999618530272,13.235288136558276,,
2022-12-28,12.199999809265137,12.600000381469728,13.559316965534437,,
2022-12-27,11.600000381469728,12.399999618530272,3.2786932660508423,,
2022-12-23,10.600000381469728,11.600000381469728,6.896544920278553,,
2022-12-22,10.800000190734863,10.600000381469728,9.433961924644256,,
2022-12-21,10.600000381469728,10.600000381469728,-1.8518500530834376,,
2022-12-20,10.800000190734863,11.0,0.0,,
2022-12-19,12.0,10.800000190734863,1.8518500530834543,,
2022-12-16,11.399999618530272,11.600000381469728,-9.999998410542805,,
2022-12-15,10.399999618530272,11.0,1.7543927160695947,,
2022-12-14,10.800000190734863,10.399999618530272,5.769234648823193,,
2022-12-13,10.800000190734863,11.0,-3.7037089364845137,,
2022-12-12,10.800000190734863,11.199999809265137,1.8518500530834543,,
2022-12-09,11.800000190734863,11.600000381469728,3.7037001061669086,,
2022-12-08,10.600000381469728,11.199999809265137,-1.6949136104435916,,
2022-12-07,11.600000381469728,10.600000381469728,5.660371756630223,,
2022-12-06,11.399999618530272,11.399999618530272,-8.620689371678274,,
2022-12-05,12.0,11.800000190734863,0.0,,
2022-12-02,12.0,12.199999809265137,-1.6666650772094727,,
2022-12-01,12.800000190734863,12.600000381469728,1.6666650772094727,,
2022-11-30,12.0,12.800000190734863,-1.562498486600825,,
2022-11-29,12.600000381469728,12.399999618530272,6.66666825612386,,
2022-11-28,12.0,12.399999618530272,-1.5873075943203072,,
2022-11-25,12.0,12.199999809265137,3.3333301544189307,,
2022-11-23,12.0,12.399999618530272,1.6666650772094727,,
2022-11-22,10.800000190734863,11.399999618530272,3.3333301544189307,,
2022-11-21,13.199999809265137,11.199999809265137,5.5555501592503465,,
2022-11-18,13.399999618530272,12.800000190734863,-15.151515370448653,,
2022-11-17,13.0,13.199999809265137,-4.477607797583035,,
2022-11-16,12.600000381469728,13.199999809265137,1.5384600712702823,,
2022-11-15,13.800000190734863,13.0,4.761900076430167,,
2022-11-14,14.600000381469728,13.399999618530272,-5.797102751288169,,
2022-11-11,14.0,14.199999809265137,-8.219183093053159,,
2022-11-10,12.199999809265137,12.600000381469728,1.428570066179548,,
2022-11-09,13.0,12.199999809265137,3.2786932660508423,,
2022-11-08,12.800000190734863,12.199999809265137,-6.15384762103741,,
2022-11-07,14.399999618530272,12.600000381469728,-4.687502910383003,,
2022-11-04,15.600000381469728,15.600000381469728,-12.499995032946114,,
2022-11-03,14.0,16.0,0.0,,
2022-11-02,14.199999809265137,14.399999618530272,14.285714285714285,,
2022-11-01,18.799999237060547,16.0,1.408449379940415,,
2022-10-31,13.399999618530272,21.39999961853028,-14.893613567498939,,
2022-10-28,11.800000190734863,13.199999809265137,59.70149423688908,,
2022-10-27,9.600000381469728,11.800000190734863,11.864403355090847,,
2022-10-26,9.600000381469728,9.600000381469728,22.916663769218747,,
2022-10-25,11.199999809265137,10.600000381469728,0.0,,
2022-10-24,9.800000190734863,10.800000190734863,-5.357137839404802,,
2022-10-21,11.0,10.399999618530272,10.204081434053666,,
2022-10-20,10.199999809265137,10.600000381469728,-5.454548922452076,,
2022-10-19,12.0,11.600000381469728,3.9215743106313825,,
2022-10-18,16.799999237060547,14.600000381469728,-3.3333301544189307,,
2022-10-17,10.0,18.0,-13.095231877973267,,
2022-10-14,7.0,6.800000190734863,80.0,,
2022-10-13,7.599999904632568,7.0,-2.857140132359096,,
2022-10-12,7.199999809265137,7.400000095367432,-7.894735686336514,,
2022-10-11,8.0,7.199999809265137,2.7777818250068513,,
2022-10-10,8.0,7.400000095367432,-10.000002384185791,Acorda Withdraws Proposal To Raise Authorized Shares From Special Meeting Of Stockholders,"(RTTNews) - Acorda Therapeutics, Inc. (ACOR) announced Monday that it has withdrawn Proposal One, a request to increase the number of authorized shares of Acorda stock, from the ballot for the Special Meeting of Stockholders scheduled for November 4, 2022. This proposal would give Acorda's Board of Directors the ability to implement a reverse stock split of Acorda's stock. Proposal Three, the Adjournment Proposal, to allow the Company to adjourn and reconvene the Special Meeting to have additional time to solicit proxies, will also remain on the ballot."
2022-10-07,7.400000095367432,7.400000095367432,-7.4999988079071045,,
2022-10-06,7.0,7.400000095367432,0.0,,
2022-10-05,6.800000190734863,7.0,5.714287076677595,,
2022-10-04,6.599999904632568,6.800000190734863,2.941173583166078,,
2022-10-03,6.599999904632568,6.800000190734863,3.0303074089730497,,
2022-09-30,5.599999904632568,6.0,3.0303074089730497,,
2022-09-29,5.199999809265137,5.599999904632568,7.142858967489158,,
2022-09-28,6.0,5.800000190734863,7.692309808449005,,
2022-09-27,6.400000095367432,5.800000190734863,-3.3333301544189453,,
2022-09-26,5.800000190734863,6.0,-9.374998370185518,,
2022-09-23,6.400000095367432,5.800000190734863,3.4482724601392922,,
2022-09-22,6.400000095367432,6.599999904632568,-9.374998370185518,,
2022-09-21,6.599999904632568,6.199999809265137,3.124996973201678,,
2022-09-20,6.800000190734863,6.800000190734863,-6.060607593140567,,
2022-09-19,6.800000190734863,7.0,0.0,,
2022-09-16,7.599999904632568,6.800000190734863,2.941173583166078,,
2022-09-15,8.199999809265137,8.0,-10.526312157057612,,
2022-09-14,8.0,8.0,-2.4390221209414906,,
2022-09-13,7.400000095367432,8.0,0.0,,
2022-09-12,8.399999618530273,8.199999809265137,8.108106714865881,,
2022-09-09,8.0,8.199999809265137,-2.3809502184254883,,
2022-09-08,7.599999904632568,8.0,2.499997615814209,,
2022-09-07,7.599999904632568,7.400000095367432,5.263159215615413,,
2022-09-06,7.400000095367432,7.400000095367432,-2.6315764707211,,
2022-09-02,8.0,8.0,0.0,,
2022-09-01,8.199999809265137,7.800000190734863,0.0,,
2022-08-31,8.600000381469727,8.199999809265137,-4.878044241882981,,
2022-08-30,8.199999809265137,8.199999809265137,-4.651169237927759,,
2022-08-29,8.600000381469727,8.199999809265137,0.0,Acorda Enters License Agreement For Nepicastat,"(RTTNews) - Acorda Therapeutics, Inc. (ACOR) has entered into a license agreement relating to its preclinical asset, Nepicastat, with Asieris Pharmaceuticals. The asset has been held by Acorda's U.S. subsidiary, Biotie Therapies, Inc. Acorda will receive an upfront payment of $500 thousand, and up to an additional $7 million based on the achievement of regulatory milestones. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2022-08-26,9.199999809265137,8.600000381469727,-4.651169237927759,,
2022-08-25,8.199999809265137,9.0,-6.521733046028573,,
2022-08-24,9.0,8.399999618530273,9.756100113940823,,
2022-08-23,8.600000381469727,8.199999809265137,-6.666670905219184,,
2022-08-22,8.800000190734863,8.600000381469727,-4.651169237927759,,
2022-08-19,9.399999618530272,8.800000190734863,-2.2727250560256556,Acorda Therapeutics COO Lauren Sabella To Resign,"(RTTNews) - Biotechnology company Acorda Therapeutics, Inc. (ACOR) announced Friday that Lauren Sabella, Chief Operating Officer, will resign from the Company effective September 30, 2022. She joined Acorda in 2010 as Executive Vice President of Commercial Development, and became Chief Commercial Officer in February 2015. Sabella, with thirteen years of contributions as a member of Acorda's executive leadership team, has been the COO since September, 2021."
2022-08-18,9.399999618530272,9.199999809265137,-6.382972895154444,,
2022-08-17,9.600000381469728,9.199999809265137,-2.1276576317181353,,
2022-08-16,9.399999618530272,9.399999618530272,-4.166672461562474,,
2022-08-15,10.0,9.399999618530272,0.0,,
2022-08-12,9.199999809265137,9.399999618530272,-6.000003814697283,,
2022-08-11,8.800000190734863,9.199999809265137,2.1739110153428385,,
2022-08-10,9.199999809265137,8.800000190734863,4.545450112051311,,
2022-08-09,9.399999618530272,9.0,-4.347822030685715,,
2022-08-08,8.399999618530273,9.0,-4.25531526343629,,
2022-08-05,8.600000381469727,9.0,7.142862008542651,,
2022-08-04,9.199999809265137,10.600000381469728,4.651158148692013,,
2022-08-03,10.199999809265137,9.399999618530272,15.217397839450811,,
2022-08-02,9.0,9.399999618530272,-7.843139271514373,,
2022-08-01,8.800000190734863,8.800000190734863,4.444440205891907,,
2022-07-29,8.800000190734863,8.800000190734863,0.0,,
2022-07-28,8.600000381469727,8.399999618530273,0.0,,
2022-07-27,8.399999618530273,8.800000190734863,-2.325590163581752,,
2022-07-26,8.800000190734863,8.600000381469727,4.761911790117163,,
2022-07-25,9.0,9.0,-2.2727250560256556,,
2022-07-22,9.399999618530272,9.0,0.0,,
2022-07-21,10.399999618530272,9.399999618530272,-4.25531526343629,,
2022-07-20,10.0,10.0,-9.615384968074835,,
2022-07-19,9.399999618530272,10.0,0.0,,
2022-07-18,9.199999809265137,9.199999809265137,6.382983040626344,,
2022-07-15,8.600000381469727,9.0,0.0,,
2022-07-14,8.600000381469727,8.800000190734863,4.651158148692013,,
2022-07-13,9.0,9.0,2.3255790743460065,,
2022-07-12,9.199999809265137,9.0,0.0,,
2022-07-11,8.600000381469727,9.199999809265137,-2.1739110153428576,,
2022-07-08,9.199999809265137,8.800000190734863,6.976737223038021,,
2022-07-07,9.199999809265137,9.0,-4.347822030685715,,
2022-07-06,9.800000190734863,9.0,-2.1739110153428576,,
2022-07-05,9.199999809265137,9.800000190734863,-8.16326709351701,,
2022-07-01,9.0,9.600000381469728,6.521743412053967,,
2022-06-30,9.0,9.399999618530272,6.6666709052192035,,
2022-06-29,9.199999809265137,9.0,4.444440205891907,,
2022-06-28,9.399999618530272,9.199999809265137,-2.1739110153428576,,
2022-06-27,10.399999618530272,9.800000190734863,-2.1276576317181353,,
2022-06-24,11.199999809265137,10.399999618530272,-5.769225478877472,,
2022-06-23,10.399999618530272,11.199999809265137,-7.142858967489173,,
2022-06-22,11.600000381469728,10.399999618530272,7.692309808449023,,
2022-06-21,12.600000381469728,12.399999618530272,-10.344833823077993,,
2022-06-17,10.600000381469728,12.800000190734863,-1.5873075943203072,,
2022-06-16,11.0,12.399999618530272,20.754714434831907,"Health Care Sector Update for 06/16/2022: DNA, RDUS, ACOR","Acorda Therapeutics (ACOR) climbed over 50% after Esteve Pharmaceuticals launched in Germany Inbrija 33-milligram inhaled powder for the treatment of episodic motor fluctuations in patients with Parkinson's disease who are receiving a levodopa/dopa-decarboxylase inhibitor as part of their therapy. Health care stocks were mostly lower this afternoon, with the NYSE Health Care Index sinking 1.7% while the SPDR Health Care Select Sector ETF (XLV) was down 1.6%. Radius Health (RDUS) rose 6.6% after 14.6%-owners Rubric Capital Management Thursday said it plans to support an alternative director nominee slate backed by Repertoire Partners and Velan Capital Investment Management, citing a ""lack of confidence"" in the company's existing board membership."
2022-06-15,7.199999809265137,8.0,12.727269259366105,,
2022-06-14,7.199999809265137,6.800000190734863,11.111114054550438,,
2022-06-13,8.0,7.199999809265137,-5.555550404536735,,
2022-06-10,7.599999904632568,7.400000095367432,-10.000002384185791,,
2022-06-09,7.599999904632568,7.199999809265137,-2.6315764707211,,
2022-06-08,7.599999904632568,7.400000095367432,-5.263159215615413,,
2022-06-07,5.800000190734863,7.199999809265137,-2.6315764707211,,
2022-06-06,6.199999809265137,6.199999809265137,24.13792366363513,,
2022-06-03,6.800000190734863,6.0,0.0,,
2022-06-02,9.0,6.599999904632568,-11.764708357286219,,
2022-06-01,10.0,8.800000190734863,-26.666667726304794,,
2022-05-31,8.399999618530273,10.199999809265137,-11.999998092651367,,
2022-05-27,8.399999618530273,8.399999618530273,21.428574672361766,,
2022-05-26,8.600000381469727,8.199999809265137,0.0,,
2022-05-25,8.199999809265137,8.199999809265137,-4.651169237927759,,
2022-05-24,9.399999618530272,8.800000190734863,0.0,,
2022-05-23,10.399999618530272,9.800000190734863,-6.382972895154444,,
2022-05-20,12.0,10.399999618530272,-5.769225478877472,,
2022-05-19,12.600000381469728,11.0,-13.333336512247737,,
2022-05-18,13.0,11.600000381469728,-12.698415341500935,Acorda Therapeutics Now the Least Expensive vs. Cardano This Year,"For example, if you had 100 Cardano coins and wished to buy shares of ACOR(Symbol: ACOR) with the proceeds, you would now be able to buy 84.91 shares of ACOR. Here's how this relationship looks charted, over the past year: The main driver of the above bar chart has, of course, been the performance of Acorda Therapeutics shares, relative to the performance of Cardano; and here's how the two compare over the past year on a total return basis: Check out our Cardano historical price chart and Acorda Therapeutics vs Crypto pages for additional charts. We noticed that as of 5/18/2022, Cardano ($ADA) can buy you the most amount of Acorda Therapeutics shares, in the past year."
2022-05-17,14.0,13.199999809265137,-10.769227834848245,,
2022-05-16,15.600000381469728,13.600000381469728,-5.714287076677595,,
2022-05-13,15.399999618530272,14.800000190734863,-12.82051250701042,,
2022-05-12,14.0,13.0,-3.896100276999036,,
2022-05-11,17.600000381469727,14.800000190734863,-7.142857142857142,,
2022-05-10,16.600000381469727,16.399999618530273,-15.909091647991447,,
2022-05-09,18.600000381469727,17.0,-1.2048238454422584,,
2022-05-06,23.200000762939453,19.39999961853028,-8.602152412124298,,
2022-05-05,24.200000762939453,24.0,-16.379314738986718,,
2022-05-04,26.0,24.799999237060547,-0.8264494075791097,,
2022-05-03,25.799999237060547,26.200000762939453,-4.615387549767128,,
2022-05-02,27.200000762939453,26.200000762939453,1.550393557005699,,
2022-04-29,26.799999237060547,27.200000762939453,-3.6764704851130743,,
2022-04-28,26.600000381469727,26.600000381469727,1.4925430495003955,,
2022-04-27,26.39999961853028,26.600000381469727,0.0,,
2022-04-26,27.799999237060547,26.600000381469727,0.7575786584446181,,
2022-04-25,27.0,27.39999961853028,-4.316542764472763,,
2022-04-22,28.200000762939453,26.799999237060547,1.4814800686306686,,
2022-04-21,30.200000762939453,28.600000381469727,-4.964544283696593,,
2022-04-20,30.799999237060547,30.200000762939453,-5.298014374334717,,
2022-04-19,31.799999237060547,31.200000762939453,-1.9480470421542637,,
2022-04-18,31.0,30.200000762939453,-1.886787699736294,,
2022-04-14,32.400001525878906,31.0,-2.5806427001953125,,
2022-04-13,30.600000381469727,31.799999237060547,-4.320992160326538,,
2022-04-12,32.79999923706055,31.39999961853028,3.921564838664175,,
2022-04-11,32.599998474121094,33.20000076293945,-4.268291619191302,,
2022-04-08,33.400001525878906,33.20000076293945,1.8404979046077568,,
2022-04-07,32.79999923706055,33.0,-0.5988046521030517,,
2022-04-06,33.0,33.0,0.6097584377790879,,
2022-04-05,32.599998474121094,32.79999923706055,0.0,,
2022-04-04,33.0,33.400001525878906,0.6134993015359189,,
2022-04-01,32.599998474121094,32.20000076293945,1.2121258359966856,,
2022-03-31,33.79999923706055,32.20000076293945,-1.2269869015459354,,
2022-03-30,33.400001525878906,33.599998474121094,-4.733723403066678,,
2022-03-29,33.599998474121094,33.400001525878906,0.5987932308542752,,
2022-03-28,34.20000076293945,33.599998474121094,-0.5952290396567317,,
2022-03-25,36.0,34.79999923706055,-1.754392618226333,,
2022-03-24,36.400001525878906,35.20000076293945,-3.333335452609592,,
2022-03-23,35.599998474121094,35.79999923706055,-3.2967052544937445,,
2022-03-22,34.20000076293945,35.599998474121094,0.5617999199770775,,
2022-03-21,34.20000076293945,34.599998474121094,4.093560467690797,,
2022-03-18,36.0,34.0,1.1695839247322322,,
2022-03-17,34.0,36.400001525878906,-5.555555555555555,,
2022-03-16,34.79999923706055,35.400001525878906,7.058828017290901,,
2022-03-15,36.20000076293945,33.400001525878906,1.7241445458980986,,
2022-03-14,36.0,35.79999923706055,-7.734804359250477,,
2022-03-11,37.400001525878906,36.0,-0.5555576748318142,,
2022-03-10,42.59999847412109,37.400001525878906,-3.7433194351881944,,
2022-03-09,44.79999923706055,45.0,-12.206566043426285,,
2022-03-08,44.0,44.0,0.44643028202108453,,
2022-03-07,42.79999923706055,43.79999923706055,0.0,,
2022-03-04,43.20000076293945,42.79999923706055,2.336448639779646,,
2022-03-03,43.59999847412109,43.400001525878906,-0.9259294417005213,,
2022-03-02,41.20000076293945,42.59999847412109,-0.4587086129392624,,
2022-03-01,40.0,40.20000076293945,3.398052634117838,,
2022-02-28,40.400001525878906,41.0,0.5000019073486328,,
2022-02-25,40.79999923706055,40.20000076293945,1.4851446818306544,,
2022-02-24,39.79999923706055,41.79999923706055,-1.4705845228940277,,
2022-02-23,40.59999847412109,41.59999847412109,5.025125724469012,,
2022-02-22,41.79999923706055,40.79999923706055,2.46305427976164,,
2022-02-18,44.0,41.0,-2.392344541273063,,
2022-02-17,43.59999847412109,42.400001525878906,-6.8181818181818175,,
2022-02-16,42.0,43.20000076293945,-2.752286674859501,,
2022-02-15,38.0,41.20000076293945,2.8571446736653643,,
2022-02-14,36.59999847412109,38.0,8.42105463931435,,
2022-02-11,37.0,37.0,3.825140940562657,,
2022-02-10,39.59999847412109,36.59999847412109,0.0,,
2022-02-09,38.0,38.79999923706055,-7.575757867668918,,
2022-02-08,38.400001525878906,37.0,2.105261150159334,,
2022-02-07,39.59999847412109,38.20000076293945,-3.6458371621037653,,
2022-02-04,38.0,37.79999923706055,-3.535347891734246,,
2022-02-03,36.59999847412109,36.79999923706055,-0.5263177972090871,,
2022-02-02,37.79999923706055,37.20000076293945,0.5464501947476189,,
2022-02-01,37.0,37.400001525878906,-1.5872975826222575,,
2022-01-31,35.79999923706055,37.0,1.081085205078125,,
2022-01-28,33.20000076293945,35.400001525878906,3.3519575098124568,,
2022-01-27,36.79999923706055,34.20000076293945,6.6265081698289405,,
2022-01-26,38.0,36.79999923706055,-7.065213391370636,,
2022-01-25,38.0,38.0,-3.157896744577508,,
2022-01-24,35.20000076293945,35.599998474121094,0.0,,
2022-01-21,37.59999847412109,37.20000076293945,1.1363571094088747,,
2022-01-20,37.400001525878906,38.400001525878906,-1.0638237431231268,,
2022-01-19,37.59999847412109,36.0,2.673796682355883,,
2022-01-18,42.20000076293945,37.59999847412109,-4.25531526343629,,
2022-01-14,44.400001525878906,43.20000076293945,-10.900479160318271,,
2022-01-13,47.400001525878906,44.400001525878906,-2.702704328151932,,
2022-01-12,44.400001525878906,47.79999923706055,-6.329113720306727,,
2022-01-11,44.0,44.400001525878906,7.657652239493559,,
2022-01-10,45.59999847412109,44.0,0.9090943769975142,,
2022-01-07,48.400001525878906,45.79999923706055,-3.508768701010194,,
2022-01-06,48.20000076293945,47.20000076293945,-5.371905386052869,,
2022-01-05,49.0,48.400001525878906,-2.0746887638410394,,
2022-01-04,50.400001525878906,50.0,-1.2244866818797833,,
2022-01-03,48.79999923706055,50.0,-0.7936537971601397,,
2021-12-31,46.79999923706055,47.79999923706055,2.459017995287442,,
2021-12-30,45.400001525878906,47.0,2.1367521715857376,,
2021-12-29,46.0,46.0,3.5242255954750634,,
2021-12-28,46.20000076293945,46.400001525878906,0.0,,
2021-12-27,47.20000076293945,46.79999923706055,0.4329020771356545,,
2021-12-23,48.59999847412109,47.59999847412109,-0.847460846214604,,
2021-12-22,48.79999923706055,48.59999847412109,-2.0576132333265154,,
2021-12-21,47.79999923706055,48.79999923706055,-0.4098376353817075,,
2021-12-20,50.400001525878906,49.0,2.092050242596395,,
2021-12-17,52.400001525878906,51.0,-2.7777807212169368,,
2021-12-16,51.79999923706055,51.20000076293945,-2.6717585593723396,,
2021-12-15,50.0,51.79999923706055,-1.15829822964905,,
2021-12-14,52.0,50.0,3.5999984741210938,,
2021-12-13,53.0,50.79999923706055,-3.8461538461538463,,
2021-12-10,54.0,53.0,-4.150944835734817,,
2021-12-09,54.400001525878906,53.79999923706055,-1.8518518518518516,,
2021-12-08,54.59999847412109,54.79999923706055,-1.1029453529204944,,
2021-12-07,50.59999847412109,54.20000076293945,0.36630177386223767,,
2021-12-06,49.59999847412109,50.400001525878906,7.114629243832003,,
2021-12-03,53.0,49.20000076293945,1.612909428163033,,
2021-12-02,49.59999847412109,52.20000076293945,-7.169809881246316,,
2021-12-01,53.0,50.400001525878906,5.241940259685539,,
2021-11-30,53.20000076293945,52.0,-4.905657498341686,,
2021-11-29,58.0,53.79999923706055,-2.255640499493011,Acorda Therapeutics Inc Shares Fall 3.9% Below Previous 52-Week Low - Market Mover,"Acorda Therapeutics Inc (ACOR) shares closed 3.9% lower than its previous 52 week low, giving the company a market cap of $27M. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -893.7% The company's stock price performance over the past 12 months lags the peer average by -344.3% This story was produced by the Kwhen Automated News Generator."
2021-11-26,61.20000076293945,57.20000076293945,-7.241380625757678,Acorda Therapeutics Inc Shares Fall 5.0% Below Previous 52-Week Low - Market Mover,"Acorda Therapeutics Inc (ACOR) shares closed 5.0% lower than its previous 52 week low, giving the company a market cap of $29M. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -882.1% The company's stock price performance over the past 12 months lags the peer average by -283.4% This story was produced by the Kwhen Automated News Generator."
2021-11-24,62.79999923706055,61.79999923706055,-6.535947630939015,,
2021-11-23,67.4000015258789,63.400001525878906,-1.5923567072431806,,
2021-11-22,69.4000015258789,68.19999694824219,-5.93471796653322,,
2021-11-19,72.0,69.4000015258789,-1.7291131862428608,,
2021-11-18,70.0,71.4000015258789,-3.6111089918348522,,
2021-11-17,68.0,70.19999694824219,2.0000021798270087,,
2021-11-16,70.4000015258789,67.5999984741211,3.2352896297679226,,
2021-11-15,72.5999984741211,71.4000015258789,-3.9772769759508266,,
2021-11-12,72.5999984741211,72.80000305175781,-1.6528883932000866,,
2021-11-11,73.4000015258789,72.5999984741211,0.27548840473875785,,
2021-11-10,76.4000015258789,73.5999984741211,-1.0899223911810854,,
2021-11-09,74.4000015258789,75.19999694824219,-3.6649253872192262,,
2021-11-08,78.80000305175781,74.80000305175781,1.0752626424140799,,
2021-11-05,80.0,77.5999984741211,-5.076141935391424,,
2021-11-04,82.19999694824219,79.80000305175781,-3.000001907348633,,
2021-11-03,81.19999694824219,82.80000305175781,-2.9197007123924203,,
2021-11-02,84.0,81.4000015258789,1.9704509404544526,,
2021-11-01,81.4000015258789,83.5999984741211,-3.095236278715588,,
2021-10-29,83.19999694824219,81.4000015258789,2.7026989029511976,,
2021-10-28,83.19999694824219,84.4000015258789,-2.163456115849426,,
2021-10-27,80.5999984741211,82.80000305175781,1.442313247178637,,
2021-10-26,82.0,81.80000305175781,2.7295342671043503,,
2021-10-25,82.5999984741211,81.19999694824219,-0.24389871736852134,,
2021-10-22,86.0,82.4000015258789,-1.6949171328587038,,
2021-10-21,90.0,87.19999694824219,-4.18604473735011,,
2021-10-20,92.0,89.80000305175781,-3.111114501953125,,
2021-10-19,93.0,92.1999969482422,-2.39130103069803,,
2021-10-18,94.1999969482422,93.0,-0.860218335223439,,
2021-10-15,94.5999984741211,94.1999969482422,-1.273882151929936,,
2021-10-14,92.5999984741211,93.1999969482422,-0.4228346007725539,,
2021-10-13,91.8000030517578,92.5999984741211,0.6479465270064658,,
2021-10-12,90.8000030517578,91.1999969482422,0.8714546794865025,,
2021-10-11,81.5999984741211,89.80000305175781,0.4405218976219626,,
2021-10-08,82.19999694824219,81.5999984741211,10.049025405603771,,
2021-10-07,82.5999984741211,83.0,-0.7299251780981051,,
2021-10-06,81.80000305175781,82.5999984741211,0.48426335746752863,,
2021-10-05,88.4000015258789,82.80000305175781,0.9779894774051479,,
2021-10-04,92.5999984741211,88.5999984741211,-6.33483979350578,,
2021-10-01,92.0,92.8000030517578,-4.319654498825806,,
2021-09-30,95.0,92.0,0.869568534519346,,
2021-09-29,96.8000030517578,93.8000030517578,-3.1578947368421053,,
2021-09-28,94.1999969482422,95.8000030517578,-3.099173456013153,,
2021-09-27,94.8000030517578,94.5999984741211,1.6985203347667974,,
2021-09-24,87.80000305175781,94.8000030517578,-0.21097528607410318,,
2021-09-23,87.4000015258789,89.19999694824219,7.972664870949388,,
2021-09-22,85.5999984741211,87.19999694824219,2.059491293979334,,
2021-09-21,87.0,85.5999984741211,1.8691571292548694,,
2021-09-20,92.1999969482422,87.19999694824219,-1.6091971561826508,,
2021-09-17,93.8000030517578,94.5999984741211,-5.422993671905257,,
2021-09-16,92.0,93.8000030517578,0.8528735568610449,,
2021-09-15,93.1999969482422,93.0,1.9565250562584762,,
2021-09-14,94.1999969482422,93.8000030517578,-0.21458900728641467,,
2021-09-13,93.4000015258789,94.0,-0.4246219845465371,,
2021-09-10,91.1999969482422,93.4000015258789,0.6423966427397204,,
2021-09-09,86.19999694824219,89.19999694824219,2.4122858018134044,Acorda Therapeutics To Reduce Headcount; Names Lauren Sabella COO - Quick Facts,"""The headcount reductions and structural changes will enable us to operate more efficiently and further align our expenses with revenue, while continuing to grow Inbrija sales,"" said Ron Cohen, Acorda's CEO. Acorda Therapeutics also announced the appointment of Lauren Sabella, currently Chief Commercial Officer, as Chief Operating Officer. (RTTNews) - Acorda Therapeutics, Inc. (ACOR) said it is reducing headcount by 15%."
2021-09-08,82.5999984741211,86.80000305175781,3.480278545486859,,
2021-09-07,86.19999694824219,83.4000015258789,5.084751398576111,,
2021-09-03,86.4000015258789,87.5999984741211,-3.248254665304114,,
2021-09-02,87.4000015258789,87.0,1.3888853322331935,,
2021-09-01,85.0,87.4000015258789,-0.45766764175681035,,
2021-08-31,83.19999694824219,84.5999984741211,2.8235312069163605,,
2021-08-30,85.0,82.5999984741211,1.6826942034022332,,
2021-08-27,84.19999694824219,85.5999984741211,-2.8235312069163605,,
2021-08-26,84.4000015258789,83.19999694824219,1.662709710951045,,
2021-08-25,81.4000015258789,84.0,-1.4218063459024592,,
2021-08-24,79.5999984741211,81.19999694824219,3.1941012596842464,,
2021-08-23,77.5999984741211,79.5999984741211,2.0100483728542686,,
2021-08-20,74.19999694824219,77.5999984741211,2.577319638307702,,
2021-08-19,73.5999984741211,72.80000305175781,4.582212487489129,,
2021-08-18,72.0,73.80000305175781,-1.0869503246587322,,
2021-08-17,67.4000015258789,72.0,2.5000042385525174,,
2021-08-16,70.0,67.5999984741211,6.8249233975979635,,
2021-08-13,71.5999984741211,71.5999984741211,-3.428573608398437,,
2021-08-12,66.19999694824219,71.5999984741211,0.0,,
2021-08-11,72.5999984741211,67.19999694824219,8.157102378872985,,
2021-08-10,72.5999984741211,72.4000015258789,-7.43801878701662,,
2021-08-09,76.5999984741211,73.19999694824219,-0.2754778959306427,,
2021-08-06,73.80000305175781,73.0,-4.438644378077343,,
2021-08-05,76.0,82.0,-1.084014930455694,,
2021-08-04,76.5999984741211,75.0,7.894736842105263,,
2021-08-03,74.0,77.4000015258789,-2.088770895552491,,
2021-08-02,75.19999694824219,74.4000015258789,4.594596656593117,,
2021-07-30,77.5999984741211,75.0,-1.0638237431231454,,
2021-07-29,79.4000015258789,79.0,-3.350513563461177,,
2021-07-28,80.0,77.80000305175781,-0.5037802496118762,,
2021-07-27,82.5999984741211,79.19999694824219,-2.7499961853027344,,
2021-07-26,84.5999984741211,85.80000305175781,-4.116224683641054,,
2021-07-23,105.5999984741211,94.5999984741211,1.4184451528137991,"Pre-Market Most Active for Jul 23, 2021 : EDU, TAL, GOTU, ACOR, DIDI, UPC, NRXP, SOS, CLOV, SQQQ, NIO, IPA | Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday","Acorda Therapeutics, Inc. (ACOR) is +1.8 at $5.61, with 5,582,623 shares traded. As reported by Zacks, the current mean recommendation for ACOR is in the ""strong buy range"". The total Pre-Market volume is currently 26,383,034 shares traded. | Acorda Therapeutics (NASDAQ:ACOR) shares are gaining over 54% after announcing plans to commercialize INBRIJA in Spain. Pre-Market Stock Movers: 10 Top Gainers Socket Mobile (NASDAQ:SCKT) stock is rocketing more than 81% higher with the release of its earnings report for the second quarter of 2021. 7 Value Stocks to Buy Ahead of Possible Interest Rate Hikes 10 Top Losers Gaotu Techedu (NYSE:GOTU) stock is diving more than 55% this morning on talk that China wants education companies to become non-profits."
2021-07-22,80.0,76.19999694824219,-10.416666817183447,,
2021-07-21,76.19999694824219,79.5999984741211,-4.750003814697266,,
2021-07-20,71.5999984741211,75.0,4.4619444383814235,,
2021-07-19,73.5999984741211,72.4000015258789,4.748605584269382,,
2021-07-16,77.19999694824219,73.80000305175781,-1.6304306700007951,,
2021-07-15,78.19999694824219,77.5999984741211,-4.404137345709819,,
2021-07-14,81.0,78.19999694824219,-0.767261505800584,,
2021-07-13,84.19999694824219,80.80000305175781,-3.4567938910590277,,
2021-07-12,82.80000305175781,84.4000015258789,-4.037997648116726,,
2021-07-09,87.80000305175781,84.19999694824219,1.9323652356883898,,
2021-07-08,86.19999694824219,87.19999694824219,-4.100234599528925,,
2021-07-07,91.0,87.19999694824219,1.1600928484956197,,
2021-07-06,89.19999694824219,91.8000030517578,-4.175827529404189,,
2021-07-02,91.8000030517578,90.1999969482422,2.91480514850718,,
2021-07-01,95.4000015258789,92.4000015258789,-1.7429259807469684,,
2021-06-30,96.8000030517578,95.4000015258789,-3.1446540377530265,,
2021-06-29,103.8000030517578,96.1999969482422,-1.4462825224605913,,
2021-06-28,103.1999969482422,104.5999984741211,-7.321778304501596,,
2021-06-25,101.4000015258789,103.8000030517578,1.3565906659677844,,
2021-06-24,98.1999969482422,100.1999969482422,2.366865374520111,,
2021-06-23,98.4000015258789,98.0,2.0366599410936135,,
2021-06-22,95.5999984741211,97.0,-0.4065056094269542,,
2021-06-21,89.0,94.4000015258789,1.4644367659251443,,
2021-06-18,93.0,89.19999694824219,6.06741744480776,,
2021-06-17,88.0,97.0,-4.086024786836358,,
2021-06-16,82.4000015258789,82.0,10.227272727272728,,
2021-06-15,83.80000305175781,83.5999984741211,-0.4854387360093434,,
2021-06-14,77.5999984741211,84.19999694824219,-0.2386689383688792,,
2021-06-11,76.4000015258789,77.0,8.505152840076581,,
2021-06-10,76.5999984741211,76.0,0.7853383012274636,,
2021-06-09,77.4000015258789,76.19999694824219,-0.7832878408265245,,
2021-06-08,75.0,75.5999984741211,-1.5503934805937878,,
2021-06-07,73.4000015258789,74.19999694824219,0.7999979654947916,,
2021-06-04,73.4000015258789,72.19999694824219,1.0899119969108229,,
2021-06-03,74.80000305175781,73.19999694824219,-1.634883586771628,,
2021-06-02,76.19999694824219,75.0,-2.139045505664621,,
2021-06-01,75.4000015258789,77.19999694824219,-1.5747992077444164,,
2021-05-28,78.4000015258789,74.4000015258789,2.3872617850617472,,
2021-05-27,74.5999984741211,75.80000305175781,-5.102040717026833,,
2021-05-26,73.4000015258789,74.5999984741211,1.6085852576163295,,
2021-05-25,76.19999694824219,73.4000015258789,1.6348731925013653,,
2021-05-24,80.0,76.5999984741211,-3.6745348221800325,,
2021-05-21,83.0,80.0,-4.250001907348633,,
2021-05-20,82.0,82.5999984741211,-3.614457831325301,,
2021-05-19,86.19999694824219,81.80000305175781,0.7317054562452362,,
2021-05-18,87.80000305175781,86.5999984741211,-5.1044014527359,,
2021-05-17,89.0,88.5999984741211,-1.3667477630146778,,
2021-05-14,86.80000305175781,89.80000305175781,-0.4494399167178722,,
2021-05-13,86.0,85.4000015258789,3.4562210766411328,,
2021-05-12,83.4000015258789,84.80000305175781,-0.6976726443268532,,
2021-05-11,81.0,83.4000015258789,1.6786588732189505,,
2021-05-10,90.0,83.4000015258789,2.9629648467640815,,
2021-05-07,93.0,92.0,-7.333331637912327,,
2021-05-06,97.8000030517578,94.1999969482422,-1.0752688172043012,,
2021-05-05,100.0,98.4000015258789,-3.680987721043729,,
2021-05-04,102.1999969482422,98.8000030517578,-1.5999984741210938,,
2021-05-03,105.5999984741211,102.4000015258789,-3.326804303336999,,
2021-04-30,97.5999984741211,104.4000015258789,-3.0303001841675177,,
2021-04-29,101.8000030517578,97.1999969482422,6.967216350480632,,
2021-04-28,94.5999984741211,99.4000015258789,-4.518669907285595,,
2021-04-27,94.0,95.4000015258789,5.073999079472404,,
2021-04-26,94.0,93.8000030517578,1.4893633254030918,,
2021-04-23,95.0,94.0,-0.21276271089595927,,
2021-04-22,91.4000015258789,94.5999984741211,-1.0526315789473684,,
2021-04-21,82.4000015258789,92.0,3.501090694551185,,
2021-04-20,84.4000015258789,83.0,11.65048336935537,,
2021-04-19,84.0,84.19999694824219,-1.6587695504361275,,
2021-04-16,79.0,83.80000305175781,0.2380916050502232,,
2021-04-15,81.80000305175781,78.5999984741211,6.07595323007318,,
2021-04-14,82.5999984741211,82.0,-3.911985890284088,,
2021-04-13,80.4000015258789,83.19999694824219,-0.7263904179236464,,
2021-04-12,84.19999694824219,81.5999984741211,3.482581305004114,,
2021-04-09,88.0,83.80000305175781,-3.0878842854582467,,
2021-04-08,94.1999969482422,88.80000305175781,-4.772723804820667,,
2021-04-07,96.0,93.1999969482422,-5.732477782829859,,
2021-04-06,96.1999969482422,96.0,-2.9166698455810396,,
2021-04-05,97.0,96.4000015258789,-0.20789704218993338,,
2021-04-01,99.5999984741211,95.5999984741211,-0.6185551279598905,,
2021-03-31,97.0,97.4000015258789,-4.016064318554497,,
2021-03-30,96.5999984741211,97.0,0.4123727070916559,,
2021-03-29,98.4000015258789,97.1999969482422,0.41408026107377804,,
2021-03-26,102.4000015258789,99.0,-1.2195168282808482,,
2021-03-25,102.0,102.0,-3.3203139406395863,,
2021-03-24,108.5999984741211,103.4000015258789,0.0,,
2021-03-23,115.0,106.5999984741211,-4.788210885179086,,
2021-03-22,115.0,115.8000030517578,-7.304349152938179,,
2021-03-19,112.5999984741211,114.8000030517578,0.6956548276154767,,
2021-03-18,119.1999969482422,109.5999984741211,1.9538229195823056,,
2021-03-17,116.0,119.1999969482422,-8.053690201258581,,
2021-03-16,117.4000015258789,118.0,2.758618058829484,,
2021-03-15,119.0,117.4000015258789,0.511071947464016,,
2021-03-12,113.1999969482422,117.1999969482422,-1.3445365328748686,,
2021-03-11,110.4000015258789,113.1999969482422,3.5335689998550945,,
2021-03-10,108.0,107.8000030517578,2.536227702593779,,
2021-03-09,102.1999969482422,106.1999969482422,-0.1851823594835201,,
2021-03-08,105.0,103.4000015258789,3.9138944417246373,,
2021-03-05,118.1999969482422,104.4000015258789,-1.5238080705915178,"Friday Sector Laggards: Advertising, Biotechnology Stocks","Also lagging the market Friday are biotechnology shares, down on the day by about 5.8% as a group, led down by Acorda Therapeutics, trading lower by about 26.8% and Allovir, trading lower by about 18.4%. Helping drag down the group were shares of Baosheng Media Group Holdings, down about 22% and shares of Izea Worldwide down about 17.5% on the day. VIDEO: Friday Sector Laggards: Advertising, Biotechnology Stocks The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2021-03-04,127.4000015258789,135.60000610351562,-11.675123332199478,,
2021-03-03,124.0,125.8000030517578,6.436424238166937,,
2021-03-02,120.0,123.8000030517578,1.4516153643208052,,
2021-03-01,116.5999984741211,119.0,3.1666692097981652,,
2021-02-26,121.0,116.4000015258789,2.0583203750312027,,
2021-02-25,127.0,121.0,-3.801651631505036,,
2021-02-24,129.60000610351562,126.5999984741211,-4.724409448818897,,
2021-02-23,124.0,122.8000030517578,-2.3148205926767704,,
2021-02-22,132.60000610351562,132.1999969482422,-0.9677394743888724,,
2021-02-19,138.0,132.60000610351562,-0.3016660157324322,,
2021-02-18,144.8000030517578,137.60000610351562,-3.9130390554234604,,
2021-02-17,147.1999969482422,148.39999389648438,-4.972373478244055,,
2021-02-16,152.39999389648438,149.0,0.8152153350003976,,
2021-02-12,153.0,150.60000610351562,-2.2309672130261204,,
2021-02-11,149.8000030517578,151.8000030517578,-1.5686234617544936,,
2021-02-10,160.0,148.0,1.3351134574469765,,
2021-02-09,160.1999969482422,157.1999969482422,-7.5,,
2021-02-08,147.1999969482422,151.1999969482422,-1.8726592117035104,,
2021-02-05,144.39999389648438,147.0,2.7173913606849207,,
2021-02-04,150.0,143.1999969482422,1.8005583195380772,,
2021-02-03,140.0,147.8000030517578,-4.533335367838542,,
2021-02-02,138.39999389648438,139.60000610351562,5.57143075125558,,
2021-02-01,134.39999389648438,134.8000030517578,0.8670608814685307,,
2021-01-29,140.1999969482422,134.8000030517578,0.29762587309455296,,
2021-01-28,143.8000030517578,138.0,-3.85163624395648,,
2021-01-27,143.8000030517578,144.39999389648438,-4.033381730645877,,
2021-01-26,150.60000610351562,149.0,0.4172397997172561,,
2021-01-25,156.39999389648438,148.8000030517578,-1.0624210084134083,,
2021-01-22,145.60000610351562,152.0,-4.85932937424328,,
2021-01-21,165.0,144.39999389648438,4.395600019366923,,
2021-01-20,160.39999389648438,160.8000030517578,-12.484852183948863,,
2021-01-19,140.60000610351562,159.39999389648438,0.24938227586940379,,
2021-01-15,124.8000030517578,134.0,13.371256740293033,Acorda Stock at $35 a Share? This Analyst Thinks It’s Possible,"“The sale of ACOR's manufacturing operations, restructuring, and disclosure of strong Q4 Inbrija sales meaningfully increase the likelihood that Acorda's balance sheet is sufficiently strong to support operations back to profitability, in our opinion."" The developments amount to “a significant improvement in Acorda's fundamentals,” according to Nadeau, who thinks Acorda is “undervalued for Inbrija's L-T potential.” To this end, Nadeau reiterates an Outperform (i.e. Buy) rating on ACOR shares, while boosting his price target from $5 all the way up to $35. (See ACOR stock analysis on TipRanks) To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights."
2021-01-14,122.0,127.4000015258789,7.371792246212305,"ACOR Rises On Restructuring, ALXN Pauses COVID-19 Trial, SYBX On Watch","Acorda Rises on Corporate Restructuring Shares of Acorda Therapeutics Inc. (ACOR) jumped over 44% on Wednesday, on news of the company agreeing to sell its INBRIJA manufacturing operations in Chelsea, Massachusetts to Catalent, Inc. (CTLT) for $80 million in cash. (RTTNews) - Today's Daily Dose brings you news about Acorda's restructuring; Alexion's decision to pause its COVID-19 trial; and analyst's rating on Synlogic. INBRIJA is a prescription medicine from Acorda Therapeutics indicated for use when needed with hypomobility or OFF episodes in adults with Parkinson's disease treated with regular carbidopa/levodopa medicine."
2021-01-13,143.1999969482422,122.4000015258789,4.426230758917137,"BUZZ-U.S. STOCKS ON THE MOVE-Zoom Video Communications, Inari Medical, Lordstown Motors, Rockwell Medical | Stock Alert: Acorda Therapeutics Gains 50% On Plan To Sell INBRIJA","The top three S&P 500 .PG.INX percentage gainers: ** Intel Corp , up 8.1% ** The Cooper Companies Inc , up 4.0% ** Eli Lilly and Company , up 3.1% The top three S&P 500 .PL.INX percentage losers: ** Gap Inc , down 4.5% ** TechnipFMC Plc , down 4.4% ** International Paper Company , down 4.2% The top three NYSE .PG.N percentage gainers: ** GameStop Corp , up 35.4% ** Volt Information Sciences , up 33.2% ** Zedge Inc , up 29.8% The top three NYSE .PL.N percentage losers: ** Party City Holdco Inc , down 10.5% ** Breakwave Dry Bulk Shipping ETF , down 9.3% ** Daqo New Energy , down 8.6% The top three Nasdaq .PG.O percentage gainers: ** Live Ventures Incorporated , up 76% ** Xenetic Biosciences Inc , up 50.3% ** Synlogic Inc , up 29.4% The top three Nasdaq .PL.O percentage losers: ** Asia Pacific Wire & Cable Corp Ltd , down 20.1% ** Provention Bio , down 14.2% ** Forward Pharma A/S , down 13.8% ** Inari Medical NARI.O : up 8.6% BUZZ-Hits record high after upbeat Q4 rev forecast ** Zoom Video Communications Inc ZM.O : up 3.6% BUZZ-Zoom ticks higher after pricing upsized $1.75 bln equity offering ** Exxon Mobil XOM.N : up 0.9% BUZZ-Up as JPM upgrades to 'overweight' for first time in seven years ** Lordstown Motors RIDE.O : up 9.5% BUZZ-Lordstown Motors in advanced talks for U.S. loan for EV truck factory; shares up ** Rockwell Medical RMTI.O : up 7.2% BUZZ-Up as enrollment begins in iron replacement drug trial in China ** Provention Bio PRVB.O : down 14.2% BUZZ-Provention Bio drops on planned equity offering ** Visa V.N : up 0.2% ** Mastercard MA.N : up 1.1% BUZZ-Visa, Mastercard well positioned in 2021 - Jefferies ** Urban Outfitters URBN.O : down 6.9% BUZZ-Slides on weak holiday sales, unit's CEO exit ** Farmer Bros Co FARM.O : up 17.2% BUZZ-Climbs on deal to distribute High Brew Coffee products ** KB Home KBH.N : up 5.3% BUZZ-Rises as housing demand fuels revenue beat ** Marathon Patent Group MARA.O : down 14.3% BUZZ-Down on discounted share offering ** Timber Pharma TMBR.N: up 5.7% BUZZ-Jumps on orphan drug tag for systemic sclerosis treatment ** Alibaba BABA.N: up 1.2% BUZZ-Alibaba rises, Primavera chairman says Jack Ma 'safe and sound' ** Apple Inc AAPL.O : up 1.2% BUZZ-Rises as brokerage sees record iPhone sales in FY 2021 ** Marinus MRNS.O : up 11.5% BUZZ-Rises on positive FDA response for data on rare genetic disorder therapy ** Marker Therapeutics MRKR.O : up 4.7% BUZZ-Up on completing new manufacturing facility to help cancer pipeline ** Hoth Therapeutics HOTH.O : up 0.4% BUZZ-Jumps as FDA to give feedback for cancer therapy trial USN ** Reed's REED.O : up 0.4% BUZZ-Gains as higher demand for natural beverages boosts sales ** Boeing Co BA.N : down 0.8% BUZZ-JPM says Boeing's 787 may face another production rate cut in 2021 ** Acorda Therapeutics ACOR.O : up 41.0% BUZZ-Surges on sale of manufacturing facility, restructuring plans ** Big Lots BIG.N : down 5.4% BUZZ-Falls on lower-than-expected Q4 profit outlook ** Orbital Energy OEG.O : down 4.4% BUZZ-Orbital Energy drops after pricing stock offering at a discount ** Inhibrx Inc INBX.O : up 2.7% BUZZ-Gains on FDA fast-track tag for potential bone cancer drug ** Intel Corp INTC.O : up 8.0% BUZZ-Jumps on CEO change, strong expectations for Q4 ** Genmab GMAB.O: up 2.5% BUZZ-Up on milestone payment from AbbVie for lymphoma therapy ** DocuSign Inc DOCU.O : down 1.6% BUZZ-DocuSign dips after pricing upsized $600 mln convertible debt offering ** Dropbox Inc DBX.O : down 3.4% BUZZ-Falls after co cuts 11% of workforce, COO to step down ** Sos Ltd SOS.N : up 1.3% BUZZ-Jumps as co plans to invest in crypto mining business The 11 major S&P 500 sectors: Communication Services .N At 10:35 ET, the Dow Jones Industrial Average .DJI was up 0.03% at 31,078.04. up 0.58% Consumer Discretionary | (RTTNews) - Acorda Therapeutics, Inc. (ACOR) shares are rising on Wednesday morning trade as the company announced an agreement to sell INBRIJA manufacturing operations in Chelsea, Massachusetts to Catalent for $80 million in cash. For the 52-week period, the shares have traded in range of $2.52 to $15.30 on average volume of 840,684. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2021-01-12,82.19999694824219,84.80000305175781,-14.525136777678266,,
2021-01-11,80.5999984741211,82.0,3.163024574262135,,
2021-01-08,83.5999984741211,82.19999694824219,1.7369746307481833,,
2021-01-07,79.19999694824219,83.19999694824219,-1.67464300410518,,
2021-01-06,81.4000015258789,78.19999694824219,5.050505245112611,,
2021-01-05,76.4000015258789,80.80000305175781,-3.931209481144008,,
2021-01-04,71.4000015258789,76.0,5.759164185865229,,
2020-12-31,86.4000015258789,82.80000305175781,6.442574756043704,,
2020-12-30,82.80000305175781,85.19999694824219,-4.166664827017169,,
2020-12-29,86.4000015258789,84.0,2.898543246410453,,
2020-12-28,87.5999984741211,85.19999694824219,-2.777779494783976,,
2020-12-24,90.0,86.4000015258789,-2.7397278169906794,,
2020-12-23,84.0,90.0,-3.999998304578993,,
2020-12-22,86.4000015258789,84.0,7.142857142857142,,
2020-12-21,84.0,86.4000015258789,-2.777779494783976,,
2020-12-18,91.1999969482422,91.1999969482422,2.8571446736653643,,
2020-12-17,90.0,91.1999969482422,0.0,,
2020-12-16,88.80000305175781,88.80000305175781,1.3333299424913352,,
2020-12-15,87.5999984741211,88.80000305175781,0.0,,
2020-12-14,88.80000305175781,86.4000015258789,1.3698682631726593,,
2020-12-11,91.1999969482422,90.0,-2.702704328151932,,
2020-12-10,90.0,92.4000015258789,-1.315786171487729,,
2020-12-09,98.4000015258789,91.1999969482422,2.6666683620876737,,
2020-12-08,96.0,94.8000030517578,-7.317077709336341,,
2020-12-07,93.5999984741211,93.5999984741211,-1.249996821085627,,
2020-12-04,94.8000030517578,96.0,0.0,,
2020-12-03,92.4000015258789,94.8000030517578,1.2658195249076536,"Pre-market Movers In Healthcare Sector: OMER, ITRM, CLSD, CDMO, ACOR…","Acorda Therapeutics Inc. (ACOR) is down over 4% at $0.78 today, erasing some of its yesterday's gain. Artelo Biosciences Inc. (ARTL) is up over 6% at $0.70 in pre-market hours today, adding to yesterday's gain of 15%. Avid Bioservices Inc. (CDMO) is up more than 5% at $10 in pre-market hours today, adding to yesterday's gain of 8%."
2020-12-02,79.19999694824219,98.4000015258789,2.5974042058935596,,
2020-12-01,81.5999984741211,78.0,24.2424309563851,,
2020-11-30,85.19999694824219,80.4000015258789,-4.411762918430457,,
2020-11-27,86.4000015258789,82.80000305175781,-5.633797645883969,,
2020-11-25,91.1999969482422,85.19999694824219,-4.166664827017169,,
2020-11-24,84.0,88.80000305175781,-6.578947588567501,,
2020-11-23,86.4000015258789,84.0,5.714289347330729,,
2020-11-20,85.19999694824219,85.19999694824219,-2.777779494783976,,
2020-11-19,94.8000030517578,86.4000015258789,0.0,,
2020-11-18,94.8000030517578,93.5999984741211,-8.860760818006257,,
2020-11-17,94.8000030517578,94.8000030517578,-1.2658275727918913,,
2020-11-16,99.5999984741211,94.8000030517578,0.0,"Pre-market Movers In Healthcare Sector: OBSC, CEMI, ABUS, CVAC, ADMP…","Acorda Therapeutics Inc. (ACOR) is up over 5% at $0.87 in pre-market hours on no news. ObsEva SA (OBSV) is up over 14% at $2.38 in pre-market trading Monday, following positive topline results from its phase IIa proof-of-concept trial of Ebopiprant in preterm labor, dubbed PROLONG. Arbutus Biopharma Corporation (ABUS) is up over 12% at $4.09 in pre-market hours today, following encouraging updated clinical data from an ongoing phase Ia/Ib clinical trial with AB-729 in subjects with chronic hepatitis B infection."
2020-11-13,97.1999969482422,99.5999984741211,-4.819272586244538,,
2020-11-12,96.0,96.0,2.469137449826118,,
2020-11-11,102.0,94.8000030517578,0.0,,
2020-11-10,103.1999969482422,100.8000030517578,-7.058820537492355,,
2020-11-09,96.0,103.1999969482422,-2.3255755498598223,,
2020-11-06,100.8000030517578,97.1999969482422,7.4999968210856265,,
2020-11-05,105.5999984741211,100.8000030517578,-3.571434518377049,"Acorda Therapeutics, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year | Pre-market Movers In Healthcare Sector: MITO, LPTX, NTEC, ABIO…","In addition to smashing expectations with revenues of US$53m, Acorda Therapeutics delivered a surprise statutory profit of US$0.05 per share, a notable improvement compared to analyst expectations of a loss. NasdaqGS:ACOR Earnings and Revenue Growth November 6th 2020 Taking into account the latest results, the current consensus, from the four analysts covering Acorda Therapeutics, is for revenues of US$90.7m in 2021, which would reflect a sizeable 45% reduction in Acorda Therapeutics' sales over the past 12 months. One more thing stood out to us about these estimates, and it's the idea that Acorda Therapeutics'decline is expected to accelerate, with revenues forecast to fall 45% next year, topping off a historical decline of 17% a year over the past five years. | Acorda Therapeutics Inc. (ACOR) is down more than 6% at $0.86 in pre-market hours today, adding to yesterday's loss of 15%. Stealth BioTherapeutics Corp (MITO) is up over 10% at $1.53 in pre-market trading Thursday, following the receipt of $20 million from Morningside Ventures, under a Development Funding Agreement, to support the clinical development of Elamipretide. Leap Therapeutics Inc. (LPTX) is up over 14% at $2.23 in pre-market hours today, as the company gears up to present esophagogastric cancer data for its DKN-01 monoclonal antibody at the Society of Immunotherapy of Cancer's 35th Anniversary Annual Meeting on November 9."
2020-11-04,118.8000030517578,110.4000015258789,-4.54545027625129,"Pre-market Movers In Healthcare Sector: DRAD, SUPN, ARGX, AZN, APVO…","Acorda Therapeutics Inc. (ACOR) is down over 9% at $0.98 in pre-market trading Wednesday. Digirad Corporation (DRAD) is up over 25% at $3.20 in pre-market trading Wednesday, following news that it has entered into a Stock Purchase Agreement to sell its DMS Health Technologies Inc. business unit for $18.75 million. Supernus Pharmaceuticals, Inc. (SUPN) is up more than 20% at $21.94 in pre-market hours today, following its third quarter financial results and upwardly revised revenue outlook for the year."
2020-11-03,126.0,129.60000610351562,-7.070708173483169,"Pre-market Movers In Healthcare Sector: DBVT, ACOR, ANPC, AGRX, CATB…","Acorda Therapeutics Inc. (ACOR) is up more than 8% at $1.18 in pre-market hours today, adding to yesterday's gain of 25%. The stock was up over 26% yesterday after the company announced that its non-invasive, once-daily epicutaneous patch to treat peanut allergies in children, Viaskin Peanut, has been accepted for review by the European Medicines Agency. AnPac Bio-Medical Science Co. Ltd. (ANPC) is up nearly 5% at $4.10 in pre-market hours, adding to yesterday's gain."
2020-11-02,105.5999984741211,132.0,2.857147701202877,,
2020-10-30,106.8000030517578,104.4000015258789,25.000001806201382,,
2020-10-29,105.5999984741211,110.4000015258789,-2.2471923757490857,,
2020-10-28,104.4000015258789,105.5999984741211,4.545457501056808,,
2020-10-27,106.8000030517578,104.4000015258789,1.1494223474170444,,
2020-10-26,99.5999984741211,108.0,-2.2471923757490857,,
2020-10-23,110.4000015258789,100.8000030517578,8.433736600971399,,
2020-10-22,114.0,104.4000015258789,-8.695650671590588,,
2020-10-21,104.4000015258789,112.8000030517578,-8.421051293088679,,
2020-10-20,146.39999389648438,115.1999969482422,8.045978355466481,"BUZZ-U.S. STOCKS ON THE MOVE-Moderna, Acorda, Cara Therapeutics, AMC | BUZZ-U.S. STOCKS ON THE MOVE-Acorda, Crown Holdings, Cleveland BioLabs, AMC | Pre-market Movers In Healthcare Sector: ACOR, APTX, CARA, CBLI, IVA, ISR… | BUZZ-U.S. STOCKS ON THE MOVE-Acorda, General Motors, AMC | BUZZ-U.S. STOCKS ON THE MOVE-Moderna, IBM, Emcore, Acorda","The top three NYSE percentage gainers premarket .PRPG.NQ: ** A.H. Belo Corp , up 11.0% ** Parsley Energy Inc , up 10.3% ** Ocwen Financial Corp , up 8.5% The top three NYSE percentage losers premarket .PRPL.NQ: ** CAE Inc , down 29.1% ** Jianpu Technology Inc , down 11.2% ** HighPoint Resources Corp , down 10.9% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Aptinyx Inc , up 96.4% ** Atlas Technical Consultants Inc , up 91.7% ** Cleveland Biolabs Inc , up 82.0% The top three Nasdaq percentage losers premarket .PRPL.O: ** Globus Maritime Ltd , down 33.5% ** Kaixin Auto Holdings , down 26.4% ** Baudax Bio Inc , down 24.2% ** Emcore Corp EMKR.O: up 14.8% premarket BUZZ-Emcore Corp: Soars as it expects Q4 rev to exceed estimates ** BancorpSouth BXS.N: up 1.9% premarket BUZZ-BancorpSouth rises as Q3 profit tops estimates ** Aptinyx APTX.O: up 96.4% premarket BUZZ-Aptinyx: Surges on positive results from PTSD therapy study ** Acorda ACOR.O: up 73.9% premarket BUZZ-Acorda jumps as co entitled to milestone payment from Biogen International ** Crown Holdings CCK.N: up 6.5% premarket BUZZ-Crown Holdings: Rises on higher annual earnings forecast ** Travelers TRV.N: up 3.2% premarket BUZZ-Travelers Companies Inc: Rises on Q3 profit beat ** Procter & Gamble PG.N: up 1.7% premarket BUZZ-P&G: Up on forecast bump on detergents, cleaning supplies demand ** Moderna MRNA.O: up 2.6% premarket BUZZ-Moderna: Up on emergency use approval likelihood for COVID-19 vaccine in Dec ** Cleveland BioLabs CBLI.O: up 82.0% premarket BUZZ-Cleveland BioLabs rises on merger agreement with Cytocom Inc ** Parsley Energy PE.N: up 10.3% premarket BUZZ-Parsley Energy: Rises on report of Pioneer Natural Resources in takeover talks ** Cara Therapeutics CARA.O: up 15.6% premarket BUZZ-Cara Therapeutics: Up on license agreement for kidney disease vaccine ** Centogene CNTG.O: up 4.9% premarket BUZZ-Centogene: Gains on raising full-year revenue outlook, CEO change ** General Motors GM.N: up 1.2% premarket BUZZ-General Motors: Rises on EV investment plans in U.S.; Citi hikes PT ** Isoray Inc ISR.N: down 17.2% premarket BUZZ-Isoray drops on planned stock-and-warrants offering ** Workday WDAY.O: up 2.2% premarket BUZZ-Workday: Piper Sandler sees potential catalysts, upgrades to 'overweight' ** UBS UBS.N: up 6.8% premarket BUZZ-UBS: U.S.-listed shares up on solid Q3 profit beat, buyback hopes ** IQVIA IQV.N: up 3.6% premarket BUZZ-IQVIA: Gains on Q3 profit beat, full-year profit forecast raise ** Rayonier Advanced Materials RYAM.N: up 5.1% premarket BUZZ-Rayonier Advanced Materials: RBC sees Q3 boost from Forest Products unit, upgrades ** AMC Entertainment AMC.N: down 6.8% premarket BUZZ-AMC falls after filing to sell up to 15 mln shares ** Synchrony Financial SYF.N: down 3.7% premarket BUZZ-Synchrony Financial slips on dismal Q3 (Compiled by Tiyashi Datta) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes were set to open higher on Tuesday as investors were hopeful of more stimulus from Washington with Senate Republicans preparing to vote on a bill to help small businesses hammered by the COVID-19 pandemic.N At 8:23 ET, Dow e-minis 1YMc1 were up 0.46% at 28,230. S&P 500 e-minis ESc1 were up 0.19% at 3,429.25, while Nasdaq 100 e-minis NQc1 were up 0.05% at 11,655.75. | The top three S&P 500 .PG.INX percentage gainers: ** Regions Financial Corp , up 7.9% ** Comerica Inc , up 7.5% ** IQVIA Holdings Inc , up 6.3% The top three S&P 500 .PL.INX percentage losers: ** International Business Machines Corp , down 6.2% ** Pioneer Natural Resources Co , down 4.8% ** Synchrony Financial , down 4.6% The top three NYSE .PG.N percentage gainers: ** Sos Ltd , up 18.8% ** Natuzzi Spa , up 17.5% ** Plantronics Inc , up 13.9% The top three NYSE .PL.N percentage losers: ** AMC Entertainment Holdings Inc , down 13.1% ** VolitionRx Ltd , down 8.2% ** Navios Maritime Holdings Inc , down 10.7% The top three Nasdaq .PG.O percentage gainers: ** Cleveland BioLabs Inc , up 89.7% ** Aptinyx Inc , up 47% ** Pioneer Power Solutions Inc , up 27.4% The top three Nasdaq .PL.O percentage losers: ** Kaixin Auto Holdings , down 29.6% ** Greenland Technologies Holding Corp , down 15.8% ** Atlas Technical Consultants Inc , down 16.3% ** Emcore Corp EMKR.O: up 5.7% BUZZ-Soars as it expects Q4 rev to exceed estimates ** BancorpSouth BXS.N: up 6.3% BUZZ-Rises as Q3 profit tops estimates ** Aptinyx APTX.O: up 47.0% BUZZ-Surges on positive results from PTSD therapy study ** Acorda ACOR.O: up 50.7% BUZZ-Jumps as co entitled to milestone payment from Biogen International ** Crown Holdings CCK.N: up 8.1% BUZZ-Rises on higher annual earnings forecast ** Hexcel HXL.N: down 3.9% BUZZ-Down on surprise quarterly loss as COVID-19 hits demand ** Travelers TRV.N: up 3.8% BUZZ-Rises on Q3 profit beat ** Procter & Gamble PG.N: up 2.4% BUZZ-Up on forecast bump on detergents, cleaning supplies demand ** Cleveland BioLabs CBLI.O: up 89.7% BUZZ-Rises on merger agreement with Cytocom Inc ** Cara Therapeutics CARA.O: up 2.6% BUZZ-Up on license agreement for kidney disease vaccine ** Centogene CNTG.O: up 3.5% BUZZ-Gains on raising full-year revenue outlook, CEO change ** General Motors GM.N: up 4.6% BUZZ-Rises on EV investment plans in U.S.; Citi hikes PT ** Isoray Inc ISR.N: down 20.4% BUZZ-Drops on planned stock-and-warrants offering ** UBS UBS.N: up 6.0% BUZZ-U.S.-listed shares up on solid Q3 profit beat, buyback hopes ** IQVIA IQV.N: up 6.3% BUZZ-Gains on Q3 profit beat, full-year profit forecast raise ** Rayonier Advanced Materials RYAM.N: up 2.2% BUZZ-RBC sees Q3 boost from Forest Products unit, upgrades ** Flour FLR.N: up 2.2% BUZZ-Up on 5-year pipeline maintenance contract in Peru ** AMC Entertainment AMC.N: down 13.1% BUZZ-Falls after filing to sell up to 15 mln shares ** Synchrony Financial SYF.N: down 4.6% BUZZ-Slips on dismal Q3 ** Amphenol Corp APH.N: up 1.9% ** TE Connectivity TEL.N: up 1.6% ** Sensata ST.N: up 2.6% BUZZ-Tech hardware cos: JPM raises PTs on upside from end market recovery ** Albertsons ACI.N: up 5.6% BUZZ-Eyes 2-month high after forecast beat ** Dave & Buster's PLAY.O: up 3.9% BUZZ-Gains after BMO upgrades to 'outperform' ** Purple Innovation Inc PRPL.O: up 4.2% BUZZ-Gains after Craig-Hallum raises PT ** Kohl's Corp KSS.N: up 6.9% BUZZ-Jumps on active wear push, new athleisure brand ** DraftKings DKNG.O: down 3.4% BUZZ-Drops as lock-up period ends The 11 major S&P 500 sectors: Communication Services .N At 10:54 ET, the Dow Jones Industrial Average .DJI was up 0.77% at 28,412.69. up 0.25% Consumer Discretionary | Acorda Therapeutics Inc. (ACOR) is up over 140% at $1.67 in pre-market trading Tuesday, on news that the company has become entitled to receive a $15 million milestone payment from Biogen International GmbH . The payment is expected to be made to Acorda by the end of October 2020. Acorda will retain roughly $14 million of milestone payment net of its payment obligations to another party. | The top three S&P 500 .PG.INX percentage gainers: ** Regions Financial Corp , up 6 % ** IQVIA Holdings Inc , up 5.4 % ** General Motors , up 5.1 % The top three S&P 500 .PL.INX percentage losers: ** International Business Machines Corp , down 6.5 % ** Pioneer Natural Resources Co , down 5.1 % ** Synchrony Financial , down 3.9 % The top NYSE .PG.N percentage gainers: ** Resolute Forest Production Inc , up 8.5 % ** Crown Holdings Inc , up 8.3 % The top three NYSE .PL.N percentage losers: ** AMC Entertainment Holdings Inc , down 9.2 % ** Aurora Cannabis Inc , down 7.2 % ** International Business Machines Corp , down 6.5 % The top three Nasdaq .PG.O percentage gainers: ** Cleveland BioLabs Inc , up 81.2 % ** Aptinyx Inc , up 55.2 % ** Aurora Mobile Ltd , up 17.6 % The top three Nasdaq .PL.O percentage losers: ** Kaixin Auto Holdings , down 28.8 % ** Atlas Technical Consultants Inc , down 19 % ** Greenland Technologies Holding Corp , down 16.5 % ** Emcore Corp EMKR.O: up 11.5% BUZZ-Emcore Corp: Soars as it expects Q4 rev to exceed estimates ** BancorpSouth BXS.N: up 4.8% BUZZ-BancorpSouth rises as Q3 profit tops estimates ** Aptinyx APTX.O: up 55.2% BUZZ-Aptinyx: Surges on positive results from PTSD therapy study ** Acorda ACOR.O: up 73.9% BUZZ-Acorda jumps as co entitled to milestone payment from Biogen International ** Crown Holdings CCK.N: up 8.3% BUZZ-Crown Holdings: Rises on higher annual earnings forecast ** Hexcel HXL.N: down 6.1% BUZZ-Hexcel: Down on surprise quarterly loss as COVID-19 hits demand ** Travelers TRV.N: up 3.4% BUZZ-Travelers Companies Inc: Rises on Q3 profit beat ** Procter & Gamble PG.N: up 2.0% BUZZ-P&G: Up on forecast bump on detergents, cleaning supplies demand ** Cleveland BioLabs CBLI.O: up 81.2% BUZZ-Cleveland BioLabs rises on merger agreement with Cytocom Inc ** Parsley Energy PE.N: up 2.7% BUZZ-Parsley Energy: Rises on report of Pioneer Natural Resources in takeover talks ** Cara Therapeutics CARA.O: up 5.1% BUZZ-Cara Therapeutics: Up on license agreement for kidney disease vaccine ** Centogene CNTG.O: up 5.1% BUZZ-Centogene: Gains on raising full-year revenue outlook, CEO change ** General Motors GM.N: up 5.1% BUZZ-General Motors: Rises on EV investment plans in U.S.; Citi hikes PT ** Isoray Inc ISR.N: down 25.9% BUZZ-Isoray drops on planned stock-and-warrants offering ** Workday WDAY.O: up 1.2% BUZZ-Workday: Piper Sandler sees potential catalysts, upgrades to 'overweight' ** UBS UBS.N: up 6.6% BUZZ-UBS: U.S.-listed shares up on solid Q3 profit beat, buyback hopes ** IQVIA IQV.N: up 5.4% BUZZ-IQVIA: Gains on Q3 profit beat, full-year profit forecast raise ** Rayonier Advanced Materials RYAM.N: up 6.1% REFILE-BUZZ-Rayonier Advanced Materials: RBC sees Q3 boost from Forest Products unit, upgrades ** Flour FLR.N: up 2.5% BUZZ-Flour: Up on 5-year pipeline maintenance contract in Peru ** AMC Entertainment AMC.N: down 9.2% BUZZ-AMC falls after filing to sell up to 15 mln shares ** Synchrony Financial SYF.N: down 3.9% BUZZ-Synchrony Financial slips on dismal Q3 ** Amphenol Corp APH.N: up 1.1% ** TE Connectivity TEL.N: up 1.8% ** Sensata ST.N: up 2.7% BUZZ-Tech hardware cos: JPM raises PTs on upside from end market recovery ** Albertsons ACI.N: up 6.3% BUZZ-Albertsons: Eyes 2-month high after forecast beat The 11 major S&P 500 sectors: Communication Services ET, the Dow Jones Industrial Average .DJI was up 0.65% at 28,378.18. up 0.45% Consumer Discretionary | The top three NYSE percentage gainers premarket .PRPG.NQ: ** Parsley Energy Inc , up 13.9% ** Montage Resources Corp , up 9.7% ** Hertz Global Holdings Inc , up 7.8% The top three NYSE percentage losers premarket .PRPL.NQ: ** Hexcel Corp , down 9.2% ** Sasol Ltd , down 6.3% ** Enzo Biochem Inc , down 4.8% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Acorda Therapeutics Inc , up 101.4% ** Aptinyx Inc , up 56.3% ** Iterum Therapeutics Plc , up 43.5% The top three Nasdaq percentage losers premarket .PRPL.O: ** Globus Maritime Ltd , down 26.1% ** Kaixin Auto Holdings , down 21.5% ** Dragon Victory International Ltd , down 21.3% ** Emcore Corp EMKR.O: up 11.2% premarket BUZZ-Emcore Corp: Soars as it expects Q4 rev to exceed estimates ** Aptinyx APTX.O: up 56.3% premarket BUZZ-Aptinyx: Surges on positive results from PTSD therapy study ** Acorda ACOR.O: up 101.4% premarket BUZZ-Acorda jumps as co entitled to milestone payment from Biogen International ** Hexcel HXL.N: down 9.2% premarket BUZZ-Hexcel: Down on surprise quarterly loss as COVID-19 hits demand ** IBM IBM.N: down 2.9% premarket BUZZ-IBM shares fall after quarterly results ** Moderna MRNA.O: up 4.1% premarket BUZZ-Moderna: Up on emergency use approval likelihood for COVID-19 vaccine in Dec ** Cleveland BioLabs CBLI.O: up 27.2% premarket BUZZ-Cleveland BioLabs rises on merger agreement with Cytocom Inc (Compiled by Tiyashi Datta) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stock index futures rose on Tuesday on expectations that Washington lawmakers would be able to settle their differences for an economic stimulus bill to pass before the Nov. 3 presidential elections. S&P 500 e-minis ESc1 were up 0.77% at 3,449.25, while Nasdaq 100 e-minis NQc1 were up 0.80% at 11,743.5."
2020-10-19,81.5999984741211,82.80000305175781,-21.311474213791893,,
2020-10-16,84.0,80.4000015258789,1.4705938726424026,,
2020-10-15,84.0,82.80000305175781,-4.285712469191778,,
2020-10-14,84.0,84.0,-1.4285677955264138,,
2020-10-13,85.19999694824219,85.19999694824219,0.0,,
2020-10-12,87.5999984741211,85.19999694824219,0.0,,
2020-10-09,78.0,88.80000305175781,-2.7397278169906794,,
2020-10-08,78.0,76.80000305175781,13.846157758663862,,
2020-10-07,81.5999984741211,78.0,-1.5384576259515224,,
2020-10-06,69.5999984741211,76.80000305175781,-4.411762918430457,,
2020-10-05,67.19999694824219,69.5999984741211,10.344834390066616,,
2020-10-02,58.79999923706055,67.19999694824219,3.5714310042713255,,
2020-10-01,60.0,62.400001525878906,14.285710578525446,,
2020-09-30,64.80000305175781,62.400001525878906,4.000002543131511,,
2020-09-29,68.4000015258789,67.19999694824219,-3.7037058840289703,,
2020-09-28,75.5999984741211,72.0,-1.754392618226333,"Pre-market Movers In Healthcare Sector: GNFT, HUGE, ACOR, AQST...","Acorda Therapeutics Inc. (ACOR) is up over 18% at $0.73 in pre-market hours on no news. Aquestive Therapeutics Inc. (AQST) is down over 30% at $5.20 in pre-market hours Monday, following FDA's refusal to approve the company's Libervant Buccal Film for management of seizure clusters. Rockwell Medical Inc. (RMTI), a revenue-generating biopharmaceutical company, is down over 4% at $1.02 in pre-market hours today, on no news."
2020-09-25,57.59999847412109,74.4000015258789,-4.761902839658683,,
2020-09-24,57.59999847412109,56.400001525878906,29.16667273751029,,
2020-09-23,66.0,58.79999923706055,-2.0833280903320217,,
2020-09-22,62.400001525878906,63.59999847412109,-10.909092065059777,,
2020-09-21,68.4000015258789,62.400001525878906,1.9230719854141514,,
2020-09-18,72.0,64.80000305175781,-8.771929628875696,,
2020-09-17,66.0,69.5999984741211,-9.999995761447483,,
2020-09-16,62.400001525878906,66.0,5.454543142607718,,
2020-09-15,54.0,61.20000076293945,5.76922818283599,,
2020-09-14,54.0,54.0,13.333334746184173,,
2020-09-11,55.20000076293945,54.0,0.0,,
2020-09-10,55.20000076293945,56.400001525878906,-2.1739143955684828,,
2020-09-09,56.400001525878906,55.20000076293945,2.1739143955684828,,
2020-09-08,56.400001525878906,57.59999847412109,-2.1276608696346186,,
2020-09-04,57.59999847412109,57.59999847412109,2.1276541059871543,"BUZZ-U.S. STOCKS ON THE MOVE-I-Mab, AnPac Bio-Medical Science, DPW Holdings","The top three NYSE percentage gainers premarket .PRPG.NQ: ** Kensington Capital Acquisition Corp , up 16.9% ** Clearwater Paper Corp , up 15.0% ** Permianville Royalty Trust , up 11.1% The top three NYSE percentage losers premarket .PRPL.NQ: ** Tortoise Acquisition Corp SHLL.N, down 11.3% ** Global Blue Group Holding Ltd GB.N, down 9.7% ** American Realty Investors Inc ARL.N, down 8.1% The top three Nasdaq percentage gainers premarket .PRPG.O: ** I-Mab IMAB.O, up 27.9% ** Addex Therapeutics Ltd , up 27.9% ** Shiloh Industries Inc , up 15.5% The top three Nasdaq percentage losers premarket .PRPL.O: ** Savara Inc SVRA.O, down 13.7% ** Priority Technology Holdings Inc , down 11.7% ** Acorda Therapeutics Inc , down 10.3% ** Plug Power Inc PLUG.O: up 3.8% premarket BUZZ-Shares up after D.E. S&P 500 e-minis ESc1 were down 0.13% at 3,457, while Nasdaq 100 e-minis NQc1 were down 1.24% at 11,654. Shaw discloses passive stake ** BioNTech SE BNTX.O: up 0.5% premarket BUZZ-Up as co to begin human trial for fifth COVID-19 vaccine candidate ** Broadcom Inc AVGO.O: up 0.3% premarket BUZZ-Street View: Broadcom shows 'meaningful' growth ahead of 5G ramp-up cycle ** I-Mab IMAB.O: up 27.9% premarket BUZZ-I-Mab up on licensing deal with Chinese firm's lead cancer drug ** AnPac Bio-Medical Science Co Ltd ANPC.O: up 18.7% premarket BUZZ-Rises on positive data from cancer monitoring technology study ** DPW Holdings Inc DPW.A: UP 40.3% premarket BUZZ-Gains as unit expects orders for EV charger products from Q4 (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2020-09-03,62.400001525878906,62.400001525878906,0.0,,
2020-09-02,63.59999847412109,62.400001525878906,0.0,,
2020-09-01,67.19999694824219,63.59999847412109,-1.886787699736283,"Pre-market Movers In Healthcare Sector: APM, TTOO, BCRX, ZSAN, BNTX...","Acorda Therapeutics Inc. (ACOR) is down over 6% at $0.51 in pre-market hours today. The net loss narrowed to $7.0 million for the six months ended June 30, 2020, compared to $9.6 million for the same period in 2019, thanks to a decline in interest expenses. In the second quarter ended June 30, 2020, the results of which were reported last month, the company generated total revenue of $33.62 million compared to $50 million in the year-ago quarter."
2020-08-31,69.5999984741211,67.19999694824219,-5.357140829773906,,
2020-08-28,62.400001525878906,66.0,-3.448278130022205,,
2020-08-27,63.59999847412109,63.59999847412109,5.76922818283599,,
2020-08-26,62.400001525878906,63.59999847412109,0.0,,
2020-08-25,68.4000015258789,62.400001525878906,1.9230719854141514,,
2020-08-24,74.4000015258789,67.19999694824219,-8.771929628875696,,
2020-08-21,73.19999694824219,73.19999694824219,-9.677425309100709,,
2020-08-20,74.4000015258789,73.19999694824219,0.0,,
2020-08-19,73.19999694824219,74.4000015258789,-1.6129093454646173,,
2020-08-18,75.5999984741211,73.19999694824219,1.639350584242798,,
2020-08-17,80.4000015258789,75.5999984741211,-3.174605257036426,,
2020-08-14,85.19999694824219,80.4000015258789,-5.970152936144911,,
2020-08-13,82.80000305175781,84.0,-5.633797645883969,,
2020-08-12,86.4000015258789,82.80000305175781,1.4492716232052265,,
2020-08-11,86.4000015258789,85.19999694824219,-4.166664827017169,,
2020-08-10,87.5999984741211,88.80000305175781,-1.388894162550782,,
2020-08-07,91.1999969482422,88.80000305175781,1.3698682631726593,,
2020-08-06,84.0,91.1999969482422,-2.631572342975442,,
2020-08-05,88.80000305175781,85.19999694824219,8.571424938383574,,
2020-08-04,81.5999984741211,76.80000305175781,-4.054060788058004,,
2020-08-03,74.4000015258789,76.80000305175781,-5.882347441324486,,
2020-07-31,76.80000305175781,75.5999984741211,3.2258084363669033,,
2020-07-30,80.4000015258789,75.5999984741211,-1.5625058983760716,,
2020-07-29,86.4000015258789,80.4000015258789,-5.970152936144911,,
2020-07-28,90.0,86.4000015258789,-6.944444321801145,,
2020-07-27,93.5999984741211,90.0,-3.999998304578993,,
2020-07-24,94.8000030517578,91.1999969482422,-3.846152278641795,,
2020-07-23,106.8000030517578,96.0,-3.7974746704914213,,
2020-07-22,100.8000030517578,102.0,-10.112362119057115,,
2020-07-21,88.80000305175781,98.4000015258789,1.190473126896672,,
2020-07-20,88.80000305175781,87.5999984741211,10.810808720947515,,
2020-07-17,87.5999984741211,88.80000305175781,-1.3513564599060726,,
2020-07-16,87.5999984741211,88.80000305175781,1.3698682631726593,,
2020-07-15,96.0,91.1999969482422,1.3698682631726593,"Pre-market Movers In Healthcare Sector: IMMP, ACOR, CLSN, MRNA, ECOR...","Acorda Therapeutics Inc. (ACOR) is up over 34% at $0.94 in pre-market trading today on news of receipt of a U.S. income tax refund from the Internal Revenue Service of about $12.7 million, including interest, pursuant to the Coronavirus Aid, Relief, and Economic Security Act (""CARES Act""). The Company's lead drug candidate is Sci-B-Vac, a tri-antigenic Prophylactic Hepatitis B (HBV) Vaccine, for which positive topline results were reported from a second pivotal Phase 3 study, dubbed CONSTANT, in January of this year. The Company announced promising results from a phase Ib clinical trial of XPro1595 in Alzheimer's disease yesterday, sending its stock up as much as 175% to touch a new high of $24.42 in intraday trading."
2020-07-14,84.0,84.0,-5.000003178914373,,
2020-07-13,88.80000305175781,84.0,0.0,,
2020-07-10,86.4000015258789,88.80000305175781,-5.405408656303864,,
2020-07-09,86.4000015258789,86.4000015258789,2.777779494783976,,
2020-07-08,86.4000015258789,85.19999694824219,0.0,,
2020-07-07,88.80000305175781,85.19999694824219,-1.388894162550782,,
2020-07-06,86.4000015258789,88.80000305175781,-4.054060788058004,,
2020-07-02,0.7269999980926514,0.7337999939918518,2.777779494783976,,
2020-07-01,88.80000305175781,86.4000015258789,0.9353501949162075,,
2020-06-30,90.0,87.5999984741211,-2.702704328151932,,
2020-06-29,90.0,88.80000305175781,-2.6666683620876737,,
2020-06-26,86.4000015258789,90.0,-1.3333299424913194,,
2020-06-25,90.0,88.80000305175781,4.166664827017169,,
2020-06-24,96.0,90.0,-1.3333299424913194,,
2020-06-23,98.4000015258789,97.1999969482422,-6.25,,
2020-06-22,100.8000030517578,98.4000015258789,-1.2195168282808482,,
2020-06-19,104.4000015258789,100.8000030517578,-2.380953822636853,,
2020-06-18,100.8000030517578,103.1999969482422,-3.4482743501002076,,
2020-06-17,102.0,100.8000030517578,2.380946253793344,,
2020-06-16,108.0,102.0,-1.176467596315884,,
2020-06-15,100.8000030517578,102.0,-5.555555555555555,,
2020-06-12,110.4000015258789,103.1999969482422,1.190473126896672,,
2020-06-11,102.0,103.1999969482422,-6.521743186705435,,
2020-06-10,123.5999984741211,112.8000030517578,1.176467596315884,,
2020-06-09,120.0,116.4000015258789,-8.737860481951833,,
2020-06-08,92.4000015258789,128.39999389648438,-2.9999987284342446,,
2020-06-05,92.4000015258789,91.1999969482422,38.961030060722216,,
2020-06-04,91.1999969482422,90.0,-1.2987062314069482,,
2020-06-03,93.5999984741211,91.1999969482422,-1.315786171487729,,
2020-06-02,93.5999984741211,92.4000015258789,-2.5641042361154036,,
2020-06-01,91.1999969482422,92.4000015258789,-1.2820480425263763,,
2020-05-29,92.4000015258789,90.0,1.3157945370521567,,
2020-05-28,93.5999984741211,92.4000015258789,-2.597404205893575,,
2020-05-27,93.5999984741211,94.8000030517578,-1.2820480425263763,,
2020-05-26,93.5999984741211,93.5999984741211,1.2820561935890273,,
2020-05-22,90.0,91.1999969482422,0.0,,
2020-05-21,91.1999969482422,90.0,1.3333299424913352,,
2020-05-20,96.0,90.0,-1.315786171487729,,
2020-05-19,102.0,94.8000030517578,-6.25,,
2020-05-18,98.4000015258789,99.5999984741211,-7.058820537492355,,
2020-05-15,91.1999969482422,93.5999984741211,1.2195090748312558,,
2020-05-14,94.8000030517578,92.4000015258789,2.6315807085398704,,
2020-05-13,96.0,94.8000030517578,-2.53164709769953,,
2020-05-12,91.1999969482422,94.8000030517578,-1.249996821085627,,
2020-05-11,94.8000030517578,88.80000305175781,3.947375245592027,,
2020-05-08,98.4000015258789,94.8000030517578,-6.329113720306713,,
2020-05-07,102.0,96.0,-3.658534977943389,,
2020-05-06,104.4000015258789,103.1999969482422,-5.88235294117647,Salesforce.com To Replace Allergan In S&P100,"S&P MidCap 400 constituent Domino's Pizza Inc. (DPZ) will replace Capri Holdings Ltd. (CPRI) in the S&P 500, STORE Capital Corp. (STOR) will replace Domino's Pizza in the S&P MidCap 400, and Capri Holdings will replace Acorda Therapeutics Inc. (ACOR) in the S&P SmallCap 600. (RTTNews) - S&P Dow Jones Indices said that S&P 500 constituent Salesforce.com (CRM) will replace Allergan in the S&P 100. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2020-05-05,110.4000015258789,112.8000030517578,-1.1494296552660919,,
2020-05-04,111.5999984741211,108.0,2.17391439556847,,
2020-05-01,115.1999969482422,106.8000030517578,-3.225805128443525,,
2020-04-30,123.5999984741211,115.1999969482422,-7.29166156163911,,
2020-04-29,124.8000030517578,124.8000030517578,-6.79611782328432,,
2020-04-28,132.0,120.0,0.0,,
2020-04-27,129.60000610351562,126.0,-9.090909090909092,,
2020-04-24,130.8000030517578,123.5999984741211,-2.777782356460837,,
2020-04-23,130.8000030517578,128.39999389648438,-5.504590527255311,,
2020-04-22,138.0,130.8000030517578,-1.8348693419554043,,
2020-04-21,144.0,134.39999389648438,-5.217389092929121,,
2020-04-20,127.1999969482422,144.0,-6.666670905219184,,
2020-04-17,132.0,127.1999969482422,13.20754988586496,,
2020-04-16,129.60000610351562,127.1999969482422,-3.6363659483013624,,
2020-04-15,135.60000610351562,127.1999969482422,-1.851858828892693,,
2020-04-14,134.39999389648438,136.8000030517578,-6.194696738332699,,
2020-04-13,128.39999389648438,129.60000610351562,1.7857211787687566,,
2020-04-09,120.0,128.39999389648438,0.9345889907118654,,
2020-04-08,111.5999984741211,117.5999984741211,6.999994913736979,,
2020-04-07,114.0,111.5999984741211,5.376344159530915,,
2020-04-06,110.4000015258789,111.5999984741211,-2.1052644963850056,,
2020-04-03,100.8000030517578,104.4000015258789,1.086953742442563,,
2020-04-02,99.5999984741211,102.0,3.571426949533539,,
2020-04-01,0.9200000166893004,0.800000011920929,2.409640123139655,,
2020-03-31,1.0399999618530271,0.9300000071525574,-13.043478542555018,,
2020-03-30,1.059999942779541,0.9800000190734864,-10.576919109158098,,
2020-03-27,1.090000033378601,1.0399999618530271,-7.547163021186405,,
2020-03-26,1.0299999713897705,1.1100000143051147,-4.587162384811314,,
2020-03-25,0.9100000262260436,0.9900000095367432,7.766994673543616,,
2020-03-24,0.9200000166893004,0.8999999761581421,8.791206703858666,,
2020-03-23,0.949999988079071,0.8700000047683716,-2.1739174096029052,,
2020-03-20,0.8700000047683716,0.9700000286102296,-8.421050980480734,,
2020-03-19,0.7699999809265137,0.8500000238418579,11.494255551007955,,
2020-03-18,0.75,0.7799999713897705,10.389616220390424,,
2020-03-17,0.800000011920929,0.800000011920929,3.9999961853027344,,
2020-03-16,0.800000011920929,0.800000011920929,0.0,,
2020-03-13,0.9100000262260436,0.8700000047683716,0.0,,
2020-03-12,0.949999988079071,0.8500000238418579,-4.395606626909703,,
2020-03-11,1.0700000524520874,1.0099999904632568,-10.526312157057612,,
2020-03-10,1.0800000429153442,1.0700000524520874,-5.607482153980293,,
2020-03-09,1.090000033378601,1.0399999618530271,-0.9259250061011975,,
2020-03-06,1.1200000047683716,1.1699999570846558,-4.587162384811314,,
2020-03-05,1.2300000190734863,1.159999966621399,4.464281437804522,,
2020-03-04,1.2300000190734863,1.2599999904632568,-5.691061086715743,,
2020-03-03,1.3799999952316284,1.2300000190734863,2.439022026387315,,
2020-03-02,1.4500000476837158,1.3600000143051147,-10.869563527278498,,
2020-02-28,1.2699999809265137,1.440000057220459,-6.20689864958077,,
2020-02-27,1.2999999523162842,1.3300000429153442,13.385832980085855,,
2020-02-26,1.3799999952316284,1.3200000524520874,2.307699361496682,,
2020-02-25,1.399999976158142,1.3700000047683716,-4.347821955569661,,
2020-02-24,1.5099999904632568,1.3799999952316284,-2.1428551357619274,,
2020-02-21,1.600000023841858,1.5199999809265137,-8.609271261766391,,
2020-02-20,1.7300000190734863,1.5700000524520874,-5.000002607703171,,
2020-02-19,1.649999976158142,1.7100000381469729,-9.248552881929333,,
2020-02-18,1.7699999809265137,1.6200000047683716,3.6363674458065667,,
2020-02-14,1.9299999475479128,1.7899999618530271,-8.474575015510679,,
2020-02-13,2.0799999237060547,1.919999957084656,-7.253885466305701,,
2020-02-12,2.049999952316284,2.009999990463257,-7.692306369719361,,
2020-02-11,2.039999961853028,1.9800000190734863,-1.9512176967531925,,
2020-02-10,2.039999961853028,2.009999990463257,-2.941173720662264,,
2020-02-07,2.059999942779541,2.0199999809265137,-1.4705868603311427,,
2020-02-06,2.1600000858306885,2.0899999141693115,-1.9417457749564655,,
2020-02-05,2.0799999237060547,2.1600000858306885,-3.2407485592509335,,
2020-02-04,2.0299999713897705,2.059999942779541,3.846161781683767,,
2020-02-03,2.039999961853028,2.0299999713897705,1.477831123772482,,
2020-01-31,2.0899999141693115,2.0299999713897705,-0.49019562011039547,,
2020-01-30,2.119999885559082,2.119999885559082,-2.870810777204673,,
2020-01-29,2.119999885559082,2.150000095367432,0.0,,
2020-01-28,2.259999990463257,2.109999895095825,1.4151043126324725,,
2020-01-27,2.119999885559082,2.180000066757202,-6.637172389398306,,
2020-01-24,2.4200000762939453,2.0999999046325684,2.830197379104905,,
2020-01-23,2.059999942779541,2.369999885559082,-13.223147172434558,,
2020-01-22,2.009999990463257,2.069999933242798,15.04854132963036,,
2020-01-21,2.0799999237060547,2.0299999713897705,2.9850717942397833,,
2020-01-17,2.180000066757202,2.069999933242798,-2.4038439495322868,,
2020-01-16,2.049999952316284,2.150000095367432,-5.04587752962925,,
2020-01-15,2.200000047683716,2.130000114440918,4.878055872057863,,
2020-01-14,2.4800000190734863,2.3399999141693115,-3.1818150784359176,,
2020-01-13,2.4200000762939453,2.4200000762939453,-5.645165476913102,,
2020-01-10,2.299999952316284,2.359999895095825,0.0,,
2020-01-09,2.2799999713897705,2.2799999713897705,2.6086932184114295,,
2020-01-08,2.380000114440918,2.259999990463257,0.0,,
2020-01-07,2.5899999141693115,2.440000057220459,-5.042021773425426,,
2020-01-06,2.220000028610229,2.4800000190734863,-5.791500460221516,,
2020-01-03,2.220000028610229,2.2699999809265137,11.71171113119414,,
2020-01-02,2.0899999141693115,1.9600000381469729,2.2522500753112937,,
2019-12-31,2.200000047683716,2.039999961853028,-6.220090017276781,,
2019-12-30,2.539999961853028,2.190000057220459,-7.272731016489983,,
2019-12-27,2.6600000858306885,2.619999885559082,-13.779524011379527,,
2019-12-26,1.9600000381469729,2.75,-1.5037668789816911,"Health Care Sector Update for 12/26/2019: HEXO,HEXO.TO,AGE,ACOR,SPPI | Health Care Sector Update for 12/26/2019: AGE,ACOR,SPPI","In other sector news: (+) Acorda Therapeutics (ACOR) raced almost 44% higher after the specialty drugmaker said it has completed the private exchange of $276 million of its 1.75% convertible senior notes maturing June 2021 for about $207 million of newly issued 6% convertible senior secured notes due 2024 and $55.2 million in cash. The new notes have an initial conversion price of about $3.50 per share, representing a 97% premium over the closing price for Acordia shares on Dec. 20. Health care stocks extended their Thursday declines, with the NYSE Health Care Index slipping over 0.3% while the shares of health care companies in the S&P 500 also were down almost 0.3% as a group. | In other sector news: (+) Acorda Therapeutics (ACOR) raced more than 34% higher after the specialty drugmaker said it has completed the private exchange of $276 million of its 1.75% convertible senior notes maturing June 2021 for about $207 million of newly issued 6% convertible senior secured notes due 2024 and $55.2 million in cash. The new notes have an initial conversion price of about $3.50 per share, representing a 97% premium over the closing price for Acordia shares on Dec. 20. Health care stocks turned narrowly lower in Thursday trading, with the NYSE Health Care Index slipping more than 0.1% while the shares of health care companies in the S&P 500 were down almost 0.2% as a group."
2019-12-24,1.7999999523162842,1.919999957084656,40.30611971823789,,
2019-12-23,1.75,1.7799999713897705,6.666667108182578,"Health Care Sector Update for 12/23/2019: ACB,ACB.TO,SRPT,ACOR","(-) Acorda Therapeutics (ACOR) declined over 1% after the specialty drugmaker disclosed plans to swap $276 million of its 1.75% convertible notes due 2021 for a combination of newly issued 6% convertible senior secured notes due 2024 and cash. Health care stocks were edging higher, with the NYSE Health Care Index climbing just over 0.2% in afternoon trade while the shares of health care companies in the S&P 500 also were up more than 0.3% as a group. Among health care stocks moving on news: (-) Aurora Cannabis (ACB) fell 8.4% after the Canadian marijuana company earlier Monday said it retired all but $3 million of its $230 million in 5% unsecured convertible debentures maturing in March 2020 in exchange for last month issuing an undisclosed amount of stock."
2019-12-20,1.7200000286102295,1.7799999713897705,1.7142840794154575,,
2019-12-19,1.690000057220459,1.7100000381469729,3.4883687082273678,,
2019-12-18,1.7000000476837158,1.6799999475479126,1.1834307839851697,,
2019-12-17,1.6799999475479126,1.7000000476837158,-1.1764764455773846,,
2019-12-16,1.7799999713897705,1.690000057220459,1.1904821881092846,,
2019-12-13,1.850000023841858,1.7599999904632568,-5.056175034600831,,
2019-12-12,1.7699999809265137,1.840000033378601,-4.864866606417649,,
2019-12-11,1.659999966621399,1.7599999904632568,3.9548052658986803,,
2019-12-10,1.7200000286102295,1.690000057220459,6.024097942928766,,
2019-12-09,1.7100000381469729,1.7200000286102295,-1.7441843541136839,,
2019-12-06,1.7000000476837158,1.7100000381469729,0.5847947508874338,,
2019-12-05,1.830000042915344,1.7000000476837158,0.5882347166332287,,
2019-12-04,2.059999942779541,1.830000042915344,-7.103824709453408,,
2019-12-03,1.649999976158142,2.059999942779541,-11.165043992858564,,
2019-12-02,1.6100000143051147,1.6100000143051147,24.848483184590243,,
2019-11-29,1.7300000190734863,1.600000023841858,0.0,,
2019-11-27,1.75,1.75,-7.514450508575765,,
2019-11-26,1.899999976158142,1.75,0.0,,
2019-11-25,1.919999957084656,1.899999976158142,-7.894735686336514,,
2019-11-22,1.7699999809265137,1.8799999952316284,-1.0416656965389746,,
2019-11-21,1.5499999523162842,1.7300000190734863,6.214690140704679,,
2019-11-20,1.559999942779541,1.5199999809265137,11.61290788997859,,
2019-11-19,1.600000023841858,1.5800000429153442,-2.5641002128344392,,
2019-11-18,1.830000042915344,1.6200000047683716,-1.2499987892806712,,
2019-11-15,1.830000042915344,1.809999942779541,-11.475411651489619,,
2019-11-14,1.909999966621399,1.830000042915344,-1.092901621135547,,
2019-11-13,1.9700000286102293,1.9299999475479128,-4.1884777541418945,,
2019-11-12,2.140000104904175,1.9800000190734863,-2.030460938141976,,
2019-11-11,2.3399999141693115,2.190000057220459,-7.476639158288872,,
2019-11-08,2.369999885559082,2.3399999141693115,-6.410250532086098,,
2019-11-07,2.5,2.4100000858306885,-1.2658216387505659,,
2019-11-06,2.400000095367432,2.490000009536743,-3.5999965667724605,,
2019-11-05,1.919999957084656,2.380000114440918,3.7499962747098303,,
2019-11-04,2.059999942779541,2.0,23.95834206448265,,
2019-11-01,1.659999966621399,2.0,-2.9126186624346984,,
2019-10-31,1.7899999618530271,1.649999976158142,20.48193013344475,,
2019-10-30,1.7799999713897705,1.830000042915344,-7.821228417790331,,
2019-10-29,1.9600000381469729,1.7899999618530271,2.808992827484989,,
2019-10-28,1.9800000190734863,1.9800000190734863,-8.673473111493792,,
2019-10-25,2.009999990463257,1.9700000286102293,0.0,,
2019-10-24,2.319999933242798,2.0,-1.9900478628265332,,
2019-10-23,2.4200000762939453,2.7100000381469727,-13.793100967701989,,
2019-10-22,2.4200000762939453,2.4200000762939453,11.983469120263056,,
2019-10-21,2.470000028610229,2.380000114440918,0.0,,
2019-10-18,2.5899999141693115,2.4600000381469727,-3.6437211792240527,,
2019-10-17,2.5899999141693115,2.5799999237060547,-5.019300398858647,,
2019-10-16,2.5899999141693115,2.549999952316284,-0.3861000306814344,,
2019-10-15,2.3499999046325684,2.549999952316284,-1.5444001227257376,,
2019-10-14,2.3499999046325684,2.400000095367432,8.51064067234448,,
2019-10-11,2.6700000762939453,2.4100000858306885,2.1276677771900356,,
2019-10-10,2.869999885559082,2.6700000762939453,-9.737827079920763,,
2019-10-09,2.890000104904175,2.859999895095825,-6.968634747042031,,
2019-10-08,3.0,2.880000114440918,-1.0380695058606009,,
2019-10-07,2.9200000762939453,3.0199999809265137,-3.9999961853027344,,
2019-10-04,2.880000114440918,2.9200000762939453,3.4246541787590608,"Health Care Sector Update for 10/04/2019: SDC,SRPT,ACOR,OVID","(+) Acorda Therapeutics (ACOR) climbed more than 3% after the biopharmaceuticals company said it has secured additional managed care agreements for its Inbrija medication at both the national and regional levels, increasing commercial coverage of the Parkinson's disease drug to about 66% and around Medicare plans. Health care stocks extended their mid-day gains, with the NYSE Health Care Index Friday rising almost 1.3% this afternoon while the shares of health care companies in the S&P 500 also were up nearly 1.5% as a group. Among health care stocks moving on news: (+) Smile Direct Club (SDC) was ahead more than 7% after refuting claims challenging the safety and legitimacy of the company's teledentistry platform by dental trade groups and in a new federal class-action lawsuit filed Thursday in Nashville, arguing the accusations have no factual basis and lack scientific or medical justification."
2019-10-03,2.799999952316284,2.8399999141693115,1.3888875091517963,,
2019-10-02,2.690000057220459,2.759999990463257,1.4285700905079517,,
2019-10-01,2.880000114440918,2.7100000381469727,2.6022279462375866,,
2019-09-30,2.990000009536743,2.869999885559082,-5.90278019231769,,
2019-09-27,2.9800000190734863,3.0,-4.013382060030608,,
2019-09-26,3.0999999046325684,3.0,0.671140295251806,,
2019-09-25,3.200000047683716,3.119999885559082,-3.225803474481751,,
2019-09-24,3.569999933242798,3.2100000381469727,-2.5000050291418283,,
2019-09-23,3.450000047683716,3.5799999237060547,-10.084030863519386,,
2019-09-20,3.390000104904175,3.490000009536743,3.768112296393128,,
2019-09-19,3.559999942779541,3.390000104904175,2.949849602892418,,
2019-09-18,3.359999895095825,3.549999952316284,-4.775276421567452,,
2019-09-17,3.5799999237060547,3.390000104904175,5.654763784301854,,
2019-09-16,3.869999885559082,3.569999933242798,-5.307257621536205,,
2019-09-13,3.859999895095825,3.859999895095825,-7.751936981593592,,
2019-09-12,4.010000228881836,3.849999904632568,0.0,,
2019-09-11,4.019999980926514,4.010000228881836,-3.9900327959303663,,
2019-09-10,3.150000095367432,4.0,-0.24875005204286174,"5 Top Gainers In Healthcare Sector (MNK, ENDP, MLNT...)","Acorda Therapeutics Inc. (ACOR) Acorda Therapeutics is a biopharmaceutical company marketing two approved products namely Parkinson's therapy INBRIJA and AMPYRA, a treatment for walking impairment in multiple sclerosis. As part of the settlement, Endo will pay a total sum of $10 million and will provide up to $1 million of its Vasostrict and Adrenalin products free of charge, to be initially allocated by and between the two plaintiff counties as follows: Cuyahoga County will receive $6.2 million in cash and up to $620,000 of Vasostrict and/or Adrenalin, and Summit County will receive $3.8 million in cash and up to $380,000 of Vasostrict and/or Adrenalin. News: No news Clinical Trials & Near-term Catalysts: -- In July of this year, Akebia's collaboration partner, Japan Tobacco, Inc. and its subsidiary Torii Pharmaceutical Co., Ltd., reported positive top-line results from their pivotal Phase 3 comparative study evaluating Riona Tablets for the treatment of iron deficiency anemia (IDA) in adult patients in Japan."
2019-09-09,2.819999933242798,3.150000095367432,26.984123139635003,,
2019-09-06,2.8299999237060547,2.799999952316284,11.702133685696854,,
2019-09-05,2.940000057220459,2.8299999237060547,-1.0600696889943286,,
2019-09-04,3.0,2.9200000762939453,-3.7415010671258573,,
2019-09-03,3.2100000381469727,2.940000057220459,-2.6666641235351562,,
2019-08-30,3.4200000762939453,3.2300000190734863,-8.411214259124302,,
2019-08-29,3.670000076293945,3.4200000762939453,-5.555557104734072,,
2019-08-28,3.3499999046325684,3.619999885559082,-6.811988959206115,,
2019-08-27,3.3499999046325684,3.380000114440918,8.0597011526222,,
2019-08-26,3.1600000858306885,3.3299999237060547,0.8955286764893227,,
2019-08-23,3.1700000762939453,3.119999885559082,5.379741558794208,,
2019-08-22,3.130000114440918,3.180000066757202,-1.5772930451572298,,
2019-08-21,3.2799999713897705,3.140000104904175,1.5974425076088279,,
2019-08-20,2.930000066757202,3.220000028610229,-4.268288649596429,,
2019-08-19,2.759999990463257,2.930000066757202,9.897609394049823,,
2019-08-16,2.609999895095825,2.700000047683716,6.159423075411365,,
2019-08-15,2.509999990463257,2.619999885559082,3.44828184694568,,
2019-08-14,2.5999999046325684,2.390000104904175,4.382465956723893,,
2019-08-13,2.8399999141693115,2.7300000190734863,-8.076915670428484,,
2019-08-12,2.890000104904175,2.8299999237060547,-3.873235859867965,,
2019-08-09,2.950000047683716,2.9200000762939453,-2.076130761943677,,
2019-08-08,3.109999895095825,2.950000047683716,-1.016948166266164,,
2019-08-07,2.950000047683716,3.039999961853028,-5.144689800935812,,
2019-08-06,3.0,3.009999990463257,3.0508444987985066,,
2019-08-05,3.119999885559082,2.9200000762939453,0.33333301544189453,,
2019-08-02,5.5,3.0999999046325684,-6.410250532086098,Acorda Therapeutics (ACOR) Q2 2019 Earnings Call Transcript,"Operator [Operator signoff] Duration: 46 minutes Call participants: Felicia Vonella -- Vice President of Investor Relations Ron Cohen -- Chief Executive Officer Lauren Sabella -- Chief Commercial Officer Matthew Holt -- J.P. Morgan -- Analyst Paul Matteis -- Stifel Financial Corp. -- Analyst Salveen Richter -- Goldman Sachs -- Analyst Phil Nadeau -- Cowen and Company -- Analyst Michael Yee -- Jefferies -- Analyst Charles Duncan -- Cantor Fitzgerald and Company-- Analyst Edward White -- Wainwright and Company -- Analyst David Lawrence -- Chief, Business Operations and Principal Accounting Officer Matthew Biegler -- Oppenheimer and Company -- Analyst More ACOR analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Acorda Therapeutics (NASDAQ: ACOR) Q2 2019 Earnings Call Aug 01, 2019, 4:30 p.m. Operator Welcome to the Acorda Therapeutics' second-quarter 2019 update."
2019-08-01,6.889999866485596,6.070000171661377,-43.63636537031694,,
2019-07-31,7.03000020980835,6.929999828338623,-11.901302042295663,,
2019-07-30,6.809999942779541,7.010000228881836,-1.4224804905440074,,
2019-07-29,6.789999961853027,6.860000133514404,2.936861788293403,,
2019-07-26,6.869999885559082,6.78000020980835,1.0309303689933091,,
2019-07-25,6.820000171661377,6.789999961853027,-1.310038970159433,,
2019-07-24,6.760000228881836,6.820000171661377,-0.4398857632439245,,
2019-07-23,6.579999923706055,6.760000228881836,0.8875730879888675,,
2019-07-22,6.889999866485596,6.579999923706055,2.7355669796786204,,
2019-07-19,6.889999866485596,6.900000095367432,-4.4992735672963615,,
2019-07-18,6.900000095367432,6.889999866485596,0.14514120574194997,,
2019-07-17,6.889999866485596,6.900000095367432,-0.14493085135679867,,
2019-07-16,6.550000190734863,6.880000114440918,0.14514120574194997,,
2019-07-15,6.590000152587891,6.559999942779541,5.038166627427701,,
2019-07-12,6.949999809265137,6.619999885559082,-0.4552383780532772,,
2019-07-11,7.119999885559082,7.0,-4.748200471403285,,
2019-07-10,6.920000076293945,7.099999904632568,-1.6853916782002771,,
2019-07-09,7.019999980926514,6.849999904632568,2.601153560030352,,
2019-07-08,7.349999904632568,7.079999923706055,-2.421653515040443,,
2019-07-05,7.550000190734863,7.360000133514404,-3.6734691759157396,,
2019-07-03,7.679999828338623,7.550000190734863,-2.5165569857020857,,
2019-07-02,7.670000076293945,7.630000114440918,-1.6927036524671635,,
2019-07-01,7.820000171661377,7.690000057220459,-0.5215118833786878,,
2019-06-28,7.480000019073486,7.670000076293945,-1.6624055190180276,,
2019-06-27,6.929999828338623,7.400000095367432,2.5401077103739556,,
2019-06-26,7.099999904632568,6.929999828338623,6.782110803334391,,
2019-06-25,7.429999828338623,7.059999942779541,-2.3943673039069284,,
2019-06-24,7.539999961853027,7.400000095367432,-4.979810149495191,,
2019-06-21,7.269999980926514,7.489999771118164,-1.8567621643752554,,
2019-06-20,7.579999923706055,7.28000020980835,3.026131922542493,,
2019-06-19,7.699999809265137,7.539999961853027,-3.9577799065600465,,
2019-06-18,7.690000057220459,7.659999847412109,-2.077920147732825,,
2019-06-17,7.550000190734863,7.679999828338623,-0.3901197605347372,,
2019-06-14,7.570000171661377,7.53000020980835,1.7218494611866562,,
2019-06-13,7.159999847412109,7.599999904632568,-0.5284010692994292,,
2019-06-12,7.630000114440918,7.110000133514404,6.145252326778909,,
2019-06-11,7.730000019073486,7.630000114440918,-6.815202793278284,,
2019-06-10,7.730000019073486,7.619999885559082,-1.2936598238786847,,
2019-06-07,7.96999979019165,7.699999809265137,-1.4230288905948651,,
2019-06-06,8.670000076293945,8.020000457763672,-3.3877037394504264,,
2019-06-05,9.31999969482422,8.649999618530273,-7.497112027801971,,
2019-06-04,9.529999732971191,9.25,-7.188842255714083,,
2019-06-03,9.220000267028809,9.390000343322754,-2.9380875216865845,,
2019-05-31,9.239999771118164,9.289999961853027,1.8438185615012859,,
2019-05-30,9.619999885559082,9.380000114440918,0.5411276187598063,,
2019-05-29,9.770000457763672,9.609999656677246,-2.494800145251936,,
2019-05-28,10.220000267028809,9.800000190734863,-1.637674448206214,,
2019-05-24,10.350000381469728,10.15999984741211,-4.10958968023637,,
2019-05-23,10.75,10.279999732971191,-1.8357538845871844,,
2019-05-22,10.880000114440918,10.970000267028809,-4.372095507244731,,
2019-05-21,10.850000381469728,10.93000030517578,0.827207276114219,,
2019-05-20,10.93000030517578,10.760000228881836,0.737326459846764,,
2019-05-17,11.31999969482422,11.020000457763672,-1.5553528961334238,,
2019-05-16,11.350000381469728,11.529999732971191,-2.650170010143336,,
2019-05-15,11.029999732971191,11.279999732971191,1.5858973167554615,,
2019-05-14,10.90999984741211,11.130000114440918,2.2665458390963766,,
2019-05-13,11.1899995803833,10.850000381469728,2.01650110087759,,
2019-05-10,11.479999542236328,11.510000228881836,-3.038420122102687,,
2019-05-09,11.640000343322754,11.619999885559082,0.261330033464998,,
2019-05-08,11.56999969482422,11.75,-0.17182523345151848,,
2019-05-07,11.989999771118164,11.630000114440918,1.5557503018457441,,
2019-05-06,11.510000228881836,12.100000381469728,-3.0024992789776612,,
2019-05-03,10.43000030517578,11.739999771118164,5.125978634712931,,
2019-05-02,10.0,10.579999923706056,12.55991781028339,,
2019-05-01,10.350000381469728,10.050000190734863,5.799999237060565,,
2019-04-30,11.119999885559082,10.449999809265137,-2.898552460654733,,
2019-04-29,11.119999885559082,11.15999984741211,-6.02518060421958,,
2019-04-26,11.149999618530272,11.020000457763672,0.3597118908694688,,
2019-04-25,11.109999656677246,11.18000030517578,-1.1659117956430523,,
2019-04-24,11.369999885559082,11.170000076293944,0.6300688628416126,,
2019-04-23,10.920000076293944,11.329999923706056,-1.7590132918044807,,
2019-04-22,11.0600004196167,10.920000076293944,3.7545773310219586,,
2019-04-18,11.5600004196167,11.140000343322754,-1.2658258409687075,,
2019-04-17,11.989999771118164,11.59000015258789,-3.63321852117953,,
2019-04-16,11.989999771118164,11.93000030517578,-3.3361103099751794,,
2019-04-15,12.260000228881836,11.920000076293944,-0.5004125695390998,,
2019-04-12,12.449999809265137,12.25,-2.773247522352631,,
2019-04-11,12.829999923706056,12.329999923706056,-1.606424195414841,,
2019-04-10,12.5600004196167,12.789999961853027,-3.897116157235102,,
2019-04-09,12.729999542236328,12.510000228881836,1.8312064852888525,,
2019-04-08,13.1899995803833,12.789999961853027,-1.7281957679932805,,
2019-04-05,13.09000015258789,13.270000457763672,-3.0325976592536743,,
2019-04-04,13.140000343322754,13.079999923706056,1.3750978080790566,,
2019-04-03,13.380000114440918,13.0600004196167,-0.4566241860654696,,
2019-04-02,13.470000267028809,13.260000228881836,-2.3916269961675547,,
2019-04-01,13.449999809265137,13.40999984741211,-1.5590202968369662,,
2019-03-29,13.3100004196167,13.289999961853027,-0.297397490113517,,
2019-03-28,13.06999969482422,13.170000076293944,-0.15026639468917347,,
2019-03-27,13.279999732971191,13.039999961853027,0.7651138776179438,,
2019-03-26,13.229999542236328,13.289999961853027,-1.8072272284938358,,
2019-03-25,13.079999923706056,13.130000114440918,0.453517926626905,,
2019-03-22,14.010000228881836,13.130000114440918,0.3822644573891906,,
2019-03-21,13.529999732971191,14.050000190734863,-6.281228408738951,,
2019-03-20,14.359999656677246,13.6899995803833,3.8433146195597123,,
2019-03-19,14.399999618530272,14.350000381469728,-4.665738804404515,,
2019-03-18,14.65999984741211,14.390000343322754,-0.3472169332296584,,
2019-03-15,14.68000030517578,14.630000114440918,-1.8417428847178179,Acorda Therapeutics (ACOR) Gains But Lags Market: What You Should Know,"In the latest trading session, Acorda Therapeutics (ACOR) closed at $14.62, marking a +0.14% move from the previous day. Investors will be hoping for strength from ACOR as it approaches its nex t earnings release. It is also important to note the recent changes to analyst estimates for ACOR."
2019-03-14,14.420000076293944,14.600000381469728,-0.3406007472440771,,
2019-03-13,14.010000228881836,14.470000267028809,1.2482684065425216,,
2019-03-12,13.630000114440918,13.93000030517578,3.283369240770427,,
2019-03-11,13.529999732971191,13.579999923706056,2.2010285268964362,,
2019-03-08,13.6899995803833,13.510000228881836,0.3695505670485701,,
2019-03-07,13.789999961853027,13.859999656677246,-1.31482364513283,,
2019-03-06,14.420000076293944,13.800000190734863,0.5076120015798213,,
2019-03-05,14.640000343322754,14.489999771118164,-4.2995830948596305,,
2019-03-04,15.1899995803833,14.630000114440918,-1.0245940484079599,,
2019-03-01,14.850000381469728,15.079999923706056,-3.6866325306919587,,
2019-02-28,14.25,14.739999771118164,1.5488184264515468,,
2019-02-27,13.970000267028809,14.25,3.4385948850397483,,
2019-02-26,13.420000076293944,14.0,2.0042929679252097,,
2019-02-25,13.140000343322754,13.420000076293944,4.321907007516417,,
2019-02-22,13.18000030517578,12.93000030517578,2.1308959334500686,,
2019-02-21,13.170000076293944,13.380000114440918,-1.8968133096463218,Validea Joseph Piotroski Strategy Daily Upgrade Report - 2/21/2019,"ACORDA THERAPEUTICS INC ( ACOR ) is a small-cap growth stock in the Biotechnology & Drugs industry. Company Description: Acorda Therapeutics, Inc. is a biopharmaceutical company. The following are today's upgrades for Validea's Book/Market Investor model based on the published strategy of Joseph Piotroski ."
2019-02-20,13.65999984741211,13.100000381469728,1.5945333100261356,,
2019-02-19,14.34000015258789,13.609999656677246,-4.099556897494938,,
2019-02-15,15.399999618530272,14.300000190734863,-5.090658913130512,Acorda (ACOR) Q4 Earnings and Revenues Surpass Estimates | Acorda Therapeutics (ACOR) Q4 2018 Earnings Conference Call Transcript,"Quarter in Detail Majority of Acorda's net product revenues were drawn from the company's key multiple sclerosis (MS) drug Ampyra, which raked in sales of $64.2 million in the reported quarter. The company expects full-year R&D and SG&A expenses (excluding share-based compensation) for 2019 in the band of $70-$80 million and $200-$210 million, respectively Acorda Therapeutics, Inc. Price, Consensus and EPS Surprise Acorda Therapeutics, Inc. Price, Consensus and EPS Surprise | Acorda Therapeutics, Inc. Quote Zacks Rank & Other Stocks to Consider Acorda currently carries a Zacks Rank #2 (Buy). Click to get this free report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Sunesis Pharmaceuticals, Inc. (SNSS): Free Stock Analysis Report BioDelivery Sciences International, Inc. (BDSI): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. | Operator [Operator signoff] Duration: 46 minutes Call Participants: Felicia Vonella -- Executive Director of Investor Relations Ron Cohen -- Chief Executive Officer Cory Kasimov -- J.P. Morgan -- Analyst Nate Tower -- Stifel Financial Corp. -- Analyst Sadia Rahman -- Cantor Fitzgerald -- Analyst Phil Nadeau -- Cowen and Company -- Analyst Michael Yee -- Jefferies -- Analyst Salveen Richter -- Goldman Sachs -- Analyst Silvan Tuerkcan -- Oppenheimer -- Analyst Edward Marks -- H.C. Wainwright and Company, LLC -- Analyst More ACOR analysis This article is a transcript of this conference call produced for The Motley Fool. Acorda Therapeutics (NASDAQ: ACOR) Q4 2018 Earnings Conference Call Feb. 14, 2019 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Welcome to the Acorda Therapeutics fourth quarter and year-end 2018 update."
2019-02-14,15.40999984741211,15.5600004196167,-7.142853604176835,Acorda Therapeutics (ACOR) Tops Q4 Earnings and Revenue Estimates,"Acorda Therapeutics (ACOR) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of a loss of $0.60 per share. Acorda, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $69.15 million for the quarter ended December 2018, surpassing the Zacks Consensus Estimate by 70.38%. Acorda shares have lost about 1% since the beginning of the year versus the S&P 500's gain of 9.8%."
2019-02-13,15.350000381469728,15.420000076293944,0.9733976229064033,,
2019-02-12,15.029999732971191,15.34000015258789,0.45602405918320166,,
2019-02-11,15.15999984741211,14.949999809265137,2.062544412004571,,
2019-02-08,15.149999618530272,15.09000015258789,-1.3852245399779524,,
2019-02-07,15.800000190734863,15.170000076293944,-0.3960360887995962,,
2019-02-06,16.239999771118164,15.899999618530272,-3.98734244832701,Array BioPharma (ARRY) Soars: Stock Adds 11% in Session,"Array BioPharma Inc. Price Array BioPharma Inc. Price | Array BioPharma Inc. Quote A better-ranked stock in the Medical - Biomedical and Genetics industry is Acorda Therapeutics, Inc. ACOR , which currently carries a Zacks Rank #1 (Strong Buy). Click to get this free report Array BioPharma Inc. (ARRY): Get Free Report Acorda Therapeutics, Inc. (ACOR): Get Free Report To read this article on Zacks.com click here. With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research."
2019-02-05,16.329999923706055,16.18000030517578,-2.093597028200466,,
2019-02-04,16.579999923706055,16.25,-0.9185524753893041,,
2019-02-01,16.68000030517578,16.579999923706055,-1.9903493680613435,,
2019-01-31,16.75,16.6299991607666,-0.5995226597130012,Is Acorda Therapeutics (ACOR) Stock Outpacing Its Medical Peers This Year?,"Looking more specifically, ACOR belongs to the Medical - Biomedical and Genetics industry, which includes 345 individual stocks and currently sits at #69 in the Zacks Industry Rank. Stocks in this group have gained about 9.22% so far this year, so ACOR is slightly underperforming its industry this group in terms of year-to-date returns. Acorda Therapeutics (ACOR) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole?"
2019-01-30,15.630000114440918,16.469999313354492,-0.7164229207964086,,
2019-01-29,15.270000457763672,15.609999656677246,5.374275065663497,,
2019-01-28,15.68000030517578,15.399999618530272,2.2265827683109833,,
2019-01-25,15.619999885559082,15.949999809265137,-1.7857186300760652,,
2019-01-24,16.040000915527344,15.5600004196167,2.1126755833791293,Vertex Terminates COO Ian Smith on Code of Conduct Violation,"Click to get this free report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report CRISPR Therapeutics AG (CRSP): Free Stock Analysis Report To read this article on Zacks.com click here. Better-ranked stocks in the healthcare sector include Acorda Therapeutics, Inc. ACOR and Aduro Biotech, Inc. ADRO , both sporting a Zacks Rank #1 (Strong Buy). Acorda's loss per share estimates have narrowed 2.1% for 2019 in the last 30 days."
2019-01-23,16.020000457763672,16.010000228881836,-2.992521624147698,,
2019-01-22,16.190000534057617,15.93000030517578,-0.0624233994761816,Vertex's Orkambi Wins EU Nod to Treat Cystic Fibrosis in Kids,"Click to get this free report Vertex Pharmaceuticals Incorporated (VRTX): Get Free Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Genmab A/S (GNMSF): Free Stock Analysis Report To read this article on Zacks.com click here. Better-ranked stocks in the healthcare sector include Genmab A/S GNMSF , Acorda Therapeutics, Inc. ACOR and Aduro Biotech, Inc. ADRO , all sporting a Zacks Rank #1 (Strong Buy). Acorda's loss per share estimates have been narrowed 1.3% for 2019 in the last 60 days."
2019-01-18,16.8700008392334,16.260000228881836,-1.6059309469131633,,
2019-01-17,16.760000228881836,16.889999389648438,-3.6158896265904508,,
2019-01-16,16.540000915527344,16.799999237060547,0.7756513066305287,,
2019-01-15,16.559999465942383,16.56999969482422,1.5719365607115725,Nabriva Therapeutics (NBRV) Jumps: Stock Rises 6.7%,"Nabriva Therapeutics plc Price Nabriva Therapeutics plc Price | Nabriva Therapeutics plc Quote A better-ranked stock in the Medical - Biomedical and Genetics industry may consider Acorda Therapeutics, Inc. ACOR , which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here . Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2019-01-14,16.899999618530273,16.399999618530273,0.06038785751414185,ASLAN's Varlitinib Fails to Meet Endpoint in Phase II Study | Apellis Pharmaceuticals (APLS) in Focus: Stock Moves 7.1% Higher,"Better-ranked stocks in the healthcare sector include Vanda Pharmaceuticals Inc. VNDA and Acorda Therapeutics, Inc. ACOR , both sporting a Zacks Rank #1 (Strong Buy). Acorda's loss per share estimates have been narrowed 1.9% for 2019 in the last 90 days. ASLAN Pharmaceuticals LimitedASLN announced that a phase II study, evaluating its pipeline candidate - varlitinib - for the treatment of first-line gastric cancer, failed to meet the primary endpoint of showing significant reductions in tumor size. | Apellis Pharmaceuticals, Inc. Price Apellis Pharmaceuticals, Inc. Price | Apellis Pharmaceuticals, Inc. Quote Investors interested in the Medical - Biomedical and Genetics industry may consider a better-ranked stock like Acorda Therapeutics, Inc. ACOR , which carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here . Predict to see what others think: Up or Down Today's Stocks from Zacks' Hottest Strategies It's hard to believe, even for us at Zacks."
2019-01-11,17.360000610351562,17.049999237060547,-2.9585799484383837,,
2019-01-10,16.84000015258789,17.469999313354492,-1.785722133593506,Acorda (ACOR) Plans to Launch Inbrija in Q1: What to Expect,"Acorda Therapeutics, Inc. Price and Consensus Acorda Therapeutics, Inc. Price and Consensus | Acorda Therapeutics, Inc. Quote Zacks Rank & Other Stocks to Consider Acorda currently sports a Zacks Rank #1 (Strong Buy). Other top-ranked stocks to look in the healthcare sector include Vanda Pharmaceuticals Inc. VNDA and Inovio Pharmaceuticals, Inc. INO , both sporting the same top Zacks Rank of 1 as Acorda. Click to get this free report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Vanda Pharmaceuticals Inc. (VNDA): Free Stock Analysis Report Inovio Pharmaceuticals, Inc. (INO): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here."
2019-01-09,16.270000457763672,16.979999542236328,3.741087619110183,Mirati Therapeutics (MRTX) Catches Eye: Stock Jumps 5.4%,"Mirati Therapeutics, Inc. Price Mirati Therapeutics, Inc. Price | Mirati Therapeutics, Inc. Quote Investors interested in the Medical - Biomedical and Genetics industry may consider Acorda Therapeutics, Inc. ACOR , which has a Zacks Rank #1 (Strong Buy). Click to get this free report Mirati Therapeutics, Inc. (MRTX): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here. Predict to see what others think: Up or Down Today's Stocks from Zacks' Hottest Strategies It's hard to believe, even for us at Zacks."
2019-01-08,16.780000686645508,16.18000030517578,4.3638541149140595,,
2019-01-07,16.889999389648438,16.5,-3.575687466730806,Myriad Genetics (MYGN) Catches Eye: Stock Jumps 6.9%,"Myriad Genetics, Inc. Price Myriad Genetics, Inc. Price | Myriad Genetics, Inc. Quote Investors interested in the Medical - Biomedical and Genetics industry may consider Acorda Therapeutics, Inc. ACOR , which also has a Zacks Rank #1. Click to get this free report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2019-01-04,16.540000915527344,16.719999313354492,-2.3090550843208484,,
2019-01-03,16.09000015258789,15.899999618530272,1.0882611116313203,,
2019-01-02,15.260000228881836,16.219999313354492,-1.180860983565992,,
2018-12-31,14.979999542236328,15.579999923706056,6.290950655791697,,
2018-12-28,15.0,14.979999542236328,4.005343122862044,,
2018-12-27,15.149999618530272,14.850000381469728,-0.13333638509114584,,
2018-12-26,13.619999885559082,15.68000030517578,-1.980193033758286,"Company News For Dec 26, 2018","Apple, Inc.'s AAPL shares declined 2.6% on reports that Chinese companies are urging their employees to boycott the iPhone maker in retaliation to the arrest of Huawei CFO Sabrina Meng Shares of MINDBODY, Inc. MB surged 65% after the company agreed to be acquired by Vista Equity in a deal worth $1.9 billion for $36.50 per share cash Tesla, Inc.'s TSLA shares declined 7.6% after the company cut prices for it Model 3 in China for the third time in two months Shares of Acorda Therapeutics, Inc. ACOR jumped 6.4% after the FDA approved its Inbrija for off episodes in people with Parkinson's disease Want the latest recommendations from Zacks Investment Research? Click to get this free report MINDBODY, Inc. (MB): Free Stock Analysis Report Tesla, Inc. (TSLA): Free Stock Analysis Report Apple Inc. (AAPL): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2018-12-24,14.170000076293944,13.770000457763672,15.124819654373567,"U.S. STOCKS ON THE MOVE-Oil stocks, bank stocks, Mindbody | Health Care Sector Update for 12/24/2018: ACOR, CDXC, RDY, JNJ, PFE, MRK, ABT, AMGN | Acorda Gets FDA Approval for Parkinson's Disease Drug Inbrija | Why Mindbody, New Gold, and Acorda Therapeutics Jumped Today | Health Care Sector Update for 12/24/2018: MB,ACOR,RDY","The top three S&P 500 percentage gainers: ** Newmont Mining, up 2.8 pct ** PG&E Corp, up 2.5 pct ** Kohl's Corp, up 2.3 pct The top three S&P 500 percentage losers: ** Hess Corp, down 8.2 pct ** Kimberly-Clark Corp, down 6.8 pct ** Campbell Soup Co, down 6.7 pct The top three NYSE percentage gainers: ** Direxion Daily Mid Cap Bear 3x Shares, up 99.5 pct ** Companhia Energetica de Minas Gerais-CEMIG, up 14.4 pct ** Aphria Inc, up 14.4 pct The top three NYSE percentage losers: ** Dell Technologies Inc, down 26 pct ** iShares MSCI Colombia ETF, down 18 pct ** VanEck Vectors Rare Earth/Strategic Metals ETF, down 16.5 pct The top three Nasdaq percentage gainers: ** Mindbody Inc, up 66.4 pct ** Aridis Pharmaceuticals, Inc, up 23.9 pct ** SG Blocks, Inc, up 23.7 pct The top three Nasdaq percentage losers: ** Astrotech Corp, down 22.1 pct ** Constellation Pharmaceuticals Inc, down 22.6 pct ** Urban One Inc, down 16.7 pct ** Histogenics Corp: down 72.4 pct Plummets on plan to suspend cartilage repair trial ** Acorda Therapeutics Inc: up 7.0 pct Gains after FDA approves Parkinson's drug ** Mindbody Inc: up 66.4 pct Jumps on buyout offer from Vista Equity ** Tesla Inc: down 6.1 pct Tesla drops on Model 3 price cut in China ** Citigroup Inc: down 0.9 pct ** Goldman Sachs Group Inc: down 1.0 pct ** Bank of America Corp: down 2.3 pct ** Morgan Stanley: down 0.8 pct ** Wells Fargo & Co: down 2.5 pct ** JPMorgan Chase & Co: down 1.1 pct Financials hit over 2-yr low; yields, Mnuchin, broader losses hurt banks ** Exxon Mobil Corp: down 3.4 pct ** Chevron Corp: down 2.1 pct ** Hess Corp: down 8.6 pct Exxon, oil cos under pressure as crude prices drop The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The Day Ahead newsletter: The Morning News Call newsletter: The Day Ahead newsletter: U.S. stocks fell for the fourth straight session on Monday, as political deadlock in Washington continued and Treasury Secretary Steven Mnuchin's move to convene a crisis group added to nerves, pushing the S&P 500 closer to bear territory. The S&P 500 was down 1.71 percent at 2,375.29 and the Nasdaq Composite was down 0.99 percent at 6,270.366. | Stocks moving on news include: (+) Acorda Therapeutics ( ACOR ), which was up by more than 13% after the US Food and Drug Administration approved Inbrija for the intermittent treatment of OFF episodes in people with Parkinson's disease treated with carbidopa/levodopa. ABT: Flat MRK: Flat AMGN: Flat Health care stocks were flat to lower in Monday's pre-market trading . In after hours Dec. 20 the company unveiled a license and supply agreement with Nestle Health Science providing the latter with exclusive right to CDXC's nicotinamide riboside ingredient TRU NIAGEN dietary supplement in its branded medical nutrition. | Acorda Therapeutics, Inc.ACOR announced that the FDA has approved its Parkinson's disease (PD) drug Inbrija (levodopa inhalation powder). Zacks Rank & Stocks to Consider Acorda currently carries a Zacks Rank #3 (Hold). Click to get this free report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. | Mindbody (NASDAQ: MB) , New Gold (NYSEMKT: NGD) , and Acorda Therapeutics (NASDAQ: ACOR) were among the best performers on the day. Acorda gets approved Finally, Acorda Therapeutics saw its shares finish 6% higher. CEO Ron Cohen praised the achievement, noting that ""today's approval of Inbrija marks a major milestone for both Acorda and the Parkinson's community, for whom we are gratified to have developed this much-needed therapy."" | In other sector news: (+) Acorda Therapeutics ( ACOR ) rose 6.4% on Monday after the US Food and Drug Administration late last week approved its Inbrija new candidate for the treatment of intermittent OFF episodes in people with Parkinson's disease treated with a combination of carbidopa and levodopa. Health care stocks closed deep underwater, including a 2.4% decline for the NYSE Health Care Index. Among health care stocks moving on news: (+) MindBody ( MB ) soared 65% on Monday after the wellness and fitness technology company agreed to a $1.9 billion buyout offer from Vista Equity Partners, which will pay $36.50 in cash for each MindBody share, representing a 68% premium over Friday's closing price."
2018-12-21,13.920000076293944,12.9399995803833,-2.8228625008934265,,
2018-12-20,14.600000381469728,13.93000030517578,-7.040233409047206,,
2018-12-19,16.0,14.619999885559082,-4.589041498548937,,
2018-12-18,16.510000228881836,15.890000343322754,-8.625000715255737,,
2018-12-17,16.25,16.34000015258789,-3.7552990730701667,,
2018-12-14,15.779999732971191,16.18000030517578,0.5538470928485577,,
2018-12-13,16.469999313354492,15.979999542236328,2.5348579149137564,,
2018-12-12,16.219999313354492,16.3700008392334,-2.97510498813958,,
2018-12-11,17.020000457763672,16.15999984741211,0.9247936635570924,Here's Why Acorda Therapeutics Shares Sunk 15% Today,"In August 2017, the FDA refused to file Acorda Therapeutics' initial application for Inbrija, requesting more information, and in September, it delayed its decision on the resubmitted application for Amprya so that it could review additional information it had requested from the company. Absent an Inbrija green light, next year could be a tough year for sales at Acorda Therapeutics, so investors are probably best served watching this one from the sidelines until there's more clarity about Inbrija's future. 10 stocks we like better than Acorda Therapeutics When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen."
2018-12-10,18.56999969482422,19.030000686645508,-5.05288241610636,,
2018-12-07,18.8799991607666,18.6299991607666,2.4771190058204433,,
2018-12-06,18.3700008392334,18.809999465942383,-1.3241526012326847,,
2018-12-04,20.600000381469727,18.549999237060547,2.3952019956867137,,
2018-12-03,20.770000457763672,20.780000686645508,-9.95146168178333,,
2018-11-30,20.239999771118164,20.43000030517578,0.04814746587113303,,
2018-11-29,20.790000915527344,20.1299991607666,0.938737827105818,,
2018-11-28,19.989999771118164,20.809999465942383,-3.1746114752107077,,
2018-11-27,20.06999969482422,19.8700008392334,4.102049545838245,,
2018-11-26,19.280000686645508,20.280000686645508,-0.9965065203383999,,
2018-11-23,18.93000030517578,19.049999237060547,5.186721806979293,,
2018-11-21,18.799999237060547,19.06999969482422,0.63390876888658,,
2018-11-20,18.93000030517578,18.559999465942383,1.4361727059617024,,
2018-11-19,19.700000762939453,19.1299991607666,-1.9545738682964202,,
2018-11-16,18.86000061035156,19.780000686645508,-2.893409036029911,,
2018-11-15,18.549999237060547,18.96999931335449,4.878049027151117,Acorda Down More Than 30% in the Past 3 Months: Here's Why,"Acorda Therapeutics, Inc. Price Acorda Therapeutics, Inc. Price | Acorda Therapeutics, Inc. Quote Zacks Rank & Stocks to Consider Acorda currently carries a Zacks Rank #3 (Hold). Click to get this free report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. Shares of Acorda Therapeutics, Inc.ACOR have witnessed a decline by a huge margin in the past three months."
2018-11-14,19.46999931335449,18.600000381469727,2.26415144780618,,
2018-11-13,18.64999961853028,19.299999237060547,-4.468407614621892,,
2018-11-12,19.950000762939453,18.39999961853028,3.4852527175627355,,
2018-11-09,20.34000015258789,19.950000762939453,-7.76942899816107,,
2018-11-08,20.84000015258789,20.6299991607666,-1.917401114664285,,
2018-11-07,20.770000457763672,20.790000915527344,-1.0076822950272932,,
2018-11-06,20.13999938964844,20.57999992370605,0.09629493174226605,,
2018-11-05,19.700000762939453,20.280000686645508,2.1847097685800407,,
2018-11-02,20.11000061035156,19.459999084472656,2.9441619352481307,,
2018-11-01,19.5,20.18000030517578,-3.2322302643010192,"Acorda (ACOR) Q3 Earnings Top Estimates, Ampyra Sales View Up","Quarter in Detail Majority of Acorda's net product revenues were drawn from the company's key drug Ampyra, which raked in sales of $137.8 million in the reported quarter. Acorda Therapeutics, Inc. Price, Consensus and EPS Surprise Acorda Therapeutics, Inc. Price, Consensus and EPS Surprise | Acorda Therapeutics, Inc. Quote Zacks Rank & Stocks to Consider Acorda currently carries a Zacks Rank #3 (Hold). Click to get this free report Caladrius Biosciences, Inc. (CLBS): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here."
2018-10-31,18.700000762939453,19.11000061035156,3.487181052183493,Acorda Therapeutics Inc (ACOR) Q3 2018 Earnings Conference Call Transcript | Acorda Therapeutics (ACOR) Q3 Earnings and Revenues Beat Estimates,"Duration: 49 minutes Call participants: Felicia Vonella -- Executive Director of Investor Relations Ron Cohen -- President & Chief Executive Officer Carmen Augustine -- J.P. Morgan -- Analyst Kelechi Chikere -- Jefferies -- Analyst Phil Nadeau -- Cowen and Company -- Analyst Ross Weinreb -- Goldman Sachs -- Analyst Laura Chico -- Raymond James -- Analyst Benjamin Burnett -- Stifel -- Analyst Raghuram Selvaraju -- H.C. Wainwright -- Analyst Silvan Turkcan -- Oppenheimer -- Analyst Ken Trbovich -- Janney Montgomery Scott -- Analyst More ACOR analysis Transcript powered by AlphaStreet This article is a transcript of this conference call produced for The Motley Fool. Acorda Therapeutics Inc (NASDAQ: ACOR) Q3 2018 Earnings Conference Call Oct. 31, 2018 , 8:30 a.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Welcome to the Acorda Therapeutics Third Quarter 2018 Update. | Acorda Therapeutics (ACOR) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.15 per share. Acorda, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $142.81 million for the quarter ended September 2018, surpassing the Zacks Consensus Estimate by 68.52%. Acorda shares have lost about 18.5% since the beginning of the year versus the S&P 500's gain of 0.3%."
2018-10-30,18.36000061035156,17.479999542236328,2.192512463553814,,
2018-10-29,18.959999084472656,18.43000030517578,-4.79303398072371,,
2018-10-26,17.8700008392334,18.670000076293945,-2.7953523464614456,,
2018-10-25,17.5,18.059999465942383,4.476772241130269,,
2018-10-24,18.190000534057617,17.3799991607666,3.1999969482421875,,
2018-10-23,17.260000228881836,18.26000022888184,-4.453003570694946,Centene's (CNC) Earnings and Revenues Top Estimates in Q3,"Click to get this free report Allergan plc (AGN): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Molina Healthcare, Inc (MOH): Free Stock Analysis Report Centene Corporation (CNC): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ACOR is slated to announce third-quarter 2018 earnings on Oct 31. Centene Inc.CNC reported third-quarter 2018 adjusted earnings per share of $1.79, which beat the Zacks Consensus Estimate by 1.1%."
2018-10-22,17.950000762939453,17.43000030517578,5.793742680991767,,
2018-10-19,18.90999984741211,17.860000610351562,-2.896938360232792,,
2018-10-18,20.11000061035156,18.96999931335449,-5.552613672835341,,
2018-10-17,19.700000762939453,19.190000534057617,-5.668827759310252,,
2018-10-16,18.39999961853028,19.88999938964844,-2.5888335488863117,,
2018-10-15,17.6299991607666,18.229999542236328,8.097825010917994,,
2018-10-12,17.75,17.68000030517578,3.4032921726108403,,
2018-10-11,16.670000076293945,17.549999237060547,-0.39436447788292256,,
2018-10-10,16.299999237060547,16.670000076293945,5.278939152604023,,
2018-10-09,17.510000228881836,16.360000610351562,2.269943905225129,,
2018-10-08,17.75,17.649999618530273,-6.567673349503496,,
2018-10-05,18.26000022888184,17.65999984741211,-0.563382430815361,,
2018-10-04,19.36000061035156,18.65999984741211,-3.285872803663549,,
2018-10-03,18.979999542236328,19.3799991607666,-3.615706306151497,,
2018-10-02,19.64999961853028,18.780000686645508,2.107479600513959,,
2018-10-01,19.61000061035156,19.770000457763672,-4.427475566281178,,
2018-09-28,19.799999237060547,19.64999961853028,0.815909446365104,,
2018-09-27,19.200000762939453,19.75,-0.757573860152001,,
2018-09-26,18.64999961853028,19.25,2.864579245862196,,
2018-09-25,18.75,18.549999237060547,3.2171602881619936,,
2018-09-24,18.100000381469727,18.75,-1.0666707356770833,,
2018-09-21,18.14999961853028,18.200000762939453,3.5911580377408434,,
2018-09-20,17.950000762939453,18.14999961853028,0.2754884047387186,,
2018-09-19,17.75,18.0,1.1141997052376507,,
2018-09-18,17.399999618530273,17.799999237060547,1.4084507042253522,,
2018-09-17,17.299999237060547,17.399999618530273,2.2988484327568064,,
2018-09-14,17.899999618530273,17.25,0.5780369125999898,"Acorda (ACOR) Stock Dips, FDA Delays Decision on Inbrija","Acorda Therapeutics, Inc.ACOR announced that the FDA has extended time to review its new drug application (NDA), which seeks an approval for its Parkinson's disease candidate Inbrija. Acorda Therapeutics, Inc. Price and Consensus Acorda Therapeutics, Inc. Price and Consensus | Acorda Therapeutics, Inc. Quote Zacks Rank Acorda currently carries a Zacks Rank #3 (Hold). Click to get this free report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here."
2018-09-13,15.75,18.049999237060547,-3.631282862472169,Here's Why Acorda Therapeutics Is Falling by Double Digits Today,"What happened In response to an announcement of a delay in the regulatory review process for a key pipeline compound, shares of Acorda Therapeutics (NASDAQ: ACOR) , a biopharmaceutical company focused on neurological disorders, fell 12% as of 10:38 a.m. EDT on Thursday. The FDA decided to delay the drug's PDUFA date because Acorda recently submitted additional data to the agency related to Inbrija's chemistry, manufacturing, and controls. 10 stocks we like better than Acorda Therapeutics When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen."
2018-09-12,19.0,18.5,14.603169759114584,,
2018-09-11,20.89999961853028,19.25,-2.631578947368421,,
2018-09-10,27.799999237060547,20.799999237060547,-7.894735160987103,"Oversold Conditions For Acorda Therapeutics | ACOR Crosses Below Key Moving Average Level | Why Brown-Forman, Acorda Therapeutics, and Energy XXI Gulf Coast Slumped Today | What's Behind Acorda Therapeutics Crashing 24.5% Today | Noteworthy Monday Option Activity: ALNY, ACOR, EROS","In trading on Monday, shares of Acorda Therapeutics Inc (Symbol: ACOR) entered into oversold territory, hitting an RSI reading of 22.2, after changing hands as low as $21.50 per share. The chart below shows the one year performance of ACOR shares: Looking at the chart above, ACOR's low point in its 52 week range is $16.55 per share, with $36.35 as the 52 week high point - that compares with a last trade of $21.93. A bullish investor could look at ACOR's 22.2 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. | In trading on Monday, shares of Acorda Therapeutics Inc (Symbol: ACOR) crossed below their 200 day moving average of $25.33, changing hands as low as $21.50 per share. The chart below shows the one year performance of ACOR shares, versus its 200 day moving average: Looking at the chart above, ACOR's low point in its 52 week range is $16.55 per share, with $36.35 as the 52 week high point - that compares with a last trade of $21.73. Acorda Therapeutics Inc shares are currently trading down about 21.2% on the day. | Acorda drops on court ruling Acorda Therapeutics plunged 24% after the Federal Circuit Court of Appeals upheld a federal trial court's ruling that invalidated four patents related to Acorda's multiple sclerosis treatment, Ampyra. Brown-Forman (NYSE: BF-B) , Acorda Therapeutics (NASDAQ: ACOR) , and Energy XXI Gulf Coast (NASDAQ: EGC) were among the worst performers on the day. Bulls had hoped that the appeals court would overturn the lower court's 2017 ruling, and Acorda CEO Ron Cohen still believes the patents behind Ampyra were valid. | What happened Acorda Therapeutics (NASDAQ: ACOR) shares fell nearly 25% on Monday following word that a U.S. District Court of Appeals has held up a lower court ruling invalidating key patents on Ampyra, a multiple sclerosis drug that accounts for most of the company's sales. Acorda Therapeutics is weighing its options, including another appeal; however, investors ought to model for a rather quick decline in revenue given the company had this to say in its second-quarter 2018 10-Q filing with the SEC: Now what Acorda Therapeutics had negotiated with drugmakers, including Teva Pharmaceutical (NYSE: TEVA) , to delay their generic versions of Ampyra until after the court's decision. Unfortunately for Acorda Therapeutics, the Court of Appeals has upheld the prior ruling, casting doubt on the company's future revenue. | Below is a chart showing ALNY's trailing twelve month trading history, with the $100 strike highlighted in orange: Acorda Therapeutics Inc (Symbol: ACOR) saw options trading volume of 1,755 contracts, representing approximately 175,500 underlying shares or approximately 51.6% of ACOR's average daily trading volume over the past month, of 340,070 shares. Below is a chart showing ACOR's trailing twelve month trading history, with the $20 strike highlighted in orange: And Eros International plc (Symbol: EROS) saw options trading volume of 1,657 contracts, representing approximately 165,700 underlying shares or approximately 50% of EROS's average daily trading volume over the past month, of 331,565 shares. Especially high volume was seen for the $20 strike put option expiring October 19, 2018 , with 378 contracts trading so far today, representing approximately 37,800 underlying shares of ACOR."
2018-09-07,27.600000381469727,27.549999237060547,-25.17985680614051,,
2018-09-06,28.200000762939453,27.799999237060547,-0.1811635641959983,,
2018-09-05,28.299999237060547,28.200000762939453,-1.4184450888547129,,
2018-09-04,28.850000381469727,28.25,-0.3533515081871089,,
2018-08-31,28.5,28.799999237060547,-2.079723998392406,,
2018-08-30,28.600000381469727,28.549999237060547,1.0526289019668311,,
2018-08-29,29.200000762939453,28.600000381469727,-0.17482917392398362,,
2018-08-28,29.14999961853028,28.89999961853028,-2.054795773263284,,
2018-08-27,29.14999961853028,29.200000762939453,-0.8576329443279931,,
2018-08-24,28.850000381469727,28.89999961853028,0.1715305147976314,,
2018-08-23,29.299999237060547,28.89999961853028,0.17330757850758416,,
2018-08-22,28.89999961853028,29.14999961853028,-1.3651864469140353,,
2018-08-21,28.350000381469727,28.89999961853028,0.8650519145325645,,
2018-08-20,28.299999237060547,28.350000381469727,1.940032556119637,,
2018-08-17,27.799999237060547,28.200000762939453,0.17668249384155527,,
2018-08-16,28.049999237060547,27.850000381469727,1.438854449124081,,
2018-08-15,28.25,27.950000762939453,-0.7130084172215431,,
2018-08-14,28.450000762939453,28.450000762939453,-1.0619442019842367,,
2018-08-13,26.89999961853028,27.75,0.0,,
2018-08-10,26.700000762939453,26.89999961853028,3.1598527640282565,,
2018-08-09,26.5,26.75,0.7490593628313034,,
2018-08-08,26.850000381469727,26.600000381469727,0.9433962264150944,,
2018-08-07,27.14999961853028,26.850000381469727,-0.9310986832332976,,
2018-08-06,26.100000381469727,27.14999961853028,-1.104969581125887,,
2018-08-03,26.14999961853028,26.25,4.022985523808743,Acorda (ACOR) Q2 Earnings and Revenues Surpass Estimates | Is the Options Market Predicting a Spike in Acorda Therapeutics (ACOR) Stock?,"Acorda Therapeutics, Inc. Price, Consensus and EPS Surprise Acorda Therapeutics, Inc. Price, Consensus and EPS Surprise | Acorda Therapeutics, Inc. Quote Zacks Rank & Other Key Picks Acorda currently carries a Zacks Rank #2 (Buy). Click to get this free report Eagle Pharmaceuticals, Inc. (EGRX): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Vanda Pharmaceuticals Inc. (VNDA): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc . | Given the way analysts feel about Acorda Therapeutics right now, this huge implied volatility could mean there's a trade developing. Investors in Acorda Therapeutics, Inc.ACOR need to pay close attention to the stock based on moves in the options market lately. Clearly, options traders are pricing in a big move for Acorda Therapeutics shares, but what is the fundamental picture for the company?"
2018-08-02,27.5,26.0,0.3824106421739972,,
2018-08-01,24.950000762939453,24.75,-5.454545454545454,,
2018-07-31,24.450000762939453,24.950000762939453,-0.8016062397742799,,
2018-07-30,23.850000381469727,24.350000381469727,2.0449897112391273,,
2018-07-27,24.950000762939453,23.950000762939453,2.096436025168684,,
2018-07-26,24.25,24.799999237060547,-4.00801590950407,,
2018-07-25,28.700000762939453,24.549999237060547,2.268038090971327,RSI Alert: Acorda Therapeutics (ACOR) Now Oversold,"In trading on Wednesday, shares of Acorda Therapeutics Inc (Symbol: ACOR) entered into oversold territory, hitting an RSI reading of 27.4, after changing hands as low as $23.325 per share. The chart below shows the one year performance of ACOR shares: Looking at the chart above, ACOR's low point in its 52 week range is $16.55 per share, with $36.35 as the 52 week high point - that compares with a last trade of $24.55. A bullish investor could look at ACOR's 27.4 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side."
2018-07-24,28.350000381469727,28.700000762939453,-14.459935245847927,What's in Store for Cardinal Health (CAH) in Q4 Earnings?,"Click to get this free report athenahealth, Inc. (ATHN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Cardinal Health, Inc. (CAH): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc ACOR has an Earnings ESP of +66.76% and a Zacks Rank of 2. athenahealth, Inc ATHN has an Earnings ESP of +8.82% and a Zacks Rank of 3. Cardinal Health, Inc. Price and Consensus Cardinal Health, Inc. Price and Consensus | Cardinal Health, Inc. Quote Pharmaceutical Segment to Drive Results In the last reported quarter, this segment accounted for 88.5% of the company's revenues."
2018-07-23,28.64999961853028,28.049999237060547,1.234569230194775,Is a Beat in Store for Vertex (VRTX) This Earnings Season?,"Click to get this free report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report BioDelivery Sciences International, Inc. (BDSI): Free Stock Analysis Report Horizon Pharma Public Limited Company (HZNP): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics ACOR is scheduled to release its results on Jul 26. The combination of a positive Earnings ESP and a favorable Zacks Rank makes us reasonably confident of an earnings beat."
2018-07-20,29.200000762939453,28.75,-2.094242197063293,Will HIV Sales Drive Gilead (GILD) to Beat in Q2 Earnings?,"Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Intercept Pharmaceuticals, Inc. (ICPT): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ACOR is scheduled to release second-quarter results on Aug 2. Zacks Rank : Gilead currently carries a Zacks Rank #2 which when combined with a positive ESP makes us reasonably confident of an earnings beat this quarter."
2018-07-19,28.700000762939453,29.14999961853028,-1.5410984629513866,5 Biotech Stocks Well Poised to Beat Q2 Earnings Estimates,"Click to get this free report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Keryx Biopharmaceuticals, Inc. (KERX): Free Stock Analysis Report Intercept Pharmaceuticals, Inc. (ICPT): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda is scheduled to report results on Jul 25. Ardsley, NY-based Acorda Therapeutics, Inc. ( ACOR ) also makes it to our list of likely outperformers in the second quarter by virtue of its Zacks Rank #2 and an Earnings ESP of +66.76%."
2018-07-18,29.5,28.700000762939453,1.5679402217017173,,
2018-07-17,29.950000762939453,29.600000381469727,-2.7118618205442266,,
2018-07-16,29.850000381469727,30.0,-1.1686156011816262,,
2018-07-13,29.549999237060547,29.799999237060547,0.5025112784366668,,
2018-07-12,29.64999961853028,29.5,0.8460237105064253,,
2018-07-11,29.799999237060547,29.450000762939453,-0.5059009121758493,,
2018-07-10,30.350000381469727,30.0,-1.1744915539656149,,
2018-07-09,30.75,30.200000762939453,-1.1532137630002148,,
2018-07-06,30.25,30.549999237060547,-1.7886154050749492,,
2018-07-05,29.39999961853028,30.25,0.991733015076188,,
2018-07-03,30.14999961853028,29.14999961853028,2.891157797614323,,
2018-07-02,28.39999961853028,29.89999961853028,-3.3167496273711294,,
2018-06-29,27.799999237060547,28.700000762939453,5.281690211788905,,
2018-06-28,28.100000381469727,27.600000381469727,3.237415649562689,,
2018-06-27,28.850000381469727,28.14999961853028,-1.779359406449404,,
2018-06-26,28.89999961853028,28.89999961853028,-2.426345766667839,,
2018-06-25,29.39999961853028,28.850000381469727,0.0,Implied Volatility Surging for Acorda (ACOR) Stock Options,"Investors in Acorda Therapeutics, Inc.ACOR need to pay close attention to the stock based on moves in the options market lately. Clearly, options traders are pricing in a big move for Acorda shares, but what is the fundamental picture for the company? Currently, Acorda is a Zacks Rank #3 (Hold) in the Medical - Biomedical and Genetics industry that ranks in the Bottom 43% of our Zacks Industry Rank."
2018-06-22,29.950000762939453,29.450000762939453,-1.8707457285608247,"Notable Friday Option Activity: ACOR, DE, HRTX","Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Acorda Therapeutics Inc (Symbol: ACOR), where a total of 3,975 contracts have traded so far, representing approximately 397,500 underlying shares. Below is a chart showing HRTX's trailing twelve month trading history, with the $33 strike highlighted in orange: For the various different available expirations for ACOR options , DE options , or HRTX options , visit StockOptionsChannel.com. That amounts to about 41.4% of ACOR's average daily trading volume over the past month of 959,970 shares."
2018-06-21,30.64999961853028,29.89999961853028,-1.6694490392758419,,
2018-06-20,30.64999961853028,30.5,-2.4469820859200513,,
2018-06-19,30.39999961853028,30.549999237060547,-0.4893951725845838,,
2018-06-18,31.0,30.700000762939453,0.4934198039885312,,
2018-06-15,31.299999237060547,31.14999961853028,-0.967739474388861,,
2018-06-14,31.850000381469727,31.5,-0.47923201976522833,,
2018-06-13,31.75,31.64999961853028,-1.0989022834466156,,
2018-06-12,32.5,31.64999961853028,-0.3149618314006912,,
2018-06-11,30.299999237060547,32.599998474121094,-2.6153857891375982,,
2018-06-08,28.299999237060547,30.39999961853028,7.590756749087212,Here's Why Acorda Therapeutics Rose as Much as 30.3% Today,"What happened Shares of Acorda Therapeutics (NASDAQ: ACOR) rose over 30% today after the company's lawyers made oral arguments in front of a panel at the U.S. Court of Appeals for the Federal Circuit late Thursday. 10 stocks we like better than Acorda Therapeutics When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Acorda Therapeutics has one remaining patent on Ampyra, but it expires in July."
2018-06-07,27.100000381469727,27.89999961853028,7.420496247645325,,
2018-06-06,26.5,27.049999237060547,2.952026663466664,,
2018-06-05,26.350000381469727,26.450000762939453,2.0754688190964035,,
2018-06-04,25.799999237060547,26.350000381469727,0.3795080835750213,,
2018-06-01,26.450000762939453,25.89999961853028,2.131787444470648,Acorda (ACOR) Up 13.4% Since Earnings Report: Can It Continue?,"Acorda Q1 Earnings Miss Estimates, Sales Down Y/Y Acorda reported adjusted earnings of 14 cents per share in the first quarter of 2018, which significantly missed the Zacks Consensus Estimate of 73 cents. Quarter in Detail Majority of Acorda's net product revenues were generated by the company's key drug Ampyra, which raked in sales of $102.8 million in the reported quarter. Acorda Therapeutics, Inc. Price and Consensus Acorda Therapeutics, Inc. Price and Consensus | Acorda Therapeutics, Inc. Quote VGM Scores At this time, ACOR has a strong Growth Score of A, though it is lagging a lot on the momentum front with an F. The stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy."
2018-05-31,26.200000762939453,26.25,-2.0793993517754803,,
2018-05-30,25.450000762939453,26.299999237060547,0.1908367771167092,,
2018-05-29,24.049999237060547,25.299999237060547,3.33987602608983,"Health Care Sector Update for 05/29/2018: AKER, ACOR, TTOO | Health Care Sector Update for 05/29/2018: INSP,AKER,ACOR,TTOO | Health Care Sector Update for 05/29/2018: AKER,ACOR,TTOO","Expected movers: - Akers Biosciences ( AKER ): pulls FDA 510(k) submission for PIFA Chlamydia rapid assay; co-founder leaves board - Acorda Therapeutics ( ACOR ): European Medicines Agency validates MAA for inhaled levodopa treatment INBRIJA - T2 Biosystems ( TTOO ): receives FDA clearance to market T2Bacteria panel for detection of sepsis-causing pathogens The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ABT: flat Health care shares were lower ahead of the bell on Tuesday. | In other sector news: + Acorda Therapeutics ( ACOR ) rose over 2% on Tuesday after the European Medicines Agency validated the Marketing Authorization Application for its Inbrija drug candidate, starting a 210-day countdown for the agency to decide on clearing Acorda to begin commercial sales of the inhaled levodopa treatment for symptoms in people with Parkinson's disease. Among health care stocks moving on news: - Inspire Medical Systems ( INSP ) declined Tuesday, sinking as much as 11%, despite analysts at least five ratings shops weighing in with new investment recommendations for the neurostimulation technology company. Stifel Tuesday initiated analyst cover of Inspire with a Buy rating and a $42 price target while analysts at Guggenheim started their coverage of the company developing treatments for patients with obstructive sleep apnea with a Buy recommendation and a $40 price target. | In other sector news: + Acorda Therapeutics ( ACOR ) rose over 2% on Tuesday after the European Medicines Agency validated the Marketing Authorization Application for its Inbrija drug candidate, starting a 210-day countdown for the agency to decide on clearing Acorda to begin commercial sales of the inhaled levodopa treatment for symptoms in people with Parkinson's disease. Health care stocks were deep underwater Tuesday, including a nearly 1.4% decline for the NYSE Health Care Index in recent trading. Among health care stocks moving on news: - Akers Biosciences ( AKER ) plunged Tuesday, sinking as much as 40%, after the company pulled the 510(k) submission for its PIFA Chlamydia rapid assay to reassess the commercial prospects for the device following a recommendation by the US Food and Drug Administration to table the medical-device marketing application."
2018-05-25,23.75,24.200000762939453,5.197505362385941,,
2018-05-24,23.350000381469727,23.549999237060547,1.8947400544819077,Bullish Two Hundred Day Moving Average Cross - ACOR,"In trading on Thursday, shares of Acorda Therapeutics Inc (Symbol: ACOR) crossed above their 200 day moving average of $23.80, changing hands as high as $23.93 per share. The chart below shows the one year performance of ACOR shares, versus its 200 day moving average: Looking at the chart above, ACOR's low point in its 52 week range is $13.60 per share, with $29.60 as the 52 week high point - that compares with a last trade of $23.95. Acorda Therapeutics Inc shares are currently trading up about 2.8% on the day."
2018-05-23,22.89999961853028,23.25,0.8565261341474623,,
2018-05-22,23.200000762939453,23.14999961853028,1.5283859707425727,,
2018-05-21,23.850000381469727,23.100000381469727,-0.2155221670899523,,
2018-05-18,24.200000762939453,23.700000762939453,-3.1446540377530265,,
2018-05-17,24.39999961853028,24.14999961853028,-2.066115637342102,,
2018-05-16,24.600000381469727,24.450000762939453,-1.0245901799528743,,
2018-05-15,24.75,24.5,-0.6097545374156279,,
2018-05-14,24.450000762939453,24.799999237060547,-1.0101010101010102,,
2018-05-11,23.64999961853028,24.350000381469727,1.4314865570540614,,
2018-05-10,23.64999961853028,23.600000381469727,2.95983414050874,,
2018-05-09,23.450000762939453,23.700000762939453,-0.2114132679367086,,
2018-05-08,23.549999237060547,23.350000381469727,1.0660980463382403,,
2018-05-07,23.5,23.450000762939453,-0.8492520682382141,,
2018-05-04,23.0,23.5,-0.21276271089594412,,
2018-05-03,23.350000381469727,23.200000762939453,2.1739130434782608,"Acorda (ACOR) Q1 Earnings Miss Estimates, Sales Down Y/Y","Quarter in Detail Majority of Acorda's net product revenues were generated by the company's key drug Ampyra, which raked in sales of $102.8 million in the reported quarter. Acorda Therapeutics, Inc. Price, Consensus and EPS Surprise Acorda Therapeutics, Inc. Price, Consensus and EPS Surprise | Acorda Therapeutics, Inc. Quote Zacks Rank & Key Picks Acorda carries a Zacks Rank #3 (Hold). Click to get this free report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report OncoMed Pharmaceuticals, Inc. (OMED): Free Stock Analysis Report Infinity Pharmaceuticals, Inc. (INFI): Free Stock Analysis Report To read this article on Zacks.com click here."
2018-05-02,22.5,23.200000762939453,-0.6423966427397204,,
2018-05-01,23.14999961853028,23.450000762939453,3.111114501953125,,
2018-04-30,23.600000381469727,23.100000381469727,1.2959012930999725,,
2018-04-27,23.549999237060547,23.39999961853028,-2.1186440335509085,,
2018-04-26,22.89999961853028,23.350000381469727,-0.6369410759649303,,
2018-04-25,22.89999961853028,22.89999961853028,1.965068866530955,,
2018-04-24,23.350000381469727,23.100000381469727,0.0,,
2018-04-23,23.350000381469727,23.350000381469727,-1.0706637940716992,,
2018-04-20,23.299999237060547,23.350000381469727,0.0,,
2018-04-19,23.75,23.39999961853028,0.2145971933323019,,
2018-04-18,23.950000762939453,23.89999961853028,-1.4736858167146083,,
2018-04-17,23.450000762939453,23.89999961853028,-0.20877303889920962,,
2018-04-16,23.64999961853028,23.350000381469727,1.9189716031993005,,
2018-04-13,23.600000381469727,23.350000381469727,-1.2684957374185246,,
2018-04-12,23.64999961853028,23.450000762939453,-1.0593220167754542,,
2018-04-11,23.200000762939453,23.5,-0.845661136645956,,
2018-04-10,23.5,23.450000762939453,1.2931001172197238,,
2018-04-09,23.049999237060547,23.14999961853028,-0.21276271089594412,,
2018-04-06,22.75,22.75,0.4338411487187807,,
2018-04-05,24.0,22.950000762939453,0.0,,
2018-04-04,22.549999237060547,23.700000762939453,-4.374996821085611,,
2018-04-03,22.5,22.950000762939453,5.099785209699244,,
2018-04-02,23.39999961853028,22.299999237060547,2.000003390842014,,
2018-03-29,23.75,23.64999961853028,-4.700856407701186,,
2018-03-28,23.700000762939453,23.75,-0.4210542377672398,,
2018-03-27,24.200000762939453,23.600000381469727,0.21096723818985053,,
2018-03-26,23.350000381469727,24.25,-2.479340341131657,,
2018-03-23,23.450000762939453,22.850000381469727,3.8543880249548175,,
2018-03-22,23.700000762939453,23.39999961853028,-2.558636937948298,,
2018-03-21,24.350000381469727,24.14999961853028,-1.265827572791876,,
2018-03-20,24.600000381469727,24.39999961853028,-0.8213583564936859,,
2018-03-19,24.950000762939453,24.549999237060547,-0.8130112188538794,,
2018-03-16,24.100000381469727,25.049999237060547,-1.6032124795485598,,
2018-03-15,25.350000381469727,24.049999237060547,3.941903902712242,,
2018-03-14,25.700000762939453,25.200000762939453,-5.128209565469873,,
2018-03-13,25.75,25.600000381469727,-1.9455252340732314,,
2018-03-12,25.549999237060547,25.600000381469727,-0.5825227904088289,,
2018-03-09,25.700000762939453,25.64999961853028,0.1956992011829593,,
2018-03-08,26.049999237060547,25.64999961853028,-0.19455697636116984,,
2018-03-07,24.700000762939453,25.850000381469727,-1.5355072178320794,,
2018-03-06,25.950000762939453,24.89999961853028,4.655868757120704,,
2018-03-05,24.5,25.950000762939453,-4.046247065659951,,
2018-03-02,24.14999961853028,24.549999237060547,5.91837046097736,,
2018-03-01,23.700000762939453,24.350000381469727,1.6563131463710121,,
2018-02-28,24.850000381469727,23.75,2.742614335889395,,
2018-02-27,24.89999961853028,24.200000762939453,-4.426560823274596,"After Hours Most Active for Feb 27, 2018 : ENDP, ACOR, INTC, SPPI, MDLZ, FRBK","Reuters Reports: U.S. STOCKS ON THE MOVE-Comcast, Discovery, Mallinckrodt, Akcea, Lumber Liquidators Acorda Therapeutics, Inc. ( ACOR ) is unchanged at $24.20, with 1,532,340 shares traded. As reported in the last short interest update the days to cover for ACOR is 11.102517; this calculation is based on the average trading volume of the stock. The consensus earnings per share forecast is -0.25 per share, which represents a -22 percent increase over the EPS one Year Ago Mondelez International, Inc. ( MDLZ ) is unchanged at $44.01, with 1,283,348 shares traded."
2018-02-26,26.0,24.799999237060547,-2.8112404269673026,,
2018-02-23,26.0,26.049999237060547,-4.615387549767128,,
2018-02-22,26.299999237060547,26.39999961853028,0.1923047579251803,,
2018-02-21,25.450000762939453,26.100000381469727,0.3802295983675106,FDA Accepts Acorda's NDA for Parkinson's Disease Candidate,"Acorda Therapeutics, Inc.ACOR announced that the FDA has accepted its new drug application (NDA) for late stage pipeline candidate, Inbrija. Acorda Therapeutics, Inc. Price Acorda Therapeutics, Inc. Price | Acorda Therapeutics, Inc. Quote Zacks Rank Acorda currently carries a Zacks Rank #4 (Sell). Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Prothena Corporation PLC (PRTA): Free Stock Analysis Report Adamas Pharmaceuticals, Inc. (ADMS): Free Stock Analysis Report To read this article on Zacks.com click here."
2018-02-20,26.049999237060547,25.299999237060547,2.5540259294483376,,
2018-02-16,26.049999237060547,25.799999237060547,-2.8790787791386867,"Acorda (ACOR) Q4 Earnings Miss Estimates, Revenues Beat","Acorda Therapeutics, Inc. Price, Consensus and EPS Surprise Acorda Therapeutics, Inc. Price, Consensus and EPS Surprise | Acorda Therapeutics, Inc. Quote Zacks Rank & Key Picks Acorda carries a Zacks Rank #4 (Sell). Click to get this free report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report XOMA Corporation (XOMA): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Exelixis, Inc. (EXEL): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc.ACOR reported adjusted earnings of 61 cents per share in the fourth quarter of 2017, which missed the Zacks Consensus Estimate of $1.09."
2018-02-15,25.89999961853028,25.100000381469727,-0.9596929263795623,Acorda Therapeutics Joins Rank Of Stocks With RS Ratings Over 90,"On Thursday, Acorda Therapeutics ( ACOR ) received an upgrade to its Relative Strength ( RS ) Rating , from 77 to 93. Start Here Acorda Therapeutics is working on a consolidation with a 29.70 buy point . [ibd-display-video id=3105496 width=50 float=left autostart=true] IBD's proprietary RS Rating identifies technical performance by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database."
2018-02-14,24.64999961853028,25.600000381469727,-3.088800188584523,,
2018-02-13,24.350000381469727,24.950000762939453,3.8539585299843035,,
2018-02-12,24.049999237060547,24.75,2.4640672364273346,,
2018-02-09,24.0,24.049999237060547,2.9106061752416466,,
2018-02-08,25.14999961853028,23.850000381469727,0.2083301544189453,,
2018-02-07,25.299999237060547,25.14999961853028,-5.16898312834457,,
2018-02-06,23.200000762939453,24.89999961853028,-0.5928838855873969,Options Traders Expect Huge Moves in Acorda Therapeutics (ACOR) Stock,"Given the way analysts feel about Acorda Therapeutics right now, this huge implied volatility could mean there's a trade developing. Investors in Acorda Therapeutics, Inc.ACOR need to pay close attention to the stock based on moves in the options market lately. Clearly, options traders are pricing in a big move for Acorda Therapeutics shares, but what is the fundamental picture for the company?"
2018-02-05,25.0,23.950000762939453,7.327581033128537,,
2018-02-02,26.0,25.299999237060547,-4.1999969482421875,,
2018-02-01,25.89999961853028,26.25,-2.6923106266902046,Alkermes Submits NDA for Depression Candidate to the FDA,"Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Alkermes PLC (ALKS): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here. Allkermes' revenues continue to be driven by proprietary products, Vivitrol and Aristada, and partnered products namely Johnson & Johnson's JNJ Risperdal Consta, Invega Sustenna/Xeplion, Invega Trinza/Trevicta, Acorda Therapeutics' ACOR Ampyra/Fampyra and AstraZeneca's AZN Bydureon. Successful development and subsequent commercialization of other interesting candidates like ALKS 3831 (phase III - schizophrenia), ALKS 8700 (phase III - multiple sclerosis) and ALKS 6428 (phase III - to help physicians transition patients from physical dependence on opioids to Vivitrol) would lend a huge boost to the company."
2018-01-31,26.75,25.950000762939453,1.3513528441108933,,
2018-01-30,27.14999961853028,26.450000762939453,-2.9906513534973715,,
2018-01-29,27.049999237060547,27.5,-2.5782646977021235,,
2018-01-26,26.799999237060547,27.25,1.6635888193405863,,
2018-01-25,27.350000381469727,26.64999961853028,1.6791073722015886,,
2018-01-24,27.799999237060547,27.100000381469727,-2.559417744702165,,
2018-01-23,27.299999237060547,27.799999237060547,-2.5179815640341547,,
2018-01-22,27.450000762939453,27.549999237060547,1.831501882685899,Acorda Therapeutics (ACOR) Jumps: Stock Rises 8.8%,"The company has seen five positive estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few months, suggesting that more solid trading could be ahead for Acorda Therapeutics. Acorda Therapeutics, Inc. Price Acorda Therapeutics, Inc. Price | Acorda Therapeutics, Inc. Quote A better-ranked stock in the Medical sector is XOMA CorporationXOMA , which currently carries a Zacks Rank #1 (Strong Buy). Click to get this free report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report XOMA Corporation (XOMA): Free Stock Analysis Report To read this article on Zacks.com click here."
2018-01-19,28.64999961853028,27.200000762939453,0.3642931560719765,"Here's Why Acorda Therapeutics Inc. Stock Is Surging Today | Health Care Sector Update for 01/19/2018: JNJ, PFE, ABT, MRK, AMGN, PAVM, ACOR, OBLN, AGIO, CHEK | Pre-Market Most Active for Jan 19, 2018 : ERIC, QQQ, TVIX, GE, IBM, SQ, NVDA, NOK, ACOR, GNC, WBK, USLV","What happened Shares of Acorda Therapeutics Inc. (NASDAQ: ACOR) , a biopharmaceutical company focused on neurological disorders, popped 15.4% during early morning trading after Bloomberg reported that Biogen Inc. (NASDAQ: BIIB) and several smaller suitors appear interested in a potential sale. 10 stocks we like better than Acorda Therapeutics When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. * David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Acorda Therapeutics wasn't one of them! | Expected movers: - Merck & Company ( MRK ): says results 'encouraging' from Keytruda monotherapy in advanced hepatocellular carcinoma - PAVmed ( PAVM ): plans public offering of shares - Acorda Therapeutics ( ACOR ): reportedly said to receive takeover approach - Obalon ( OBLN ): shares eye new low pre-bell; prices share sale at 10.4% discount - Agios ( AGIO ): prices offering of 7.1 million shares at $67 each Other news: - Check-Cap (CHEK): gets notice of non-compliance with Nasdaq minimum bid price rule The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. All rights reserved. Unauthorized reproduction is strictly prohibited. | Acorda Therapeutics, Inc. ( ACOR ) is +3.35 at $28.35, with 183,971 shares traded. As reported in the last short interest update the days to cover for ACOR is 17.415026; this calculation is based on the average trading volume of the stock. The total Pre-Market volume is currently 4,725,926 shares traded."
2018-01-18,24.850000381469727,25.0,-5.0610780973728025,,
2018-01-17,25.14999961853028,24.75,0.6036201860267411,,
2018-01-16,25.89999961853028,25.049999237060547,-1.5904557638067105,,
2018-01-12,25.600000381469727,25.850000381469727,-3.281854803046394,,
2018-01-11,24.299999237060547,25.600000381469727,0.976562485448085,,
2018-01-10,23.100000381469727,24.299999237060547,5.3497991161518845,,
2018-01-09,22.700000762939453,23.25,5.194800154866798,Acorda's Shares Down on Disappointing Ampyra View for 2018,"Acorda Therapeutics, Inc. Price Acorda Therapeutics, Inc. Price | Acorda Therapeutics, Inc. Quote Zacks Rank & Key Picks Acorda carries a Zacks Rank #3 (Hold). Click to get this free report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report XOMA Corporation (XOMA): Free Stock Analysis Report Exelixis, Inc. (EXEL): Free Stock Analysis Report Sucampo Pharmaceuticals, Inc. (SCMP): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc.ACOR announced preliminary sales numbers of its key multiple sclerosis drug, Ampyra, for the fourth quarter of 2017 and issued a financial outlook for 2018 at the JP Morgan healthcare conference."
2018-01-08,23.100000381469727,22.39999961853028,2.4229040465870306,,
2018-01-05,21.100000381469727,23.549999237060547,-3.0303062830291987,,
2018-01-04,21.89999961853028,21.049999237060547,11.611368773919258,,
2018-01-03,22.75,21.89999961853028,-3.881280348290607,,
2018-01-02,21.700000762939453,22.64999961853028,-3.7362654130537116,,
2017-12-29,22.450000762939453,21.450000762939453,4.377874756637298,,
2017-12-28,22.350000381469727,22.549999237060547,-4.45434283303368,,
2017-12-27,22.299999237060547,22.39999961853028,0.8948494504574522,,
2017-12-26,21.549999237060547,22.200000762939453,0.4484322192421524,,
2017-12-22,21.75,21.600000381469727,3.0162484867334385,,
2017-12-21,21.25,21.75,-0.6896534185299928,,
2017-12-20,21.25,21.25,2.3529411764705883,,
2017-12-19,21.200000762939453,21.14999961853028,0.0,,
2017-12-18,21.100000381469727,21.049999237060547,-0.23585444627238658,Surging Earnings Estimates Signal Good News for Acorda Therapeutics (ACOR),"Current Quarter Estimates for ACOR In the past 30 days, five estimates have gone higher for Acorda Therapeutics while one have gone lower in the same time period. Current Year Estimates for ACOR Meanwhile, Acorda Therapeutics' current year figures are also looking quite promising, with the consensus estimate trend increasing from $1.42 per share 60 days ago to $1.47 per share today, an increase of 3.5%. Acorda Therapeutics, Inc. Price and Consensus Acorda Therapeutics, Inc. Price and Consensus | Acorda Therapeutics, Inc. Quote Bottom Line The stock has also started to move higher lately, adding 23% over the past four weeks, suggesting that investors are starting to take note of this impressive story."
2017-12-15,20.75,21.049999237060547,-0.23697224410048492,,
2017-12-14,21.200000762939453,20.700000762939453,1.4457794557134789,,
2017-12-13,20.549999237060547,21.299999237060547,-2.3584904811610645,ACOR Crosses Above Key Moving Average Level,"In trading on Wednesday, shares of Acorda Therapeutics Inc (Symbol: ACOR) crossed above their 200 day moving average of $21.37, changing hands as high as $21.65 per share. The chart below shows the one year performance of ACOR shares, versus its 200 day moving average: Looking at the chart above, ACOR's low point in its 52 week range is $13.60 per share, with $33.00 as the 52 week high point - that compares with a last trade of $21.40. Acorda Therapeutics Inc shares are currently trading up about 3.9% on the day."
2017-12-12,20.39999961853028,20.549999237060547,3.649635171992733,,
2017-12-11,21.25,20.39999961853028,0.7352922614469787,,
2017-12-08,20.850000381469727,21.049999237060547,-4.000001795151621,Acorda Resubmits NDA for Parkinson's Disease Candidate Inbrija,"Acorda Therapeutics, Inc. Price Acorda Therapeutics, Inc. Price | Acorda Therapeutics, Inc. Quote Zacks Rank Acorda carries a Zacks Rank #3 (Hold). Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Prothena Corporation PLC (PRTA): Free Stock Analysis Report Adamas Pharmaceuticals, Inc. (ADMS): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda TherapeuticsACOR announced that it has resubmitted the new drug application (NDA) for its late stage pipeline candidate, Inbrija, to the FDA."
2017-12-07,20.450000762939453,20.75,0.9592271075858959,,
2017-12-06,20.39999961853028,20.350000381469727,1.466988879551638,,
2017-12-05,20.950000762939453,20.450000762939453,-0.24509430389958106,,
2017-12-04,20.950000762939453,20.799999237060547,-2.386634757954281,,
2017-12-01,20.200000762939453,20.799999237060547,-0.7159977108175524,,
2017-11-30,20.5,20.299999237060547,2.970289363661309,,
2017-11-29,20.100000381469727,20.5,-0.9756134777534299,,
2017-11-28,20.299999237060547,20.100000381469727,1.9900478156161368,,
2017-11-27,20.5,20.0,-0.9852160744208003,,
2017-11-24,20.450000762939453,20.5,-2.4390243902439024,,
2017-11-22,20.450000762939453,20.25,0.24449503762932895,"Biotech Stock Roundup: RARE drug Gets FDA Nod, Acorda, Cytokinetics Hit by Pipeline Setbacks","Pipeline and regulatory updates were the focus this week with Ultragenyx Pharmaceutical RARE gaining FDA approval for its first drug while companies like Cytokinetics CYTK and Acorda Therapeutics ACOR were hit by pipeline setbacks. Acorda Scraps Tozadenant Program: Just a few days after announcing safety issues associated with a late-stage study on its investigational treatment for Parkinson's disease, Acorda said that it is discontinuing its clinical development program for tozadenant (Read more: Acorda Stock Up Despite Phase III Trial on Tozadenant Stops ). Click to get this free report Celgene Corporation (CELG): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Cytokinetics, Incorporated (CYTK): Free Stock Analysis Report Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis Report United Therapeutics Corporation (UTHR): Free Stock Analysis Report TESARO, Inc. (TSRO): Free Stock Analysis Report To read this article on Zacks.com click here."
2017-11-21,19.64999961853028,20.100000381469727,-0.9779988042929798,Acorda Stock Up Despite Phase III Trial on Tozadenant Stops,"Acorda Therapeutics, Inc. Price Acorda Therapeutics, Inc. Price | Acorda Therapeutics, Inc. Quote Zacks Rank Acorda carries a Zacks Rank #3 (Hold). Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Prothena Corporation PLC (PRTA): Free Stock Analysis Report Adamas Pharmaceuticals, Inc. (ADMS): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc.ACOR announced that it has decided to immediately discontinue the phase III study on one of its lead Parkinson's disease (""PD"") candidates, tozadenant."
2017-11-20,17.950000762939453,19.5,2.2900802629791794,"Health Care Sector Update for 11/20/2017: ACOR,ACST,ACST.V,ANTH","In company news, Acorda Therapeutics ( ACOR ) climbed to a session high of $19.65 a share on Monday, rising more than 10% and reversing a small dip soon after the opening bell, after the specialty pharmaceuticals company said it was discontinuing clinical development of its tozadenant investigational treatment for Parkininson's disease following instances of agranulocytosis and other serious adverse events during late-stage testing earlier this month. Health care stocks were mixed this afternoon, with the NYSE Health Care Index falling over 0.3% while shares of health care companies in the S&P 500 were up less than 0.1% as a group. The company said it has told regulatory authorities and trial investigators of its decision to close down the Phase III trial as well as immediately discontinuing dosing of all participating patients after concluding weekly white blood cell count screening could not ensure patient safety."
2017-11-17,17.100000381469727,17.799999237060547,8.635092875654687,,
2017-11-16,16.549999237060547,17.25,4.093560467690797,"Acorda Reports Death in Parkinson's Trials, Stock Down 40%","Acorda Therapeutics, Inc. 's ACOR shares sank 40% on Wednesday after the company announced death of several patients in a late-stage study, evaluating one of its lead Parkinson's disease (""PD"") candidates, tozadenant. Acorda Therapeutics, Inc. Price Acorda Therapeutics, Inc. Price | Acorda Therapeutics, Inc. Quote Zacks Rank Acorda carries a Zacks Rank #3 (Hold). Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Prothena Corporation PLC (PRTA): Free Stock Analysis Report Adamas Pharmaceuticals, Inc. (ADMS): Free Stock Analysis Report To read this article on Zacks.com click here."
2017-11-15,18.75,17.0,4.229612055642491,"Mid-Day Market Update: YY Climbs After Strong Q3 Results; SandRidge Energy Shares Plummet | Mid-Afternoon Market Update: OncoCyte Drops Following Q3 Results; Sorl Auto Parts Shares Jump | Mid-Morning Market Update: Markets Open Lower; Target Profit Beats Estimates | Here's Why Acorda Therapeutics Got Crushed Today | Acorda Nose-Dives To 5-Month Low On Deaths In Parkinson's Studies | Health Care Sector Update for 11/15/2017: ARA,APHB,ACOR","Equities Trading DOWN Acorda Therapeutics Inc (NASDAQ: ACOR ) shares dropped 38 percent to $17.42 after the company issued an update on Toazdenant development program. Midway through trading Wednesday, the Dow traded down 0.40 percent to 23,316.29 while the NASDAQ declined 0.35 percent to 6,714.46. The eurozone's STOXX 600 declined 0.59 percent, the Spanish Ibex Index fell 0.04 percent, while Italy's FTSE MIB Index dropped 0.83 percent. | Equities Trading DOWN Acorda Therapeutics Inc (NASDAQ: ACOR ) shares dropped 38 percent to $17.60 after the company issued an update on Toazdenant development program. Toward the end of trading Wednesday, the Dow traded down 0.38 percent to 23,321.54 while the NASDAQ declined 0.33 percent to 6,715.50. The eurozone's STOXX 600 declined 0.49 percent, the Spanish Ibex Index rose 0.24 percent, while Italy's FTSE MIB Index dropped 0.62 percent. | Shares of Synacor Inc (NASDAQ: SYNC ) got a boost, shooting up 10 percent to $2.53. Synacor reported Q3 earnings of $0.01 per share on revenue of $36.3 million. Equities Trading DOWN Acorda Therapeutics Inc (NASDAQ: ACOR ) shares dropped 38 percent to $17.62 after the company issued an update on Toazdenant development program. | 10 stocks we like better than Acorda Therapeutics When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. * David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Acorda Therapeutics wasn't one of them! What happened Shares of biopharma Acorda Therapeutics (NASDAQ: ACOR) dropped as much as 40.1% Wednesday after the company issued an update on its second-leading drug candidate. | Acorda Therapeutics ( ACOR ) lost more than a third of its value Wednesday after announcing five patients died in late-stage Parkinson's disease drug trials and that it would stop adding new patients to those studies. These were possibly associated with use of Acorda's drug called tozadenant, the firm said in a news release. This Biotech Is Feeling The Pain After FDA Sets Panel On Anesthetic Acorda Dives On Merger Talk As Investor Tries To Urge A Sale The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (-) ACOR, (-39.0%) Temporarily suspends new enrollment in Phase III testing of its tozadenant prospective drug treatment for Parkinson's disease after five patients in the study die from sepsis. Health care stocks were trending lower in recent trade, with the NYSE Health Care Index falling almost 0.3% while shares of health care companies in the S&P 500 were down about 0.2% as a group. Excluding one-time items, adjusted net income during the three months ended Sept. 30 was $0.19 a share, down compared with a $0.28 per share non-GAAP profit during the same quarter last year but besting the Capital IQ consensus by $0.03 per share."
2017-11-14,27.75,28.200000762939453,-9.333333333333334,,
2017-11-13,27.700000762939453,27.700000762939453,1.6216243709529843,,
2017-11-10,28.25,27.950000762939453,0.0,,
2017-11-09,28.100000381469727,28.350000381469727,-1.0619442019842367,,
2017-11-08,27.799999237060547,28.64999961853028,0.889679703224702,,
2017-11-07,27.799999237060547,27.5,3.0575554129389575,,
2017-11-06,27.600000381469727,27.75,-1.0791339758765675,,
2017-11-03,27.25,27.700000762939453,0.5434768712212815,,
2017-11-02,27.850000381469727,27.200000762939453,1.6513789465668005,,
2017-11-01,26.64999961853028,28.14999961853028,-2.3339303756805587,"Adamas Pharmaceuticals, Inc.: Substantial Upside For A Misunderstood Drug Maker | Company News For Nov 1, 2017 | Acorda (ACOR) Q3 Earnings Lag Estimates, Revenues Up Y/Y","Similarly, Acorda Therapeutics ( ACOR ) has achieved high market share and ~$500M of annual revenue with an extended-release version of an old drug that the vast majority of patients don't even respond to. Our analysis of Gocovri's Phase 2 results in MS strongly suggests that the drug works better than Acorda's drug Ampyra (already discussed above as an example of a commercially successful yet mediocre repackaged drug); assuming that Gocovri achieved a similar level of success after completing pivot trials, we estimate incremental value of $1.6B or $62 per share. - Acorda Therapeutics : $1B+ market cap >$500M run-rate revenue generated by a repackaged, extended-release formulation of a drug already available much less expensively from compounding pharmacies. | Shares of Pfizer Inc. PFE fell 0.3% after posting third quarter 2017 revenues of $13,168 million, below the Zacks Consensus Estimate of $13,169 million Shares of Under Armour, Inc. UA plummeted almost 22% after posting third quarter 2017 earnings of $0.22 a share, lower than $0.29 a share in the year ago quarter Shares of Aetna Inc. AET dipped 0.7% after posting third quarter 2017 revenues of $14,948 million, below the Zacks Consensus Estimate of $15,108 million Shares of Acorda Therapeutics, Inc. ACOR declined 2.7% after posting third quarter 2017 revenues of $141 million, below the Zacks Consensus Estimate of $151 million Want the latest recommendations from Zacks Investment Research? Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Aetna Inc. (AET): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acorda Therapeutics, Inc. Price, Consensus and EPS Surprise Acorda Therapeutics, Inc. Price, Consensus and EPS Surprise | Acorda Therapeutics, Inc. Quote Zacks Rank & Key Picks Acorda currently carries a Zacks Rank #3 (Hold). Click to get this free report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Exelixis, Inc. (EXEL): Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc.ACOR reported adjusted earnings of 43 cents per share in the third quarter of 2017, which missed the Zacks Consensus Estimate of 66 cents."
2017-10-31,25.64999961853028,26.57999992370605,5.628517904206722,,
2017-10-30,26.950000762939453,27.299999237060547,3.6257322378434353,,
2017-10-27,26.0,26.850000381469727,1.2986956000476164,,
2017-10-26,25.799999237060547,26.0,3.269232236422025,Allergan (AGN) to Report Q3 Earnings: What's in the Cards?,"Stocks to Consider Some stocks in the biotech/pharma sector that have a positive Earnings ESP and a favorable Zacks Rank are: Acorda Therapeutics, Inc. ACOR , scheduled to release results on Oct 31, has an Earnings ESP of + 5.53% and a Zacks Rank #3. (AGN): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report Shire PLC (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen."
2017-10-25,26.14999961853028,26.049999237060547,0.7751967785028495,,
2017-10-24,26.200000762939453,26.100000381469727,-0.3824106421740515,,
2017-10-23,27.049999237060547,26.200000762939453,-0.38168083418982024,,
2017-10-20,26.89999961853028,27.200000762939453,-3.142323468004138,,
2017-10-19,26.75,26.700000762939453,1.1152459058122601,"Zacks Industry Outlook Highlights: Acorda Therapeutics, BioMarin Pharmaceutical, Valeant Pharmaceuticals International, Teva Pharmaceuticals and Sanofi","For Immediate Release Chicago, IL - October 19, 2017 - Today, Zacks Equity Research discusses the Industry: Pharmaceuticals, Part 3, including Acorda Therapeutics (Nasdaq: ACOR - Free Report ), BioMarin Pharmaceutical (Nasdaq: BMRN - Free Report ), Valeant Pharmaceuticals International (NYSE: VRX - Free Report ), Teva Pharmaceuticals (NYSE: TEVA - Free Report ) and Sanofi (NYSE: SNY - Free Report ). Companies like Acorda Therapeutics(Nasdaq: ACOR - Free Report) , BioMarin Pharmaceutical(Nasdaq: BMRN - Free Report) , Valeant Pharmaceuticals International(NYSE: VRX - Free Report) , Teva Pharmaceuticals(NYSE: TEVA - Free Report) and Sanofi(NYSE: SNY - Free Report) are all sell-ranked stocks. Click to get this free report Sanofi (SNY): Free Stock Analysis Report BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Valeant Pharmaceuticals International, Inc. (VRX): Free Stock Analysis Report Teva Pharmaceutical Industries Limited (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here."
2017-10-18,26.700000762939453,27.049999237060547,-0.18691303574036217,,
2017-10-17,26.14999961853028,26.64999961853028,1.310855670861643,,
2017-10-16,26.049999237060547,26.049999237060547,1.9120459169937902,,
2017-10-13,25.700000762939453,25.850000381469727,0.0,,
2017-10-12,25.64999961853028,25.5,0.5836560859040113,,
2017-10-11,25.450000762939453,25.850000381469727,-0.5847938431231656,,
2017-10-10,25.350000381469727,25.350000381469727,1.5717076877764062,,
2017-10-09,25.39999961853028,25.049999237060547,0.0,,
2017-10-06,26.25,25.5,-1.3779542784496535,,
2017-10-05,25.600000381469727,26.64999961853028,-2.857142857142857,,
2017-10-04,26.299999237060547,25.700000762939453,4.10155945864979,,
2017-10-03,25.75,26.25,-2.28136308565214,Acorda Therapeutics Shows Market Leadership With Jump To 91 RS Rating,"Acorda Therapeutics ( ACOR ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Tuesday, rising from 80 to 91. Acorda Therapeutics earns the No. Celgene ( CELG ), Corcept Therapeutics ( CORT ) and Ligand Pharmaceuticals ( LGND ) are among the top 5 highly rated stocks within the group."
2017-10-02,23.64999961853028,26.0,1.9417475728155338,,
2017-09-29,23.450000762939453,23.64999961853028,9.936576826108885,,
2017-09-28,23.549999237060547,23.350000381469727,0.85287355686106,,
2017-09-27,23.75,23.450000762939453,-0.8492520682382141,,
2017-09-26,23.450000762939453,23.549999237060547,-1.2631546823601973,Acorda Therapeutics Getting Closer To Key Technical Measure,"Acorda Therapeutics ( ACOR ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Tuesday, rising from 67 to 78. See if Acorda Therapeutics can continue to show renewed price strength and hit that benchmark. Acorda Therapeutics earns the No."
2017-09-25,23.5,23.89999961853028,0.4264327115892126,,
2017-09-22,23.549999237060547,23.450000762939453,1.7021260362990662,,
2017-09-21,23.950000762939453,23.600000381469727,-0.424621984546507,,
2017-09-20,23.450000762939453,23.89999961853028,-1.4613794167861647,,
2017-09-19,23.200000762939453,23.350000381469727,1.9189716031993005,,
2017-09-18,22.89999961853028,23.049999237060547,0.6465500586098619,,
2017-09-15,23.14999961853028,22.950000762939453,0.6550201791658077,,
2017-09-14,23.049999237060547,23.100000381469727,-0.8639259563129301,,
2017-09-13,23.200000762939453,23.049999237060547,0.2169247117752013,,
2017-09-12,23.100000381469727,23.200000762939453,-0.6465582799399054,,
2017-09-11,23.0,23.200000762939453,0.4329020771356545,,
2017-09-08,22.25,22.799999237060547,0.8695685345193614,,
2017-09-07,22.25,22.25,2.471906683418188,,
2017-09-06,21.75,22.799999237060547,0.0,,
2017-09-05,21.549999237060547,21.64999961853028,4.827582699128951,,
2017-09-01,21.25,21.700000762939453,0.4640389095594877,,
2017-08-31,19.850000381469727,20.799999237060547,2.1176506491268383,"Biotech Stock Roundup: CAR-T in Focus on Gilead-Kite Deal, Incyte Up on Baricitinib Update","Click to get this free report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report The Medicines Company (MDCO): Free Stock Analysis Report BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Incyte Corporation (INCY): Free Stock Analysis Report Kite Pharma, Inc. (KITE): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Down on Inbrija Regulatory Update: Acorda Therapeutics ACOR saw its shares fall 24.3% on news that the FDA has issued a Refusal to File ('RTF"") letter for Inbrija. Acorda intends to meet with the FDA to discuss the RTF."
2017-08-30,19.64999961853028,19.549999237060547,4.785888349290202,AstraZeneca and Takeda Ink Deal to Develop Parkinson's Drug | FDA's Refusal-to-File Letter for Inbrija Pushes Acorda Down,"Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Astrazeneca PLC (AZN): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Prothena Corporation PLC (PRTA): Free Stock Analysis Report To read this article on Zacks.com click here. However, another company Acorda Therapeutics, Inc. ACOR received a refusal to file (RTF) letter from the FDA in connection with the new drug application (NDA) for its Pakinson's candidate, Inbrija. AstraZeneca PLCAZN and Takeda Pharmaceutical Company Limited, a Japanese pharma company, have entered into an agreement to jointly develop and commercialize preclinical candidate MEDI1341. | Shares of Acorda Therapeutics, Inc.ACOR have plunged almost 25% after the company announced that it has received a refusal to file (RTF) letter from the FDA in connection with the new drug application (NDA) for pipeline candidate, Inbrija. Acorda Therapeutics, Inc. Price Acorda Therapeutics, Inc. Price | Acorda Therapeutics, Inc. Quote Zacks Rank & Stocks to Consider Acorda currently carries a Zacks Rank #3 (Hold). Click to get this free report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Akebia Therapeutics, Inc. (AKBA): Free Stock Analysis Report To read this article on Zacks.com click here."
2017-08-29,18.049999237060547,19.450000762939453,-0.5089078036186404,"Health Care Sector Update for 08/29/2017: IMGN,JAZZ,JUNO,ACOR | Pre-Market Most Active for Aug 29, 2017 : TVIX, BBY, FINL, QQQ, ACOR, XIV, ABCO, BAC, MYCC, SAP, BABA, GSK | What Happened in the Stock Market Today | Mid-Afternoon Market Update: U.S. Stocks Turn Higher; J.Jill Shares Plummet | Mid-Day Market Update: Movado Rises After Strong Q2 Results; Finish Line Shares Slide | Health Care Sector Update for 08/29/2017: CTLT,JUNO,ACOR | Why Acorda Therapeutics Is Losing One-Quarter of Its Value Today","(-) ACOR, Receives a letter from the FDA refusing to file the company's new drug application for its Inbrija investigational treatment for patients with Parkinson's disease already taking a carbidopa/levodopa drug regimen. Health care stocks have turned narrowly higher again this afternoon, with the NYSE Health Care Index adding slightly more than 0.1% in value today, recouping a small rise earlier Tuesday, while shares of health care companies in the S&P 500 were up just over 0.2% as a group. climbing to within 13 cents of its 52-week high of $8.04 a share after the biotech company working to develop cancer vaccines today announced a collaboration pact worth at least $175 million with Jazz Pharmaceuticals ( JAZZ ) to develop and commercialize antibody-drug conjugate products. | Acorda Therapeutics, Inc. ( ACOR ) is -8.05 at $17.65, with 350,978 shares traded. As reported in the last short interest update the days to cover for ACOR is 14.433436; this calculation is based on the average trading volume of the stock. The following are the most active stocks for the pre-market session : VelocityShares Daily 2x VIX Short-Term ETN ( TVIX ) is +1.93 at $18.59, with 1,061,129 shares traded. | As for individual stocks, positive earnings news curiously sent shares of Best Buy (NYSE: BBY) tumbling, and a hiccup with the approval of a new Parkinson's treatment from Acorda Therapeutics (NASDAQ: ACOR) left investors in the biotech specialist reeling. Acorda's FDA rejection Acorda Therapeutics stock plummeted 24.3% after the company revealed it received a ""Refusal to File"" (RTF) letter from the U.S. Food and Drug Administration regarding a new drug application for its INBRIJA Parkinson's treatment. The FDA determined that Acorda's application ""was not sufficiently complete to permit a substantive review"" for two reasons: First, the date when its manufacturing site would be ready for inspection. | Equities Trading DOWN Acorda Therapeutics Inc (NASDAQ: ACOR ) shares dropped 27 percent to $18.75 after the company reported that it has received a Refusal to File letter from the FDA for INBRIJA regarding its previously filed NDA. Toward the end of trading Tuesday, the Dow traded up 0.14 percent to 21,837.76 while the NASDAQ climbed 0.22 percent to 6,296.78. The eurozone's STOXX 600 declined 1.04 percent, the Spanish Ibex Index fell 0.91 percent, while Italy's FTSE MIB Index fell 1.46 percent. | Equities Trading DOWN Acorda Therapeutics Inc (NASDAQ: ACOR ) shares dropped 27 percent to $18.83 after the company reported that it has received a Refusal to File letter from the FDA for INBRIJA regarding its previously filed NDA. Midway through trading Tuesday, the Dow traded down 0.07 percent to 21,793.10 while the NASDAQ declined 0.08 percent to 6,277.86. The eurozone's STOXX 600 declined 1.05 percent, the Spanish Ibex Index fell 0.77 percent, while Italy's FTSE MIB Index fell 1.38 percent. | (-) ACOR, (-26.2%) Receives a letter from the FDA refusing to file the company's new drug application for its Inbrija investigational treatment for patients with Parkinson's disease already taking a carbidopa/levodopa drug regimen. Health care stocks have turned narrowly mixed this afternoon, with the NYSE Health Care Index declining nearly 0.1% in value, reversing a small rise earlier Tuesday, while shares of health care companies in the S&P 500 still were up almost 0.1% as a group. In company news, Catalent ( CTLT ) jumped out to a new, all-time high on Tuesday, rising 17% to a best-ever $41.37 a share after the specialty drugmaker last night reported Q4 financial results topping analyst expectations and guided its FY18 revenue above Wall Street projections. | What happened After reporting that it has received a refuse-to-file letter from the FDA regarding its Parkinson's disease drug, Inbrija, shares in Acorda Therapeutics (NASDAQ: ACOR) are crashing 25% at 12:30 p.m. EDT Tuesday. So what Acorda Therapeutics reported positive phase 3 trial results for Inbrija in February, and optimism that it could win FDA approval in time to offset the risk of generic competition to the company's multiple sclerosis drug, Ampyra, has helped prop up the company's share price. Unfortunately, hope for a speedy review of Inbrija was dashed Tuesday by news that the FDA isn't accepting Inbrija's application for approval, which Acorda Therapeutics filed with the regulator in late June."
2017-08-28,25.5,25.700000762939453,7.7562414684450545,,
2017-08-25,23.549999237060547,25.14999961853028,0.7843167174096201,,
2017-08-24,22.64999961853028,23.0,6.794057041631742,,
2017-08-23,22.75,22.64999961853028,1.5452555733527662,,
2017-08-22,21.950000762939453,22.89999961853028,-0.4395621163504152,,
2017-08-21,21.799999237060547,21.850000381469727,4.3280128590920715,,
2017-08-18,21.64999961853028,21.89999961853028,0.2293630557756006,,
2017-08-17,21.39999961853028,21.799999237060547,1.154734431431696,,
2017-08-16,21.299999237060547,21.549999237060547,1.8691571292548355,,
2017-08-15,21.75,21.200000762939453,1.1737089622285857,,
2017-08-14,21.450000762939453,21.64999961853028,-2.5287321244163072,,
2017-08-11,20.549999237060547,21.350000381469727,0.9323955639963348,,
2017-08-10,20.5,20.450000762939453,3.8929497523602397,,
2017-08-09,21.049999237060547,20.64999961853028,-0.24389871736852134,,
2017-08-08,22.049999237060547,21.200000762939453,-1.9002357863558899,,
2017-08-07,22.5,22.200000762939453,-3.854868496741072,,
2017-08-04,21.89999961853028,21.43000030517578,-1.3333299424913194,,
2017-08-03,22.299999237060547,21.75,-2.1461156234761667,,
2017-08-02,21.850000381469727,22.25,-2.4663643761319003,,
2017-08-01,21.75,21.75,1.830661837743033,,
2017-07-31,21.600000381469727,21.64999961853028,0.0,,
2017-07-28,21.64999961853028,21.700000762939453,0.23147794526636895,"Acorda (ACOR) Q2 Earnings Miss Estimates, Revenues in Line","Acorda Therapeutics, Inc.ACOR reported adjusted earnings of 6 cents per share in the second quarter of 2017 (including the impact of stock-based compensation expenses), compared with a loss of 41 cents per share in the year-ago quarter. Acorda Therapeutics, Inc. Price, Consensus and EPS Surprise Acorda Therapeutics, Inc. Price, Consensus and EPS Surprise | Acorda Therapeutics, Inc. Quote Zacks Rank & Key Picks Acorda currently carries a Zacks Rank #5 (Strong Sell). Click to get this free report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Enzo Biochem, Inc. (ENZ): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Exelixis, Inc. (EXEL): Free Stock Analysis Report To read this article on Zacks.com click here."
2017-07-27,19.850000381469727,21.700000762939453,0.23095217224104012,,
2017-07-26,22.850000381469727,22.549999237060547,9.319900986988038,,
2017-07-25,22.549999237060547,22.850000381469727,-1.3129152709006802,,
2017-07-24,20.64999961853028,22.39999961853028,1.3303820601294427,,
2017-07-21,21.0,20.64999961853028,8.474576427738223,,
2017-07-20,20.299999237060547,20.89999961853028,-1.6666684831891403,,
2017-07-19,20.200000762939453,20.350000381469727,2.9556670148752877,,
2017-07-18,20.25,20.100000381469727,0.7425723409153272,,
2017-07-17,20.450000762939453,20.299999237060547,-0.7407388569396219,,
2017-07-14,20.850000381469727,20.5,-0.733503766663651,,
2017-07-13,20.200000762939453,20.850000381469727,-1.6786588732189505,,
2017-07-12,20.25,20.14999961853028,3.2178197721794892,,
2017-07-11,20.299999237060547,20.100000381469727,-0.4938290442949109,,
2017-07-10,20.799999237060547,20.450000762939453,-0.9852160744208003,,
2017-07-07,20.350000381469727,20.850000381469727,-1.682685033456547,,
2017-07-06,20.25,20.25,2.457002410944863,,
2017-07-05,20.0,20.5,0.0,,
2017-07-03,19.850000381469727,20.100000381469727,2.5,,
2017-06-30,19.549999237060547,19.700000762939453,1.259445819625166,Acorda Files NDA for Parkinson's Disease Candidate Inbrija,"Acorda Therapeutics, Inc. Price Acorda Therapeutics, Inc. Price | Acorda Therapeutics, Inc. Quote Zacks Rank & Key Picks Acorda currently carries a Zacks Rank #3 (Hold). Click to get this free report Bayer AG (BAYRY): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report VIVUS, Inc. (VVUS): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc.ACOR has submitted a new drug application (NDA) to FDA for its late stage pipeline candidate Inbrija (formerly known as CVT-301) for treatment of patients suffering from Parkinson's disease."
2017-06-29,19.75,19.549999237060547,0.7672712620599561,,
2017-06-28,19.14999961853028,19.75,-1.0126620908326742,,
2017-06-27,19.200000762939453,19.049999237060547,3.1331613233513376,,
2017-06-26,19.64999961853028,19.200000762939453,-0.7812579162415697,,
2017-06-23,18.600000381469727,19.450000762939453,-2.290070556370245,,
2017-06-22,18.799999237060547,18.64999961853028,4.569894430306252,,
2017-06-21,18.350000381469727,18.700000762939453,-0.7978703437102872,"Wednesday 6/21 Insider Buying Report: ACOR, SBBX","On Friday, Acorda Therapeutics ( ACOR )'s CEO, Ron Cohen, made a $338,998 purchase of ACOR, buying 20,000 shares at a cost of $16.95 a piece. Cohen was up about 9.4% on the purchase at the high point of today's trading session, with ACOR trading as high as $18.55 in trading on Wednesday. VIDEO: Wednesday 6/21 Insider Buying Report: ACOR, SBBX The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2017-06-20,17.799999237060547,18.14999961853028,1.9073589874317682,,
2017-06-19,17.350000381469727,17.799999237060547,1.966294362198703,,
2017-06-16,16.950000762939453,17.25,2.593653289318837,,
2017-06-15,17.149999618530273,17.100000381469727,1.769906923641467,,
2017-06-14,17.049999237060547,17.25,-0.2915407473626039,,
2017-06-13,17.149999618530273,17.100000381469727,1.1730250550670034,,
2017-06-12,16.950000762939453,17.200000762939453,-0.2915407473626039,,
2017-06-09,16.149999618530273,16.899999618530273,1.4749261872991517,Health Care Sector Update for 06/09/2017: ACOR,"In health-care stocks news, Acorda Therapeutics ( ACOR ) said in a regulatory filing it is appealing a Delaware district court's decision to invalidate four patents protecting multiple sclerosis treatment Ampyra. Top Health-care stocks: JNJ: flat AMGN: flat Health-care shares were mainly unchanged in pre-market trade on Friday."
2017-06-08,15.350000381469728,16.200000762939453,4.643962957989553,,
2017-06-07,15.350000381469728,15.25,5.537461630918469,Acorda Presents Phase III Data on PD Candidate CVT-301,"Acorda Therapeutics, Inc.ACOR presented data from a phase III study SPAN-PD, evaluating its late stage candidate CVT-301 (levodopa inhalation powder) at the International Congress of Parkinson's Disease and Movement Disorders (MDS). Acorda Therapeutics, Inc. Price Acorda Therapeutics, Inc. Price | Acorda Therapeutics, Inc. Quote Zacks Rank & Key Picks Acorda currently carries a Zacks Rank #3 (Hold). Click to get this free report Bayer AG (BAYRY): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report VIVUS, Inc. (VVUS): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here."
2017-06-06,16.600000381469727,15.350000381469728,-0.6514682670004829,,
2017-06-05,15.25,15.300000190734863,-7.530120308884753,,
2017-06-02,14.850000381469728,15.199999809265137,0.3278701031794313,,
2017-06-01,13.800000190734863,14.699999809265137,2.356898443128312,Why Is Acorda (ACOR) Down 8.4% Since the Last Earnings Report?,"Acorda First Quarter Loss Wider Than Expected, Revenues Miss Acorda Therapeutics reported loss of $0.25 per share in the first quarter of 2017 (including the impact of stock-based compensation expenses), wider than the Zacks Consensus Estimate of a loss of $0.16. Acorda's research and development (R&D) expenses (including stock-based compensation expenses) increased 4.3% year over year to $46.5 million due to increased investment in late-stage programs (INBRIJA or CVT-301 and tozadenant) as well as the addition of Biotie's R&D expenses. Acorda Therapeutics, Inc. Price and Consensus Acorda Therapeutics, Inc. Price and Consensus | Acorda Therapeutics, Inc. Quote VGM Scores At this time, Acorda's stock has a poor Growth Score of 'F', however its Momentum is doing a lot better with a 'B'."
2017-05-31,14.149999618530272,13.800000190734863,6.521736276022091,,
2017-05-30,14.25,14.100000381469728,-2.473494256049754,,
2017-05-26,14.5,14.25,-1.0526289019668187,,
2017-05-25,15.199999809265137,14.550000190734863,-1.7241379310344827,Biogen's Fampyra Conditional Approval Converted to Standard,"Biogen acquired ex-U.S. rights to Fampyra from Acorda in Jul 2009 Biogen has a strong position in the MS market with a wide range of products including Avonex, Tysabri, Tecfidera and Plegridy. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS): Free Stock Analysis Report To read this article on Zacks.com click here. Fampyra is available in the U.S. under the trade name Ampyra where it is marketed by Acorda Therapeutics, Inc. ACOR ."
2017-05-24,15.050000190734863,15.149999618530272,-4.276313333465091,,
2017-05-23,15.300000190734863,15.100000381469728,0.6644480167978364,,
2017-05-22,15.199999809265137,15.300000190734863,-1.3071882795547136,,
2017-05-19,15.149999618530272,15.25,0.6578972547668815,,
2017-05-18,15.0,15.199999809265137,0.6600685411728714,,
2017-05-17,15.25,15.0,1.3333320617675781,,
2017-05-16,15.75,15.5,-1.639344262295082,,
2017-05-15,15.800000190734863,15.649999618530272,-1.5873015873015872,,
2017-05-12,16.149999618530273,15.699999809265137,-0.9493706986950046,,
2017-05-11,15.600000381469728,16.200000762939453,-2.7863765937728786,,
2017-05-10,16.100000381469727,15.699999809265137,3.8461561974218155,,
2017-05-09,15.899999618530272,16.100000381469727,-2.4844755448886198,,
2017-05-08,16.0,15.800000190734863,1.2578664637599666,,
2017-05-05,16.200000762939453,16.049999237060547,-1.2499988079071045,,
2017-05-04,16.100000381469727,16.149999618530273,-0.9259353013245711,,
2017-05-03,16.100000381469727,16.0,0.3105542600986111,,
2017-05-02,16.600000381469727,16.100000381469727,-0.6211203670828596,,
2017-05-01,16.25,16.5,-3.012048123553905,,
2017-04-28,15.300000190734863,16.149999618530273,1.5384615384615385,"Acorda (ACOR) Q1 Loss Wider Than Expected, Revenues Miss","Acorda Therapeutics, Inc.ACOR reported loss of 25 cents per share in the first quarter of 2017 (including the impact of stock-based compensation expenses), wider than the Zacks Consensus Estimate of a loss of 16 cents. Acorda Therapeutics, Inc. Price, Consensus and EPS Surprise Acorda Therapeutics, Inc. Price, Consensus and EPS Surprise | Acorda Therapeutics, Inc. Quote Zacks Rank & Key Picks Acorda currently carries a Zacks Rank #3 (Hold). Click to get this free report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Galena Biopharma, Inc. (GALE): Free Stock Analysis Report Heska Corporation (HSKA): Free Stock Analysis Report To read this article on Zacks.com click here."
2017-04-27,16.5,15.550000190734863,5.555551746398929,,
2017-04-26,16.450000762939453,16.5,-5.75757460160689,,
2017-04-25,16.149999618530273,16.5,0.3039467157545135,,
2017-04-24,16.100000381469727,16.0,2.1671850757701643,,
2017-04-21,15.899999618530272,15.850000381469728,-0.6211203670828596,,
2017-04-20,16.0,15.949999809265137,-0.31446061798814706,,
2017-04-19,16.200000762939453,16.0,-0.3125011920928955,,
2017-04-18,16.549999237060547,16.149999618530273,-1.234572552595136,,
2017-04-17,16.799999237060547,16.649999618530273,-2.4169162354675584,,
2017-04-13,16.850000381469727,16.799999237060547,-0.8928549127512847,,
2017-04-12,17.0,16.899999618530273,-0.29674269007238074,,
2017-04-11,17.0,16.950000762939453,-0.588237538057215,,
2017-04-10,16.549999237060547,17.049999237060547,-0.2941131591796875,,
2017-04-07,16.950000762939453,16.600000381469727,3.0211481755258696,,
2017-04-06,17.049999237060547,17.049999237060547,-2.06489891277757,,
2017-04-05,18.14999961853028,17.049999237060547,0.0,"Biotech Stock Roundup: Acorda Down on Court Ruling, Patent Challenge for CELG Drug","Click to get this free report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Kite Pharma, Inc. (KITE): Free Stock Analysis Report Paratek Pharmaceuticals, Inc. (PRTK): Free Stock Analysis Report To read this article on Zacks.com click here. Recap of the Week's Most Important Stories Acorda Slumps on Court Ruling: Acorda ACOR suffered a big setback in a patent infringement lawsuit for its flagship drug, Ampyra, with the United States District Court for the District of Delaware upholding only one of the 5 patents that were challenged. However, with the recent court ruling, Acorda could well start facing generic competition for Ampyra from the third quarter of 2018 if it fails in its appeal efforts."
2017-04-04,18.350000381469727,18.049999237060547,-6.060608289747213,,
2017-04-03,20.049999237060547,18.39999961853028,-1.634883586771628,"Monday's ETF Movers: GDXJ, VIOO | Acorda's (ACOR) MS Drug Patents Invalidated, Shares Plunge | Why Acorda Therapeutics Inc Plummeted for a Second Straight Day","Among components of that ETF with the weakest showing on Monday were shares of Acorda Therapeutics, lower by about 7.5%, and shares of Gentherm, lower by about 7.4% on the day. In trading on Monday, the Junior Gold Miners ETF is outperforming other ETFs, up about 2% on the day. VIDEO: Monday's ETF Movers: GDXJ, VIOO The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acorda Therapeutics, Inc. 's ACOR shares were down almost 21.5% after the U.S. District Court for the District of Delaware invalidated four patents of its key multiple sclerosis drug, Ampyra, thereby making way for generic versions of the drug. (AGN): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. We remind the investors that Acorda holds five Orange Book listed patents for Ampyra that run up to 2027. | So what JPMorgan analyst Cory Kasimov pegged Acorda's value at $24 per share, down from his previous valuation of $32 per share, but investors sent shares even lower, ending the day at $18.40. 10 stocks we like better than Acorda Therapeutics When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. * David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now...and Acorda Therapeutics wasn't one of them!"
2017-03-31,26.700000762939453,21.0,-8.229424844467808,"Why Acorda Therapeutics Inc and Forward Pharma A/S Got Crushed Today | Health Care Sector Update for 03/31/2017: ACOR,ALTX,DRIO | Noteworthy Friday Option Activity: AMBA, ACOR, CC","What happened Forward Pharma (NASDAQ: FWP) ended the day down 19.9% while Acorda Therapeutics (NASDAQ: ACOR) didn't fare any better, down 21.5%, after investors received word that the companies had lost separate patent battles. Separately, Acorda Therapeutics announced that the U.S. District Court invalidated four of its patents covering its multiple sclerosis drug Ampyra. Now what While these news items were big blows to Forward Pharma and Acorda Therapeutics, the fight isn't over. | In company news, shares of Acorda Therapeutics ( ACOR ) plunged Friday after a federal court in Delaware today invalidated four patents linked to the company's Ampyra multiple sclerosis drug. In tossing out Acorda's claims, the U.S. district court judge ruled the company's method of treatment was not unique enough to merit continued patent protection. ""We are disappointed by the Court's decision and are preparing our appeal,"" Acorda CEO Ron Cohen said in prepared remarks. | Below is a chart showing AMBA's trailing twelve month trading history, with the $61 strike highlighted in orange: Acorda Therapeutics Inc (Symbol: ACOR) saw options trading volume of 10,354 contracts, representing approximately 1.0 million underlying shares or approximately 112% of ACOR's average daily trading volume over the past month, of 924,825 shares. Especially high volume was seen for the $25 strike put option expiring April 21, 2017 , with 1,123 contracts trading so far today, representing approximately 112,300 underlying shares of ACOR. Below is a chart showing ACOR's trailing twelve month trading history, with the $25 strike highlighted in orange: And Chemours Co (Symbol: CC) options are showing a volume of 19,542 contracts thus far today."
2017-03-30,27.0,26.75,-21.348316854174985,Acorda Presents Data for Parkinson's Candidate CVT-301,"Acorda Therapeutics, Inc. Price Acorda Therapeutics, Inc. Price | Acorda Therapeutics, Inc. Quote Zacks Rank & Stocks to Consider Acorda currently carries a Zacks Rank #3 (Hold). Click to get this free report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Galena Biopharma, Inc. (GALE): Free Stock Analysis Report Retrophin, Inc. (RTRX): Free Stock Analysis Report Heska Corporation (HSKA): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc.ACOR announced results from two ongoing, long-term safety studies of CVT-301 in patients suffering with Parkinson's disease."
2017-03-29,26.100000381469727,26.950000762939453,-0.9259259259259258,,
2017-03-28,26.5,26.100000381469727,3.256706394813707,,
2017-03-27,25.14999961853028,26.39999961853028,-1.5094325227557488,,
2017-03-24,25.450000762939453,25.39999961853028,4.970179001827944,,
2017-03-23,25.549999237060547,25.39999961853028,-0.196468145030411,,
2017-03-22,25.549999237060547,25.549999237060547,-0.5870826732264254,,
2017-03-21,27.5,25.600000381469727,0.0,,
2017-03-20,26.850000381469727,27.0,-6.9090895219282675,,
2017-03-17,27.25,26.850000381469727,0.5586577891961382,Why Is Acorda (ACOR) Up 10.6% Since the Last Earnings Report? | Alkermes Starts Phase III Study to Treat Multiple Sclerosis,"Acorda Reports Narrower-than-Expected Loss in Q4 Acorda reported loss of $0.07 per share in the fourth quarter of 2016 narrower than the Zacks Consensus Estimate of a loss of $0.18. Acorda's research and development (R&D) expenses (including stock-based compensation expenses) shot up 22.3% year over year to $53.8 million due to increased investment in late-stage programs as well as the addition of Biotie's R&D expenses. Acorda Therapeutics, Inc. Price and Consensus Acorda Therapeutics, Inc. Price and Consensus | Acorda Therapeutics, Inc. Quote VGM Scores At this time, Acorda's stock has a subpar Growth Score of 'D', however its Momentum is doing a bit better with a 'C'. | Click to get this free report Alkermes PLC (ALKS): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Heska Corporation (HSKA): Free Stock Analysis Report To read this article on Zacks.com click here. In fact, one of its drugs Ampyra/Fampyra, which is marketed in the U.S. by Acorda Therapeutics, Inc. ACOR , helps in improving walking ability in multiple sclerosis patients. Alkermes PLC Price Alkermes PLC Price | Alkermes PLC Quote Zacks Rank & Stocks to Consider Alkermes currently has a Zacks Rank #3 (Hold)."
2017-03-16,28.049999237060547,27.700000762939453,-1.4678885083679758,"Biotech Stock Roundup: Amgen's Data on Repatha, Catalyst Soars on Firdapse Data","While this decision is a bit of good news for Acorda, the company is still awaiting a decision from the U.S. District Court for the District of Delaware regarding a patent infringement lawsuit involving these four patents as well as another patent (Read more: Acorda's Four Ampyra Patents Upheld by PTAB, Shares Rise ). Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Incyte Corporation (INCY): Free Stock Analysis Report Catalyst Pharmaceuticals, Inc. (CPRX): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Favorable PTAB Ruling for Acorda's Ampyra: Acorda ACOR got a bit of a breather with the United States Patent and Trademark Office (USPTO) Patent Trials and Appeal Board (PTAB) upholding four of the company's patents protecting its flagship drug, Ampyra."
2017-03-15,27.350000381469727,28.100000381469727,-1.2477664300919649,,
2017-03-14,28.64999961853028,27.299999237060547,2.7422303091013585,,
2017-03-13,29.39999961853028,28.299999237060547,-4.712043279039274,"Acorda's Four Ampyra Patents Upheld by PTAB, Shares Rise","Acorda Therapeutics, Inc. 's ACOR shares gained almost 7% after the U.S. Patent and Trademark Office (USPTO) Patent Trials and Appeal Board (PTAB) upheld four patents of its key growth driver, Ampyra. (AGN): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda holds five Orange Book listed patents for Ampyra that run until 2027."
2017-03-10,30.25,28.14999961853028,-3.741497944702093,Acorda Therapeutics (ACOR) Jumps: Stock Adds 6.5% in Session,"Acorda Therapeutics, Inc. Price Acorda Therapeutics, Inc. Price | Acorda Therapeutics, Inc. Quote A better-ranked stock in the Medical - Biomedical and Genetics space is Cellectis, S.A. CLLS sporting a Zacks Rank #1 (Strong Buy). Click to get this free report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Cellectis S.A. (CLLS): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc.ACOR was a big mover last session, as its shares rose above 6% on the day."
2017-03-09,28.299999237060547,30.14999961853028,-6.942150021387502,,
2017-03-08,27.200000762939453,28.299999237060547,6.537103997681553,,
2017-03-07,26.799999237060547,27.200000762939453,4.044111923775619,,
2017-03-06,27.100000381469727,27.14999961853028,1.4925430495003955,,
2017-03-03,27.14999961853028,27.25,0.18449902714666438,,
2017-03-02,27.350000381469727,27.200000762939453,0.36832553545034935,,
2017-03-01,26.850000381469727,27.479999542236328,-0.5484446670498101,,
2017-02-28,27.39999961853028,26.450000762939453,2.346365556111461,,
2017-02-27,24.850000381469727,27.39999961853028,-3.467149156266246,,
2017-02-24,24.89999961853028,24.89999961853028,10.261566188795918,,
2017-02-23,25.25,25.0,0.0,Implied Volatility Surging for Acorda Therapeutics (ACOR) Stock Options,"Given the way analysts feel about Acorda Therapeutics right now, this huge implied volatility could mean there's a trade developing. Investors in Acorda Therapeutics, Inc.ACOR need to pay close attention to the stock based on moves in the options market lately. Clearly, options traders are pricing in a big move for Acorda Therapeutics shares, but what is the fundamental picture for the company?"
2017-02-22,25.14999961853028,25.25,-0.9900990099009901,,
2017-02-21,25.39999961853028,25.299999237060547,0.3976158369244671,,
2017-02-17,25.14999961853028,25.299999237060547,-0.39370229516373506,,
2017-02-16,25.39999961853028,25.299999237060547,0.5964199634410652,,
2017-02-15,24.850000381469727,25.39999961853028,-0.39370229516373506,"Biotech Stock Roundup: Regeneron's Praluent to Remain on Market for Now, GILD Presents HIV Data","Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Incyte Corporation (INCY): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Seattle Genetics, Inc. (SGEN): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Shoots Up on Parkinson's Study Data: Acorda's ACOR shares soared on positive data from a late-stage study on CVT-301, which showed a statistically significant improvement in motor function in people with Parkinson's disease experiencing OFF periods. Acorda expects to seek FDA approval for the drug in the second quarter while data from a couple of long-term safety studies is expected this quarter."
2017-02-14,23.64999961853028,23.850000381469727,2.2132765739137783,"The Zacks Analyst Blog Highlights: Incyte, Prothena, Acorda Therapeutics and Axovant Sciences","Stocks recently featured in the blog include Incyte Corporation (NASDAQ: INCY - Free Report ), Prothena Corporation (NASDAQ: PRTA - Free Report ), Acorda Therapeutics, Inc. (NASDAQ: ACOR - Free Report ) and Axovant Sciences (NYSE: AXON - Free Report ). Get the full Report on INCY - FREE Get the full Report on PRTA - FREE Get the full Report on ACOR - FREE Get the full Report on AXON - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Click to get this free report Incyte Corporation (INCY): Free Stock Analysis Report Prothena Corporation PLC (PRTA): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Axovant Sciences Ltd. (AXON): Free Stock Analysis Report To read this article on Zacks.com click here."
2017-02-13,24.950000762939453,24.39999961853028,0.8456692015451076,,
2017-02-10,25.450000762939453,24.799999237060547,-2.204413337037409,Agios Pharmaceuticals (AGIO) Q4 Earnings: What's in Store? | Perrigo Company (PRGO) Q4 Earnings: Disappointment in Store? | Acorda (ACOR) Catches Eye: Stock Gains 20.8% in Session | Alexion (ALXN) Q4 Earnings: Can the Stock Pull a Surprise?,"Click to get this free report AMAG Pharmaceuticals, Inc. (AMAG): Free Stock Analysis Report BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Agios Pharmaceuticals, Inc. (AGIO): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ACOR is expected to release results on Feb 14. Agios Pharmaceuticals, Inc. Price and EPS Surprise Agios Pharmaceuticals, Inc. Price and EPS Surprise | Agios Pharmaceuticals, Inc. Quote Factors at Play Agios, a development-stage biopharmaceutical company, is focused on the formulation of treatments for cancer and rare genetic metabolic disorders. | Click to get this free report AMAG Pharmaceuticals, Inc. (AMAG): Free Stock Analysis Report Perrigo Company (PRGO): Free Stock Analysis Report BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ACOR is expected to release results on Feb 14. Perrigo Company Price and EPS Surprise Perrigo Company Price and EPS Surprise | Perrigo Company Quote Factors Influencing This Quarter According to the company, price erosion and changing market dynamics across the Prescription Pharmaceuticals (Rx) business will continue to hurt its performance. | Acorda Therapeutics, Inc. Price Acorda Therapeutics, Inc. Price | Acorda Therapeutics, Inc. Quote A better-ranked stock in the Medical-Biomedical and Genetics space is Cellectis S.A. CLLS , sporting a Zacks Rank #1 (Strong Buy). Click to get this free report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Cellectis S.A. (CLLS): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc.ACOR was a big mover last session, as its shares rose almost 21% on the day. | Click to get this free report AMAG Pharmaceuticals, Inc. (AMAG): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Incyte Corporation (INCY): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ACOR has an Earnings ESP of +5.56% and a Zacks Rank #3. Zacks ESP: The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is 0.00%, since both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at $1.10."
2017-02-09,22.64999961853028,24.64999961853028,-2.5540334239417586,Why Acorda Therapeutics Stock Is Jumping Today,"10 stocks we like better than Acorda Therapeutics When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. * David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Acorda Therapeutics wasn't one of them! What happened As of 10:47 a.m. EST Thursday, shares of specialty pharmaceutical company Acorda Therapeutics (NASDAQ: ACOR) were up by more than 15%."
2017-02-08,21.049999237060547,20.39999961853028,8.830022223769806,"Teva (TEVA) Q4 Earnings: What's in Store for the Stock? | Can Prothena (PRTA) Pull a Surprise This Earnings Season? | Notable Wednesday Option Activity: ACOR, AAP, SBAC","Click to get this free report AMAG Pharmaceuticals, Inc. (AMAG): Get Free Report BioMarin Pharmaceutical Inc. (BMRN): Get Free Report Acorda Therapeutics, Inc. (ACOR): Get Free Report Teva Pharmaceutical Industries Limited (TEVA): Get Free Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ACOR is expected to release results on Feb 14. Teva Pharmaceutical Industries Limited Price and EPS Surprise Teva Pharmaceutical Industries Limited Price and EPS Surprise | Teva Pharmaceutical Industries Limited Quote Let's see how things are shaping up for this announcement. | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Incyte Corporation (INCY): Free Stock Analysis Report Prothena Corporation PLC (PRTA): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ACOR has an Earnings ESP of +5.56% and is a Zacks Rank #3 company. Zacks Rank: Prothena's Zacks Rank #4 (Sell) decreases the predictive power of ESP and its negative ESP of 13.71% makes a surprise prediction difficult. | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Acorda Therapeutics Inc (Symbol: ACOR), where a total volume of 4,296 contracts has been traded thus far today, a contract volume which is representative of approximately 429,600 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 80.9% of ACOR's average daily trading volume over the past month, of 531,055 shares. Especially high volume was seen for the $23 strike put option expiring March 17, 2017 , with 2,772 contracts trading so far today, representing approximately 277,200 underlying shares of ACOR."
2017-02-07,21.950000762939453,21.200000762939453,-3.087884285458213,,
2017-02-06,21.549999237060547,21.950000762939453,-3.41685637326403,Can Humana (HUM) Pull a Surprise This Earnings Season?,"Click to get this free report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Humana Inc. (HUM): Free Stock Analysis Report Molina Healthcare Inc (MOH): Free Stock Analysis Report DaVita HealthCare Partners Inc. (DVA): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ACOR has an Earnings ESP of +5.56% and a Zacks Rank #3. Humana Inc. Price and EPS Surprise Humana Inc. Price and EPS Surprise | Humana Inc. Quote Earnings Whispers Our proven model does not conclusively show whether Humana is likely to beat on earnings this quarter."
2017-02-03,21.350000381469727,21.549999237060547,1.8561556382378188,Gilead Sciences (GILD) Q4 Earnings: What's in the Cards?,"Click to get this free report AMAG Pharmaceuticals, Inc. (AMAG): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Incyte Corporation (INCY): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ACOR) has an Earnings ESP of +5.56% and a Zacks Rank #3. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) to likely post an earnings beat."
2017-02-02,20.89999961853028,21.100000381469727,0.9367627729150066,Implied Volatility Surging for Acorda Therapeutics (ACOR) Stock Options | GlaxoSmithKline (GSK) Q4 Earnings: What's in the Cards? | GW Pharmaceuticals (GWPH) Q1 Earnings: What's in Store?,"Given the way analysts feel about Acorda Therapeutics right now, this huge implied volatility could mean there's a trade developing. Investors in Acorda Therapeutics, Inc.ACOR need to pay close attention to the stock based on moves in the options market lately. Clearly, options traders are pricing in a big move for Acorda Therapeutics shares, but what is the fundamental picture for the company? | GlaxoSmithKline PLC Price and EPS Surprise GlaxoSmithKline PLC Price and EPS Surprise | GlaxoSmithKline PLC Quote Stocks to Consider A couple of stocks in the healthcare sector that have both a positive Earnings ESP and a favorable Zacks Rank are: Acorda Therapeutics, Inc. ACOR is expected to release results on Feb 14. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Kite Pharma, Inc. (KITE): Free Stock Analysis Report To read this article on Zacks.com click here. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. | Click to get this free report AMAG Pharmaceuticals, Inc. (AMAG): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Incyte Corporation (INCY): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ACOR has an Earnings ESP of +5.56% and a Zacks Rank #3. Stocks that Warrant a Look Here are a couple of health care stocks that you might want to consider, as our model shows that they have the right combination of elements - a positive Zacks Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) - to post an earnings beat this quarter."
2017-02-01,20.850000381469727,20.950000762939453,0.9569414669372629,,
2017-01-31,19.450000762939453,20.5,0.479618127770401,,
2017-01-30,20.200000762939453,19.600000381469727,5.398453449221674,,
2017-01-27,20.950000762939453,20.200000762939453,-2.9702988059809163,,
2017-01-26,21.14999961853028,20.950000762939453,-3.5799521369314213,,
2017-01-25,21.049999237060547,21.14999961853028,-0.9456210836788914,"The Zacks Analyst Blog Highlights: RedHill Biopharma, Cempra, Vertex Pharmaceuticals, Acorda Therapeutics and Kite Pharma","Stocks recently featured in the blog include RedHill Biopharma Ltd.( NASDAQ: RDHL - Free Report ) , Cempra, Inc. ( NASDAQ: CEMP - Free Report ) , Vertex Pharmaceuticals Incorporated ( NASDAQ: VRTX - Free Report ) , Acorda Therapeutics, Inc. ( NASDAQ: ACOR - Free Report ) and Kite Pharma, Inc. ( NASDAQ: KITE - Free Report ) . Get the full Report on RDHL - FREE Get the full Report on CEMP - FREE Get the full Report on VRTX - FREE Get the full Report on ACOR - FREE Get the full Report on KITE - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Click to get this free report Redhill Biopharma Ltd. (RDHL): Free Stock Analysis Report Cempra, Inc. (CEMP): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Kite Pharma, Inc. (KITE): Free Stock Analysis Report To read this article on Zacks.com click here."
2017-01-24,20.799999237060547,20.850000381469727,0.4750612118487557,Will These 5 Drug Stocks Be Big Winners in the Q4 Earnings Season?,"Click to get this free report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Kite Pharma, Inc. (KITE): Free Stock Analysis Report Redhill Biopharma Ltd. (RDHL): Free Stock Analysis Report Cempra, Inc. (CEMP): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ACOR : Ardsley, NY-based Acorda is focused on developing treatments that restore function and improve the lives of people with neurological disorders. Acorda, which posted an average surprise of 168.27% over the last four quarters, is expected to deliver a positive earnings surprise of 72.73% in the fourth quarter."
2017-01-23,21.049999237060547,20.700000762939453,0.2403901261692827,,
2017-01-20,20.75,21.0,-1.6627006499120807,,
2017-01-19,21.14999961853028,20.700000762939453,1.2048192771084338,,
2017-01-18,20.600000381469727,21.100000381469727,-2.12765420192522,Kura Oncology Starts Dosing Patients in Phase II CMML Study,"While Anika and Sunesis are Zacks Rank #1 (Strong Buy) stocks, Acorda carries a Zacks Rank #2 (Buy). Click to get this free report Acorda Therapeutics Inc. (ACOR): Free Stock Analysis Report Anika Therapeutics Inc. (ANIK): Free Stock Analysis Report Kura Oncology Inc. (KURA): Free Stock Analysis Report Sunesis Pharmaceuticals Inc. (SNSS): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in this industry include Anika Therapeutics, Inc. ANIK , Acorda Therapeutics, Inc. ACOR and Sunesis Pharmaceuticals, Inc. SNSS ."
2017-01-17,21.25,20.5,2.4271844210729427,What's Behind Clovis' (CLVS) One-Year Rally of 146.3%?,"Clovis Oncology, Inc. Price and Consensus Clovis Oncology, Inc. Price and Consensus | Clovis Oncology, Inc. Quote Stocks to Consider A couple of better-ranked stocks in this industry include Anika Therapeutics, Inc. ANIK and Acorda Therapeutics, Inc. ACOR . Click to get this free report Foundation Medicine, Inc. (FMI): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Anika Therapeutics Inc. (ANIK): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report To read this article on Zacks.com click here. While Anika is a Zacks Rank #1 (Strong Buy) stock, Acorda a Zacks Rank #2 (Buy)."
2017-01-13,20.799999237060547,21.39999961853028,-3.5294117647058822,,
2017-01-12,20.549999237060547,20.799999237060547,2.8846173244116216,,
2017-01-11,21.299999237060547,20.75,1.216545057330911,,
2017-01-10,21.39999961853028,21.350000381469727,-2.582156135027393,,
2017-01-09,21.450000762939453,21.299999237060547,-0.23364129884030274,,
2017-01-06,20.950000762939453,21.14999961853028,-0.6993077880821036,,
2017-01-05,20.450000762939453,20.75,0.9546484406082951,,
2017-01-04,19.64999961853028,20.5,1.466988879551638,,
2017-01-03,18.89999961853028,19.5,4.3257017708445895,,
2016-12-30,18.350000381469727,18.799999237060547,3.174605257036387,,
2016-12-29,18.25,18.350000381469727,2.4523097887520486,,
2016-12-28,18.450000762939453,18.14999961853028,0.547947295724529,,
2016-12-27,18.100000381469727,18.350000381469727,-1.6260223956835025,,
2016-12-23,18.049999237060547,18.14999961853028,1.3812154405032113,,
2016-12-22,18.39999961853028,18.14999961853028,0.5540187573216695,,
2016-12-21,18.549999237060547,18.5,-1.35869568034246,,
2016-12-20,18.75,18.64999961853028,-0.2695376771803566,,
2016-12-19,19.950000762939453,18.700000762939453,-0.5333353678385038,,
2016-12-16,21.39999961853028,20.100000381469727,-6.265663920785855,,
2016-12-15,20.799999237060547,21.39999961853028,-6.074762898289416,,
2016-12-14,21.100000381469727,20.700000762939453,2.8846173244116216,,
2016-12-13,21.350000381469727,21.14999961853028,-1.8957327549697958,,
2016-12-12,21.25,21.200000762939453,-0.9367717066320634,,
2016-12-09,21.25,21.39999961853028,-0.23529052734374997,,
2016-12-08,20.39999961853028,21.200000762939453,0.7058805577895555,,
2016-12-07,21.200000762939453,20.5,3.9215743106313288,,
2016-12-06,21.25,21.64999961853028,-3.3018902723963657,,
2016-12-05,20.600000381469727,21.200000762939453,1.8823511460248497,,
2016-12-02,20.200000762939453,20.299999237060547,2.9126231570822863,,
2016-12-01,20.950000762939453,20.25,0.4950419323971463,,
2016-11-30,21.200000762939453,20.799999237060547,-3.341292302851627,,
2016-11-29,20.700000762939453,20.64999961853028,-1.8867995824706032,,
2016-11-28,21.200000762939453,20.600000381469727,-0.24155141336367897,,
2016-11-25,21.799999237060547,21.18000030517578,-2.830190376778715,,
2016-11-23,20.25,21.700000762939453,-2.844031897169757,,
2016-11-22,20.75,20.799999237060547,7.160497594762731,Acorda Stops Post-Stroke Development Program on Ampyra,"It is also advancing its early-stage assets - CVT-427 in migraine, SYN120 in dementia associated with Parkinson's disease and rHIgM22 in MS. ACORDA THERAPT Price ACORDA THERAPT Price | ACORDA THERAPT Quote Zacks Rank & Key Picks Acorda currently carries a Zacks Rank #3 (Hold). Click to get this free report ALKERMES INC (ALKS): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report CAMBREX CORP (CBM): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc.ACOR has decided to discontinue development of Ampyra (dalfampridine) for an expanded indication of post-stroke walking difficulties (PSWD)."
2016-11-21,19.75,20.39999961853028,0.24096017860504518,"Why Acorda Therapeutics Stock Is Slumping Today | Mid-Morning Market Update: Markets Open Higher; Symantec To Acquire Lifelock | Health Care Sector Update for 11/21/2016: MNK,OGEN,ACOR | Health Care Sector Update for 11/21/2016: IMUC,OGEN,ACOR | Monday Sector Laggards: Drugs, Biotechnology Stocks","What happened Shares of Acorda Therapeutics (NASDAQ: ACOR) fell by more than 15% in pre-market trading Monday after the company announced that it will discontinue the development of its flagship drug Ampyra as a treatment for post-stroke walking difficulties. * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now… and Acorda Therapeutics wasn't one of them! That said, Acorda's other clinical assets remain in the early- to mid-stage development phases, giving the company a razor-thin margin of error in terms of boosting its growth organically within the next few years. | Meanwhile, top losers in the sector included Acorda Therapeutics Inc (NASDAQ: ACOR ), down 7 percent, and Simulations Plus, Inc. (NASDAQ: SLP ), down 4 percent. Applied Micro Circuits Corporation (NASDAQ: AMCC ) shares were also up, gaining 12 percent to $8.12 after MACOM Technology Solutions Holdings Inc (NASDAQ: MTSI ) agreed to buy Applied Micro for about $770 million. The eurozone's STOXX 600 gained 0.35 percent, the Spanish Ibex Index fell 0.02 percent, while Italy's FTSE MIB Index fell 0.10 percent. | (-) ACOR, Dalfampridine drug candidate fails to show sufficient efficacy during recent clinical testing to improve walking difficulty in patients following a stoke to support continued development. Health care stocks were ending slightly higher today, with the NYSE Health Care Index climbing just over 0.1% while shares of health care companies in the S&P 500 were up nearly 0.2% as a group. In company news, Mallinckrodt plc ( MNK ) surged Monday after U.S. regulators granted fast track designation for an investigational new drug application for the company's Acthar gel drug candidate to treat patients with amyotrophic lateral sclerosis. | (-) ACOR, (-6.3%) Company discontinues development of dalfampridine drug candidate after it fails to show sufficient efficacy during recent clinical testing to improve walking difficulty in patients. Health care stocks were mostly higher today, with the NYSE Health Care Index climbing nearly 0.2% while shares of health care companies in the S&P 500 were up nearly 0.4% as a group. In company news, ImmunoCellular Therapeutics Ltd ( IMUC ) rallied on Monday after the biotech company reported additional survival data supporting its ICT-107 drug candidate in patients with certain forms of brain cancer. | Also lagging the market Monday are biotechnology shares, down on the day by about 0.4% as a group, led down by Adverum Biotechnologies ( ADVM ), trading lower by about 15.8% and Acorda Therapeutics ( ACOR ), trading lower by about 6.8%. VIDEO: Monday Sector Laggards: Drugs, Biotechnology Stocks The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2016-11-18,21.25,21.299999237060547,3.2911373090140783,,
2016-11-17,20.350000381469727,21.25,0.23529052734374997,,
2016-11-16,20.64999961853028,20.39999961853028,4.422602465156677,,
2016-11-15,21.39999961853028,20.850000381469727,-1.2106537753911746,,
2016-11-14,20.89999961853028,21.39999961853028,-2.570089938619948,,
2016-11-11,20.450000762939453,20.75,2.3923445412730624,,
2016-11-10,20.100000381469727,20.600000381469727,1.466988879551638,,
2016-11-09,19.049999237060547,19.950000762939453,2.487562141844296,,
2016-11-08,17.799999237060547,18.0,4.724417647891613,,
2016-11-07,17.25,17.799999237060547,1.123599839954155,,
2016-11-04,16.450000762939453,16.899999618530273,3.1884013742640396,,
2016-11-03,17.700000762939453,16.450000762939453,2.7355552262625547,,
2016-11-02,17.75,17.549999237060547,-7.062146588249138,,
2016-11-01,17.600000381469727,17.75,-1.126764861630722,,
2016-10-31,17.850000381469727,17.700000762939453,0.8522705413586326,,
2016-10-28,18.049999237060547,17.700000762939453,-0.8403339794098247,"Acorda (ACOR) Reports Wider Q3 Loss, Revenues Down Y/Y","Acorda Therapeutics, Inc.ACOR reported a loss of 28 cents per share in the third quarter of 2016 (including the impact of stock-based compensation expense and other non-recurring items), which was wider than the Zacks Consensus Estimate of a loss of 26 cents. ACORDA THERAPT Price, Consensus and EPS Surprise ACORDA THERAPT Price, Consensus and EPS Surprise | ACORDA THERAPT Quote Zacks Rank & Key Picks Acorda currently carries a Zacks Rank #3 (Hold). Click to get this free report GERON CORP (GERN): Free Stock Analysis Report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here."
2016-10-27,19.75,18.25,-1.9390498000823806,Oversold Conditions For Acorda Therapeutics,"In trading on Thursday, shares of Acorda Therapeutics Inc (Symbol: ACOR) entered into oversold territory, hitting an RSI reading of 28.3, after changing hands as low as $18.10 per share. The chart below shows the one year performance of ACOR shares: Looking at the chart above, ACOR's low point in its 52 week range is $18.10 per share, with $43.63 as the 52 week high point - that compares with a last trade of $18.25. A bullish investor could look at ACOR's 28.3 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side."
2016-10-26,19.600000381469727,19.75,-7.59493670886076,,
2016-10-25,20.25,19.600000381469727,0.7653041612799477,,
2016-10-24,20.299999237060547,20.100000381469727,-3.2098746594087575,,
2016-10-21,20.14999961853028,20.100000381469727,-0.9852160744208003,,
2016-10-20,20.049999237060547,20.200000762939453,-0.24813517621396797,,
2016-10-19,20.299999237060547,20.049999237060547,0.7481373146470872,,
2016-10-18,20.25,20.14999961853028,-1.2315271398808199,,
2016-10-17,19.700000762939453,19.799999237060547,-0.4938290442949109,,
2016-10-14,20.040000915527344,19.6299991607666,0.507606447961238,,
2016-10-13,18.88999938964844,19.979999542236328,-2.0459168464561577,,
2016-10-12,19.63999938964844,19.0,5.770249803105858,,
2016-10-11,20.020000457763672,19.56999969482422,-3.258652798053356,,
2016-10-10,20.059999465942383,20.190000534057617,-2.2477560072429705,,
2016-10-07,20.81999969482422,19.81999969482422,0.6480611743581977,,
2016-10-06,20.479999542236328,20.709999084472656,-4.803074037741684,,
2016-10-05,20.59000015258789,20.670000076293945,1.1230446649278252,,
2016-10-04,20.770000457763672,20.459999084472656,0.38853775188534784,,
2016-10-03,20.76000022888184,20.82999992370605,-1.4925438924347227,,
2016-09-30,20.75,20.8799991607666,0.3371854241447757,,
2016-09-29,21.86000061035156,20.63999938964844,0.6265019795980797,,
2016-09-28,22.25,21.989999771118164,-5.580975236228493,,
2016-09-27,23.100000381469727,22.059999465942383,-1.1685403545251054,,
2016-09-26,25.0,22.989999771118164,-4.502168391138244,Mid-Morning Market Update: Markets Open Lower; Cal-Maine Posts Wider-Than-Expected Loss | Mid-Afternoon Market Update: Dow Falls 150 Points; Himax Technologies Shares Slide After Nomura Downgrade,"Meanwhile, top losers in the sector included Acorda Therapeutics Inc (NASDAQ: ACOR ), down 11 percent, and Natus Medical Inc (NASDAQ: BABY ), down 11 percent. The eurozone's STOXX 600 dropped 1.45 percent, the Spanish Ibex Index fell 1.23 percent, while Italy's FTSE MIB Index tumbled 1.69 percent. Meanwhile the German DAX declined 1.83 percent, and the French CAC 40 declined 1.65 percent while U.K. shares fell 1.40 percent. | Meanwhile, top losers in the sector included Acorda Therapeutics Inc (NASDAQ: ACOR ), down 15 percent, and Natus Medical Inc (NASDAQ: BABY ), down 10 percent. Toward the end of trading Monday, the Dow traded down 0.83 percent to 18,109.35 while the NASDAQ declined 0.88 percent to 5,258.98. The eurozone's STOXX 600 dropped 1.55 percent, the Spanish Ibex Index fell 1.27 percent, while Italy's FTSE MIB Index tumbled 1.58 percent."
2016-09-23,27.239999771118164,27.280000686645508,-8.040000915527344,,
2016-09-22,27.059999465942383,27.21999931335449,0.14684624032102836,,
2016-09-21,26.43000030517578,27.06999969482422,0.591278087841358,,
2016-09-20,26.84000015258789,26.36000061035156,2.4214883929574023,,
2016-09-19,26.600000381469727,26.68000030517578,-1.7883738431724656,,
2016-09-16,25.68000030517578,26.34000015258789,0.30075158856683615,,
2016-09-15,25.030000686645508,25.709999084472656,2.5700928332118713,,
2016-09-14,24.96999931335449,25.059999465942383,2.7167334365674005,,
2016-09-13,24.729999542236328,24.8700008392334,0.3604331400191917,,
2016-09-12,23.75,24.940000534057617,0.5661192866500556,,
2016-09-09,24.63999938964844,23.75,5.010528564453125,,
2016-09-08,24.51000022888184,24.8799991607666,-3.6120105994091074,,
2016-09-07,24.46999931335449,24.489999771118164,1.5095835513243552,,
2016-09-06,24.280000686645508,24.450000762939453,0.08173460696731687,,
2016-09-02,24.440000534057617,24.270000457763672,0.7001650390704017,,
2016-09-01,24.209999084472656,24.34000015258789,-0.6955813116986103,,
2016-08-31,24.440000534057617,24.07999992370605,0.536972627143187,,
2016-08-30,24.440000534057617,24.530000686645508,-1.4729975551755745,,
2016-08-29,24.350000381469727,24.530000686645508,0.36824938879388996,,
2016-08-26,24.6299991607666,24.299999237060547,0.7392209542335816,"Health Care Sector Update for 08/26/2016: ALR,ABT,TGTX,ACOR | Health Care Sector Update for 08/26/2016: PTLA,TGTX,ACOR","(-) ACOR, Confirms Orphan Drug designation for its BTT1023 for the treatment of primary sclerosing cholangitis. Health care stocks remained mixed late Friday, with the NYSE Health Care Index climbing late to its break-even mark while shares of health care companies in the S&P 500 were ahead over 0.4% as a group. In company news, Alere ( ALR ) was lower in late trade after the diagnostics products company Friday said it plans to release a redacted version of its complaint against Abbott Laboratories ( ABT ) in a bid to to convince the larger rival to follow through with a proposed $5.8 billion buyout proposal. | (-) ACOR, (-1.3%) Wins Orphan Drug designation for its BTT1023 medication for the treatment of primary sclerosing cholangitis. Health care stocks were narrowly mixed Friday, with the NYSE Health Care Index dropping less than 0.1% while shares of health care companies in the S&P 500 were ahead less than 0.1% as a group. In company news, investors were betting on good news Friday after Portola Pharmaceuticals ( PTLA ) today said it would be discussing interim results from clinical testing of its AndexXa anticoagulant antidote candidate next week at an industry conference in Rome."
2016-08-25,24.209999084472656,24.479999542236328,-1.3398292121410837,"Notable Thursday Option Activity: ACOR, PG, SFL","Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Acorda Therapeutics Inc (Symbol: ACOR), where a total of 3,537 contracts have traded so far, representing approximately 353,700 underlying shares. Below is a chart showing SFL's trailing twelve month trading history, with the $15 strike highlighted in orange: For the various different available expirations for ACOR options , PG options , or SFL options , visit StockOptionsChannel.com. That amounts to about 67.4% of ACOR's average daily trading volume over the past month of 524,765 shares."
2016-08-24,25.600000381469727,24.290000915527344,1.1152435686659716,,
2016-08-23,26.09000015258789,25.6200008392334,-5.11718533758543,,
2016-08-22,24.93000030517578,25.940000534057617,-1.8014538543721414,,
2016-08-19,24.979999542236328,24.850000381469727,4.051344631039363,,
2016-08-18,24.1200008392334,25.0,-0.520412982981838,,
2016-08-17,24.15999984741211,24.190000534057617,3.648420937594671,,
2016-08-16,24.21999931335449,24.049999237060547,0.12417502829049615,,
2016-08-15,24.239999771118164,24.26000022888184,-0.7018995917155401,,
2016-08-12,23.93000030517578,24.21999931335449,0.0825101400681772,,
2016-08-11,23.790000915527344,24.020000457763672,1.2118637880501153,,
2016-08-10,23.940000534057617,23.75,0.9667908086805125,,
2016-08-09,24.15999984741211,23.989999771118164,-0.7936530067629609,,
2016-08-08,24.63999938964844,24.209999084472656,-0.7036427043361708,,
2016-08-05,25.1200008392334,24.71999931335449,-1.745131151896185,,
2016-08-04,25.0,24.989999771118164,-1.5923627090576038,,
2016-08-03,24.90999984741211,24.89999961853028,-0.04000091552734375,"Notable Wednesday Option Activity: ACOR, SQ, AGN","Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Acorda Therapeutics Inc (Symbol: ACOR), where a total of 3,278 contracts have traded so far, representing approximately 327,800 underlying shares. Particularly high volume was seen for the $27 strike call option expiring October 21, 2016 , with 3,102 contracts trading so far today, representing approximately 310,200 underlying shares of ACOR. Below is a chart showing ACOR's trailing twelve month trading history, with the $27 strike highlighted in orange: Square Inc (Symbol: SQ) saw options trading volume of 13,954 contracts, representing approximately 1.4 million underlying shares or approximately 56.3% of SQ's average daily trading volume over the past month, of 2.5 million shares."
2016-08-02,24.71999931335449,24.959999084472656,-0.04014543935401811,How The Parts Add Up: PBE Headed For $52,"Three of PBE's underlying holdings with notable upside to their analyst target prices are Acorda Therapeutics Inc (Symbol: ACOR), Insys Therapeutics Inc (Symbol: INSY), and Emergent BioSolutions Inc (Symbol: EBS). Although ACOR has traded at a recent price of $25.13/share, the average analyst target is 105.59% higher at $51.67/share. Below is a twelve month price history chart comparing the stock performance of ACOR, INSY, and EBS: Combined, ACOR, INSY, and EBS represent 6.82% of the PowerShares Dynamic Biotechnology & Genome Portfolio ETF."
2016-08-01,25.239999771118164,25.1299991607666,0.9708728874782472,,
2016-07-29,24.600000381469727,25.280000686645508,-0.4358185869614583,,
2016-07-28,25.290000915527344,24.950000762939453,2.7642288399637605,,
2016-07-27,25.90999984741211,26.709999084472656,-1.3444054578073983,,
2016-07-26,25.809999465942383,25.90999984741211,3.087608034627028,,
2016-07-25,25.670000076293945,26.049999237060547,0.387448212084166,,
2016-07-22,25.459999084472656,25.600000381469727,1.4803239565142345,,
2016-07-21,26.239999771118164,25.40999984741211,0.5498872821344805,,
2016-07-20,24.540000915527344,25.979999542236328,-3.163109492933833,,
2016-07-19,25.040000915527344,24.290000915527344,5.8679648450943835,,
2016-07-18,25.32999992370605,25.1299991607666,-2.995207558219073,,
2016-07-15,25.200000762939453,25.290000915527344,-0.7895805903744643,,
2016-07-14,24.76000022888184,25.01000022888184,0.3571434518377077,,
2016-07-13,25.39999961853028,24.51000022888184,1.0096930439781744,,
2016-07-12,25.8700008392334,25.21999931335449,-3.5039346575389403,,
2016-07-11,26.31999969482422,25.56999969482422,-2.512568630817915,,
2016-07-08,25.65999984741211,26.209999084472656,-2.849544105988292,,
2016-07-07,25.790000915527344,25.64999961853028,2.1434109132156367,,
2016-07-06,25.290000915527344,25.780000686645508,-0.5428510741648437,,
2016-07-05,25.799999237060547,25.450000762939453,1.9375237381558104,,
2016-07-01,25.559999465942383,25.989999771118164,-1.3565832731434215,,
2016-06-30,25.31999969482422,25.51000022888184,1.6823173480450908,,
2016-06-29,25.690000534057617,25.38999938964844,0.750397062984403,,
2016-06-28,24.75,25.309999465942383,-1.167773990551149,,
2016-06-27,24.979999542236328,24.479999542236328,2.262624104817708,,
2016-06-24,25.270000457763672,25.239999771118164,-2.001601317704578,,
2016-06-23,25.600000381469727,26.309999465942383,-0.11872056233497509,Anavex's Lead Candidate Gets Orphan Drug Status Yet Again,"Click to get this free report ACORDA THERAPT (ACOR): Free Stock Analysis Report RETROPHIN INC (RTRX): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report ANAVEX LIFE SCI (AVXL): Free Stock Analysis Report To read this article on Zacks.com click here. Some other favorably ranked stocks in the health care sector include ANI Pharmaceuticals, Inc. ANIP and Retrophin, Inc. RTRX - both sporting a Zacks Rank #1 (Strong Buy) and Acorda Therapeutics, Inc. ACOR - carrying a Zacks Rank #2 (Buy). Anavex Life Sciences Corp.AVXL announced that the FDA has granted orphan drug status to its lead candidate ANAVEX 2-73 for the treatment of patients suffering from infantile spasms."
2016-06-22,25.09000015258789,25.270000457763672,2.7734338823939284,,
2016-06-21,25.21999931335449,25.07999992370605,0.7174185096894679,"Fate's (FATE) ProTmune Gets Fast Track Status, Stock Up | First Week of August 19th Options Trading For Acorda Therapeutics (ACOR) | Health Care Sector Update for 06/21/2016: ACOR","Some better-ranked stocks in the health care sector include ANI Pharmaceuticals, Inc. ANIP and Retrophin, Inc. RTRX - both sporting a Zacks Rank #1 (Strong Buy) and Acorda Therapeutics, Inc. ACOR - carrying a Zacks Rank #2 (Buy). Click to get this free report ACORDA THERAPT (ACOR): Free Stock Analysis Report RETROPHIN INC (RTRX): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report FATE THERAPEUTC (FATE): Free Stock Analysis Report To read this article on Zacks.com click here. Fate Therapeutics, Inc. 's FATE shares were up 19% after the company announced that it has received Fast Track designation from the FDA for ProTmune for the reduction of incidence and severity of acute graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic cell transplantation (HCT). | Below is a chart showing the trailing twelve month trading history for Acorda Therapeutics Inc, and highlighting in green where the $23.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $26.00 strike price has a current bid of $1.65. Below is a chart showing ACOR's trailing twelve month trading history, with the $26.00 strike highlighted in red: Considering the fact that the $26.00 strike represents an approximate 5% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acorda Therapeutics Inc (Symbol: ACOR) saw new options become available this week, for the August 19th expiration. | In health-care stocks news, Acorda Therapeutics ( ACOR ) said in a regulatory filing that the United States Court of Appeals for the Federal Circuit denied a request by Mylan Pharmaceuticals, Inc. and Mylan, Inc. ( MYL ) for a rehearing of the court's previous decision to uphold a lower court ruling that Acorda Therapeutics' abbreviated new drug application ( ANDA ) litigation against Mylan can continue in the District Court of Delaware. Shares in Acorda Therapeutics were unchanged at $25.31 pre-bell. MRK: flat AMGN: flat Health-care shares were mainly unchanged in pre-market trade on Tuesday."
2016-06-20,26.0,25.309999465942383,-0.5551125831090132,,
2016-06-17,25.86000061035156,25.75,-2.6538482079139123,7 Biotech Stocks that are Buys Right Now,"Click to get this free report ACORDA THERAPT (ACOR): Free Stock Analysis Report LIGAND PHARMA-B (LGND): Free Stock Analysis Report AVEO PHARMACEUT (AVEO): Free Stock Analysis Report BIND THERAPEUTC (BIND): Free Stock Analysis Report RETROPHIN INC (RTRX): Free Stock Analysis Report MAST THERAPEUTC (MSTX): Free Stock Analysis Report SUNESIS PHARMA (SNSS): Free Stock Analysis Report To read this article on Zacks.com click here. RETROPHIN INC Price and Consensus RETROPHIN INC Price and Consensus | RETROPHIN INC Quote Acorda Therapeutics, Inc.ACOR is a commercial-stage biotech company focused on the development and commercialization of therapies that improve neurological function in people suffering from multiple sclerosis, spinal cord injury and other nervous system disorders. ACORDA THERAPT Price and Consensus ACORDA THERAPT Price and Consensus | ACORDA THERAPT Quote Cambridge, MA-based AVEO Pharmaceuticals, Inc.AVEO is a development-stage biotech company that focuses on the development of treatments targeting cancer using its proprietary human response platform."
2016-06-16,25.93000030517578,25.770000457763672,-0.42536971289755715,,
2016-06-15,25.979999542236328,26.15999984741211,-0.6170452970653165,,
2016-06-14,26.170000076293945,25.75,0.6928418335156253,,
2016-06-13,26.979999542236328,26.229999542236328,-1.6048913835288896,,
2016-06-10,27.200000762939453,27.06999969482422,-2.7798369633991244,,
2016-06-09,27.81999969482422,27.520000457763672,-0.47794508995883356,"The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics","Click to get this free report BIOGEN INC (BIIB): Free Stock Analysis Report MERRIMACK PHAR (MACK): Free Stock Analysis Report RETROPHIN INC (RTRX): Free Stock Analysis Report IDERA PHARMACT (IDRA): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include Biogen Inc. ( BIIB ), Merrimack Pharmaceuticals, Inc. ( MACK ), Retrophin, Inc. ( RTRX ), Idera Pharmaceuticals, Inc. ( IDRA ) and Acorda Therapeutics, Inc. ( ACOR ). Ardsley, NY-based Acorda Therapeutics, Inc. ( ACOR ) is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel treatments that improve neurological function in people suffering from multiple sclerosis (MS), spinal cord injury (SCI) and other nervous system disorders."
2016-06-08,28.40999984741211,27.93000030517578,-1.0783581608606572,"Forget Biogen (BIIB), Buy These 5 Biotech Stocks Instead","Click to get this free report ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report LIGAND PHARMA-B (LGND): Free Stock Analysis Report IDERA PHARMACT (IDRA): Free Stock Analysis Report RETROPHIN INC (RTRX): Free Stock Analysis Report MERRIMACK PHAR (MACK): Free Stock Analysis Report To read this article on Zacks.com click here. Ardsley, NY-based Acorda Therapeutics, Inc. ACOR is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel treatments that improve neurological function in people suffering from multiple sclerosis (MS), spinal cord injury (SCI) and other nervous system disorders. Ampyra continues to perform well and Acorda is progressing with its pipeline."
2016-06-07,29.51000022888184,28.26000022888184,-1.6895443323279418,,
2016-06-06,29.049999237060547,29.700000762939453,-4.235852220619802,,
2016-06-03,29.100000381469727,28.89999961853028,2.237526825989264,,
2016-06-02,28.86000061035156,29.100000381469727,-0.6872878361431306,,
2016-06-01,28.450000762939453,28.950000762939453,0.8316000209372277,,
2016-05-31,27.420000076293945,28.450000762939453,1.7574691971584326,,
2016-05-27,26.96999931335449,27.290000915527344,3.756384696497497,The Medicines Co. Carbavance TANGO 1 Study Enrolled,"Click to get this free report MEDICINES CO (MDCO): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report RETROPHIN INC (RTRX): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are ANI Pharmaceuticals, Inc. ANIP , Retrophin, Inc. RTRX and Acorda Therapeutics, Inc. ACOR . While ANI Pharmaceuticals and Retrophin sport a Zacks Rank #1 (Strong Buy), Acorda carries a Zacks Rank #2 (Buy)."
2016-05-26,27.239999771118164,26.8799991607666,1.1865094932145692,Alkermes Begins Phase I Study on Immuno-Oncology Drug,"Click to get this free report ALKERMES INC (ALKS): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report RETROPHIN INC (RTRX): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are ANI Pharmaceuticals, Inc. ANIP , Retrophin, Inc. RTRX and Acorda Therapeutics, Inc. ACOR . While ANI Pharmaceuticals and Retrophin sport a Zacks Rank #1 (Strong Buy), Acorda Therapeutics carries a Zacks Rank #2 (Buy)."
2016-05-25,27.65999984741211,27.209999084472656,-1.3215881548327377,"Biotech Stock Roundup: XenoPort Soars on Acquisition Deal, AbbVie Crohn's Disease Drug Fares Well","Click to get this free report VERTEX PHARM (VRTX): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report XENOPORT INC (XNPT): Free Stock Analysis Report BIODEL INC (BIOD): Free Stock Analysis Report HORIZON PHARMA (HZNP): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report INTERCEPT PHARM (ICPT): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda ACOR has decided to terminate the development of one of its most advanced pipeline candidates - Plumiaz Nasal Spray, which was being evaluated for the treatment of seizure clusters in people with epilepsy. With data from ongoing studies showing that Plumiaz did not demonstrate its bioequivalence to Diastat rectal gel, Acorda decided to discontinue the development of the product which became a part of its pipeline following its Dec 2012 acquisition of Neuronex."
2016-05-24,26.809999465942383,27.59000015258789,-1.6269008149743556,,
2016-05-23,26.32999992370605,26.64999961853028,2.9093647974009404,"Acorda Shelves Development of Epilepsy Treatment, Plumiaz","Plumiaz became a part of Acorda's pipeline following its Dec 2012 acquisition of Neuronex and Acorda was forecasting Plumiaz U.S. annual peak sales of more than $200 million. Meanwhile, Acorda will be focusing on the development of its other pipeline candidates including CVT-301 (phase III program ongoing for the treatment of OFF episodes in Parkinson's disease patients), Ampyra (dalfampridine - post-stroke walking difficulty), and tozadenant (in phase III development for the reduction of OFF time in Parkinson's disease patients). Click to get this free report ACORDA THERAPT (ACOR): Free Stock Analysis Report RETROPHIN INC (RTRX): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here."
2016-05-20,25.5,26.309999465942383,1.2153425588737645,,
2016-05-19,26.40999984741211,25.709999084472656,3.176468493891697,,
2016-05-18,26.11000061035156,26.540000915527344,-2.6505140741530355,,
2016-05-17,26.82999992370605,26.25,1.6468797208886585,,
2016-05-16,26.559999465942383,26.8799991607666,-2.161758946535007,,
2016-05-13,26.1299991607666,26.40999984741211,1.2048181523292238,Aegerion Enters into Settlement Agreement with DoJ and SEC,"Click to get this free report SANOFI-AVENTIS (SNY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report AEGERION PHARMA (AEGR): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the healthcare sector include Acorda Therapeutics ACOR , Abbott Laboratories ABT and Sanofi SNY . As a result of the settlement agreement, Aegerion will pay $40 million to the DoJ and the SEC over a period of five years in following tranches: approximately $3 million upon finalization of the settlement; around $3.7 million per year, payable quarterly, for three years following finalization of the settlement, and roughly $13 million per year, payable quarterly, during the fourth and fifth year after finalization of the settlement."
2016-05-12,26.540000915527344,26.26000022888184,1.0715679128911735,,
2016-05-11,27.190000534057617,26.39999961853028,-1.0550138545085304,,
2016-05-10,27.26000022888184,27.36000061035156,-2.905483265944766,"Drug Stocks Q1 Earnings Slated on May 11: ACRS, EARS & More","Click to get this free report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report BIO-PATH HLDGS (BPTH): Free Stock Analysis Report CARDIOME PHARMA (CRME): Free Stock Analysis Report AURIS MEDICAL (EARS): Free Stock Analysis Report ACLARIS THERAPT (ACRS): Free Stock Analysis Report BIOTIE THERAPS (BITI): Free Stock Analysis Report To read this article on Zacks.com click here. The company is set to be acquired by Acorda Therapeutics, Inc. ACOR . This clinical-stage biotechnology company currently carries a Zacks Rank #3 and has an Earnings ESP of 0.00% which makes it difficult for us to predict an earnings beat for this quarter."
2016-05-09,26.239999771118164,27.1299991607666,0.36683925396218275,,
2016-05-06,25.40999984741211,26.11000061035156,3.3917659962331315,,
2016-05-05,25.68000030517578,25.63999938964844,2.7548239556984546,,
2016-05-04,25.559999465942383,25.459999084472656,-0.1557668031619067,VIVUS (VVUS) Q1 Loss Narrower but Qsymia Sales Decline,"ANI Pharmaceuticals, Inc. ANIP , Acorda Therapeutics, Inc. ACOR and Alnylam Pharmaceuticals, Inc. ALNY are better-ranked stocks in the health care sector - while ANIP is a Zacks Rank #1 (Strong Buy) stock, Acorda and Alnylam are Zacks Rank #2 (Buy) stocks. Click to get this free report VIVUS INC (VVUS): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report ALNYLAM PHARMA (ALNY): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. In the reported quarter, research and development expenses were $1 million, down 63% year over year reflecting the timing of clinical projects to support Qsymia post marketing requirements and cost control initiatives."
2016-05-03,26.75,25.690000534057617,-0.3912378073519635,,
2016-05-02,25.86000061035156,27.190000534057617,-3.962614825952833,,
2016-04-29,27.049999237060547,25.850000381469727,5.143077696501173,,
2016-04-28,28.959999084472656,27.34000015258789,-4.436225099580525,,
2016-04-27,28.920000076293945,28.90999984741211,-5.593919140533926,,
2016-04-26,30.0,29.040000915527344,-0.0345789379510868,Analysts See 10% Gains Ahead For The Holdings of IJT,"Similarly, ACOR has 66.33% upside from the recent share price of $30.06 if the average analyst target price of $50.00/share is reached, and analysts on average are expecting SSP to reach a target price of $24.75/share, which is 59.16% above the recent price of $15.55. Below is a twelve month price history chart comparing the stock performance of EHTH, ACOR, and SSP: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of IJT's underlying holdings with notable upside to their analyst target prices are eHealth Inc (Symbol: EHTH), Acorda Therapeutics Inc (Symbol: ACOR), and E.W."
2016-04-25,30.200000762939453,30.059999465942383,-3.1999969482421875,,
2016-04-22,29.68000030517578,30.1200008392334,-0.46358044192129877,,
2016-04-21,29.040000915527344,29.71999931335449,1.4824815685089032,,
2016-04-20,28.63999938964844,29.14999961853028,2.341592205197066,,
2016-04-19,28.68000030517578,28.489999771118164,1.7807270941010305,,
2016-04-18,28.39999961853028,28.700000762939453,-0.6624844213245299,,
2016-04-15,28.07999992370605,28.540000915527344,1.0563420719675976,Seth Klarman Profits From Biotie Therapies Buyout,"He disclosed the increase the same day Acorda Therapeutics Inc. ( ACOR ), a developer of treatments for neurological disorders, announced a tender offer to acquire all of the company's existing common stock, American Depository Shares, options and warrants. Acorda offered to buy the shares for $26.50 per ADS, an approximately 94% premium on its closing price Jan. 15, the last day it traded before the announcement. Klarman gave up 381,945 common shares, 1,395,999 ADSs and 381,945 warrants of Biotie to Acorda in the buyout, and the transaction closed April 11."
2016-04-14,28.51000022888184,28.100000381469727,1.6381801747547184,,
2016-04-13,27.850000381469727,28.420000076293945,-1.438091350826317,,
2016-04-12,27.5,27.68000030517578,2.0466775117298512,Why Acorda Therapeutics' Stock Sank 22.9% in March,"Until these patent issues are resolves, investors should take comfort in the Street's healthy 9.9% estimated increase in annual revenue next year for the biotech, implying that Acorda's recent volatility will eventually subside once the market changes its outlook toward the pharmaceutical industry. What: Shares of Acorda Therapeutics fell by 22.9% last month, according to data from S&P Global Market Intelligence . Now what: While Acorda would certainly benefit from a broader product portfolio to diversify its revenue base, the fact remains that the company's key patents for Ampyra are unlikely to be completely invalidated -- if history is any guide."
2016-04-11,27.86000061035156,27.40999984741211,0.6545465642755681,,
2016-04-08,27.799999237060547,27.65999984741211,-1.6152216549925307,,
2016-04-07,27.799999237060547,27.440000534057617,-0.5035949406135323,,
2016-04-06,26.540000915527344,27.979999542236328,-1.2949593988585821,,
2016-04-05,25.88999938964844,26.40999984741211,5.425767057402424,,
2016-04-04,27.09000015258789,26.049999237060547,2.0084993048380655,,
2016-04-01,26.350000381469727,27.09000015258789,-3.83905835979847,,
2016-03-31,26.209999084472656,26.450000762939453,2.8083482368317485,,
2016-03-30,25.299999237060547,26.3799991607666,0.9156874736748039,,
2016-03-29,25.309999465942383,26.11000061035156,4.268774530728141,,
2016-03-28,25.89999961853028,25.3799991607666,3.1608105937958353,,
2016-03-24,25.670000076293945,25.790000915527344,-2.0077238047202215,,
2016-03-23,27.34000015258789,25.709999084472656,0.4674750248412283,,
2016-03-22,25.89999961853028,27.32999992370605,-5.961964370950983,Acorda Gets Favorable Court Ruling in Ampyra Patent Lawsuit,"Acorda Therapeutics, Inc.ACOR received encouraging news with the U.S. Court of Appeals for the Federal Circuit ruling in favor of the company in its abbreviated new drug application (ANDA) lawsuit against Mylan N.V. MYL for its key growth driver, Ampyra. The U.S. Court of Appeals for the Federal Circuit backed a lower court ruling and announced that Acorda's ANDA lawsuit against Mylan can continue in the District Court of Delaware. Click to get this free report ALLERGAN PLC (AGN): Free Stock Analysis Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report To read this article on Zacks.com click here."
2016-03-21,26.100000381469727,25.93000030517578,5.52123678084022,,
2016-03-18,25.76000022888184,26.43000030517578,-0.6513412789627414,,
2016-03-17,26.90999984741211,25.61000061035156,2.6009319500810593,,
2016-03-16,28.18000030517578,26.790000915527344,-4.830915066636722,,
2016-03-15,29.450000762939453,28.13999938964844,-4.932574075924117,,
2016-03-14,31.75,29.450000762939453,-4.448221865377835,"Why Petroleo Brasileiro SA Petrobras (ADR) (PBR), Acorda Therapeutics Inc (ACOR) and ArcelorMittal SA (ADR) (MT) Are 3 of Today’s Worst Stocks | Acorda Therapeutics' Stock Slumped in February: Is It Now a Bargain?","Some investors would have been thrilled with a lethargic day, though … like owners of ArcelorMittal SA (ADR) (NYSE: MT ), Acorda Therapeutics Inc (NASDAQ: ACOR ) and Petroleo Brasileiro SA Petrobras(ADR) (NYSE: PBR ). More From InvestorPlace 7 Stocks That Are Rotten Inside and Out7 Big Bear Plays for a Suddenly Disappointed MarketThe 10 Best Funds for Your 401k The post Why Petroleo Brasileiro SA Petrobras (ADR) (PBR), Acorda Therapeutics Inc (ACOR) and ArcelorMittal SA (ADR) (MT) Are 3 of Today's Worst Stocks appeared first on InvestorPlace . Acorda Therapeutics Inc (ACOR) Finally, Acorda Therapeutics shares fell another 7% on Monday after losing 8% of their value on Friday. | Source: Acorda So what: This double-digit sell off occurred despite Acorda reporting a healthy 11% rise in revenue for the quarter and a 22% increase in total annual revenue -- reflecting the market's overwhelmingly negative view of drugmakers at the moment. Now what: Acorda is in the midst of an ongoing battle to defend Ampyra's suite of patents -- with the United States Patent and Trademark Office Patent Trials and Appeal Board reportedly initiating an inter partes review for four out of five of the drug's Orange Book-listed patents. What: According to data provided by S&P Global Market Intelligence , Acorda Therapeutics -- maker of themultiple sclerosis drug Ampyra -- saw its shares fall by nearly 14% in February."
2016-03-11,34.900001525878906,32.0,-7.244092085230069,,
2016-03-10,36.130001068115234,34.709999084472656,-8.309459596236719,,
2016-03-09,35.38999938964844,36.02999877929688,-3.930257242355111,,
2016-03-08,36.95000076293945,35.34000015258789,1.8084187643010932,,
2016-03-07,35.779998779296875,37.04999923706055,-4.357241074718407,,
2016-03-04,35.43000030517578,36.0,3.5494703775633534,,
2016-03-03,35.43000030517578,35.470001220703125,1.6088052213224242,,
2016-03-02,34.11000061035156,35.529998779296875,0.11290125651367898,Acorda Therapeutics (ACOR) Shares Cross Above 200 DMA,"In trading on Wednesday, shares of Acorda Therapeutics Inc (Symbol: ACOR) crossed above their 200 day moving average of $34.54, changing hands as high as $35.69 per share. The chart below shows the one year performance of ACOR shares, versus its 200 day moving average: Looking at the chart above, ACOR's low point in its 52 week range is $25.50 per share, with $43.63 as the 52 week high point - that compares with a last trade of $35.76. Acorda Therapeutics Inc shares are currently trading up about 3% on the day."
2016-03-01,33.029998779296875,34.310001373291016,4.162996609605388,,
2016-02-29,33.099998474121094,32.709999084472656,3.875272907356095,,
2016-02-26,33.560001373291016,33.0099983215332,-1.1782459444925797,,
2016-02-25,33.880001068115234,33.56999969482422,-1.6388648070662377,,
2016-02-24,33.630001068115234,33.65999984741211,-0.9149981213629909,,
2016-02-23,34.58000183105469,33.95000076293945,0.0892024333752311,,
2016-02-22,34.779998779296875,34.84000015258789,-1.821865340531763,,
2016-02-19,34.04999923706055,34.290000915527344,0.17251689303316484,,
2016-02-18,36.15999984741211,34.150001525878906,0.7048507601890791,,
2016-02-17,34.529998779296875,35.84000015258789,-5.558623700262693,,
2016-02-16,34.119998931884766,34.400001525878906,3.793806601801713,,
2016-02-12,33.5,33.630001068115234,0.820640688040823,"Acorda Q4 Earnings Decline Y/Y, Ampyra & Pipeline in Focus","The Quarter in Detail The bulk of net product revenues at Acorda came from Ampyra, which generated $122 million in the reported quarter, up 11% from the year-ago period and 4.3% on a sequential basis. Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report BIOTIE THERAPS (BITI): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. 's ACOR fourth-quarter 2015 earnings came in at 28 cents per share (excluding the impact of stock-based compensation expense), 39.1% below the year-ago earnings."
2016-02-11,35.5,33.47999954223633,0.388062889896222,,
2016-02-10,35.65999984741211,36.220001220703125,-5.690142134545555,Why Acorda Therapeutics (ACOR) Might Surprise This Earnings Season | Will Teva (TEVA) Continue with its Earnings Streak in Q4?,"This suggests that analysts have very recently bumped up their estimates for ACOR, giving the stock a Zacks Earnings ESP of 150.00% heading into earnings season. Given that ACOR has a Zacks Rank #2 (Buy) and an ESP in positive territory, investors might want to consider this stock ahead of earnings. Investors are always looking for stocks that are poised to beat at earnings season and Acorda Therapeutics, Inc.ACOR may be one such company. | Click to get this free report ALLERGAN PLC (AGN): Free Stock Analysis Report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. The Earnings ESP for Acorda Therapeutics, Inc. ACOR is +150% and it carries a Zacks Rank #2. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) to be able to beat earnings."
2016-02-09,34.72999954223633,35.349998474121094,1.570390846010213,,
2016-02-08,36.0099983215332,35.58000183105469,1.7851970632212764,Mylan (MYL) to Report Q4 Earnings: What's in the Cards? | 3 Biotech Stocks to Turn the Tide This Earnings Season,"Click to get this free report ACORDA THERAPT (ACOR): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ACOR has an Earnings ESP of +150% and a Zacks Rank #2. Zacks Rank: Although the company's Zacks Rank #2 enhances the predictive power of the ESP, the company's negative ESP makes a surprise prediction difficult. | Below are three biotech stocks we believe are best positioned to stand out as we take a stand in the ongoing earnings season: Acorda Therapeutics ( ACOR ) carries a Zacks Rank #2 with an Earnings ESP of +150.0%. Click to get this free report ACORDA THERAPT (ACOR): Free Stock Analysis Report NEKTAR THERAP (NKTR): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel treatments that improve the lives of patients with neurological disorders."
2016-02-05,37.220001220703125,36.66999816894531,-1.194103056154232,,
2016-02-04,37.59000015258789,37.27999877929688,-1.4777083119811418,,
2016-02-03,37.310001373291016,37.880001068115234,-0.8246910668598826,,
2016-02-02,37.52000045776367,37.16999816894531,1.5277396779520425,Should Acorda Therapeutics (ACOR) Be On Your Radar Now?,"And if this isn't enough, ACOR currently carries a Zacks Rank #2 (Buy) which further underscores the potential for its outperformance (See the performance of Zacks' portfolios and strategies here: About Zacks Performance ). One such company that looks well positioned for a solid gain, but has been overlooked by investors lately, is Acorda Therapeutics, Inc.ACOR . So if you are looking for a stock flying under-the-radar that is well-equipped to bounce down the road, make sure to consider Acorda Therapeutics."
2016-02-01,36.63999938964844,37.91999816894531,-0.9328419097765139,,
2016-01-29,35.95000076293945,36.81999969482422,3.4934465082401207,Will Pfizer (PFE) Keep the Earnings Streak Alive in Q4?,"Click to get this free report PFIZER INC (PFE): Free Stock Analysis Report ALLERGAN PLC (AGN): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here. The Earnings ESP for Acorda Therapeutics, Inc. ACOR is +150.00% and it carries a Zacks Rank #2. Zacks ESP : The Earnings ESP , which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is 0.00% since the Most Accurate estimate is in line with the Zacks Consensus Estimate of 52 cents per share."
2016-01-28,38.13999938964844,36.290000915527344,2.4200247939400326,,
2016-01-27,38.959999084472656,37.77999877929688,-4.850546679933092,,
2016-01-26,39.72999954223633,38.959999084472656,-3.028748287743308,Will Lilly (LLY) Keep the Earnings Streak Alive in Q4? | Allergan's Botox Gains FDA Nod for Lower Limb Spasticity,"Click to get this free report ASTRAZENECA PLC (AZN): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here. The Earnings ESP for Acorda Therapeutics, Inc. ACOR is +150.00% and it carries a Zacks Rank #2. Zacks ESP : The Earnings ESP , which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is 0.00% since the Most Accurate estimate is in line with the Zacks Consensus Estimate of 77 cents per share. | Click to get this free report PFIZER INC (PFE): Free Stock Analysis Report ALLERGAN PLC (AGN): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Acorda Therapeutics, Inc.'s ACOR Zanaflex, a short-acting drug, is also approved for the management of spasticity. Regulatory updates include events like filing of marketing applications, acceptance of these applications for review by the regulatory agencies, reviews by advisory panels and, finally, a response from the regulatory agency regarding the approval/label expansion status."
2016-01-25,37.68000030517578,39.88999938964844,-1.9380832283803495,Will Biogen (BIIB) Beat 4Q Earnings on MS Franchise Sales? | Will Higher Expenses Hurt Vertex's (VRTX) 4Q Earnings?,"Click to get this free report ASTRAZENECA PLC (AZN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. The Earnings ESP for Acorda Therapeutics, Inc. ACOR is +150.00% and it carries a Zacks Rank #2. Positive Zacks ESP : Earnings Surprise Prediction or Earnings ESP , which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is +2.21%. | Click to get this free report ASTRAZENECA PLC (AZN): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here. The Earnings ESP for Acorda Therapeutics, Inc. ACOR is +150.00% and it carries a Zacks Rank #2. While the company's flagship product, Kalydeco, is expected to deliver fourth quarter sales of approximately $180 million, newly approved CF treatment, Orkambi sales are expected to come in at approximately $220 million."
2016-01-22,38.09000015258789,38.0,5.865177989844887,,
2016-01-21,37.77999877929688,37.5099983215332,-0.23628288849396575,,
2016-01-20,36.86000061035156,37.9900016784668,-0.7146650780508679,"What Makes Incyte (INCY) a Strong Sell? | Biotie Therapies (BITI) Catches Eye: Stock Moves Up 86.5% | J&J Plans to Cut 3,000 Medical Devices Jobs, 2015 View Intact | Biotech Stock Roundup: Sarepta Plunges on Briefing Documents, Acorda to Buy Biotie","Click to get this free report ACORDA THERAPT (ACOR): Free Stock Analysis Report INCYTE CORP (INCY): Free Stock Analysis Report To read this article on Zacks.com click here. If you are still interested in the Medical-Biomedical/Genetics industry, you may instead consider a better-ranked stock - Acorda Therapeutics, Inc. ACOR . For the full year, we have seen 1 estimate moving down in the past 30 days, compared to no upward revision, with estimates widening from a loss of 15 cents per share a month ago to its current level of a loss of 18 cents per share. | Click to get this free report ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOTIE THERAPS (BITI): Free Stock Analysis Report To read this article on Zacks.com click here. The stock rallied after the company agreed to an all-cash buyout offer of $363 million from Acorda Therapeutics ACOR . Click to get this free report >> Want the latest recommendations from Zacks Investment Research? | Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report BAXALTA INC (BXLT): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector include Acorda Therapeutics, Inc. ACOR , Anika Therapeutics Inc. ANIK and Baxalta Incorporated BXLT . Johnson & JohnsonJNJ announced a restructuring plan that will see the company cut about 3,000 positions within its Medical Devices segment to address the changing needs of the global medical device market. | Click to get this free report VERTEX PHARM (VRTX): Free Stock Analysis Report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ELEVEN BIOTHERP (EBIO): Free Stock Analysis Report SAREPTA THERAP (SRPT): Free Stock Analysis Report To read this article on Zacks.com click here. This week saw another acquisition agreement being announced with Acorda ACOR saying that it will be acquiring Biotie Therapies Corp. in a deal worth approximately $363 million. With this acquisition, Acorda, which focuses on developing treatments that restore function and improve the lives of people with neurological disorders, will be adding a late-stage Parkinson's disease (PD) candidate (tozadenant) to its pipeline."
2016-01-19,40.04999923706055,37.54999923706055,3.065656672284186,"Mid-Day Market Update: Dow Surges 150 Points; Progressive Waste Shares Spike Higher | Here's Why Biotie Therapies Corp.'s Stock Skyrocketed Today | Closing Update: Dow, S&P 500 Hang On For Narrow Gains; Nasdaq Struggles as Energy, Mining Stocks Slump | Eleven Biotherapeutics' Eye Drug Fails in Phase III Study | Health Care Sector Update for 01/19/2016: BITI,ACOR,AEZS,AEZ.TO,EBIO | Mid-Afternoon Market Update: US Stocks Turn Red; Crude Oil Falls Over 3%","Equities Trading UP Biotie Therapies Oyj (ADR) (NASDAQ: BITI ) shares shot up 89 percent to $24.63 after the company agreed to be acquired by Acorda Therapeutics Inc (NASDAQ: ACOR ) for $25.60 per ADS. Midway through trading Tuesday, the Dow traded up 0.93 percent to 16,137.44 while the NASDAQ climbed 1.03 percent to 4,534.46. The eurozone's STOXX 600 rose 1.41 percent, the Spanish Ibex Index gained 1.20 percent, while Italy's FTSE MIB Index rose 1.03 percent. | So what: Acorda is reportedly buying Biotie mainly for its experimental Parkinson's disease drug tozadenant, indicated as a treatment to reduce daily ""off time,"" or the amount of time patients taking levodopa experience re-emerging symptoms as a result of the drug wearing off. The catalyst behind this eye-popping move is the news that Biotie has agreed to an all-cash buyout offer, worth $363 million or $25.60 per ADS, from the U.S. biotech Acorda Therapeutics . Given this long lead time, however, this buyout probably won't make much of an impact on Acorda's near-term outlook. | (+) BITI, Agrees to $363 mln buyout offer from Acorda Therapeutics ( ACOR ), which will pay around $25.60 for each American depository share, a nearly 94% premium to Friday's closing price. Stocks finished mixed Tuesday, giving back larger gains from earlier in today's session after crude oil's price turned lower again and dropped under $30 per barrel. China overnight reported 6.8% year-over-year growth in its Q4 gross domestic product, reflecting a 25-year low and generating speculation the People's Bank of China will soon step in to supply its economy with new stimulus measures. | Click to get this free report ACORDA THERAPT (ACOR): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report ELEVEN BIOTHERP (EBIO): Free Stock Analysis Report BAXALTA INC (BXLT): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector include Acorda Therapeutics, Inc. ACOR , Anika Therapeutics Inc. ANIK and Baxalta Incorporated BXLT . Eleven Biotherapeutics, Inc.EBIO announced disappointing top-line results and reported that its lead pipeline candidate, isunakinra (EBI-005), failed to achieve the primary endpoint in a phase III study. | In company news, Biotie Therapies ( BITI ) rallied after the early-state drugmaker agreed to a $363 million buyout offer from Acorda Therapeutics ( ACOR ), which will pay around $25.60 for each American depository share, a nearly 94% premium to Friday's closing price at current exchange rates. Acorda gains worldwide rights to Biotie's tozadenant drug candidate, an oral adenosine A2a receptor antagonist currently in Phase III testing to treat Parkinson's disease as an adjunct to other treatment regimens including levodopa and carbidopa. ACOR shares closed down almost 6% at $37.55 apiece, rebounding from an earlier session low of $36.60 a share. | Equities Trading UP Biotie Therapies Oyj (ADR) (NASDAQ: BITI ) shares shot up 85 percent to $24.20 after the company agreed to be acquired by Acorda Therapeutics Inc (NASDAQ: ACOR ) for $25.60 per ADS. Toward the end of trading Tuesday, the Dow traded down 0.20 percent to 15,955.72 while the NASDAQ dipped 0.86 percent to 4,449.67. The eurozone's STOXX 600 rose 1.31 percent, the Spanish Ibex Index gained 1.01 percent, while Italy's FTSE MIB Index rose 1.04 percent."
2016-01-15,38.09000015258789,39.900001525878906,-6.242197372345035,"Is Acorda Therapeutics (ACOR) a Great Growth Stock? | Vertex Pharmaceuticals (VRTX) Jumps: Stock Moves Up 5.8% | Geron Up, Myelodysplastic Syndromes Phase II/III Study Begins","Not only does it have double digit earnings growth prospect, but its impressive Zacks Rank suggests that analysts believe better days are ahead for ACOR as well. Click to get this free report ACORDA THERAPT (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here. One such company that might be well-positioned for future earnings growth is Acorda Therapeutics, Inc.ACOR . | Click to get this free report VERTEX PHARM (VRTX): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked biomedical stock is Acorda Therapeutics, Inc. ACOR with a Zacks Rank #1 (Strong Buy). Over the last 30 days, the company witnessed one positive estimate revision and the Zacks Consensus Estimate also moved higher, suggesting solid trading ahead. | Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report GERON CORP (GERN): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ACOR and Anika Therapeutics Inc. ANIK are other favorable stocks in the health care sector, each carrying a Zacks Rank #1 (Strong Buy). Geron CorporationGERN announced the dosing of the first patient in a phase II/III study (IMerge) with its sole pipeline candidate, imetelstat, in patients suffering from myelodysplastic syndromes (MDS)."
2016-01-14,38.29999923706055,39.25,4.751906973064272,,
2016-01-13,41.56999969482422,38.310001373291016,2.4804197959883925,"New Strong Buy Stocks for January 13th | Sangamo Biosciences (SGMO) Worth a Look: Stock Up 9.2% | Arena, Boehringer Ingelheim Ink Deal, Schizophrenia in Focus","Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today: Acorda Therapeutics Inc ( ACOR ) Braskem SA ( BAK ) Cray Inc. ( CRAY ) Dominion Midstream Partners LP ( DM ) The Ensign Group, Inc. ( ENSG ) View the entire Zacks Rank #1 List . Click to get this free report ACORDA THERAPT (ACOR): Free Stock Analysis Report BRASKEM SA (BAK): Free Stock Analysis Report CRAY INC (CRAY): Free Stock Analysis Report DOMINION MIDSTR (DM): Free Stock Analysis Report ENSIGN GROUP (ENSG): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Click to get this free report ACORDA THERAPT (ACOR): Free Stock Analysis Report SANGAMO BIOSCI (SGMO): Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked stock in the Med-Biomed/Gene industry is Acorda Therapeutics, Inc. ACOR , which carries a Zacks Rank #2 (Buy). Click to get this free report >> Want the latest recommendations from Zacks Investment Research? | Click to get this free report ALLERGAN PLC (AGN): Free Stock Analysis Report ALKERMES INC (ALKS): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report ARENA PHARMA (ARNA): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ACOR is another favorably ranked stock in the health care sector, carrying a Zacks Rank #1 (Strong Buy). Arena Pharmaceuticals, Inc.ARNA and Boehringer Ingelheim announced the signing of an exclusive agreement under which the companies will jointly conduct research to identify drug candidates targeting an undisclosed G protein-coupled receptor (GPCR), part of the group of orphan central nervous system (CNS) receptors."
2016-01-12,40.11000061035156,41.2400016784668,-7.842189909708125,"Acorda's Ampyra Ends 2015 on Strong Note, Pipeline in Focus","Click to get this free report ACORDA THERAPT (ACOR): Free Stock Analysis Report LIGAND PHARMA-B (LGND): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report BAXALTA INC (BXLT): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc.ACOR provided a preliminary look at its fourth quarter and full year Ampyra sales. 2016 Outlook Acorda expects Ampyra sales of $475-$485 million in 2016."
2016-01-11,40.130001068115234,39.97999954223633,2.8172551755673734,,
2016-01-08,41.959999084472656,40.220001220703125,-0.3737889904969078,,
2016-01-07,41.11000061035156,41.0099983215332,-4.146801481731727,,
2016-01-06,41.4900016784668,41.68000030517578,-0.24325538149755863,,
2016-01-05,42.380001068115234,42.040000915527344,0.4579383442338909,,
2016-01-04,41.970001220703125,42.25,-0.8022655592703397,,
2015-12-31,42.869998931884766,42.77999877929688,0.667140269604653,,
2015-12-30,43.08000183105469,43.02999877929688,-0.20993738005658188,,
2015-12-29,43.04999923706055,43.25,-0.1160702173456273,,
2015-12-28,42.79999923706055,42.72999954223633,0.46457785478258046,,
2015-12-24,42.95000076293945,42.95000076293945,-0.16355069175703624,,
2015-12-23,43.040000915527344,42.95000076293945,0.0,,
2015-12-22,41.959999084472656,42.97999954223633,-0.20910815676916417,,
2015-12-21,41.04999923706055,41.970001220703125,2.4308877026194318,,
2015-12-18,40.16999816894531,40.720001220703125,2.2411741796379543,,
2015-12-17,39.9900016784668,40.40999984741211,1.3691886403495277,,
2015-12-16,38.630001068115234,39.66999816894531,1.0502579427783987,,
2015-12-15,37.47999954223633,38.470001220703125,2.6922005489885423,,
2015-12-14,37.0,37.15999984741211,2.6414132618949497,,
2015-12-11,37.41999816894531,37.130001068115234,0.432432020032728,,
2015-12-10,37.310001373291016,38.02000045776367,-0.774978928434971,,
2015-12-09,37.08000183105469,37.290000915527344,1.9029725498239218,,
2015-12-08,36.08000183105469,37.34999847412109,0.5663405450449059,,
2015-12-07,37.4900016784668,36.33000183105469,3.5199461713255538,,
2015-12-04,36.52000045776367,37.650001525878906,-3.094157896712981,,
2015-12-03,37.380001068115234,36.61000061035156,3.0941978476208125,,
2015-12-02,37.83000183105469,37.31999969482422,-2.0599262593934875,,
2015-12-01,38.2599983215332,37.86000061035156,-1.3481419813514455,,
2015-11-30,38.209999084472656,38.18999862670898,-1.0454723699151782,,
2015-11-27,38.060001373291016,38.18999862670898,-0.052343518039513745,,
2015-11-25,37.43999862670898,38.060001373291016,0.34155871972508256,,
2015-11-24,37.18999862670898,37.380001068115234,1.6559903026805676,,
2015-11-23,37.15999984741211,37.59000015258789,0.5108966077503478,,
2015-11-20,37.470001220703125,37.400001525878906,1.1571590606605646,,
2015-11-19,37.79999923706055,37.41999816894531,-0.1868152990225742,,
2015-11-18,37.5,37.88999938964844,-1.0052938512831158,,
2015-11-17,37.29999923706055,37.43000030517578,1.0399983723958335,Bristol-Myers' Opdivo Gets Priority Review from the FDA,"Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector include Gilead and Acorda Therapeutics, Inc. ACOR . The company is looking to get Opdivo approved for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy to Opdivo's label."
2015-11-16,36.84999847412109,37.20000076293945,0.3485283398774654,,
2015-11-13,36.93000030517578,37.0,0.9498027226898397,,
2015-11-12,36.84000015258789,37.20000076293945,0.18954696519297948,,
2015-11-11,37.52999877929688,37.02000045776367,0.9772003497841288,,
2015-11-10,36.86000061035156,37.4900016784668,-1.3589084415706048,,
2015-11-09,37.52000045776367,36.91999816894531,1.7091727012568423,,
2015-11-06,37.59999847412109,37.54999923706055,-1.5991532022868256,Why Acorda Therapeutics (ACOR) Could Be Positioned for a Surge?,"Current Quarter Estimates for ACOR In the past 30 days, 2 estimates have gone higher for Acorda Therapeutics while none have gone lower in the same time period. Current Year Estimates for ACOR Meanwhile, Acorda Therapeutics' current year figures are also looking quite promising, with 2 estimates moving higher in the past month, compared to none lower. Acorda Therapeutics, Inc.ACOR is a biotechnology company that could be an interesting play for investors."
2015-11-05,37.84000015258789,37.84999847412109,-0.13297669970639145,,
2015-11-04,37.68000030517578,38.02000045776367,0.02642262550972065,,
2015-11-03,36.869998931884766,37.59999847412109,0.9023358541246819,,
2015-11-02,36.31999969482422,37.060001373291016,1.9799282977603385,Looking for a Top Momentum Stock? 3 Reasons Why Acorda Therapeutics (ACOR) is a Great Choice,"And while there are numerous ways in which this company could be a great choice, we have highlighted three of the most vital reasons for ACOR's status as a solid momentum stock below: Short Term Price Change for Acorda Therapeutics A great place to look for finding momentum stocks is by inspecting short term price activity. ACOR Earnings Estimate Revisions Moving in the Right Direction While the great momentum factors outlined in the preceding paragraphs might be enough for some investors, we should also take into account broad earnings estimate revision trends. These revisions have helped to boost the consensus estimate as two months ago ACOR was expected to post loss of 33 cents share for the full year, though today it looks to have lost of 9 cents for the full year now, representing a solid improvement which is something that should definitely be welcomed news to would-be investors."
2015-10-30,36.41999816894531,36.040000915527344,2.037449572369492,,
2015-10-29,36.7599983215332,36.20000076293945,-1.043375267772489,"Vertex (VRTX) Posts Narrower Q3 Loss, Ups Kalydeco View","Click to get this free report VERTEX PHARM (VRTX): Free Stock Analysis Report ACTELION LTD (ALIOF): Free Stock Analysis Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector include Actelion Ltd. ALIOF , AMAG Pharmaceuticals, Inc. AMAG and Acorda Therapeutics, Inc. ACOR . While Actelion and AMAG are Zacks Rank #1 (Strong Buy) stocks, Acorda is a Zacks Rank #2 (Buy) stock."
2015-10-28,37.04999923706055,37.310001373291016,-1.5233884226423255,,
2015-10-27,36.61000061035156,37.20000076293945,0.7017601662199027,,
2015-10-26,36.18999862670898,36.77000045776367,1.611581925024789,,
2015-10-23,35.36000061035156,36.13999938964844,1.6026577868578342,"Acorda Up on Q3 Earnings & Revenue Beat, Ampyra in Focus","The Quarter in Detail The bulk of net product revenues at Acorda came from Ampyra, which generated $117 million in the reported quarter, up 21.4% from the year-ago period and almost 11% on a sequential basis. Raises Ampyra Guidance Encouraged by the growth in Ampyra sales in the last three quarters, Acorda raised its 2015 Ampyra revenue guidance range to $420-$430 million from $410-$420 million. Click to get this free report ALLERGAN PLC (AGN): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here."
2015-10-22,33.40999984741211,34.91999816894531,2.205878862650619,Acorda Therapeutics Breaks Above 200-Day Moving Average - Bullish for ACOR,"In trading on Thursday, shares of Acorda Therapeutics Inc (Symbol: ACOR) crossed above their 200 day moving average of $33.87, changing hands as high as $35.19 per share. The chart below shows the one year performance of ACOR shares, versus its 200 day moving average: Looking at the chart above, ACOR's low point in its 52 week range is $25.50 per share, with $45.45 as the 52 week high point - that compares with a last trade of $34.92. Acorda Therapeutics Inc shares are currently trading up about 10.1% on the day."
2015-10-21,30.8799991607666,31.709999084472656,4.519599905506031,,
2015-10-20,30.88999938964844,30.39999961853028,2.6878236601786547,,
2015-10-19,30.61000061035156,31.0,-1.5862731654257154,,
2015-10-16,31.049999237060547,30.790000915527344,1.2740914141522517,,
2015-10-15,29.82999992370605,30.90999984741211,-0.8373537131133816,,
2015-10-14,29.6299991607666,29.920000076293945,3.620516012297328,,
2015-10-13,29.790000915527344,29.71999931335449,0.9787408833657243,,
2015-10-12,30.13999938964844,30.040000915527344,-0.23498355159958526,,
2015-10-09,30.190000534057617,29.88999938964844,-0.3317799473992083,,
2015-10-08,29.71999931335449,30.11000061035156,-0.9937102984504491,"The Zacks Analyst Blog Highlights: Amgen, Regeneron, Acorda, Amicus and AbbVie","Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report AMICUS THERAPT (FOLD): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include the Amgen ( AMGN ), Regeneron ( REGN ), Acorda ( ACOR ), Amicus ( FOLD ) and AbbVie ( ABBV ). Meanwhile, Acorda's ( ACOR ) shares were up on news that the company has settled its patent infringement lawsuit with Allergan for its flagship product, Ampyra (Read more: Acorda Soars, Settles Ampyra Patent Dispute with Allergan )."
2015-10-07,29.81999969482422,29.940000534057617,1.312252039056494,,
2015-10-06,31.1200008392334,29.709999084472656,0.40241730537048487,"Acorda Therapeutics (ACOR) Jumps: Stock Moves Up 12% | Acorda Soars, Settles Ampyra Patent Dispute with Allergan","Click to get this free report ACORDA THERAPT (ACOR): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc.ACOR was a big mover last session, as its shares rose roughly 12% on the day. Acorda Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%. | Acorda said that the settlement with Allergan, however, does not resolve patent infringement lawsuits with other companies seeking FDA approval for their generic versions of Ampyra. In Aug 2015, Acorda's shares had gone up when the United States Patent and Trademark Office Patent Trials and Appeal Board declined to institute the inter partes review related to a couple of patents covering Ampyra. Click to get this free report ALLERGAN PLC (AGN): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here."
2015-10-05,30.100000381469727,31.420000076293945,-4.530853845553675,Why Acorda Therapeutics Is Soaring 12% Today,"Source: Acorda Therapeutics What: After reporting that it has entered into a legal settlement with Actavis to resolve patent litigation relating to its multiple sclerosis drug Ampyra, shares in Acorda Therapeutics surged 12% higher earlier today. Acorda Therapeutics expects Ampyra sales of at least $410 million this year, and management is guiding for the company to be cash flow positive this year, so the patent news and resulting clarity should be viewed by investors as bullish -- especially in light of analysts prediction that Ampyra sales growth will lead to EPS of $0.71 this year and $0.91 next year. So what: Acorda Therapeutics had filed suit against Actavis, which is now a part of Allergan , after Actavis filed an abbreviated new drug application with the FDA for a generic version of Ampyra extended release tablets."
2015-10-02,26.989999771118164,28.049999237060547,4.385380990349893,,
2015-10-01,26.61000061035156,27.459999084472656,3.927378565881582,"After Hours Most Active for Oct 1, 2015 : HLX, MU, CAA, RMBS, QQQ, ETE, SUNE, MSFT, ACOR, CSCO, PFE, RAD","Acorda Therapeutics, Inc. ( ACOR ) is -0.01 at $27.45, with 845,106 shares traded. As reported in the last short interest update the days to cover for ACOR is 15.319981; this calculation is based on the average trading volume of the stock. The total After hours volume is currently 36,476,766 shares traded."
2015-09-30,26.100000381469727,26.51000022888184,3.1942820542079935,,
2015-09-29,26.299999237060547,25.780000686645508,1.5708806184662027,,
2015-09-28,27.799999237060547,26.209999084472656,-1.977180857413429,,
2015-09-25,29.68000030517578,27.82999992370605,-5.719425166272093,,
2015-09-24,29.600000381469727,29.540000915527344,-6.233154859998825,,
2015-09-23,30.030000686645508,29.799999237060547,-0.20270089584169007,,
2015-09-22,30.530000686645508,29.989999771118164,-0.7659055755108382,,
2015-09-21,32.52000045776367,30.799999237060547,-1.768755006165303,,
2015-09-18,32.18000030517578,32.18000030517578,-5.289056569777815,,
2015-09-17,31.89999961853028,32.54999923706055,0.0,,
2015-09-16,32.279998779296875,31.989999771118164,2.0376163833954726,,
2015-09-15,32.5,32.18000030517578,-0.898386056831901,,
2015-09-14,33.09000015258789,32.380001068115234,-0.9846144456129807,,
2015-09-11,32.79999923706055,33.06999969482422,-2.1456605657257115,,
2015-09-10,32.529998779296875,32.93000030517578,0.8231721464755395,,
2015-09-09,33.45000076293945,32.59000015258789,1.229638920655232,,
2015-09-08,32.279998779296875,33.36000061035156,-2.571003260796306,,
2015-09-04,31.459999084472656,31.709999084472656,3.3457307059979144,,
2015-09-03,32.33000183105469,31.86000061035156,0.7946599086946242,,
2015-09-02,32.09000015258789,32.560001373291016,-1.4537618128176764,,
2015-09-01,31.31999969482422,31.770000457763672,1.4646345231170772,,
2015-08-31,32.4900016784668,31.96999931335449,1.4367840591448597,,
2015-08-28,31.63999938964844,32.72999954223633,-1.6004996560432532,3 Biotech Stocks Bucking the Stock Market Crash,"Acorda Therapeutics Finally, mid-cap biotech Acorda Therapeutics has trudged higher by 1% over the past week, mostly due to Tuesday's welcome stock price surge following news that the Patent Trials and Appeal Board (PTAB) had declined to institute the inter partes review request for two patents concerning multiple sclerosis drug Ampyra. Source: Acorda Therapeutics. One of those companies was Acorda Therapeutics."
2015-08-27,32.2400016784668,31.690000534057617,3.4450068698310377,"The Zacks Analyst Blog Highlights: Vital Therapies, Amgen, BioMarin, Acorda and Macrocure","Click to get this free report VITAL THERAPIES (VTL): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report MACROCURE LTD (MCUR): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include the Vital Therapies ( VTL ), Amgen ( AMGN ), BioMarin ( BMRN ), Acorda ( ACOR ) and Macrocure ( MCUR ). Acorda's ( ACOR ) shares were up with the company announcing that the United States Patent and Trademark Office (USPTO) Patent Trials and Appeal Board (PTAB) will not institute the inter partes review (IPR) of a couple of patents covering the company's flagship product, Ampyra (Read more: Acorda Gets Favorable Outcome in Ampyra IPR Issue )."
2015-08-26,32.18000030517578,31.959999084472656,-1.7059587958288702,Acorda Therapeutics (ACOR) Jumps: Stock Moves 8.3% Higher,"Acorda Therapeutics, Inc. ( ACOR ) was a big mover last session with its shares rising over 8% on the day. Click to get this free report ACORDA THERAPT (ACOR): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics currently has a Zacks Rank #3 (Hold) and its Earnings ESP is 0.00%."
2015-08-25,35.189998626708984,31.3700008392334,-0.6836582306300983,"Mid-Morning Market Update: Markets Open Higher; Best Buy Tops Q2 Views | Acorda (ACOR) Gets Favorable Outcome in Ampyra IPR Issue | Why Acorda Therapeutics, Inc. Stock Surged Higher Today","Equities Trading UP Acorda Therapeutics Inc (NASDAQ: ACOR ) shares shot up 16 percent to $33.48 after the company reported that the Patent Trials and Appeal Board has denied both inter partes reviews of AMPYRA patents. China Information Technology, Inc. - Ordinary Shares (NASDAQ: CNIT ) shares were also up, gaining 13 percent to $1.44 after the company reported management changes. The eurozone's STOXX 600 gained 3.9 percent, the Spanish Ibex Index rose 3.3 percent, while Italy's FTSE MIB Index surged 4.4 percent. | Acorda Therapeutics, Inc.ACOR received encouraging news with the U.S. Patent and Trademark Office (USPTO) Patent Trials and Appeal Board declining to institute the inter partes review (IPR) related to two patents - U.S. Patent Nos. Meanwhile, Acorda remains entangled in patent infringement litigation for Ampyra with several companies including Allergan plc AGN and Teva Pharmaceutical Industries Ltd. TEVA among others. Click to get this free report ALLERGAN PLC (AGN): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. | What : Shares of Acorda Therapeutics , a biopharmaceutical company specializing in neurological disorders, saw its shares rise by as much as 21% today on exceptional volume, before settling in on a gain of 12% at the time of this writing. Acorda's rally was triggered by the news that the hedge fund manager Kyle Bass's attempts to invalidate two key patents, 8,663,685 and 8,007,826, protecting Acorda's flagship multiple sclerosis drug Ampyra were shot down by the U.S. Patent and Trademark Office, or USPTO. Specifically, Acorda announced that the USPTO declined a so-called ""inter partes review"" of these two patents, previously filed by Bass's Coalition for Affordable Drugs."
2015-08-24,27.920000076293945,28.959999084472656,-10.855350771671334,,
2015-08-21,28.6299991607666,29.89999961853028,3.724924804214967,,
2015-08-20,30.299999237060547,29.209999084472656,4.43590812082187,Oversold Conditions For Acorda Therapeutics (ACOR),"In trading on Thursday, shares of Acorda Therapeutics Inc (Symbol: ACOR) entered into oversold territory, hitting an RSI reading of 29.2, after changing hands as low as $29.16 per share. The chart below shows the one year performance of ACOR shares: Looking at the chart above, ACOR's low point in its 52 week range is $28.52 per share, with $45.45 as the 52 week high point - that compares with a last trade of $29.21. A bullish investor could look at ACOR's 29.2 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side."
2015-08-19,30.8799991607666,30.479999542236328,-3.5973603301438013,,
2015-08-18,32.400001525878906,31.14999961853028,-1.2953355874389971,,
2015-08-17,31.600000381469727,32.38999938964844,-3.8580303965424494,,
2015-08-14,31.739999771118164,31.84000015258789,2.499996831145506,,
2015-08-13,32.290000915527344,31.64999961853028,0.31506106550360463,,
2015-08-12,31.46999931335449,32.16999816894531,-1.9820417431121993,,
2015-08-11,32.41999816894531,31.93000030517578,2.224337053905734,,
2015-08-10,32.18000030517578,32.369998931884766,-1.5114062043312937,,
2015-08-07,32.630001068115234,32.150001525878906,0.5904245646586439,,
2015-08-06,34.720001220703125,32.81999969482422,-1.4710374701929292,,
2015-08-05,34.630001068115234,34.540000915527344,-5.4723544328274905,,
2015-08-04,34.88999938964844,34.529998779296875,-0.2598907011607232,,
2015-08-03,34.52000045776367,34.7400016784668,-1.03181604084055,,
2015-07-31,34.75,34.36000061035156,0.6373152311289901,"Acorda 2Q Earnings & Revenues Top, Ampyra in Focus - Analyst Blog","Narrows Ampyra Guidance Acorda narrowed its 2015 Ampyra revenue guidance range to $410 million - $420 million from $405 million - $420 million. Click to get this free report ACORDA THERAPT (ACOR): Free Stock Analysis Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report LIGAND PHARMA-B (LGND): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc.'sACOR second quarter earnings came in at 11 cents per share, well above the Zacks Consensus Estimate of a loss of 1 cent per share but below the year-ago earnings of 24 cents per share."
2015-07-30,34.02000045776367,34.22999954223633,-1.1223004018660072,,
2015-07-29,34.65999984741211,33.779998779296875,0.6172812511668634,,
2015-07-28,34.36000061035156,34.61000061035156,-2.5389528909098935,,
2015-07-27,33.560001373291016,34.119998931884766,0.7275902082629272,,
2015-07-24,34.470001220703125,33.709999084472656,1.66864581548983,,
2015-07-23,35.310001373291016,34.75,-2.204821901120217,,
2015-07-22,34.400001525878906,35.22999954223633,-1.5859568153815156,,
2015-07-21,35.22999954223633,34.459999084472656,2.4127848242478116,,
2015-07-20,34.810001373291016,35.290000915527344,-2.1856385687446247,,
2015-07-17,35.349998474121094,34.779998779296875,1.37891273570768,,
2015-07-16,35.540000915527344,35.25,-1.6124461652848505,8 Biotech Stocks to Buy,"Acorda Therapeutics (ACOR) Acorda Therapeutics (ACOR) offers something that few other biotech stocks on this list offer: a blend of solid revenue from its currently marketed products, as well as potential explosive growth from its pipeline. While at least something in the pipeline is sure to boost the top line in the foreseeable future, Acorda Therapeutics may not even need anything to pan out there to really wow investors and make it one of the market’s top stocks to buy. Anacor Pharmaceuticals (ANAC) Anacor Pharmaceuticals (ANAC) may not be profitable yet, but give it time."
2015-07-15,35.54999923706055,35.4900016784668,-0.8159845471490774,,
2015-07-14,34.720001220703125,35.2400016784668,-0.16876950740185417,,
2015-07-13,34.130001068115234,34.61000061035156,1.4976971183215333,,
2015-07-10,33.720001220703125,34.06999969482422,1.4063859572648858,,
2015-07-09,33.02000045776367,33.41999816894531,1.037955105132691,,
2015-07-08,33.29999923706055,32.709999084472656,1.2113800897528246,,
2015-07-07,32.63999938964844,33.5,-1.7717722705869077,,
2015-07-06,31.88999938964844,32.4900016784668,2.6348058407878097,,
2015-07-02,32.0,32.08000183105469,1.8814747579240085,,
2015-07-01,33.5099983215332,32.09000015258789,0.25000572204589844,Bayer Files Hemophilia A Drug Marketing Application in Japan - Analyst Blog,"Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report EMERGENT BIOSOL (EBS): Free Stock Analysis Report To read this article on Zacks.com click here. Other well-ranked stocks in the health care sector are Emergent BioSolutions, Inc. EBS and Acorda Therapeutics, Inc. ACOR . While Emergent BioSolutions holds a Zacks Rank #1 (Strong Buy), Acorda carries the same Zacks Rank as Bayer."
2015-06-30,33.79999923706055,33.33000183105469,-4.2375357805757785,AMAG Down on Cord Blood Registry Deal for $700 Million - Analyst Blog,"Click to get this free report AMERISOURCEBRGN (ABC): Free Stock Analysis Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector include Valeant Pharmaceuticals International, Inc. VRX , AmerisourceBergen Corporation ABC and Acorda Therapeutics, Inc. ACOR . While Valeant carries a Zacks Rank #1 (Strong Buy), AmerisourceBergen and Acorda hold a Zacks Rank #2 (Buy)."
2015-06-29,33.720001220703125,33.43000030517578,-1.3905249012269896,Regeneron/Bayer's Eylea Gets Label Expansion in Japan - Analyst Blog | Alexion's Strensiq and Kanuma Get Positive CHMP Opinions - Analyst Blog,"Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report To read this article on Zacks.com click here. Other well-ranked stocks in the health care sector are Valeant Pharmaceuticals International, Inc. VRX and Acorda Therapeutics, Inc. ACOR . While Valeant holds a Zacks Rank #1 (Strong Buy), Acorda carries the same Zacks Rank as Bayer. | Click to get this free report ALEXION PHARMA (ALXN): Free Stock Analysis Report AMERISOURCEBRGN (ABC): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report To read this article on Zacks.com click here. Better-ranked stocks in the health care sector include Valeant Pharmaceuticals International, Inc. VRX , AmerisourceBergen Corporation ABC and Acorda Therapeutics, Inc. ACOR . While Valeant carries a Zacks Rank #1 (Strong Buy), AmerisourceBergen and Acorda hold a Zacks Rank #2 (Buy)."
2015-06-26,34.349998474121094,33.93000030517578,-0.860026408745476,"Bristol-Myers Announces Job Cuts, Changes in R&D Sites - Analyst Blog","Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report RIGEL PHARMCTCL (RIGL): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are Valeant Pharmaceuticals International, Inc. VRX and Acorda Therapeutics, Inc. ACOR . While Valeant holds a Zacks Rank #1 (Strong Buy), Acorda carries a Zacks Rank #2 (Buy)."
2015-06-25,34.52000045776367,34.209999084472656,-1.2227021473137312,Catalyst Pharmaceuticals Reports Tourette's Disorder Data - Analyst Blog | Bayer Contraceptive Essure to Face FDA Panel on Complaints - Analyst Blog,"Click to get this free report AMERISOURCEBRGN (ABC): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report CATALYST PHARMA (CPRX): Free Stock Analysis Report To read this article on Zacks.com click here. Better-ranked stocks in the health care sector include Valeant Pharmaceuticals International, Inc. VRX , AmerisourceBergen Corporation ABC and Acorda Therapeutics, Inc. ACOR . While Valeant carries a Zacks Rank #1 (Strong Buy), AmerisourceBergen and Acorda hold a Zacks Rank #2 (Buy). | Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report To read this article on Zacks.com click here. Other well-ranked stocks in the health care sector are Valeant Pharmaceuticals International, Inc. VRX and Acorda Therapeutics, Inc. ACOR . While Valeant holds a Zacks Rank #1 (Strong Buy), Acorda carries the same Zacks Rank as Bayer."
2015-06-24,34.79999923706055,34.27000045776367,-0.8980340938011059,Synta Reports Encouraging Preclinical Data on Ganetespib - Analyst Blog | Vanda Pharmaceuticals' Schizophrenia Drug Shows Success - Analyst Blog,"Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report SYNTA PHARMACT (SNTA): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are Valeant Pharmaceuticals International, Inc. VRX and Acorda Therapeutics, Inc. ACOR . While Valeant holds a Zacks Rank #1 (Strong Buy), Acorda carries a Zacks Rank #2 (Buy). | Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report ANACOR PHARMACT (ANAC): Free Stock Analysis Report VANDA PHARMACT (VNDA): Free Stock Analysis Report To read this article on Zacks.com click here. Better-ranked stocks in the health care sector include Gilead Sciences Inc. GILD , Acorda Therapeutics, Inc. ACOR and Anacor Pharmaceuticals, Inc. ANAC . While Gilead holds a Zacks Rank #1 (Strong Buy), Acorda and Anacor carry a Zacks Rank #2 (Buy)."
2015-06-23,35.38999938964844,34.869998931884766,-1.5229850313687605,"Acorda Therapeutics (ACOR) Shares March Higher, Can It Continue? - Tale of the Tape | Vical's Genital Herpes Vaccine Fails in Phase I/II Study - Analyst Blog | Isis Pharmaceuticals Up on Spinal Muscular Atrophy Data - Analyst Blog","From this look, the company's future is quite favorable; as ACOR has earned itself a Zacks Rank #2 (Buy), meaning that its recent run may continue for a bit longer, and that this isn't the top for the in-focus company. Click to get this free report ACORDA THERAPT (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here. As of late, it has definitely been a great time to be an investor in Acorda Therapeutics Inc ( ACOR ) . | Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report ASTELLAS PHARMA (ALPMY): Free Stock Analysis Report VICAL INC (VICL): Free Stock Analysis Report To read this article on Zacks.com click here. Better-ranked stocks in the health care sector are Gilead Sciences Inc. GILD and Acorda Therapeutics, Inc. ACOR . While Gilead carries a Zacks Rank #1 (Strong Buy), Acorda holds a Zacks Rank #2 (Buy). | Click to get this free report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Better-ranked stocks in the health care sector include Gilead Sciences Inc. GILD and Acorda Therapeutics, Inc. ACOR . While Gilead carries a Zacks Rank #1 (Strong Buy), Acorda holds a Zacks Rank #2 (Buy)."
2015-06-22,34.380001068115234,35.439998626708984,-1.469342940751143,Epizyme Lead Candidate Effective in Ongoing Cancer Study - Analyst Blog | Bullish Two Hundred Day Moving Average Cross - ACOR,"Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report ACTELION LTD (ALIOF): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report EPIZYME INC (EPZM): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are Actelion Ltd. ALIOF , Gilead Sciences Inc. GILD and Acorda Therapeutics, Inc. ACOR . While Actelion and Gilead hold a Zacks Rank #1 (Strong Buy), Acorda carries a Zacks Rank #2 (Buy). | In trading on Monday, shares of Acorda Therapeutics Inc (Symbol: ACOR) crossed above their 200 day moving average of $35.05, changing hands as high as $35.70 per share. The chart below shows the one year performance of ACOR shares, versus its 200 day moving average: Looking at the chart above, ACOR's low point in its 52 week range is $28.26 per share, with $45.45 as the 52 week high point - that compares with a last trade of $35.44. Acorda Therapeutics Inc shares are currently trading up about 2.8% on the day."
2015-06-19,33.91999816894531,34.459999084472656,3.0831807029139826,,
2015-06-18,33.72999954223633,34.060001373291016,1.5919839170915093,,
2015-06-17,33.34000015258789,33.630001068115234,0.9783629870538922,,
2015-06-16,32.18000030517578,33.310001373291016,0.869828776844902,,
2015-06-15,31.520000457763672,32.189998626708984,3.5115011106245597,,
2015-06-12,31.020000457763672,31.549999237060547,2.1256286777124256,,
2015-06-11,30.780000686645508,31.030000686645508,1.708571152403794,Bayer (BAYRY) Up on Deal to Sell Diabetes Care Business - Analyst Blog,"Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ACTELION LTD (ALIOF): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are Gilead Sciences Inc. GILD , Actelion Ltd. ALIOF and Acorda Therapeutics, Inc. ACOR . While both Gilead and Actelion hold a Zacks Rank #1 (Strong Buy), Acorda carries a Zacks Rank #2 (Buy)."
2015-06-10,30.40999984741211,30.6299991607666,0.8122157063773793,,
2015-06-09,30.65999984741211,30.489999771118164,0.7234439804616248,,
2015-06-08,30.790000915527344,30.88999938964844,-0.5544686142857055,Novo Nordisk Reveals New Findings from Additional Studies - Analyst Blog,"Click to get this free report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ACTELION LTD (ALIOF): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are Actelion Ltd. ALIOF , Valeant Pharmaceuticals International, Inc. VRX and Acorda Therapeutics, Inc. ACOR . While Actelion and Valeant sport a Zacks Rank #1 (Strong Buy), Acorda carries a Zacks Rank #2 (Buy)."
2015-06-05,30.489999771118164,30.850000381469727,0.3247758075598765,,
2015-06-04,30.06999969482422,30.39999961853028,1.1807169991932085,,
2015-06-03,30.170000076293945,30.25,1.0974390656973063,"Ultragenyx KRN23 Positive in Children, to be Studied in Adults - Analyst Blog","Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report ACTELION LTD (ALIOF): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report ULTRAGENYX PHAR (RARE): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are Actelion Ltd. ALIOF , Gilead Sciences Inc. GILD and Acorda Therapeutics, Inc. ACOR . While Actelion and Gilead sport a Zacks Rank #1 (Strong Buy), Acorda carries a Zacks Rank #2 (Buy)."
2015-06-02,28.920000076293945,29.989999771118164,0.2651638167177685,,
2015-06-01,30.780000686645508,30.3700008392334,3.69986062241165,Gilead Reveals Encouraging Data from Leukemia Study - Analyst Blog,"Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report ACTELION LTD (ALIOF): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report To read this article on Zacks.com click here. Other well-ranked stocks in the health care sector include Valeant Pharmaceuticals International, Inc. VRX , Actelion Ltd. ALIOF and Acorda Therapeutics, Inc. ACOR . While Valeant and Actelion carry the same Zacks Rank as Gilead, Acorda holds a Zacks Rank #2 (Buy)."
2015-05-29,30.459999084472656,30.479999542236328,-1.3320332627217764,,
2015-05-28,31.32999992370605,30.479999542236328,0.06566138662120756,,
2015-05-27,31.770000457763672,31.489999771118164,-2.713055804467349,Aegerion's Juxtapid Successful in Phase III Japanese Study - Analyst Blog,"Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report ACTELION LTD (ALIOF): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report AEGERION PHARMA (AEGR): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are Actelion Ltd. ALIOF , Gilead Sciences Inc. GILD and Acorda Therapeutics, Inc. ACOR . While Actelion and Gilead hold a Zacks Rank #1 (Strong Buy), Acorda carries a Zacks Rank #2 (Buy)."
2015-05-26,31.850000381469727,31.61000061035156,-0.8813367409854214,Actavis to Continue Selling Namenda IR under Court Ruling - Analyst Blog,"Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector include Gilead Sciences Inc. GILD , Amgen, Inc. AMGN and Acorda Therapeutics, Inc. ACOR . While Gilead is a Zacks Rank #1 (Strong Buy) stock, Amgen and Acorda are Zacks Rank #2 (Buy) stocks."
2015-05-22,32.08000183105469,32.0099983215332,-0.7535314544542331,,
2015-05-21,32.029998779296875,32.2599983215332,-0.2182154162276832,,
2015-05-20,31.520000457763672,31.950000762939453,0.7180754011923103,,
2015-05-19,30.68000030517578,31.39999961853028,1.3642141463543924,XBiotech's Xilonix Recommended for Colorectal Cancer Study - Analyst Blog,"Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report ACTELION LTD (ALIOF): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here. Investors looking for well-ranked stocks in the health care sector may consider Actelion Ltd. ALIOF , Gilead Sciences Inc. GILD and Acorda Therapeutics, Inc. ACOR . While Actelion and Gilead carry a Zacks Rank #1 (Strong Buy), Acorda holds a Zacks Rank #2 (Buy)."
2015-05-18,29.959999084472656,30.709999084472656,2.3468034752041183,,
2015-05-15,29.850000381469727,30.040000915527344,2.503337860209421,"Teva Presents Encouraging Data from Chronic Migraine Study - Analyst Blog | Eli Lilly, Sanford-Burnham Ink Deal for Immunotherapies - Analyst Blog","Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report ACTELION LTD (ALIOF): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector include Gilead Sciences Inc. GILD , Actelion Ltd. ALIOF and Acorda Therapeutics, Inc. ACOR . While Gilead and Actelion hold a Zacks Rank #1 (Strong Buy), Acorda is a Zacks Rank #2 (Buy) stock. | Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked health care stocks are Gilead Sciences Inc. GILD , Valeant Pharmaceuticals International, Inc. VRX and Acorda Therapeutics, Inc. ACOR . While Gilead and Valeant sport a Zacks Rank #1 (Strong Buy), Acorda is a Zacks Rank #2 (Buy) stock."
2015-05-14,29.780000686645508,29.89999961853028,0.6365176939011553,Sanofi (SNY) Exercises Celiac Disease Program Option - Analyst Blog,"Click to get this free report SANOFI-AVENTIS (SNY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ACTELION LTD (ALIOF): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are Actelion Ltd. ALIOF , Gilead Sciences Inc. GILD and Acorda Therapeutics, Inc. ACOR . While Actelion and Gilead carry a Zacks Rank #1 (Strong Buy), Acorda holds a Zacks Rank #2 (Buy)."
2015-05-13,29.89999961853028,29.790000915527344,0.4029514073805406,,
2015-05-12,29.940000534057617,29.96999931335449,-0.36788864349939987,"Inovio Narrows Q1 Loss Y/Y, Misses Earnings Estimates - Analyst Blog","While Gilead sports a Zacks Rank #1 (Strong Buy), Acorda is a Zacks Rank #2 (Buy) stock. Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report INOVIO PHARMAC (INO): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked health care stocks are, Gilead Sciences Inc. GILD and Acorda Therapeutics, Inc. ACOR ."
2015-05-11,30.46999931335449,30.200000762939453,0.10019632184958369,,
2015-05-08,29.989999771118164,30.34000015258789,-0.8861127551673416,,
2015-05-07,29.459999084472656,29.75,1.1670569661250683,,
2015-05-06,29.280000686645508,29.350000381469727,0.98438874589169,,
2015-05-05,30.63999938964844,29.13999938964844,0.23906999037792148,,
2015-05-04,30.01000022888184,30.84000015258789,-4.895561455222374,"Acorda Posts 1Q Loss, Ampyra Generic Challenges in Focus - Analyst Blog","The Quarter in Detail The bulk of net product revenues at Acorda came from Ampyra, which generated $92.4 million in the reported quarter, up 27% from the year-ago period. Click to get this free report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc.'sACOR first quarter loss of 2 cents per share missed both the Zacks Consensus Estimate of earnings of 3 cents per share and the year-ago earnings of 7 cents per share."
2015-05-01,30.14999961853028,29.770000457763672,2.7657444764270718,,
2015-04-30,32.02000045776367,30.06999969482422,-1.2603620748739912,,
2015-04-29,30.950000762939453,31.670000076293945,-6.089946080767934,,
2015-04-28,31.479999542236328,31.040000915527344,2.326330518920836,,
2015-04-27,33.31999969482422,31.440000534057617,-1.3977084914459532,Will United Therapeutics (UTHR) Miss This Earnings Season? - Analyst Blog | Will Bristol-Myers (BMY) Earnings Streak Continue in Q1? - Analyst Blog,"Click to get this free report UTD THERAPEUTIC (UTHR): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ACOR has an Earnings ESP of +133.33% and it carries a Zacks Rank #3. Zacks Rank: United Therapeutics carries a Zacks Rank #3 (Hold). | Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report TETRAPHASE PHAR (TTPH): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ACOR has an Earnings ESP of +133.33% and a Zacks Rank #3. Last quarter, Bristol-Myers delivered a positive 15% earnings surprise - the sixth successive earnings beat - driven by strong sales of its oncology drugs."
2015-04-24,33.40999984741211,33.119998931884766,-5.642254435730479,,
2015-04-23,33.04999923706055,33.5,-0.8680063359826887,Acorda Reports Encouraging Data on MS Drug - Analyst Blog,"Acorda Therapeutics, Inc.ACOR presented data from a phase I study on rHIgM22, a remyelinating antibody being evaluated for the treatment of multiple sclerosis (MS). Click to get this free report ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report AVEO PHARMACEUT (AVEO): Free Stock Analysis Report HORIZON PHARMA (HZNP): Free Stock Analysis Report To read this article on Zacks.com click here. Based on encouraging data from this study, Acorda intends to move rHIgM22 into a second study in patients who experience acute relapses."
2015-04-22,34.70000076293945,33.34000015258789,1.3615757135475082,,
2015-04-21,35.130001068115234,34.66999816894531,-3.9193100301141213,,
2015-04-20,34.40999984741211,34.88999938964844,-1.3094303591907108,,
2015-04-17,34.5,34.4900016784668,1.3949420062913127,,
2015-04-16,35.2400016784668,34.68000030517578,-0.028980642125226448,,
2015-04-15,34.22999954223633,35.18000030517578,-1.5891071129919987,Acorda Therapeutics (ACOR) Shares Cross Above 200 DMA,"In trading on Wednesday, shares of Acorda Therapeutics Inc (Symbol: ACOR) crossed above their 200 day moving average of $34.94, changing hands as high as $35.44 per share. The chart below shows the one year performance of ACOR shares, versus its 200 day moving average: Looking at the chart above, ACOR's low point in its 52 week range is $28.26 per share, with $45.45 as the 52 week high point - that compares with a last trade of $35.18. Acorda Therapeutics Inc shares are currently trading up about 2.9% on the day."
2015-04-14,34.720001220703125,34.20000076293945,2.7753455321179574,,
2015-04-13,34.380001068115234,34.81999969482422,-1.4976971183215333,Tekmira Up on Ebola Candidate Update from the FDA - Analyst Blog | OvaScience (OVAS) Looks Good: Stock Up 8.2% - Tale of the Tape | Adamas Pharma's Lead Candidate Gets Orphan Status in U.S. - Analyst Blog | Horizon Pharma's Actimmune Gets Fast Track Status - Analyst Blog,"Click to get this free report ACORDA THERAPT (ACOR): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report TEKMIRA PHARMAC (TKMR): Free Stock Analysis Report SAREPTA THERAP (SRPT): Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked health care stock is Acorda Therapeutics, Inc. ACOR carrying a Zacks Rank #1 (Strong Buy). The FDA has notified Tekmira Pharmaceuticals CorporationTKMR that it has modified the partial clinical hold on the Investigational New Drug application (IND) for its Ebola candidate, TKM-Ebola. | Click to get this free report OVASCIENCE (OVAS): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked stock in the same space is Acorda Therapeutics, Inc. ( ACOR ), sporting a Zacks Rank #1 (Strong Buy). The company has seen no estimate revisions in the past 7 days and the Zacks Consensus Estimate has also remained unchanged over the same time frame. | Click to get this free report ACORDA THERAPT (ACOR): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report ADAMAS PHARMA (ADMS): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are ANI Pharmaceuticals, Inc. ANIP , Cytokinetics, Incorporated CYTK and Acorda Therapeutics, Inc. ACOR . Moreover, Adamas Pharma is now eligible to receive tax credits for research and development costs incurred, seek study design assistance from the FDA as well as request for the reduction of certain regulatory fees. | Click to get this free report ACORDA THERAPT (ACOR): Free Stock Analysis Report HORIZON PHARMA (HZNP): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. Other well-ranked stocks in the health care sector include ANI Pharmaceuticals, Inc. ANIP , Cytokinetics, Incorporated CYTK and Acorda Therapeutics, Inc. ACOR . Horizon Pharma plcHZNP announced that the FDA has granted fast track status to Actimmune for the treatment of Friedreich's ataxia."
2015-04-10,33.939998626708984,34.459999084472656,1.2798098110504386,,
2015-04-09,33.869998931884766,33.849998474121094,1.5321169086744129,,
2015-04-08,33.4900016784668,34.0099983215332,-0.059050659564218975,Gilead Submits Regulatory Application for HIV Drug in U.S. - Analyst Blog | Ocular Therapeutix Slumps 19% after Negative Study Data - Analyst Blog | Hospira Slammed with Another Warning Letter by the FDA - Analyst Blog,"Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Get Free Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector include Acorda Therapeutics, Inc. ACOR and Cytokinetics, Incorporated CYTK . Gilead Sciences, Inc.GILD announced that it has submitted a new drug application (NDA) to the FDA for two doses of a fixed-dose combination of Emtriva (emtricitabine) and tenofovir alafenamide (TAF) for the treatment of adults suffering from HIV-1 infection in pediatric patients above 12 years, in combination with other HIV antiretroviral drugs. | Click to get this free report AFFYMETRIX INC (AFFX): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Get Free Report OCULAR THERAPTX (OCUL): Get Free Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care space include Acorda Therapeutics, Inc. ACOR , Cytokinetics, Incorporated CYTK and Affymetrix Inc. AFFX . Ocular Therapeutix, Inc.OCUL crumbled almost 19% after announcing disappointing results from its second phase III study on its pipeline candidate OTX-DP. | Click to get this free report HOSPIRA INC (HSP): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report AFFYMETRIX INC (AFFX): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here. Other well-ranked stocks in the health care space include Acorda Therapeutics, Inc. ACOR and Affymetrix Inc. AFFX , both holding a Zacks Rank #1 (Strong Buy). Hospira Inc.HSP received disappointing news when the FDA slammed a warning letter related to the company's manufacturing facility in Liscate, Italy."
2015-04-07,33.060001373291016,33.369998931884766,1.5526921976858263,Alkermes Reports Encouraging Data on Schizophrenia Drug - Analyst Blog | Repros Gets EU Update on Secondary Hypogonadism Drug - Analyst Blog,"Click to get this free report ALKERMES INC (ALKS): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Get Free Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector include Acorda Therapeutics, Inc. ACOR and Cytokinetics, Incorporated CYTK . Earlier this year, the company had announced positive top-line data from this stage with ALKS 3831 meting the study's primary endpoint of demonstrating antipsychotic efficacy equivalent to Zyprexa. | Click to get this free report ACORDA THERAPT (ACOR): Free Stock Analysis Report REPROS THERAPEU (RPRX): Get Free Report HORIZON PHARMA (HZNP): Get Free Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are Acorda Therapeutics, Inc. ACOR and Horizon Pharma plc HZNP . Repros Therapeutics Inc.RPRX received encouraging news with the European Medicines Agency saying that the company's enclomiphene citrate (previously known as Androxal) capsules can be submitted for a centralized marketing authorization application (MAA) as a new active substance (NAS)."
2015-04-06,33.209999084472656,33.0099983215332,0.937681626487152,,
2015-04-02,33.66999816894531,33.5099983215332,-0.6022305584252892,Repros' Secondary Hypogonadism Drug Under FDA Review - Analyst Blog,"Click to get this free report REPROS THERAPEU (RPRX): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report HORIZON PHARMA (HZNP): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector include Acorda Therapeutics, Inc. ACOR and Horizon Pharma plc HZNP . With no approved product in Repros' portfolio at the moment and enclomiphene citrate being the company's lead pipeline candidate, we expect investor focus to remain on the candidate's approval status, going forward."
2015-04-01,33.290000915527344,33.56999969482422,-0.4752000478564958,Cambrex (CBM) Looks Good: Stock Adds 11.6% in Session - Tale of the Tape | Raptor Pharmaceuticals (RPTP) in Focus: Stock Falls 9.7% - Tale of the Tape,"Click to get this free report CAMBREX CORP (CBM): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here. Another favorably-ranked biomedical stock is Acorda Therapeutics, Inc. ( ACOR ) with a Zacks Rank #1. Yesterday's rally breaks the recent trend for the company, as the stock is now trading above the volatile price range of $33.53 to $36.77 in the past one-month time frame. | Investors interested in the Medical - Biomedical/Genetics industry may consider a better-ranked stock like Acorda Therapeutics, Inc. ( ACOR ), carrying a Zacks Rank #1 (Strong Buy). Click to get this free report RAPTOR PHARMACT (RPTP): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2015-03-31,33.66999816894531,33.279998779296875,0.8410897314402779,What Makes Novavax (NVAX) a Strong Sell? - Tale of the Tape | BioDelivery Sciences International (BDSI) Crumbles: Stock Falls 24.3% - Tale of the Tape | Amgen's Kyprolis Gets FDA Priority Review for Expanded Use - Analyst Blog,"Click to get this free report NOVAVAX INC (NVAX): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here. If you are still interested in the medical sector, you may instead consider a better-ranked stock - Acorda Therapeutics, Inc. ( ACOR ). One such stock that you may want to consider dropping is Novavax, Inc. ( NVAX ), which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. | Click to get this free report BIODELIVERY SCI (BDSI): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked stock in the same sector is Acorda Therapeutics, Inc. ( ACOR ), holding a Zacks Rank #1 (Strong Buy). Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >> Want the latest recommendations from Zacks Investment Research? | Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report HORIZON PHARMA (HZNP): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector include Acorda Therapeutics, Inc. ACOR , Cytokinetics, Inc. CYTK and Horizon Pharma plc HZNP . Amgen Inc.AMGN received encouraging news with the FDA granting priority review to the company's supplemental new drug application for its multiple myeloma drug, Kyprolis."
2015-03-30,34.630001068115234,33.90999984741211,-1.1582994085462819,Falling Earnings Estimates Signal Weakness Ahead for Achillion Pharmaceuticals (ACHN) - Tale of the Tape,"Click to get this free report ACHILLION PHARM (ACHN): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here. If you are still interested in the Biomedicine sector, you may instead a better-ranked stock Acorda Therapeutics, Inc. ( ACOR ) with a Zacks Rank #1 (Strong Buy). One such stock that you may want to consider dropping is Achillion Pharmaceuticals, Inc. ( ACHN ), which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year."
2015-03-27,32.79999923706055,34.20000076293945,-2.0791256092857857,Avalanche Biotechnologies (AAVL) Crumbles: Stock Falls by 6.4% - Tale of the Tape | Orexigen's Obesity Drug Mysimba Gains European Approval - Analyst Blog,"Click to get this free report AVALANCHE BIOT (AAVL): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here. Another better-ranked stock in the same sector is Acorda Therapeutics, Inc. ( ACOR ) with a Zacks Rank #1 (Strong Buy). This slump shouldn't be too much of a surprise to investors, as the biomedicine company has seen 2 negative revisions in the past few weeks and its current year earnings consensus has moved lower over the last 30 days. | While Acorda is a Zacks Rank #1 (Strong Buy) stock, Takeda and Novo Nordisk hold a Zacks Rank #2 (Buy). Click to get this free report OREXIGEN THERAP (OREX): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report TAKEDA PHARMACT (TKPYY): Get Free Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector include Acorda Therapeutics, Inc. ACOR , Takeda and Novo Nordisk."
2015-03-26,33.619998931884766,32.939998626708984,4.268297434278754,"Merck in $10B Buyback; Keytruda Tops Melanoma Study - Analyst Blog | Sanofi Reveals Cerdelga Data, FDA OK's Quadracel Vaccine - Analyst Blog","Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector include Acorda Therapeutics, Inc. ACOR and Novo Nordisk NVO . While Acorda is a Zacks Rank #1 (Strong Buy) stock, Novo Nordisk holds a Zacks Rank #2 (Buy). | Click to get this free report SANOFI-AVENTIS (SNY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector include Acorda Therapeutics, Inc. ACOR , Cytokinetics, Inc. CYTK and Novo Nordisk NVO . While Acorda and Cytokinetics are Zacks Rank #1 (Strong Buy) stocks, Novo Nordisk holds a Zacks Rank #2 (Buy)."
2015-03-25,34.939998626708984,33.630001068115234,-2.022606563889203,"The Zacks Analyst Blog Highlights: HSBC Holdings, Goldman Sachs, Acorda Therapeutics, Biogen Idec and Ross Stores - Press Releases | OvaScience, Inc. (OVAS) in Focus: Stock Surges 12.2% - Tale of the Tape | Coronado Biosciences, Inc. (CNDO) in Focus: Stock Jumps 8.6% - Tale of the Tape","Stocks recently featured in the blog include the HSBC Holdings plc ( HSBC - Free Report ), Goldman Sachs ( GS - Free Report ), Acorda Therapeutics, Inc. ( ACOR - Free Report ), Biogen Idec ( BIIB - Free Report ) and Ross Stores Inc. ( ROST - Free Report ). Get the full Report on HSBC - FREE Get the full Report on GS - FREE Get the full Report on ACOR - FREE Get the full Report on BIIB - FREE Get the full Report on ROST - FREE Follow us on Twitter: http://twitter.com/zacksresearch Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Click to get this free report HSBC HOLDINGS (HSBC): Free Stock Analysis Report GOLDMAN SACHS (GS): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ROSS STORES (ROST): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report OVASCIENCE (OVAS): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked stock in the same industry is Acorda Therapeutics, Inc. ( ACOR ), sporting a Zacks Rank #1 (Strong Buy). Click to get this free report >> Want the latest recommendations from Zacks Investment Research? | Click to get this free report CORONADO BIOSCI (CNDO): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked stock in the same industry is Acorda Therapeutics, Inc. ( ACOR ), sporting a Zacks Rank #1 (Strong Buy). Click to get this free report >> Want the latest recommendations from Zacks Investment Research?"
2015-03-24,34.84000015258789,34.7599983215332,-3.7492776476309193,2 Stocks to Beat the Dollar's Volatile Run - Analyst Blog | Vertex Falls on Disappointing Kalydeco+VX-661 Combo Data - Analyst Blog,"Click to get this free report ACORDA THERAPT (ACOR): Free Stock Analysis Report ROSS STORES (ROST): Free Stock Analysis Report GOLDMAN SACHS (GS): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report HSBC HOLDINGS (HSBC): Free Stock Analysis Report To read this article on Zacks.com click here. 2 Safe Bets Acorda Therapeutics, Inc.ACOR is a biopharmaceutical company based in Ardsley, NY. It manufactures and sells its drugs including Ampyra, Zanaflex and Qutenza in the U.S. Acorda's fourth quarter revenues came in at $117.9 million. | Click to get this free report VERTEX PHARM (VRTX): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report HORIZON PHARMA (HZNP): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector include Acorda Therapeutics, Inc. ACOR , Cytokinetics, Incorporated CYTK and Horizon Pharma plc HZNP . Vertex Pharmaceuticals Incorporated 's VRTX shares fell almost 4% after the company reported disappointing data from a 12-week phase II study evaluating VX-661 in combination with Kalydeco (ivacaftor) in patients suffering from cystic fibrosis (CF) aged 18 years and above with two copies of the F508del mutation."
2015-03-23,34.70000076293945,34.720001220703125,-0.2296263797482935,"Aeterna Zentaris Inc. (AEZS) in Focus: Stock Jumps 5.3% - Tale of the Tape | Amicus Therapeutics Slumps: FOLD Falls 6.8% in Session - Tale of the Tape | Dicerna Pharmaceuticals (DRNA) Crumbles: Stock Falls by 6.4% - Tale of the Tape | Biogen Gains on Positive Alzheimer's Drug Interim Results - Analyst Blog | Celgene Presents Efficacy, Safety Data on Otezla - Analyst Blog","Click to get this free report AETERNA ZENTARS (AEZS): Get Free Report ACORDA THERAPT (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here. Another favorably-placed stock in the same industry is Acorda Therapeutics, Inc. ( ACOR ), sporting a Zacks Rank #1 (Strong Buy). Click to get this free report >> Want the latest recommendations from Zacks Investment Research? | Click to get this free report AMICUS THERAPT (FOLD): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked stock in the med-biomed/gene sector is Acorda Therapeutics, Inc. ( ACOR ), which currently carries a Zacks Rank #1 (Strong Buy). On Mar 3, the company reported its fourth quarter results where the company reported a net loss per share which was wider than the year ago figure. | Click to get this free report DICERNA PHARMA (DRNA): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked stock in the med-biomed/gene sector is Acorda Therapeutics, Inc. ( ACOR ), which currently carries a Zacks Rank #1 (Strong Buy). Click to get this free report >> Want the latest recommendations from Zacks Investment Research? | Click to get this free report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked stock in the biotech sector is Acorda Therapeutics, Inc. ACOR carrying a Zacks Rank #1 (Strong Buy). Biogen Idec Inc. 's BIIB shares hit a new 52-week high of $475.98 on Mar 20 after the company reported positive pre-specified interim results from a phase Ib study (PRIME) on its anti-amyloid beta antibody, aducanumab (BIIB037). | Click to get this free report CELGENE CORP (CELG): Free Stock Analysis Report AFFYMETRIX INC (AFFX): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector include Acorda Therapeutics, Inc. ACOR , Cytokinetics, Inc. CYTK and Affymetrix Inc. AFFX . Results from the ESTEEM 2 study showed continued improvement in difficult-to-treat areas such as nails, scalp and the palms of the hands and soles of the feet (palmoplantar psoriasis) at week 52 in patients who achieved a 50% reduction in Psoriasis Area and Severity Index (PASI) at week 32."
2015-03-20,35.41999816894531,34.7400016784668,0.057638205544458976,"Inovio Pharmaceuticals, Inc. (INO) Jumps: Stock Rises 12.8% - Tale of the Tape | Sanofi Inks Multi-Component Strategic Deal with Evotec - Analyst Blog","Click to get this free report INOVIO PHARMAC (INO): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked stock in the med-biomed/gene industry is Acorda Therapeutics, Inc. ( ACOR ), sporting a Zacks Rank #1 (Strong Buy). Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >> Want the latest recommendations from Zacks Investment Research? | Click to get this free report SANOFI-AVENTIS (SNY): Free Stock Analysis Report AFFYMETRIX INC (AFFX): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks that warrant a look in the health care sector include Cytokinetics, Inc. CYTK , Acorda Therapeutics, Inc. ACOR and Affymetrix Inc. AFFX . The Deal in Details The deal, confirmed a minimum guaranteed commitment from Sanofi of €250 million (including more than €40 million as upfront cash payment) to Evotec."
2015-03-19,34.04999923706055,35.130001068115234,-1.9198095020645893,DBV Technologies (DBVT) Jumps: Stock Up 7.2% in Session - Tale of the Tape,"Click to get this free report DBV TECH SA-ADR (DBVT): Get Free Report ACORDA THERAPT (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked stock in the med-biomed/gene industry is Acorda Therapeutics, Inc. ( ACOR ), which sports a Zacks Rank #1 (Strong Buy). In the last 30 days, the company witnessed one positive estimate revision and the Zacks Consensus Estimate also moved higher over the same time frame, suggesting that more solid trading could be ahead for DBV Technologies."
2015-03-18,34.02000045776367,34.0,3.17181161601671,Regeneron Hits a 52-Week High on Positive Praluent Data - Analyst Blog | Will Acorda Therapeutics (ACOR) Crush Estimates at Its Next Earnings Report? - Tale of the Tape | Teva Sells Four Oncology Development Assets to Ignyta - Analyst Blog | AstraZeneca Presents Encouraging Heart Drug Brilinta Data - Analyst Blog,"Click to get this free report REGENERON PHARM (REGN): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ACOR is a better-ranked stock in the health care sector sporting a Zacks Rank #1 (Strong Buy). Shares of Regeneron Pharmaceuticals, Inc.REGN have been riding high after the company announced that 18-month data from a phase III study on its PCSK9 (proprotein convertase subtilisin/kexin type 9) antibody, Praluent, were published online in The New England Journal of Medicine.. Shares of the company hit a 52-week high of $468.50 on Mar 17, eventually closing a little lower at $467.80. | Earnings in Focus Two quarters ago, ACOR expected to earn 4 cents per share, while it actually produced earnings of 34 cents per share, a beat of 750.0%. And when you add this solid Zacks Rank to a positive Earnings ESP, a positive earnings surprise happens nearly 70% of the time, so it seems pretty likely that ACOR could see another beat at its next report, especially if recent trends are any guide. Consider Acorda Therapeutics, Inc. ( ACOR ), a firm in the Medical-Biomedical industry, which could be a great candidate for another beat. | Click to get this free report TEVA PHARM ADR (TEVA): Free Stock Analysis Report IGNYTA INC (RXDX): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report AKORN INC (AKRX): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector include Akorn, Inc. AKRX and Acorda Therapeutics, Inc. ACOR , each holding a Zacks Rank #1 (Strong Buy). Terms of the Asset Purchase Deal Under the terms of the asset purchase deal, Teva sold worldwide rights and assets related to four oncology development programs to Ignyta for 1.5 million shares of the latter's stock. | Click to get this free report ASTRAZENECA PLC (AZN): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report AKORN INC (AKRX): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector include Akorn, Inc. AKRX , Acorda Therapeutics, Inc. ACOR and Novo Nordisk A/S NVO . While Akorn and Acorda hold a Zacks Rank #1 (Strong Buy), Novo Nordisk is a Zacks Rank #2 (Buy) stock."
2015-03-17,34.25,33.959999084472656,-0.05879029245899845,Why You Shouldn't Bet Against Acorda Therapeutics (ACOR) Stock - Tale of the Tape | TrovaGene (TROV) in Focus: Stock Adds 6.1% in Session - Tale of the Tape | Eleven Biotherapeutics (EBIO) Crumbles: Stock Falls by 5.6% - Tale of the Tape,"One stock that might be an intriguing choice for investors right now is Acorda Therapeutics, Inc. ( ACOR ). Meanwhile, Acorda Therapeutics is actually looking pretty good on its own too. This has helped ACOR to earn a Zacks Rank #1 (Strong Buy), further underscoring the company's solid position. | A better-ranked stock in the same space is Acorda Therapeutics, Inc. ( ACOR ), sporting a Zacks Rank #1 (Strong Buy). Click to get this free report TROVAGENE INC (TROV): Get Free Report ACORDA THERAPT (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here. Click to get this free report >> Want the latest recommendations from Zacks Investment Research? | Click to get this free report ELEVEN BIOTHERP (EBIO): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here. Investors interested in the Medical - Biomedical/Genetics industry may consider a better-ranked stock like Acorda Therapeutics, Inc. ( ACOR ), carrying a Zacks Rank #1 (Strong Buy). So make sure to keep an eye on this stock going forward to see if this recent slump will continue, as the earnings picture definitely suggests that this might be the case."
2015-03-16,34.65999984741211,34.470001220703125,-0.8467180015396899,"Regeneron/Sanofi's PCSK9 Drug Praluent Data Published - Analyst Blog | Amgen Presents Encouraging PCSK9 Inhibitor Repatha Data - Analyst Blog | Merck's Sugammadex Faces Setback, FDA Delays Meeting - Analyst Blog | Alnylam Announces Positive Data from Natural History Study - Analyst Blog","Click to get this free report REGENERON PHARM (REGN): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ACOR is a better-ranked stock in the health care sector sporting a Zacks Rank #1 (Strong Buy). The phase III ODYSSEY LONG TERM study compared the use of Praluent 150 mg every two weeks to placebo in patients who were at high cardiovascular (CV) risk and who were receiving maximally-tolerated statin therapy with or without other lipid lowering treatment. | Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked stock in the biotech sector is Acorda Therapeutics, Inc. ACOR carrying a Zacks Rank #1 (Strong Buy). Amgen Inc.AMGN presented encouraging one-year data from the phase II (OSLER-1) and phase III (OSLER-2) open-label extension studies and phase III YUKAWA-2 study on its PCSK9 inhibitor, Repatha (evolocumab), at the American College of Cardiology's Annual Scientific Session. | Click to get this free report ACORDA THERAPT (ACOR): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report HORIZON PHARMA (HZNP): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector include Acorda Therapeutics, Inc. ACOR , Cytokinetics, Incorporated CYTK and Horizon Pharma plc HZNP . Merck & Co. Inc.MRK received disappointing news with the FDA cancelling a previously scheduled meeting with the Anesthetic and Analgesic Drug Products Advisory Committee on Mar 18 to consider the company's resubmitted new drug application (NDA) for sugammadex. | Click to get this free report ALNYLAM PHARMA (ALNY): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector include Acorda Therapeutics, Inc. ACOR and Cytokinetics, Inc. CYTK . Alnylam said that it now believes that revusiran has the potential to show a decline from baseline in 6-MWD at 18 months in the ongoing phase III ENDEAVOUR study, which is the co-primary endpoint of the study."
2015-03-13,34.29999923706055,34.349998474121094,-0.5481783829931858,Geron Corporation (GERN) Jumps: Stock Rises 5.6% - Tale of the Tape,"Click to get this free report GERON CORP (GERN): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here. Investors interested in the med-biomed/gene industry may also consider Acorda Therapeutics, Inc. ( ACOR ), sporting a Zacks Rank #1 (Strong Buy). Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >> Want the latest recommendations from Zacks Investment Research?"
2015-03-12,35.25,34.25,0.14577037368130194,Zacks Rank #1 Additions for Thursday - Tale of the Tape,"Here are 4 stocks added to the Zacks Rank #1 (Strong Buy) List today: Acorda Therapeutics, Inc. ( ACOR ) Burlington Stores, Inc. ( BURL ) Ferrellgas Partners LP ( FGP ) Inogen, Inc. ( INGN ) View the entire Zacks Rank #1 List . Click to get this free report ACORDA THERAPT (ACOR): Free Stock Analysis Report BURLINGTON STRS (BURL): Free Stock Analysis Report FERRELLGAS -LP (FGP): Free Stock Analysis Report INOGEN INC (INGN): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2015-03-11,35.709999084472656,35.18000030517578,-2.8368794326241136,,
2015-03-10,33.630001068115234,35.43000030517578,-1.4841747210442464,,
2015-03-09,34.880001068115234,33.880001068115234,5.352361522126548,,
2015-03-06,35.220001220703125,34.7400016784668,-2.866972389270158,,
2015-03-05,36.0,35.29999923706055,-1.3628606632590727,,
2015-03-04,35.0,35.7400016784668,-1.9444465637207031,,
2015-03-03,35.08000183105469,35.20000076293945,2.114290509905134,,
2015-03-02,34.0099983215332,35.0099983215332,0.3420721939031833,,
2015-02-27,35.2400016784668,33.84000015258789,2.940311818148067,Relative Strength Alert For Acorda Therapeutics,"In trading on Friday, shares of Acorda Therapeutics Inc (Symbol: ACOR) entered into oversold territory, hitting an RSI reading of 28.3, after changing hands as low as $33.08 per share. The chart below shows the one year performance of ACOR shares: Looking at the chart above, ACOR's low point in its 52 week range is $28.26 per share, with $45.45 as the 52 week high point - that compares with a last trade of $34.01. A bullish investor could look at ACOR's 28.3 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side."
2015-02-26,35.45000076293945,35.560001373291016,-3.9727623700266994,,
2015-02-25,36.369998931884766,36.040000915527344,0.3102979068665087,,
2015-02-24,37.34999847412109,36.54999923706055,-0.90733578787136,,
2015-02-23,37.720001220703125,37.18999862670898,-2.1418989819098386,,
2015-02-20,37.970001220703125,37.40999984741211,-1.4050969693586561,,
2015-02-19,38.43999862670898,37.93999862670898,-1.4748521340201464,,
2015-02-18,37.45000076293945,37.47999954223633,-1.300728454377698,,
2015-02-17,36.20000076293945,37.43999862670898,0.08010354789247912,,
2015-02-13,36.88999938964844,36.13999938964844,3.425408391258929,Acorda Beats Q4 Earnings Estimates; Ampyra Sales Grow - Analyst Blog,"Strong Quarter for Ampyra The bulk of net product revenues at Acorda came from Ampyra, which generated $109.9 million in the reported quarter, up 29.9% from the year-ago period, benefiting from the company's efforts to increase awareness about the drug. Click to get this free report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ACHILLION PHARM (ACHN): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. 's ( ACOR ) fourth quarter earnings of 33 cents per share surpassed both the Zacks Consensus Estimate and the year-ago earnings of 15 cents per share."
2015-02-12,38.38999938964844,36.650001525878906,-2.0330713266708664,"Health Care Sector Update for 02/12/2015: PLX, THLD, ACOR","Acorda Therapeutics ( ACOR ), a biopharmaceutical company, Thursday reported better-than-expected financial results for Q4, along with its revenue target for 2015 for its lead product AMPYRA. Shares were trading 7.3% higher at $2.05 during pre-market trading. Meanwhile Threshold Pharmaceuticals ( THLD ) has priced an underwritten offering of 8.3 million shares with accompanying warrants to purchase 8.3 million shares at a combined offering price of each share of common stock and accompanying warrant of $3.62."
2015-02-11,35.869998931884766,36.88999938964844,-4.532424827906374,Will Kite Pharma (KITE) Disappoint this Earnings Season? - Analyst Blog,"Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report KITE PHARMA INC (KITE): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ( ACOR ) has an earnings ESP of +40.00% and a Zacks Rank #3. Zacks Rank: Kite Pharma's Zacks Rank #3 (Hold) when combined with a 0.00% ESP makes surprise prediction difficult."
2015-02-10,40.41999816894531,36.060001373291016,2.8436032565838625,Will Hospira (HSP) Miss Q4 Earnings on Low Precedex Sales? - Analyst Blog | Why Earnings Season Could Be Great for Acorda Therapeutics (ACOR) - Tale of the Tape | DaVita Healthcare (DVA): What's in Store for Q4 Earnings? - Analyst Blog,"Click to get this free report HOSPIRA INC (HSP): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ( ACOR ) has an Earnings ESP of +106.67% and a Zacks Rank #3 (Hold). Hospira's earnings track record has been pretty good - last quarter, the company delivered a positive earnings surprise of 39.62%. | This suggests that analysts have very recently bumped up their estimates for ACOR, giving the stock a Zacks Earnings ESP of 40.00% heading into earnings season. Given that ACOR has a Zacks Rank #3 (Hold) and an ESP in positive territory, investors might want to consider this stock ahead of earnings. Investors are always looking for stocks that are poised to beat at earnings season and Acorda Therapeutics, Inc. ( ACOR ) may be one such company. | Click to get this free report DAVITA HEALTHCR (DVA): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report LIFEPOINT HOSP (LPNT): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ( ACOR ) has an Earnings ESP of +40.00% and a Zacks Rank #3. Zacks Rank: DaVita has a Zacks Rank #3 (Hold) which increases the predictive power of ESP; but when combined with a 0.00% ESP, the surprise prediction becomes difficult."
2015-02-09,40.27999877929688,39.90999984741211,-10.786731799023393,Will Regeneron (REGN) Beat Q4 Earnings on Eylea Sales? - Analyst Blog | Will Avalanche (AAVL) Miss This Earnings on Higher Costs? - Analyst Blog | Will Zoetis (ZTS) Earnings Disappoint Expectation in Q4? - Analyst Blog,"Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ( ACOR ) has an Earnings ESP of +106.67% and a Zacks Rank #3. Zacks ESP: Regeneron has a positive Zacks ESP . | Click to get this free report REGENERON PHARM (REGN): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report AVALANCHE BIOT (AAVL): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ( ACOR ) has an Earnings ESP of +106.67% and a Zacks Rank #3. Higher Expenses to Hit Revenues We expect Avalanche's revenues to be affected by operating expenses which are expected to rise this quarter as the company continues to invest in its pipeline. | Stocks that Warrant a Look Here are some companies you may want to consider as our model shows that these have the right combination of elements: Acorda Therapeutics, Inc. ( ACOR ) has an Earnings ESP of +106.67% and a Zacks Rank #3 (Hold). Click to get this free report PFIZER INC (PFE): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report ZOETIS INC (ZTS): Free Stock Analysis Report To read this article on Zacks.com click here. As it is, we caution against stocks with Zacks Ranks #4 and 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions."
2015-02-06,42.130001068115234,40.400001525878906,-0.9185673860420891,,
2015-02-05,40.34999847412109,42.29999923706055,-4.106336336045393,,
2015-02-04,40.369998931884766,40.27000045776367,4.832715828205333,,
2015-02-03,40.900001525878906,40.790000915527344,-0.24770492139427236,Will Perrigo (PRGO) Disappoint This Earnings Season? - Analyst Blog,"Click to get this free report PERRIGO CO PLC (PRGO): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ( ACOR ) has an Earnings ESP of +106.67% and a Zacks Rank #3 (Hold). Negative Zacks ESP: The Earnings ESP for Perrigo is -4.49% since the Most Accurate estimate is $1.70 while the Zacks Consensus Estimate is $1.78."
2015-02-02,41.7599983215332,40.88999938964844,-0.2689501375249611,Will Glaxo (GSK) Q4 Earnings Suffer from Lower Revenues? - Analyst Blog | Will Gilead (GILD) Miss Q4 Earnings on Low HCV Drug Sales? - Analyst Blog | Will Allergan (AGN) Disappoint on Earnings This Quarter? - Analyst Blog | Will Merck's (MRK) Q4 Earnings be Hit by Patent Expiries? - Analyst Blog,"Click to get this free report ACORDA THERAPT (ACOR): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ( ACOR ) has an Earnings ESP of +106.67% and a Zacks Rank #3 (Hold). Generics and Competition May Hit Q4 Sales Glaxo is facing generic competition for several of its key drugs which has put significant pressure on the company. | Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report EXPRESS SCRIPTS (ESRX): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ( ACOR ) has an Earnings ESP of +106.67% and a Zacks Rank #3. Sovaldi and Harvoni in Focus Gilead's blockbuster hepatitis C virus (HCV) treatment, Sovaldi, is expected to contribute meaningfully to the company's top line in the fourth quarter, as it has done so since its launch in the U.S. in Dec 2013. | Click to get this free report ALLERGAN INC (AGN): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report BIODEL INC (BIOD): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ( ACOR ) has an Earnings ESP of +106.67% and a Zacks Rank #3 (Hold). Zacks Rank: Allergan's Zacks Rank #3 (Hold) when combined with a 0.0% ESP makes surprise prediction difficult. | Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ( ACOR ) has an Earnings ESP of +106.67% and a Zacks Rank #3. Zacks ESP: Earnings ESP for Merck is 0.00%."
2015-01-30,41.84999847412109,41.54999923706055,-2.083330859321797,,
2015-01-29,42.880001068115234,42.0,-0.7168440812394563,Will Generics Continue to Hit Eli Lilly's (LLY) Q4 Earnings? - Analyst Blog,"Stocks that Warrant a Look Here are some companies you may want to consider as our model shows that these have the right combination of elements: Acorda Therapeutics, Inc. ( ACOR ) has an Earnings ESP of +200% and a Zacks Rank #3. Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report BIODEL INC (BIOD): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report To read this article on Zacks.com click here. We caution against stocks with Zacks Ranks #4 and 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions."
2015-01-28,44.119998931884766,42.540000915527344,-2.052241245790422,Is AbbVie (ABBV) Set to Beat 4Q Earnings on Humira Sales? - Analyst Blog,"Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ( ACOR ) has an Earnings ESP of +200% and a Zacks Rank #3. AbbVie ( ABBV ), which has been in the news thanks to the recent approval of its hepatitis C virus (HCV) treatment Viekira Pak, will be reporting fourth quarter and full year 2014 results on Jan 30, before the market opens."
2015-01-27,44.08000183105469,43.70000076293945,-3.5811379297554438,Will Biogen (BIIB) Surpass Q4 Earnings Expectations? - Analyst Blog,"Click to get this free report ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ( ACOR ) has an Earnings ESP of +200% and a Zacks Rank #3. Key focus this quarter will be on the impact of the confirmation of a case of progressive multifocal leukoencephalopathy (PML) in a patient on Tecfidera, the company's oral MS treatment."
2015-01-26,43.869998931884766,44.5,-0.8620713528362896,,
2015-01-23,43.38999938964844,43.7599983215332,1.4360635592752407,First Week of March 20th Options Trading For Acorda Therapeutics (ACOR),"Below is a chart showing the trailing twelve month trading history for Acorda Therapeutics Inc, and highlighting in green where the $35.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $50.00 strike price has a current bid of 50 cents. Below is a chart showing ACOR's trailing twelve month trading history, with the $50.00 strike highlighted in red: Considering the fact that the $50.00 strike represents an approximate 17% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acorda Therapeutics Inc (Symbol: ACOR) saw new options begin trading this week, for the March 20th expiration."
2015-01-22,43.27999877929688,43.54999923706055,0.8527285943521732,,
2015-01-21,43.900001525878906,42.81999969482422,0.6238458072527032,,
2015-01-20,42.7599983215332,43.90999984741211,-2.4601407597173544,"Closing Update: Late Bounce Carries Stocks to Second Positive Day in a Row; Tech Shares Pace Advance | Health Care Sector Update for 01/20/2015: VBLT,ACOR,BLRX,PETS,MDWD","(+) VBLT, Rallies to new all-time high after saying Dr. Ron Cohen, CEO at Acorda Therapeutics ( ACOR ) and Philip Serlin, the chief financial and operation officer at BioLineRx Ltd ( BLRX ), agreed to stand for election to the board of directors next month. Another steep decline in crude oil prices weighed on the U.S, markets throughout much of today's session, although led by technology shares, began to pare losses shortly after mid-day and edged back onto positive ground just before the closing bell. (+) GFIG, BGC Partners ( BGCP ) boosts take-over offer to $6.10 per share hours after CME Group ( CME ) matched its $5.85 per share bid. | The two board nominees are Dr. Ron Cohen, CEO at Acorda Therapeutics ( ACOR ) and Philip Serlin, the chief financial and operation officer at BioLineRx Ltd ( BLRX ). Health care stocks were moderately lower today with the NYSE Health Care Sector Index dropping 0.2% and shares of health care companies in the S&P 500 also sliding 0.2% as a group. In company news, VBL Therapeutics ( VBLT ) rallied to an all-time high Tuesday after the Israeli biotech company today said a pair of top executives at two U.S. firms have agreed to stand for election to its board of directors next month."
2015-01-16,41.119998931884766,42.59000015258789,2.6894330472875283,,
2015-01-15,43.040000915527344,41.27999877929688,3.5749057852316106,,
2015-01-14,43.810001373291016,42.93000030517578,-4.089224207231636,,
2015-01-13,43.95000076293945,44.22999954223633,-2.0086761938604534,,
2015-01-12,42.5,43.43999862670898,0.6370848110041039,,
2015-01-09,42.0,42.08000183105469,2.211761474609358,,
2015-01-08,43.02000045776367,41.93999862670898,0.19048055013020831,,
2015-01-07,40.43000030517578,41.81999969482422,-2.5104644806199445,,
2015-01-06,40.5099983215332,40.119998931884766,3.4380395230184853,,
2015-01-05,40.34000015258789,40.36000061035156,-0.9627237862439807,,
2015-01-02,41.27000045776367,40.5099983215332,0.0495797166287041,,
2014-12-31,40.66999816894531,40.869998931884766,-1.8415365345301273,,
2014-12-30,40.86000061035156,40.63999938964844,0.49176486831555644,"Strength Seen in Alliqua (ALQA): Stock Up 13.2% in Session - Tale of the Tape | Zacks Rank #1 Additions for Tuesday - Tale of the Tape | AMAG, Takeda Mutually End Agreement for Feraheme - Analyst Blog | BioMarin's Vimizim OK'd in Japan for Morquio A Syndrome - Analyst Blog | Qiagen Poised on Molecular Diagnostics, International Strength - Analyst Blog","Click to get this free report ALLIQUA INC (ALQA): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked medical stock is Acorda Therapeutics, Inc. ( ACOR ) sporting a Zacks Rank #1 (Strong Buy). Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >> Want the latest recommendations from Zacks Investment Research? | Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today: ACCO Brands Corporation ( ACCO ) Acorda Therapeutics Inc ( ACOR ) Alleghany Corporation ( Y ) Altisource Portfolio Solutions S.A. ( ASPS ) AMAG Pharmaceuticals, Inc. ( AMAG ) View the entire Zacks Rank #1 List . Click to get this free report ACCO BRANDS CP (ACCO): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report ALLEGHANY CORP (Y): Free Stock Analysis Report ALTISOURCE PORT (ASPS): Free Stock Analysis Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Click to get this free report AMAG PHARMA INC (AMAG): Free Stock Analysis Report TAKEDA PHARMACT (TKPYY): Get Free Report ACORDA THERAPT (ACOR): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. Some equally well-ranked stocks in the health care sector include Acorda Therapeutics, Inc. ( ACOR ) and ANI Pharmaceuticals, Inc. ( ANIP ). AMAG Pharmaceuticals, Inc. ( AMAG ) and Takeda Pharmaceutical Company Ltd. ( TKPYY ) announced their decision to mutually terminate their licensing deal for Feraheme in the ex-U.S. territories including Europe. | Click to get this free report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report PROSENA HLDG BV (RNA): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector include Acorda Therapeutics, Inc. ( ACOR ) and ANI Pharmaceuticals, Inc. ( ANIP ). BioMarin Pharmaceutical Inc. ( BMRN ) announced that the Japanese Ministry of Health, Labour and Welfare has approved the company's enzyme replacement therapy, Vimizim, for the treatment of patients suffering from mucopolysaccharidosis type IVA or Morquio A syndrome. | Click to get this free report AFFYMETRIX INC (AFFX): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report QIAGEN NV (QGEN): Free Stock Analysis Report GTX INC (GTXI): Free Stock Analysis Report To read this article on Zacks.com click here. However, stocks worth considering in the same sector are Affymetrix Inc. ( AFFX ), Acorda Therapeutics, Inc. ( ACOR ) and GTX Inc. ( GTXI ). After a sluggish performance in the second quarter of 2014, an improvement was observed in Qiagen's Asia/Pacific segment which delivered faster growth in the reported quarter with solid double-digit growth in China, mainly driven by a healthy performance in Molecular Diagnostics."
2014-12-29,39.7400016784668,41.06999969482422,-0.5384268659246897,,
2014-12-26,39.119998931884766,39.65999984741211,3.3467487674467917,,
2014-12-24,38.470001220703125,39.13999938964844,1.380370476153607,,
2014-12-23,40.33000183105469,38.400001525878906,1.7416120293355863,,
2014-12-22,40.02999877929688,40.04999923706055,-4.785520003844019,,
2014-12-19,40.2400016784668,40.060001373291016,0.04996367317904793,,
2014-12-18,39.11000061035156,40.34999847412109,-0.44731684311062764,,
2014-12-17,38.25,38.470001220703125,3.170539106157221,3 Companies Growing Faster Than MannKind Corporation,"Although Acorda has three FDA-approved drugs -- Ampyra for walking improvement in multiple sclerosis patients; Zanaflex for spasticity; and Qutenza for post-shingles nerve pain -- Ampyra is without question the workhorse drug generating big profits for Acorda. Acorda Therapeutics Next up we have Acorda Therapeutics, a company focused on developing therapies to treat central nervous system disorders. Source: Acorda Therapeutics."
2014-12-16,38.310001373291016,38.25,0.5751665900735294,Acorda's Ampyra in Phase III for Post-Stroke Walking Deficit - Analyst Blog,"Acorda Therapeutics, Inc. ( ACOR ) enrolled the first patient in a phase III study on Ampyra (dalfampridine). Click to get this free report ACORDA THERAPT (ACOR): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda is developing a twice-daily formulation of Ampyra for the treatment of post-stroke walking deficits (PSWD)."
2014-12-15,39.41999816894531,38.400001525878906,-0.15662065032669878,,
2014-12-12,38.220001220703125,38.70000076293945,-2.587510630251499,,
2014-12-11,38.68999862670898,38.63999938964844,1.2558857323539816,,
2014-12-10,38.77999877929688,38.290000915527344,-0.1292303924405509,,
2014-12-09,37.2400016784668,38.77999877929688,-1.2635324373221202,,
2014-12-08,37.66999816894531,37.84999847412109,4.135330374382217,,
2014-12-05,36.02999877929688,37.650001525878906,0.477834653371882,,
2014-12-04,36.90999984741211,36.400001525878906,4.496260897774135,,
2014-12-03,36.34999847412109,36.84000015258789,-1.3817348242794993,,
2014-12-02,35.68000030517578,36.470001220703125,1.348010176164531,,
2014-12-01,36.220001220703125,35.47999954223633,2.2141281075402497,Is Acorda Therapeutics (ACOR) Stock a Solid Choice Right Now? - Tale of the Tape,"One stock that might be an intriguing choice for investors right now is Acorda Therapeutics, Inc. ( ACOR ). Meanwhile, Acorda Therapeutics is actually looking pretty good on its own too. So, if you are looking for a decent pick in a strong industry, consider Acorda Therapeutics."
2014-11-28,36.79999923706055,36.45000076293945,-2.0430746922333527,,
2014-11-26,36.459999084472656,36.810001373291016,-0.9510828298295649,,
2014-11-25,36.41999816894531,36.5,0.9599624180117329,,
2014-11-24,35.959999084472656,36.40999984741211,0.21966456638348666,,
2014-11-21,36.70000076293945,35.939998626708984,1.2513925873089389,,
2014-11-20,34.869998931884766,36.09000015258789,-2.0708504643900096,,
2014-11-19,34.61000061035156,34.97999954223633,3.498713100296566,,
2014-11-18,34.150001525878906,34.529998779296875,1.0690520813631597,,
2014-11-17,33.470001220703125,34.099998474121094,1.1127298285184746,,
2014-11-14,33.849998474121094,33.470001220703125,1.8822743664206356,ACOR Crosses Below Key Moving Average Level,"In trading on Friday, shares of Acorda Therapeutics Inc (Symbol: ACOR) crossed below their 200 day moving average of $33.41, changing hands as low as $33.15 per share. The chart below shows the one year performance of ACOR shares, versus its 200 day moving average: Looking at the chart above, ACOR's low point in its 52 week range is $27.51 per share, with $39.95 as the 52 week high point - that compares with a last trade of $33.41. Acorda Therapeutics Inc shares are currently trading down about 1.1% on the day."
2014-11-13,34.81999969482422,33.72999954223633,-1.1225916412034205,,
2014-11-12,35.54999923706055,34.900001525878906,-3.1303853019559695,,
2014-11-11,36.2400016784668,35.90999984741211,-1.8284042901019926,,
2014-11-10,35.060001373291016,36.2400016784668,-0.9106010368944576,,
2014-11-07,35.83000183105469,35.11000061035156,3.365659609114319,,
2014-11-06,34.689998626708984,35.959999084472656,-2.009492559051681,,
2014-11-05,35.189998626708984,34.529998779296875,3.660998870106199,,
2014-11-04,35.119998931884766,34.779998779296875,-1.8755324614055928,,
2014-11-03,34.77000045776367,35.18000030517578,-0.9681098033269331,,
2014-10-31,36.95000076293945,34.81999969482422,1.1791769974525899,"Alkermes Incurs Wider Q3 Loss but Revenues Grow Y/Y - Analyst Blog | Acorda (ACOR) Beats on Q3 Earnings, Ups Ampyra Outlook - Analyst Blog","Click to get this free report ASTRAZENECA PLC (AZN): Free Stock Analysis Report ALKERMES INC (ALKS): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. 2014 Outlook Alkermes' 2014 guidance includes the impact of the Civitas Therapeutics acquisition by Acorda Therapeutics ( ACOR ) completed in September this year. Last month, AstraZeneca launched the Bydureon dual-chamber pen device in the U.S. Alkermes also earned revenues on Emend ($4.4 million), Ritalin LA/Focalin XR franchise ($8.7 million) and Verelan ($6.3 million). | Strong Quarter for Ampyra The bulk of net product revenues at Acorda came from Ampyra, which generated $96.4 million in the reported quarter, up 24% from the year-ago period, benefiting from the company's efforts to increase awareness about Ampyra. Click to get this free report ACORDA THERAPT (ACOR): Free Stock Analysis Report MEDIVATION INC (MDVN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report NEWLINK GENETIC (NLNK): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc.'s ( ACOR ) third quarter earnings of 34 cents per share surpassed the Zacks Consensus Estimate of 4 cents by a wide margin and the year-ago earnings of 20 cents."
2014-10-30,36.380001068115234,36.150001525878906,-5.764549456387584,,
2014-10-29,35.119998931884766,35.880001068115234,-0.632214226177987,,
2014-10-28,34.779998779296875,35.060001373291016,2.164015260092954,,
2014-10-27,34.0,34.459999084472656,0.8050678660771398,,
2014-10-24,35.029998779296875,34.25,1.3529384837431067,,
2014-10-23,32.70000076293945,35.029998779296875,-2.22665945326228,,
2014-10-22,32.54999923706055,32.27000045776367,7.125376030566106,,
2014-10-21,32.70000076293945,32.58000183105469,-0.8602113236859188,,
2014-10-20,31.600000381469727,32.380001068115234,-0.36696920209484035,,
2014-10-17,32.61000061035156,31.770000457763672,2.468356573510996,,
2014-10-16,30.25,31.96999931335449,-2.5758973838266197,,
2014-10-15,30.690000534057617,31.14999961853028,5.685948143320624,,
2014-10-14,31.25,31.190000534057617,1.4988565541476238,,
2014-10-13,31.780000686645508,30.89999961853028,-0.19199829101562502,,
2014-10-10,32.529998779296875,31.739999771118164,-2.7690404314088592,,
2014-10-09,33.63999938964844,32.77000045776367,-2.428524555252954,,
2014-10-08,32.130001068115234,33.849998474121094,-2.586203768340371,,
2014-10-07,33.599998474121094,32.22999954223633,5.353244160681739,,
2014-10-06,34.470001220703125,33.790000915527344,-4.077377958632785,,
2014-10-03,34.400001525878906,34.18000030517578,-1.9727307255427782,,
2014-10-02,34.0,34.06999969482422,-0.6395384039085564,,
2014-10-01,33.97999954223633,34.13999938964844,0.20588145536534927,,
2014-09-30,35.75,33.880001068115234,0.47086477212347627,,
2014-09-29,35.0,35.689998626708984,-5.230766243034309,,
2014-09-26,35.849998474121094,35.619998931884766,1.9714246477399555,,
2014-09-25,37.220001220703125,35.540000915527344,-0.6415608145767623,Acorda Skyrockets on $525M Civitas Therapeutics Deal - Analyst Blog,"Acorda Therapeutics, Inc. ( ACOR ) shot up 28.2% after the company announced that it is set to acquire privately-held biopharmaceutical company, Civitas Therapeutics, in a cash transaction worth $525 million (including approximately $35 million that will be used for change-in-control costs). Click to get this free report ACORDA THERAPT (ACOR): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report MEDIVATION INC (MDVN): Free Stock Analysis Report To read this article on Zacks.com click here. The acquisition will add Parkinson's disease (PD) candidate, CVT-301 to Acorda's portfolio."
2014-09-24,32.33000183105469,37.619998931884766,-4.513702982474121,"ACOR Makes Bullish Cross Above Critical Moving Average | Markets Edge Lower; KB Home Posts Downbeat Results | Sector Update: Health Care | Sector Update: Health-Care Shares Flat Pre-Market | Pre-Market Most Active for Sep 24, 2014 : AAPL, GSK, MACK, AVNR, SAN, BABA, ACOR, SIRI, TVIX, NOK, BAC, AZN | Dow Jumps 170 Points; Bed Bath & Beyond Shares Rise On Upbeat Results | Wednesday's ETF Movers: XBI, GDXJ | U.S. Stocks Rise; Accenture Shares Decline On Weak Forecast","In trading on Wednesday, shares of Acorda Therapeutics Inc (Symbol: ACOR) crossed above their 200 day moving average of $32.63, changing hands as high as $35.12 per share. The chart below shows the one year performance of ACOR shares, versus its 200 day moving average: Looking at the chart above, ACOR's low point in its 52 week range is $27.51 per share, with $39.95 as the 52 week high point - that compares with a last trade of $34.75. Acorda Therapeutics Inc shares are currently trading up about 18.3% on the day. | Shares of Acorda Therapeutics (NASDAQ: ACOR ) got a boost, shooting up 14.99 percent to $33.75 after the company announced its plans to acquire Civitas Therapeutics. Top gainers in the sector included BHP Billiton plc (NYSE: BBL ), up 1.8 percent, and POSCO (NYSE: PKX ), up 1.7 percent. The eurozone's STOXX 600 gained 0.29 percent, the Spanish Ibex Index fell 0.16 percent, while Italy's FTSE MIB Index surged 0.83 percent. | And, Acorda Therapeutics, Inc. ( ACOR ) was up about 8.6% after it said it entered into an agreement to acquire Civitas Therapeutics, a privately-held biopharmaceutical company, for $525 million in cash. Acorda will obtain worldwide rights to CVT-301, a Phase 3 treatment candidate for OFF episodes of Parkinson's disease. In health-care stocks news, Merrimack Pharmaceuticals ( MACK ) was higher nearly 23% in recent pre-market trade after selling the right to develop and commercialize its investigational metastatic pancreatic cancer drug outside of the U.S. and Taiwan to Baxter International ( BAX ). | And, Acorda Therapeutics, Inc. ( ACOR ) was up about 8.6% after it said it entered into an agreement to acquire Civitas Therapeutics, a privately-held biopharmaceutical company, for $525 million in cash. Acorda will obtain worldwide rights to CVT-301, a Phase 3 treatment candidate for OFF episodes of Parkinson's disease. PFE: flat ABT: flat MRK: flat | As reported in the last short interest update the days to cover for ACOR is 12.596351; this calculation is based on the average trading volume of the stock. Acorda Therapeutics, Inc. ( ACOR ) is +2.29 at $31.64, with 397,233 shares traded. As reported in the last short interest update the days to cover for MACK is 12.63447; this calculation is based on the average trading volume of the stock. | Top gainers in the sector included Acorda Therapeutics (NASDAQ: ACOR ), up 27.7 percent, and BioCryst Pharmaceuticals (NASDAQ: BCRX ), up 10 percent. Shares of Acorda Therapeutics (NASDAQ: ACOR ) got a boost, shooting up 27.29 percent to $37.36 after the company announced its plans to acquire Civitas Therapeutics. Toward the end of trading Wednesday, the Dow traded up 1 percent to 17,226.56 while the NASDAQ surged 1 percent to 4,553.96. | Components of that ETF showing particular strength include shares of Acorda Therapeutics ( ACOR ), up about 21.6% and shares of Biocryst Pharmaceuticals ( BCRX ), up about 8.8% on the day. In trading on Wednesday, the SPDR S&P Biotech ETF ( XBI ) is outperforming other ETFs, up about 2.7% on the day. Among components of that ETF with the weakest showing on Wednesday were shares of Endeavour Mining (EDV.CA), lower by about 5.8%, and shares of Sulliden Mining Capital (SMC.CA), lower by about 5.7% on the day. | Top gainers in the sector included Acorda Therapeutics (NASDAQ: ACOR ), up 19 percent, and BioCryst Pharmaceuticals (NASDAQ: BCRX ), up 8.3 percent. Shares of Acorda Therapeutics (NASDAQ: ACOR ) got a boost, shooting up 19.22 percent to $34.99 after the company announced its plans to acquire Civitas Therapeutics. Midway through trading Wednesday, the Dow traded up 0.32 percent to 17,109.62 while the NASDAQ surged 0.44 percent to 4,528.69."
2014-09-23,29.15999984741211,29.350000381469727,16.362501704991413,,
2014-09-22,29.38999938964844,29.25,0.6515793383122371,,
2014-09-19,30.530000686645508,30.0,-0.4763504340110696,,
2014-09-18,29.920000076293945,30.420000076293945,-1.735999589667031,,
2014-09-17,30.030000686645508,29.690000534057617,1.6711229903911575,,
2014-09-16,29.65999984741211,29.90999984741211,-1.132201614431166,,
2014-09-15,30.40999984741211,29.670000076293945,0.8428860461434323,,
2014-09-12,31.040000915527344,30.530000686645508,-2.4334093220363435,,
2014-09-11,30.770000457763672,30.89999961853028,-1.6430419260287945,,
2014-09-10,30.86000061035156,30.989999771118164,0.42248670403840755,,
2014-09-09,31.8700008392334,30.770000457763672,0.4212545631739188,,
2014-09-08,31.61000061035156,31.959999084472656,-3.4515229134088283,,
2014-09-05,31.75,31.540000915527344,1.1072396942835894,,
2014-09-04,31.989999771118164,31.96999931335449,-0.6614144392839567,,
2014-09-03,32.150001525878906,31.739999771118164,-0.06252096876140846,,
2014-09-02,32.869998931884766,32.16999816894531,-1.2752775592583232,,
2014-08-29,32.29999923706055,32.58000183105469,-2.129603850581309,,
2014-08-28,32.900001525878906,32.290000915527344,0.8668811164331847,,
2014-08-27,32.84000015258789,33.0099983215332,-1.8541051126448744,,
2014-08-26,32.34000015258789,32.72999954223633,0.5176558104611219,Bullish Two Hundred Day Moving Average Cross - ACOR,"In trading on Tuesday, shares of Acorda Therapeutics Inc (Symbol: ACOR) crossed above their 200 day moving average of $32.86, changing hands as high as $33.00 per share. The chart below shows the one year performance of ACOR shares, versus its 200 day moving average: Looking at the chart above, ACOR's low point in its 52 week range is $27.51 per share, with $39.95 as the 52 week high point - that compares with a last trade of $32.73. Acorda Therapeutics Inc shares are currently trading up about 1.1% on the day."
2014-08-25,31.670000076293945,32.36000061035156,1.2059350272366316,,
2014-08-22,31.63999938964844,31.5,2.1787197107527185,,
2014-08-21,31.450000762939453,31.6299991607666,-0.4424759555913399,,
2014-08-20,31.5,31.31999969482422,0.5723319346918992,,
2014-08-19,32.040000915527344,31.700000762939453,-0.5714295402405754,,
2014-08-18,31.93000030517578,31.709999084472656,-1.0611739790029735,,
2014-08-15,31.780000686645508,31.6200008392334,-0.6890110197320083,,
2014-08-14,30.86000061035156,31.450000762939453,-0.5034608053968482,,
2014-08-13,30.799999237060547,30.82999992370605,1.9118604696008554,,
2014-08-12,30.11000061035156,30.68000030517578,0.09740482918390951,,
2014-08-11,30.440000534057617,30.350000381469727,1.893057732547044,,
2014-08-08,29.57999992370605,30.290000915527344,-0.29566409661259524,,
2014-08-07,30.059999465942383,29.540000915527344,2.400273812212834,,
2014-08-06,29.31999969482422,29.84000015258789,-1.729868794589272,,
2014-08-05,28.940000534057617,29.39999961853028,1.7735350040111568,,
2014-08-04,28.559999465942383,29.100000381469727,1.5894923150789861,"Acorda Beats on Q2 Earnings & Revenues, Maintains View - Analyst Blog","Acorda Therapeutics, Inc.'s ( ACOR ) second quarter earnings of 24 cents per share surpassed the Zacks Consensus Estimate of 14 cents and the year-ago earnings of 18 cents. Quarter in Detail The bulk of net product revenues at Acorda came from Ampyra, which generated $87.4 million in the reported quarter, up 12.3% from the year-ago period. Click to get this free report CELGENE CORP (CELG): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here."
2014-08-01,29.26000022888184,28.450000762939453,1.890759543505214,,
2014-07-31,31.3799991607666,29.270000457763672,-2.768282500363262,,
2014-07-30,29.780000686645508,29.81999969482422,-6.724024089971911,Will Teva Pharmaceutical (TEVA) Beat Q2 Earnings Estimates? - Analyst Blog,"Other Stocks to Consider Here are some other companies you may want to consider as our model shows these also have the right combination of elements to post an earnings beat this quarter: Acorda Therapeutics, Inc. ( ACOR ) has an earnings ESP of +14.29% and carries a Zacks Rank #3. Click to get this free report TEVA PHARM ADR (TEVA): Free Stock Analysis Report ENDO INTL PLC (ENDP): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Rank: Teva carries a Zacks Rank #2 (Buy) which when combined with a +2.46% ESP makes us confident of an earnings beat."
2014-07-29,29.3700008392334,29.450000762939453,0.13431500086112497,,
2014-07-28,29.5,29.239999771118164,0.272386521689125,,
2014-07-25,29.43000030517578,29.51000022888184,-0.8813567080740201,,
2014-07-24,30.440000534057617,29.559999465942383,0.27183120243457437,,
2014-07-23,30.040000915527344,30.3799991607666,-2.8909364411168466,Healthcare Spending Uptrend: 3 Medical Stocks for Strong Growth - Analyst Blog,"Click to get this free report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report AMSURG CORP (AMSG): Free Stock Analysis Report ACADIA HEALTHCR (ACHC): Free Stock Analysis Report To read this article on Zacks.com click here. Biogen has collaborations with companies like Roche Holding AG ( RHHBY ), Acorda Therapeutics, Inc. ( ACOR ) and AbbVie Inc. ( ABBV ) among others. Healthcare Spending Healthcare spending is forecasted to rise 6.8% in 2015, up from the 6.5% increase expected this year."
2014-07-22,30.11000061035156,29.75,1.1318183584459096,,
2014-07-21,29.96999931335449,29.8799991607666,-1.1956180772304397,,
2014-07-18,29.299999237060547,30.100000381469727,-0.30030081631594646,,
2014-07-17,29.84000015258789,29.3799991607666,2.7303794035505846,,
2014-07-16,30.450000762939453,30.170000076293945,-1.541558275700596,,
2014-07-15,31.39999961853028,30.229999542236328,-0.9195424618389345,,
2014-07-14,31.739999771118164,31.40999984741211,-3.7261149379234157,,
2014-07-11,31.209999084472656,31.43000030517578,-1.039697309658894,,
2014-07-10,30.489999771118164,31.309999465942383,0.7049062068463123,,
2014-07-09,31.0,31.01000022888184,2.6894053820261696,Markets Edge Higher; Alcoa Profit Beats Street View,"Top losers in the sector included Acorda Therapeutics (NASDAQ: ACOR ), down 5.1 percent, and Isis Pharmaceuticals (NASDAQ: ISIS ), off 3.9 percent. MSC Industrial Direct Co (NYSE: MSM ) was down, falling 4.23 percent to $89.43 after the company reported Q3 earnings of $1.06 per share on revenue of $720.50 million. The eurozone's STOXX 600 fell 0.15 percent, the Spanish Ibex Index gained 0.18 percent, while Italy's FTSE MIB Index surged 0.77 percent."
2014-07-08,32.970001220703125,32.060001373291016,0.03225880284464352,,
2014-07-07,33.86000061035156,32.959999084472656,-2.760084360690547,,
2014-07-03,34.20000076293945,33.97999954223633,-2.658008002527209,,
2014-07-02,34.16999816894531,34.0099983215332,-0.6432784087581878,,
2014-07-01,34.029998779296875,34.099998474121094,-0.4682465788292663,,
2014-06-30,33.95000076293945,33.709999084472656,0.20569996278344,,
2014-06-27,33.20000076293945,33.88999938964844,-0.706926872086518,,
2014-06-26,33.72999954223633,33.4900016784668,2.0783090688335677,Sector Update: Healthcare,"In healthcare stocks news, Acorda Therapeutics ( ACOR ) said it has received a notice letter that Actavis ( ACT ) has submitted an abbreviated new drug application to the U.S. Food and Drug Administration requesting permission to make and market a generic version of its Ampyra extended release tablets to improve walking in patients with multiple sclerosis. Acorda said it has 45 days from receiving the letter to start a patent infringement lawsuit against Actavis in order to trigger a statutory stay period that would restrict the FDA from approving an ANDA until July 2017 at the earliest, unless a district court issues a decision adverse to all of Acorda's asserted Orange Book patents prior to that date. ACOR closed lower 1.5% on Wednesday, below the mid-point of the 52-week range between $27.51 and $39.94."
2014-06-25,33.869998931884766,33.599998474121094,-0.7115264364857421,ACOR Makes Notable Cross Below Critical Moving Average,"In trading on Wednesday, shares of Acorda Therapeutics Inc (Symbol: ACOR) crossed below their 200 day moving average of $33.56, changing hands as low as $33.43 per share. The chart below shows the one year performance of ACOR shares, versus its 200 day moving average: Looking at the chart above, ACOR's low point in its 52 week range is $27.51 per share, with $39.95 as the 52 week high point - that compares with a last trade of $33.60. Acorda Therapeutics Inc shares are currently trading off about 1.4% on the day."
2014-06-24,35.27000045776367,34.099998474121094,-0.7971670099744144,,
2014-06-23,34.900001525878906,35.130001068115234,-3.3172723800887733,,
2014-06-20,34.689998626708984,34.97999954223633,0.659024447508347,,
2014-06-19,34.61000061035156,34.5099983215332,0.8359784577911813,Acorda Therapeutics (ACOR) in Focus: Stock Moves 7.8% Higher - Tale of the Tape,"Click to get this free report ACORDA THERAPT (ACOR): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ILLUMINA INC (ILMN): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ( ACOR ) was a big mover last session, as the company saw its shares rise by roughly 8% on the day. Acorda Therapeutics has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%."
2014-06-18,32.31999969482422,34.61000061035156,-0.28894044222712184,Sector Update: Healthcare | Acorda Therapeutics (ACOR) in Focus: Stock Tumbles 9% - Tale of the Tape | Sector Update: Healthcare Shares Flat Pre-Market; Pfizer Teams with Cellectis on Immunotherapy,"And, Acorda Therapeutics, Inc. ( ACOR ) priced a public offering of $300 million principal amount of convertible senior notes due 2021. Both doses of the drug, 441 mg and 882 mg administered once-monthly, met the primary endpoint with statistically and clinically significant reductions in Positive and Negative Syndrome Scale scores, met all secondary endpoints and demonstrated significant improvements in schizophrenia symptoms versus placebo, Alkermes said in a statement. And, Pfizer ( PFE ) is collaborating with Cellectis, a drug developer with focus on cancer, to develop immunotherapies in the field of oncology using Cellectis' Chimeric Antigen Receptor T-cell platform technology. | Click to get this free report ACORDA THERAPT (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ( ACOR ) saw a big move last session, as the company's shares fell by nearly 9% on the day. Acorda Therapeutics has seen a mixed track record when it comes to current year estimate revisions over the past few weeks (no increase, no decrease), and the consensus for earnings hasn't been in a trend either. | And, Acorda Therapeutics, Inc. ( ACOR ) priced a public offering of $300 million principal amount of convertible senior notes due 2021. PFE: flat ABT: flat MRK: flat AMGN: flat Healthcare shares were fairly flat in pre-market trade on Wednesday. Both doses of the drug, 441 mg and 882 mg administered once-monthly, met the primary endpoint with statistically and clinically significant reductions in Positive and Negative Syndrome Scale (PANSS) scores, met all secondary endpoints and demonstrated significant improvements in schizophrenia symptoms versus placebo, Alkermes said in a statement."
2014-06-17,34.189998626708984,32.119998931884766,7.085398939202553,"Mid-Day Market Update: Amira Rises On Upbeat Earnings; Acorda Therapeutics Shares Tumble | Mid-Afternoon Market Update: Oil Falls, US Indexes Rise In Afternoon Session","Acorda Therapeutics (NASDAQ: ACOR ) was down, falling 5.26 percent to $33.42 after the company announced a public offering of $300 million principal amount of convertible senior notes due 2021. Commodities In commodity news, oil traded up 0.22 percent to $107.13, while gold traded down 0.41 percent to $1,270.10. The eurozone's STOXX 600 climbed 0.23 percent, the Spanish Ibex Index gained 0.40 percent, while Italy's FTSE MIB Index rose 0.09 percent. Meanwhile, the German DAX gained 0.34 percent and the French CAC 40 rose 0.58 percent while UK shares gained 0.15 percent. | Acorda Therapeutics (NASDAQ: ACOR ) was down, falling 7.14 percent to $32.76 after the company announced a public offering of $300 million principal amount of convertible senior notes due 2021. Commodities In commodity news, oil reversed gains, trading down 0.54 percent to $106.32, while gold traded down 0.35 percent to $1,270.80. The eurozone's STOXX 600 climbed 0.23 percent, the Spanish IBEX Index gained 0.46 percent, while Italy's FTSE MIB Index rose 0.09 percent. Meanwhile, the German DAX gained 0.37 percent and the French CAC 40 rose 0.58 percent while UK shares gained 0.15 percent."
2014-06-16,34.939998626708984,35.279998779296875,-6.05440122248835,,
2014-06-13,35.41999816894531,35.11000061035156,0.9730972122248059,,
2014-06-12,34.66999816894531,35.459999084472656,-0.8752048972874937,,
2014-06-11,34.04999923706055,34.810001373291016,2.27862981612432,,
2014-06-10,35.45000076293945,34.349998474121094,2.232018071246447,,
2014-06-09,35.540000915527344,35.560001373291016,-3.1029683078831876,,
2014-06-06,35.209999084472656,35.45000076293945,0.05627590672045741,,
2014-06-05,34.189998626708984,34.959999084472656,0.6816293232243672,,
2014-06-04,33.150001525878906,34.0,2.252121932412577,,
2014-06-03,32.5,33.290000915527344,2.5640978431253862,,
2014-06-02,32.68000030517578,32.54999923706055,2.4307720477764425,,
2014-05-30,32.95000076293945,32.880001068115234,-0.39780008231715075,,
2014-05-29,33.13999938964844,32.849998474121094,-0.21244216450201414,,
2014-05-28,33.31999969482422,33.099998474121094,-0.8750782162594971,,
2014-05-27,32.400001525878906,33.47999954223633,-0.6602677752644128,,
2014-05-23,32.150001525878906,32.119998931884766,3.333327053996566,,
2014-05-22,31.020000457763672,32.119998931884766,-0.0933206611825205,,
2014-05-21,30.43000030517578,30.770000457763672,3.5460943194337915,,
2014-05-20,30.940000534057617,30.200000762939453,1.1173189259878538,First Week of January 2015 Options Trading For Acorda Therapeutics (ACOR),"At Stock Options Channel , our YieldBoost formula has looked up and down the ACOR options chain for the new January 2015 contracts and identified one put and one call contract of particular interest. Below is a chart showing the trailing twelve month trading history for Acorda Therapeutics Inc, and highlighting in green where the $28.00 strike is located relative to that history: Top YieldBoost Calls of the S&P 500 » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Investors in Acorda Therapeutics Inc (Symbol: ACOR) saw new options become available this week, for the January 2015 expiration."
2014-05-19,30.690000534057617,30.950000762939453,-2.3917251400936452,,
2014-05-16,30.299999237060547,30.96999931335449,0.8471822233867539,,
2014-05-15,29.82999992370605,30.290000915527344,2.2112214295848927,,
2014-05-14,30.31999969482422,30.1299991607666,1.542075068715396,,
2014-05-13,30.739999771118164,30.350000381469727,-0.6266508442282447,,
2014-05-12,30.450000762939453,30.670000076293945,-1.2687032939241016,,
2014-05-09,29.46999931335449,30.170000076293945,0.7224936218138039,,
2014-05-08,30.59000015258789,29.690000534057617,2.375299556326245,,
2014-05-07,31.65999984741211,30.75,-2.9421366918631224,"Acorda Misses on Earnings, Beats Revs - Analyst Blog","Quarter in Details The bulk of net product revenues at Acorda came from Ampyra, which generated $72.5 million in the reported quarter, up 16.4% from the year-ago period. On the fourth quarter call, Acorda stated that it expects Zanaflex and Fampyra revenues to come around $25 million in 2014 and spend $60 million-$70 million on R&D. ACORDA THERAPT (ACOR): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here."
2014-05-06,32.0,31.8700008392334,-2.8742888559631274,,
2014-05-05,32.2400016784668,31.729999542236328,-0.4062473773956299,Acorda Down on Plumiaz CRL - Analyst Blog,"Consequently, Acorda does not expect Plumiaz to receive FDA approval in 2014. ACORDA THERAPT (ACOR): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Shares of Acorda Therapeutics, Inc ."
2014-05-02,34.5,32.38999938964844,-1.5818923997485423,,
2014-05-01,35.43000030517578,35.900001525878906,-6.115943798120471,,
2014-04-30,34.77000045776367,35.45000076293945,1.3265628468946555,,
2014-04-29,34.189998626708984,35.099998474121094,1.9557097964430608,,
2014-04-28,33.689998626708984,33.970001220703125,2.6615966187878817,,
2014-04-25,34.849998474121094,33.459999084472656,0.8311148869331159,,
2014-04-24,35.58000183105469,34.9900016784668,-3.9885206614302233,,
2014-04-23,35.779998779296875,35.25,-1.6582353069834046,,
2014-04-22,35.33000183105469,35.77000045776367,-1.4812710938479527,,
2014-04-21,34.84000015258789,35.09000015258789,1.2453965578972328,,
2014-04-17,35.189998626708984,34.619998931884766,0.7175660129307726,,
2014-04-16,35.540000915527344,35.34000015258789,-1.6197775421099125,,
2014-04-15,36.18999862670898,35.119998931884766,-0.5627483336728707,,
2014-04-14,34.400001525878906,35.869998931884766,-2.956617119168746,,
2014-04-11,36.5099983215332,35.189998626708984,4.273248083724617,,
2014-04-10,38.470001220703125,36.93000030517578,-3.61544715285757,Next Chapter In The Acorda Story Will Be A Page Turner,"ByPropThink: By Jake King When Mr. Deryugin penned his original thoughts on Acorda Therapeutics ( ACOR ) in mid-2013, the stock traded around $38. Acorda is leveraging the dalfampridine platform to boost future sales and is Phase 3-ready to expand the label in patients with post-stroke walking deficits. Acorda's prospects are improving with a NDA submission for Plumiaz (nasally administered diazepam) in cluster seizures; an approval decision is expected by 3Q14."
2014-04-09,37.06999969482422,38.47999954223633,-4.003121566574249,,
2014-04-08,37.59999847412109,36.959999084472656,3.8036144025352563,,
2014-04-07,36.18999862670898,37.43000030517578,-1.7021261053745045,,
2014-04-04,38.18000030517578,36.27999877929688,3.4263656411184744,,
2014-04-03,38.45000076293945,37.7400016784668,-4.976431405688936,,
2014-04-02,39.08000183105469,38.470001220703125,-1.8465515484644628,,
2014-04-01,38.16999816894531,38.88999938964844,-1.5609022051448043,,
2014-03-31,36.900001525878906,37.90999984741211,1.8863014284577828,,
2014-03-28,38.150001525878906,36.619998931884766,2.737122709398442,,
2014-03-27,37.29999923706055,38.18999862670898,-4.010491566969582,,
2014-03-26,39.41999816894531,37.33000183105469,2.386057393706712,,
2014-03-25,38.06999969482422,39.09000015258789,-5.301868175978516,,
2014-03-24,38.59999847412109,37.79999923706055,2.679276243604345,,
2014-03-21,39.5,38.38999938964844,-2.072536965505037,,
2014-03-20,39.310001373291016,39.40999984741211,-2.8101281274723102,,
2014-03-19,39.27000045776367,39.43000030517578,0.2543843058449681,,
2014-03-18,37.7400016784668,39.15999984741211,0.4074353082429808,,
2014-03-17,37.65999984741211,37.65999984741211,3.7625810964272337,,
2014-03-14,36.720001220703125,37.290000915527344,0.0,,
2014-03-13,38.09000015258789,36.95000076293945,1.5522866990070983,,
2014-03-12,37.040000915527344,37.869998931884766,-2.9929099109520068,,
2014-03-11,37.93999862670898,37.369998931884766,2.2408153235479076,,
2014-03-10,37.83000183105469,37.7400016784668,-1.502371416595001,,
2014-03-07,38.20000076293945,37.880001068115234,-0.23790681530977195,,
2014-03-06,39.41999816894531,37.869998931884766,-0.8376955194584009,,
2014-03-05,39.0,39.380001068115234,-3.9320124532162484,Acorda Therapeutics (ACOR) Jumps: Stock Rises 7.5% - Tale of the Tape,"Click to get this free report >> ACORDA THERAPT (ACOR): Free Stock Analysis Report ALKERMES INC (ALKS): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ( ACOR ) was a big mover last session, as the company saw its shares rise by roughly 8% on the day. Acorda Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%."
2014-03-04,36.97999954223633,39.09000015258789,0.9743617131159855,,
2014-03-03,36.31999969482422,36.36000061035156,5.70578863296536,,
2014-02-28,36.9900016784668,36.63999938964844,0.11013468024077125,,
2014-02-27,36.5,37.16999816894531,-0.946207820861247,,
2014-02-26,37.459999084472656,36.54999923706055,1.8356114217679793,,
2014-02-25,36.68999862670898,37.31999969482422,-2.4292575271025796,,
2014-02-24,35.790000915527344,36.4900016784668,1.7170921005612243,,
2014-02-21,35.720001220703125,35.599998474121094,1.9558556720677835,,
2014-02-20,34.91999816894531,35.47999954223633,-0.3359539263186763,,
2014-02-19,34.7400016784668,34.77000045776367,1.6036695379584247,,
2014-02-18,33.540000915527344,34.68000030517578,0.08635226783961099,Acorda Up After Q4 Earnings - Analyst Blog,"Acorda's fourth quarter earnings of 15 cents per share were 3 cents below the Zacks Consensus Estimate but well above the year-ago earnings of 9 cents per share. Quarter in Details The bulk of net product revenues at Acorda came from Ampyra, which generated $84.6 million in the reported quarter, up 16.4% from the year-ago period. ACORDA THERAPT (ACOR): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here."
2014-02-14,33.970001220703125,33.27000045776367,3.398924742189482,,
2014-02-13,30.959999084472656,34.060001373291016,-2.060643914586719,Sector Update: Healthcare Shares Fairly Flat; Acorda Q4 Earnings Top Street View,"In healthcare stocks news, biopharmaceutical company Acorda Therapeutics Inc. ( ACOR ) says non-GAAP earnings for Q4 2013 were $13.3 million, or $0.32 per diluted share. Healthcare stocks: JNJ: flat PFE: flat ABT: flat Revenues for the period were $92.6 million, up from $81.5 million last year, beating the Capital IQ consensus of $90.3 million."
2014-02-12,30.739999771118164,30.959999084472656,10.012927585560236,,
2014-02-11,30.489999771118164,30.850000381469727,0.7156776675099166,,
2014-02-10,30.25,30.40999984741211,1.1807169991932085,Will Zoetis (ZTS) Miss Estimates in Q4? - Analyst Blog,"Other Stocks to Consider Here are some companies you may want to consider as our model shows they have the right combination of elements to post an earnings beat this quarter: Acorda Therapeutics, Inc. ( ACOR ) has an Earnings ESP of +61.11% and holds a Zacks Rank #3. ACORDA THERAPT (ACOR): Free Stock Analysis Report CHARLES RVR LAB (CRL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report ZOETIS INC (ZTS): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda will be reporting fourth quarter earnings on Feb 13."
2014-02-07,29.200000762939453,30.200000762939453,0.5289251154119318,,
2014-02-06,28.75,28.989999771118164,3.4246574447669085,,
2014-02-05,28.65999984741211,28.59000015258789,0.8347818125849185,,
2014-02-04,28.84000015258789,28.770000457763672,-0.24424178365981208,,
2014-02-03,29.39999961853028,28.549999237060547,-0.2427173871493114,,
2014-01-31,29.5,29.350000381469727,-2.8911577976143716,,
2014-01-30,30.3700008392334,29.979999542236328,-0.5084732831534693,,
2014-01-29,30.56999969482422,30.100000381469727,-1.2841662371416476,,
2014-01-28,29.940000534057617,30.850000381469727,-1.5374527904691717,,
2014-01-27,31.190000534057617,29.81999969482422,3.039411593787242,,
2014-01-24,31.209999084472656,30.75,-4.392436087769346,,
2014-01-23,31.3700008392334,31.39999961853028,-1.4738836846089856,,
2014-01-22,31.59000015258789,31.40999984741211,0.09562887629688441,,
2014-01-21,30.530000686645508,31.59000015258789,-0.5698015331001365,,
2014-01-17,30.71999931335449,30.5,3.471992931877168,"Acorda Therapeutics, Inc. (ACOR): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report","Overview: Ardsley, NY based Acorda Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel treatments that improve neurological function in people suffering from multiple sclerosis (MS), spinal cord injury (SCI) and other nervous system disorders. Acorda's third marketed product is Qutenza, which was acquired from NeurogesX, Inc. Quenteza is approved for the treatment of postherpetic neuralgia. Summary: Acorda's fourth quarter results were better-than-expected with Ampyra sales picking up."
2014-01-16,30.030000686645508,30.670000076293945,-0.7161436141661999,,
2014-01-15,30.600000381469727,30.21999931335449,2.131200049998828,,
2014-01-14,29.8700008392334,30.350000381469727,-1.2418335404510423,ACOR Preliminary Q4 Revs Look Good - Analyst Blog,"Acorda expects to spend $60 million - $70 million on R&D - the company is looking to advance its pipeline and expects to have four programs in progress during the year. ACORDA THERAPT (ACOR): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MEDIVATION INC (MDVN): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ( ACOR ) announced preliminary unaudited Ampyra sales information."
2014-01-13,29.5,29.770000457763672,1.6069619308676495,,
2014-01-10,28.68000030517578,29.100000381469727,0.9152557890293962,,
2014-01-09,28.56999969482422,28.68000030517578,1.4644353968788115,,
2014-01-08,27.93000030517578,28.31999969482422,0.3850213914125115,,
2014-01-07,28.09000015258789,27.8799991607666,1.3963458123420274,,
2014-01-06,28.5,27.950000762939453,-0.7476005364205809,,
2014-01-03,29.049999237060547,29.229999542236328,-1.9298218844229715,,
2014-01-02,29.190000534057617,28.959999084472656,0.6196224093050777,,
2013-12-31,28.850000381469727,29.200000762939453,-0.7879460273274244,,
2013-12-30,29.40999984741211,28.88999938964844,1.2131728833339317,,
2013-12-27,30.299999237060547,29.450000762939453,-1.768107652028516,,
2013-12-26,29.440000534057617,30.13999938964844,-2.805275562784316,,
2013-12-24,30.1299991607666,29.479999542236328,2.377713460911902,,
2013-12-23,30.13999938964844,30.0,-2.157317081431128,,
2013-12-20,29.0,29.82999992370605,-0.46449698899636915,,
2013-12-19,29.700000762939453,28.93000030517578,2.862068702434659,,
2013-12-18,29.530000686645508,29.690000534057617,-2.59259406728535,,
2013-12-17,30.020000457763672,29.530000686645508,0.5418213467379527,,
2013-12-16,29.8799991607666,30.0,-1.6322443825660968,,
2013-12-13,30.01000022888184,29.770000457763672,0.40160924566210626,,
2013-12-12,29.690000534057617,29.89999961853028,-0.7997326534079467,,
2013-12-11,30.920000076293945,29.64999961853028,0.7073057618566624,,
2013-12-10,31.280000686645508,30.950000762939453,-4.107375338389347,Positive Data on Incyte's Jakafi - Analyst Blog,"ACORDA THERAPT (ACOR): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report INCYTE CORP (INCY): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report To read this article on Zacks.com click here. Some better ranked stocks in the bio pharma sector include Actelion Ltd ( ALIOF ) and Acorda Therapeutics, Inc. ( ACOR ). While Actelion holds a Zacks Rank #1 (Strong Buy), Acorda carries a Zacks Rank #2 (Buy)."
2013-12-09,31.459999084472656,31.440000534057617,-1.054986945211107,,
2013-12-06,32.0,31.57999992370605,-0.06356818498735911,Another R&D Failure for Eli Lilly - Analyst Blog,"ACORDA THERAPT (ACOR): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the pharma/biotech sector are Actelion Ltd. ( ALIOF ), Bayer ( BAYRY ) and Acorda Therapeutics ( ACOR ). While Actelion is a Zacks Rank #1 (Strong Buy) stock, Bayer and Acorda are Zacks Rank #2 (Buy) stocks."
2013-12-05,31.979999542236328,31.57999992370605,-1.3125002384185902,MDCO Acquires Rempex - Analyst Blog,"ACORDA THERAPT (ACOR): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report MEDICINES CO (MDCO): Free Stock Analysis Report VANDA PHARMACT (VNDA): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks include Actelion Ltd. ( ALIOF ), Vanda Pharmaceuticals, Inc. ( VNDA ) and Acorda Therapeutics, Inc. ( ACOR ). While Actelion and Vanda are Zacks Rank #1 (Strong Buy) stocks, Acorda is a Zacks Rank #2 (Buy) stock."
2013-12-04,33.65999984741211,32.06999969482422,-1.2507805636519576,,
2013-12-03,33.380001068115234,33.709999084472656,-4.723708139618827,Biogen's Hemophilia B Drug Approval Delayed - Analyst Blog,"ACORDA THERAPT (ACOR): Free Stock Analysis Report AETERNA ZENTARS (AEZS): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks include Actelion Ltd. ( ALIOF ), Acorda Therapeutics ( ACOR ) and Aeterna Zentaris ( AEZS ). While Actelion is a Zacks Rank #1 (Strong Buy) stock, Acorda and Aeterna are Zacks Rank #2 (Buy) stocks."
2013-12-02,33.150001525878906,33.59000015258789,0.9886099634449619,,
2013-11-29,35.15999984741211,34.810001373291016,1.3272959470770904,,
2013-11-27,34.4900016784668,34.91999816894531,-0.9954450387941478,,
2013-11-26,35.130001068115234,34.52000045776367,1.2467279488332876,,
2013-11-25,34.2400016784668,34.9900016784668,-1.7364093134207517,,
2013-11-22,33.349998474121094,34.220001220703125,2.190420453371846,,
2013-11-21,33.36000061035156,33.22999954223633,2.6087040071595067,,
2013-11-20,33.400001525878906,33.09000015258789,-0.3896914440549957,,
2013-11-19,32.93000030517578,33.27000045776367,-0.9281477818221688,,
2013-11-18,33.95000076293945,33.0099983215332,1.0324936211265416,,
2013-11-15,33.5,33.91999816894531,-2.7687847430989656,"Dendreon Narrows Loss, Provenge Disappoints Again - Analyst Blog","ACORDA THERAPT (ACOR): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report DENDREON CORP (DNDN): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, companies such as Actelion Ltd. ( ALIOF ), AMAG Pharmaceuticals, Inc. ( AMAG ) and Acorda Therapeutics, Inc. ( ACOR ) currently look better positioned. While Actelion carries a Zacks Rank #1 (Strong Buy), AMAG and Acorda carry a Zacks Rank #2 (Buy)."
2013-11-14,33.5,33.560001373291016,1.2537258774486941,,
2013-11-13,32.65999984741211,33.4900016784668,0.17910857698810634,,
2013-11-12,31.850000381469727,32.7400016784668,2.5413405846064467,Chelsea Therapeutics (CHTP) Worth Watching: Stock Surges 11% - Tale of the Tape,"While Actelion and AMAG carry a Zacks Rank #1 (Strong Buy), Acorda Therapeutics holds a Zacks Rank #2 (Buy). Click to get this free report >> ACORDA THERAPT (ACOR): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report CHELSEA THERAP (CHTP): Free Stock Analysis Report To read this article on Zacks.com click here. Some better performing biomedical stocks include Actelion Ltd. ( ALIOF ), AMAG Pharmaceuticals, Inc. ( AMAG ) and Acorda Therapeutics, Inc. ( ACOR )."
2013-11-11,31.88999938964844,32.04999923706055,2.794352547370365,,
2013-11-08,31.8799991607666,31.799999237060547,0.5017242097033157,,
2013-11-07,32.86000061035156,31.75,-0.2509407961481608,,
2013-11-06,33.290000915527344,32.54999923706055,-3.377968927979538,,
2013-11-05,32.119998931884766,32.599998474121094,-2.2228947375055204,,
2013-11-04,31.0,32.33000183105469,1.4943946394713106,Acorda Down on Q3 Earnings - Analyst Blog,Guidance Narrowed Acorda narrowed its Ampyra revenue guidance to $295 million - $305 million from the earlier guidance of $285 million - $315 million. Acorda cut its 2013 R&D guidance by $15 million to $45 million - $55 million (old guidance: $60 million - $70 million). Acorda also lowered its 2013 SG&A guidance by $5 million to $165 million - $175 million (old guidance: $170 million - $180 million).
2013-11-01,31.020000457763672,30.88999938964844,4.290328487273185,,
2013-10-31,33.56999969482422,30.61000061035156,-0.4190878987646637,,
2013-10-30,33.2400016784668,32.0,-8.81739383789458,,
2013-10-29,33.029998779296875,33.279998779296875,-3.7304501078592978,,
2013-10-28,33.2400016784668,32.849998474121094,0.7568877058412107,,
2013-10-25,33.189998626708984,33.119998931884766,-1.173294779339169,,
2013-10-24,33.349998474121094,33.029998779296875,-0.21090598891404566,,
2013-10-23,32.54999923706055,33.22999954223633,-0.9595193687116114,,
2013-10-22,32.7400016784668,32.709999084472656,2.089094688523222,,
2013-10-21,32.93000030517578,32.5099983215332,-0.09163895069032152,,
2013-10-18,33.529998779296875,32.79999923706055,-1.2754387481027876,,
2013-10-17,32.75,33.119998931884766,-2.1771535007841005,,
2013-10-16,32.470001220703125,32.9900016784668,1.1297677309458494,Acorda's Label Expansion Efforts - Analyst Blog,"Acorda has a license and collaboration agreement with Biogen Idec ( BIIB ) for the development and commercialization of Fampyra outside the U.S. Ampyra is being studied for other indications as well including cerebral palsy (encouraging efficacy data presented from a phase II proof-of-concept study) and post-stroke deficits. ACORDA THERAPT (ACOR): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ( ACOR ) continues to work on expanding the label of its lead product, Ampyra (dalfampridine-ER)."
2013-10-15,32.380001068115234,32.15999984741211,1.6014796372477977,,
2013-10-14,35.31999969482422,32.5,-0.6794354955094841,Acorda's GGF2 in Another Study - Analyst Blog,"Acorda Therapeutics, Inc. ( ACOR ) continues to progress with its pipeline with the company enrolling the first patient in a phase Ib single-infusion study being conducted with glial growth factor 2 (GGF2). Apart from studying Ampyra for additional indications like cerebral palsy and post-stroke deficits (phase IIb/III study to commence in the second quarter of 2014), Acorda is evaluating other candidates like rHIgM22 (multiple sclerosis - phase I ongoing) and AC105. ACORDA THERAPT (ACOR): Free Stock Analysis Report AGENUS INC (AGEN): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report To read this article on Zacks.com click here."
2013-10-11,35.150001525878906,35.34000015258789,-7.984144165316797,,
2013-10-10,34.63999938964844,35.33000183105469,0.5405366101310107,,
2013-10-09,34.93000030517578,33.97999954223633,1.9919239421593213,Biotech Stocks Continue Recent Downtrend; Ariad Tumbles to Lowest Price in Nearly Three Years,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The decliners included Genomic Health Inc. ( GHDX ), down 3.2%, Acorda Therapuetics Inc. ( ACOR ), down 2.4%; Amarin Corp. ( AMRN ), down 5.2%, Exelis ( EXEL ), down 1%; Discovery Labs Inc. ( DSCO ), down 3.3%, and Achillion Pharmaceuticals Inc. (ACHN), down 11%. Biotech stocks were getting hit hard again Wednesday, with the S&P Biotechnology Select Industry Index (SPSIBI) down 4.9%, much worse than the 0.2% decline in the S&P 500 and a 0.8% drop in the Nasdaq Composite."
2013-10-08,36.0,34.68000030517578,-2.71972732504868,,
2013-10-07,36.22999954223633,35.90999984741211,-3.6666658189561634,,
2013-10-04,36.02999877929688,36.540000915527344,-0.8832450976190835,,
2013-10-03,35.9900016784668,36.060001373291016,1.4154930710780729,,
2013-10-02,35.29999923706055,36.08000183105469,0.19449761478088598,,
2013-10-01,34.209999084472656,35.43000030517578,2.2096391242276185,,
2013-09-30,34.349998474121094,34.20000076293945,3.5662123746061805,,
2013-09-27,34.970001220703125,34.7400016784668,-0.43667457887850336,,
2013-09-26,34.93000030517578,35.2400016784668,-0.6577052736851566,,
2013-09-25,35.2599983215332,34.7599983215332,0.8874931880406566,,
2013-09-24,35.470001220703125,35.11000061035156,-1.4180375036905521,,
2013-09-23,35.119998931884766,35.349998474121094,-1.014943890504964,,
2013-09-20,35.7599983215332,35.0099983215332,0.654896210795485,,
2013-09-19,35.939998626708984,35.560001373291016,-2.097315534683291,,
2013-09-18,35.720001220703125,35.81999969482422,-1.0573101500776685,,
2013-09-17,35.93000030517578,35.619998931884766,0.27995092582229575,,
2013-09-16,36.27000045776367,35.97999954223633,-0.8627925707152286,,
2013-09-13,37.13999938964844,35.83000183105469,-0.7995613781837392,,
2013-09-12,37.18999862670898,37.150001525878906,-3.527187884011837,,
2013-09-11,36.79999923706055,37.11000061035156,-0.10754800297665525,,
2013-09-10,37.310001373291016,36.91999816894531,0.842395053581467,,
2013-09-09,35.84000015258789,37.040000915527344,-1.0453047172088645,,
2013-09-06,35.61000061035156,35.689998626708984,3.3482164001966526,,
2013-09-05,35.900001525878906,35.90999984741211,0.22465042119141962,,
2013-09-04,35.06999969482422,35.880001068115234,0.02785047662461999,,
2013-09-03,34.2599983215332,34.93000030517578,2.3096703174781013,,
2013-08-30,34.459999084472656,33.790000915527344,1.9556392774878404,,
2013-08-29,34.119998931884766,34.5099983215332,-1.9442779650194686,,
2013-08-28,33.45000076293945,34.04999923706055,1.1430228659356356,,
2013-08-27,34.22999954223633,33.47999954223633,1.7937173705115586,,
2013-08-26,34.36000061035156,34.65999984741211,-2.191060502570491,,
2013-08-23,34.52000045776367,34.36000061035156,0.8731060294864103,,
2013-08-22,33.790000915527344,34.540000915527344,-0.4634989724518524,,
2013-08-21,34.91999816894531,33.7599983215332,2.219591535007495,,
2013-08-20,34.04999923706055,34.90999984741211,-3.32187831683138,,
2013-08-19,34.119998931884766,33.970001220703125,2.525699352778618,,
2013-08-16,34.27000045776367,34.04999923706055,-0.4396181590775767,,
2013-08-15,34.209999084472656,34.4900016784668,-0.6419644521868834,,
2013-08-14,34.29999923706055,34.41999816894531,0.8184817348364943,,
2013-08-13,35.58000183105469,34.38999938964844,0.3498511211484485,,
2013-08-12,34.47999954223633,35.45000076293945,-3.34458229388735,,
2013-08-09,35.20000076293945,34.4900016784668,2.813228635675939,,
2013-08-08,35.2400016784668,35.38999938964844,-2.017042809897275,,
2013-08-07,36.04999923706055,34.95000076293945,0.42564615220576413,,
2013-08-06,36.65999984741211,36.380001068115234,-3.0513134463266796,,
2013-08-05,36.34000015258789,36.72999954223633,-0.7637719052435854,Acorda Misses on Earnings by a Penny - Analyst Blog,Guidance Maintained Acorda maintained its Ampyra revenue guidance of $285 million to $315 million. ACORDA THERAPT (ACOR): Free Stock Analysis Report ACTAVIS INC (ACT): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics Inc.'s ( ACOR ) second quarter 2013 earnings (including share-based compensation charges) of 9 cents per share were a penny short of the Zacks Consensus Estimate and 30.8% below the year-ago earnings.
2013-08-02,37.77999877929688,37.47999954223633,1.0731958943612288,,
2013-08-01,37.970001220703125,37.2599983215332,-0.7940689432339288,,
2013-07-31,37.72999954223633,37.970001220703125,-1.8699048626387538,,
2013-07-30,38.27999877929688,37.720001220703125,0.6361030516264128,,
2013-07-29,38.4900016784668,38.0,-1.4628985800715926,,
2013-07-26,37.59999847412109,38.4900016784668,-1.2730622423976874,,
2013-07-25,37.02000045776367,37.95000076293945,2.3670298948503197,,
2013-07-24,36.95000076293945,36.88999938964844,2.51215638486235,,
2013-07-23,37.5099983215332,36.7400016784668,-0.16238531001925313,,
2013-07-22,37.369998931884766,37.290000915527344,-2.0527770661732543,,
2013-07-19,37.7599983215332,37.59000015258789,-0.21407015960379414,,
2013-07-18,38.0,37.88999938964844,-0.45020703522745786,,
2013-07-17,38.18999862670898,37.86000061035156,-0.2894752903988487,,
2013-07-16,38.34000015258789,37.93999862670898,-0.864095386813195,,
2013-07-15,37.86000061035156,38.2599983215332,-1.0433007936540497,,
2013-07-12,36.41999816894531,37.72999954223633,1.0565179734103716,,
2013-07-11,37.38999938964844,36.810001373291016,3.5969287181569123,Acorda Expands Pipeline - Analyst Blog,"Acorda intends to use its existing commercial organization, including its specialty neurology sales force of about 100 sales reps, for promoting Qutenza. ACORDA THERAPT (ACOR): Free Stock Analysis Report ASTELLAS PHARMA (ALPMY): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report NEUROGESX INC (NGSX): Get Free Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ( ACOR ) recently added two neuropathic pain management assets to its portfolio."
2013-07-10,35.849998474121094,36.790000915527344,-1.5512116229613968,,
2013-07-09,36.77999877929688,35.97999954223633,2.6220431838645855,,
2013-07-08,36.900001525878906,36.61000061035156,-2.1750931582707556,,
2013-07-05,35.7400016784668,36.59999847412109,-0.7859103076837511,,
2013-07-03,34.689998626708984,35.20000076293945,2.4062584086906584,,
2013-07-02,34.56999969482422,34.86000061035156,1.4701705287408144,,
2013-07-01,33.31999969482422,34.709999084472656,0.8388802953063443,,
2013-06-28,33.36000061035156,32.9900016784668,4.171666873887618,,
2013-06-27,32.59000015258789,33.34000015258789,-1.109109487755691,Data on Acorda Pipeline Candidate - Analyst Blog,"Acorda Therapeutics, Inc. ( ACOR ) recently presented data on diazepam nasal spray from the first study that was conducted to evaluate the candidate's pharmacokinetics, safety and tolerability in people with epilepsy. Diazepam nasal spray became a part of Acorda's pipeline following its Dec 2012 acquisition of Neuronex, Inc. Acorda has been working on strengthening its pipeline. ACORDA THERAPT (ACOR): Free Stock Analysis Report AETERNA ZENTARS (AEZS): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report PROTALIX BIOTHR (PLX): Free Stock Analysis Report To read this article on Zacks.com click here."
2013-06-26,31.89999961853028,32.40999984741211,2.301319412361047,,
2013-06-25,32.16999816894531,31.71999931335449,1.5987468181208897,,
2013-06-24,32.79999923706055,31.959999084472656,-1.3988152974942398,,
2013-06-21,32.869998931884766,33.18000030517578,-2.56097613453228,,
2013-06-20,34.439998626708984,32.689998626708984,0.9431134267251409,,
2013-06-19,35.060001373291016,34.84000015258789,-5.081301015624421,,
2013-06-18,34.220001220703125,34.95000076293945,-0.6274991787955937,,
2013-06-17,34.349998474121094,34.220001220703125,2.1332539923893337,,
2013-06-14,33.7599983215332,34.029998779296875,-0.37844908061904936,,
2013-06-13,33.560001373291016,33.849998474121094,0.7997644288727852,,
2013-06-12,34.25,33.720001220703125,0.8641152829656156,,
2013-06-11,34.15999984741211,34.0099983215332,-1.5474416913777373,,
2013-06-10,34.459999084472656,34.47999954223633,-0.4391145390776986,,
2013-06-07,33.720001220703125,34.43000030517578,0.05803963521485956,,
2013-06-06,32.59000015258789,33.4900016784668,2.105572534904705,,
2013-06-05,32.95000076293945,32.689998626708984,2.761587976879587,,
2013-06-04,33.09000015258789,33.06999969482422,-0.7890808200614866,,
2013-06-03,33.45000076293945,33.08000183105469,-0.06044260402370439,,
2013-05-31,33.849998474121094,33.45000076293945,-1.1061253316762305,,
2013-05-30,33.09000015258789,33.970001220703125,-1.1816771911746045,,
2013-05-29,33.16999816894531,33.0,2.659416935803222,,
2013-05-28,33.029998779296875,33.43000030517578,-0.5125058134747489,,
2013-05-24,32.130001068115234,32.66999816894531,1.211024949021876,,
2013-05-23,31.709999084472656,32.22999954223633,1.680663189787297,,
2013-05-22,32.400001525878906,32.08000183105469,1.6398627334502165,Additional Patent for Acorda's Ampyra - Analyst Blog,"ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report SANTARUS INC (SNTS): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ( ACOR ) recently announced that an additional method of use patent (US patent application no. Acorda has a license and collaboration agreement with Biogen Idec ( BIIB ) for the development and commercialization of Fampyra outside the US."
2013-05-21,32.06999969482422,32.400001525878906,-0.9876533325735336,,
2013-05-20,32.91999816894531,32.15999984741211,1.0290047838944836,,
2013-05-17,32.72999954223633,32.939998626708984,-2.3086220042689383,,
2013-05-16,33.63999938964844,32.529998779296875,0.6416104106621314,,
2013-05-15,33.939998626708984,33.63999938964844,-3.29964515603745,,
2013-05-14,34.459999084472656,34.11000061035156,-0.8839105751302635,,
2013-05-13,34.13999938964844,34.5099983215332,-1.0156659414387497,"Acorda Therapeutics, Inc. (ACOR): Today's Most Compelling Stock Buy","Stop Loss Acorda Therapeutics, Inc. ACOR Biotechnology 9.7 +36.19% .52 Why We Like The Stock: Acorda Therapeutics Inc (ACOR) is our most compelling buy today due to the fact that it is a top- rated stock (in terms of earnings strength and company/industry performance) in our top rated industry, Biotechnology. Following weaker than expected EPS and Revs during its Q1 earnings announcement, ACOR dropped from ~ back down to its 50-day moving average at a pinch higher than .50. We would take a shot at current prices with a buy of ACOR, mainly for its extremely high short-term upside back to its mid-April highs of .87."
2013-05-10,34.09000015258789,34.279998779296875,1.083769591387142,,
2013-05-09,33.849998474121094,34.060001373291016,0.5573441650294652,,
2013-05-08,33.650001525878906,34.09000015258789,0.6203926399892535,,
2013-05-07,34.52000045776367,33.849998474121094,1.3075738685200313,,
2013-05-06,34.56999969482422,34.369998931884766,-1.9409095444895694,"Acorda Incurs Loss, Maintains Guidance - Analyst Blog",Guidance for 2013 Acorda maintained its Ampyra revenue guidance of $285 million to $315 million. ACORDA THERAPT (ACOR): Free Stock Analysis Report ACTAVIS INC (ACT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics Inc. 's ( ACOR ) first quarter 2013 loss (including share-based compensation charges but excluding other special items) of 3 cents per share compared unfavorably with the Zacks Consensus Estimate of earnings of 18 cents and the year-ago earnings of 26 cents per share.
2013-05-03,36.68000030517578,34.95000076293945,-0.5785385152010777,,
2013-05-02,38.56999969482422,36.36000061035156,-4.716465452134182,,
2013-05-01,39.310001373291016,38.27000045776367,-5.729839517652939,,
2013-04-30,39.13999938964844,39.56999969482422,-2.645639479000291,,
2013-04-29,39.08000183105469,39.27000045776367,1.0986211340859289,,
2013-04-26,38.72999954223633,38.81999969482422,0.48617865354858586,,
2013-04-25,37.95000076293945,38.900001525878906,0.23237839827429516,Acorda Initiates Study on rHIgM22 - Analyst Blog,"Acorda already has a presence in the MS market in the form of Ampyra, which is approved for the improvement of walking in patients suffering from MS. Acorda is currently working on expanding Amypra's label into additional indications. ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report UCB SA (UCBJF): Get Free Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ( ACOR ) and Mayo Clinic announced the enrollment of the first patient in a phase I safety study of rHIgM22."
2013-04-24,39.08000183105469,37.65999984741211,2.503295767696501,,
2013-04-23,40.869998931884766,39.220001220703125,-3.6335770652758317,,
2013-04-22,40.68999862670898,40.02999877929688,-4.037185598980756,,
2013-04-19,39.04999923706055,40.43999862670898,-1.6220198321139048,,
2013-04-18,39.59999847412109,39.0,3.5595375590410927,,
2013-04-17,39.630001068115234,39.400001525878906,-1.5151477203040562,,
2013-04-16,35.939998626708984,39.77999877929688,-0.5803672370359255,"Market Wrap for Tuesday, April 16: Stock Market Rebounds Strongly From Monday's Sharp Losses","Stock Movers Acorda Therapeutics (NASDAQ: ACOR ) was a big gainer for the second straight day. Consumer prices fell 0.2 percent for March after registering an increase of 0.7 percent in February. Yields on the 10-Year Note and 30-Year Bond both rose four basis points to 1.72 percent and 2.90 percent, respectively."
2013-04-15,33.5,35.5,10.684474956362918,"Mid-Afternoon Market Update: Explosions Rock Downtown Boston, Authorities Unsure if Explosive Devices | Mid-Day Market Update: Sprint Surges On Dish Network Offer, AuRico Gold Tumbles","Acorda Therapeutics (NASDAQ: ACOR ) was also up, gaining 11.96 percent to $35.29 on Ampyra study. Toward the end of trading Monday, the Dow traded down 1.26 percent to 14,677.61 while the NASDAQ dropped 2.14 percent to 3,224.64. Commodities In commodity news, oil traded down 2.76 percent to $88.77, while gold traded down 9.20 percent to $1,363.30. | Acorda Therapeutics (NASDAQ: ACOR ) was also up, gaining 9.03 percent to $34.37 on Ampyra study. Midway through trading Monday, the Dow traded down 0.82 percent to 14,742.61 while the NASDAQ dropped 1.19 percent to 3,255.64. Shares of Life Technologies (NASDAQ: LIFE ) got a boost, shooting up 7.54 percent to $73.13 after Thermo Fisher (NYSE: TMO ) announced its plans to buy the company for $13.6 billion."
2013-04-12,31.520000457763672,31.520000457763672,5.970149253731343,,
2013-04-11,32.0,31.75,0.0,,
2013-04-10,31.299999237060547,31.979999542236328,-0.78125,,
2013-04-09,31.309999465942383,31.13999938964844,2.17252498961927,,
2013-04-08,31.200000762939453,31.15999984741211,-0.5429577744926513,,
2013-04-05,31.06999969482422,31.049999237060547,-0.12820805945254451,,
2013-04-04,31.81999969482422,31.6299991607666,-0.06437224963025552,,
2013-04-03,32.40999984741211,31.489999771118164,-0.5971104207412118,,
2013-04-02,31.959999084472656,32.27000045776367,-2.838630301219844,,
2013-04-01,32.18000030517578,31.780000686645508,0.9699667777575929,,
2013-03-28,31.670000076293945,32.029998779296875,-1.2430068823397062,,
2013-03-27,30.959999084472656,31.64999961853028,1.1367183521808728,,
2013-03-26,30.350000381469727,31.209999084472656,2.2286839614400367,Acorda Reports Data on Epilepsy Drug - Analyst Blog,"Acorda Therapeutics, Inc. ( ACOR ) recently announced data from a phase I study evaluating its epilepsy candidate, diazepam nasal spray. ACORDA THERAPT (ACOR): Free Stock Analysis Report AGENUS INC (AGEN): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report OSIRIS THERAPTC (OSIR): Free Stock Analysis Report To read this article on Zacks.com click here. Currently, Acorda is preparing to submit a 505(b)(2) type new drug application (NDA) for diazepam nasal spray."
2013-03-25,30.549999237060547,30.200000762939453,2.833603598660922,,
2013-03-22,30.38999938964844,30.530000686645508,-1.1456578817079204,,
2013-03-21,30.75,30.3700008392334,0.46068213165135674,,
2013-03-20,30.420000076293945,30.84000015258789,-1.2357696285092734,,
2013-03-19,30.61000061035156,30.18000030517578,1.380670858779017,,
2013-03-18,30.479999542236328,30.6299991607666,-1.4047706520801637,,
2013-03-15,30.790000915527344,30.549999237060547,0.4921247401018429,,
2013-03-14,30.530000686645508,30.799999237060547,-0.7794792833077326,,
2013-03-13,30.39999961853028,30.46999931335449,0.8843712556257568,,
2013-03-12,30.34000015258789,30.43000030517578,0.2302621569164095,,
2013-03-11,30.0,30.3700008392334,0.296638602950745,,
2013-03-08,30.489999771118164,29.989999771118164,1.2333361307779949,Acorda Presents GGF2 Data - Analyst Blog,"Acorda Therapeutics, Inc. ( ACOR ) recently announced data from a phase I trial (n=40) evaluating the safety, tolerability and exploratory efficacy of glial growth factor 2 (GGF2) in patients with heart failure, who have already received currently available treatments. ACORDA THERAPT (ACOR): Free Stock Analysis Report AGENUS INC (AGEN): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report OSIRIS THERAPTC (OSIR): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda has collaborated with Vanderbilt University Medical Center for the candidate."
2013-03-07,30.3700008392334,30.459999084472656,-1.6398819408113872,,
2013-03-06,30.46999931335449,30.459999084472656,0.2963392912488624,,
2013-03-05,30.13999938964844,30.36000061035156,-0.03281991830386899,,
2013-03-04,30.190000534057617,30.09000015258789,0.7299310721906556,,
2013-03-01,29.51000022888184,30.39999961853028,-0.3312367661501536,,
2013-02-28,29.59000015258789,29.75,3.015924712794094,,
2013-02-27,29.100000381469727,29.57999992370605,0.5407226988409328,,
2013-02-26,29.32999992370605,29.21999931335449,1.649482941388476,,
2013-02-25,30.25,29.36000061035156,-0.3750447004353867,,
2013-02-22,30.06999969482422,30.0,-2.9421467426394745,,
2013-02-21,30.65999984741211,30.020000457763672,-0.2327891437799629,,
2013-02-20,30.270000457763672,30.71999931335449,-2.087408326267351,,
2013-02-19,29.6299991607666,30.350000381469727,1.4866166131008456,,
2013-02-15,29.549999237060547,29.76000022888184,2.429973814027259,,
2013-02-14,29.959999084472656,29.549999237060547,0.7106632732427178,Earnings Miss at Acorda - Analyst Blog | Zacks Rank #5 Additions for Thursday - Tale of the Tape,"Acorda Therapeutics Inc.'s ( ACOR ) fourth quarter earnings (including share-based compensation charges but excluding other special items) of 9 cents per share were way below the Zacks Consensus Estimate of 18 cents and the year-ago earnings of 32 cents per share. Guidance for 2013 Acorda maintained its Ampyra revenue guidance of $285 million - $315 million, issued earlier on Jan 7. Quarter in Detail Bulk of the net product revenues at Acorda came from Ampyra sales. | ACORDA THERAPT (ACOR): Free Stock Analysis Report ACTIVISION BLZD (ATVI): Free Stock Analysis Report AMER AXLE & MFG (AXL): Free Stock Analysis Report BUNGE LTD (BG): Free Stock Analysis Report CAPELLA EDUCATN (CPLA): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Here are 5 stocks added to the Zacks Rank #5 (""strong sell"") List today: Acorda Therapeutics Inc. ( ACOR ) Activision Blizzard, Inc. ( ATVI ) American Axle & Manufact."
2013-02-13,29.489999771118164,29.959999084472656,-1.3684908542757588,,
2013-02-12,29.299999237060547,29.530000686645508,1.593758280780995,,
2013-02-11,29.489999771118164,29.25,0.7849879029827419,,
2013-02-08,29.100000381469727,29.420000076293945,-0.8138344285550466,,
2013-02-07,29.39999961853028,29.0,1.099655294258992,,
2013-02-06,29.270000457763672,29.31999969482422,-1.3605429378242853,,
2013-02-05,28.8700008392334,29.31999969482422,0.1708207594075555,,
2013-02-04,28.82999992370605,28.65999984741211,1.5587074558698537,,
2013-02-01,29.06999969482422,29.01000022888184,-0.5896638111127976,,
2013-01-31,28.850000381469727,28.8799991607666,-0.20639651383643423,,
2013-01-30,29.57999992370605,28.81999969482422,0.10398190260040042,,
2013-01-29,29.5,29.68000030517578,-2.5693043639014745,,
2013-01-28,29.40999984741211,29.59000015258789,0.6101705260195975,,
2013-01-25,29.479999542236328,29.43000030517578,0.6120377630386833,Acorda Gets US Army Support - Analyst Blog,"ACORDA THERAPT (ACOR): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ( ACOR ) recently announced that it has been awarded a research contract worth $2.67 million by the US Army Medical Research and Material Command (USAMRMC). Acorda intends to seek orphan drug status from the US Food and Drug Administration (FDA) and other regulatory authorities for the acute treatment of SCI."
2013-01-24,28.43000030517578,29.459999084472656,-0.1696039275336908,,
2013-01-23,28.729999542236328,28.540000915527344,3.6229291883242087,Zacks Rank #5 Additions for Wednesday - Tale of the Tape,"ACORDA THERAPT (ACOR): Free Stock Analysis Report ANWORTH MTGE (ANH): Free Stock Analysis Report ALLIED NEV GOLD (ANV): Free Stock Analysis Report CALAMOS ASSET-A (CLMS): Free Stock Analysis Report BANCO SANTAN SA (SAN): Free Stock Analysis Report To read this article on Zacks.com click here. Here are 5 stocks added to the Zacks Rank #5 (""strong sell"") List today: Acorda Therapeutics Inc. ( ACOR ) Allied Nevada Gold Corp. ( ANV ) Anworth Mortgage Asset Corp . Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2013-01-22,28.100000381469727,28.809999465942383,-0.6613248511531128,,
2013-01-18,27.940000534057617,27.959999084472656,2.5266870990537718,,
2013-01-17,27.64999961853028,27.790000915527344,0.07157677177085849,,
2013-01-16,27.700000762939453,27.520000457763672,0.5063338116765764,,
2013-01-15,27.670000076293945,27.84000015258789,-0.6498205784044898,,
2013-01-14,27.299999237060547,27.739999771118164,0.6143840832136157,,
2013-01-11,28.0,27.32999992370605,1.6117236130186539,,
2013-01-10,27.200000762939453,27.979999542236328,-2.3928574153355315,,
2013-01-09,27.26000022888184,27.1200008392334,2.867642490509188,Alkermes Maintains Fiscal 2013 View - Analyst Blog,"ACORDA THERAPT (ACOR): Free Stock Analysis Report ALKERMES INC (ALKS): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report IRONWOOD PHARMA (IRWD): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report To read this article on Zacks.com click here. Ampyra is marketed in the US by Acorda ( ACOR ). Recently, Acorda announced that the unaudited total Ampyra sales in calendar 2012 were $266 million, up approximately 26% year over year."
2013-01-08,26.989999771118164,27.26000022888184,-0.513570757421023,Acorda Provides Guidance - Analyst Blog,"ACORDA THERAPT (ACOR): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ( ACOR ) recently disclosed unaudited sales of Ampyra (dalfampridine) extended release tablets, 10 mg for the fourth quarter and full year 2012. Acorda announced that the Ampyra revenues were approximately $73 million in the fourth quarter of 2012, up 4.6% from the previous quarter."
2013-01-07,27.540000915527344,28.3799991607666,1.0003722121279945,,
2013-01-04,27.100000381469727,27.75,3.050102459385388,,
2013-01-03,26.040000915527344,26.950000762939453,2.3985225438399853,,
2013-01-02,25.420000076293945,25.170000076293945,3.4946229470732746,,
2012-12-31,24.270000457763672,24.86000061035156,-0.983477573759505,,
2012-12-28,24.059999465942383,24.209999084472656,2.430985337699709,,
2012-12-27,24.540000915527344,24.270000457763672,0.6234398248537045,Acorda Completes Acquisition of Neuronex - Analyst Blog,"Acorda Therapeutics, Inc. ( ACOR ) recently completed the acquisition of privately-held Neuronex, Inc. As per the agreement terms, Acorda paid $6.8 million to Neuronex. ACORDA THERAPT (ACOR): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report To read this article on Zacks.com click here. The acquisition of Neuronex adds diazepam nasal spray to Acorda's neurology pipeline."
2012-12-26,24.739999771118164,24.56999969482422,-1.1002463231076445,,
2012-12-24,25.1299991607666,24.6299991607666,-0.6871466364862536,,
2012-12-21,24.799999237060547,25.18000030517578,-1.989653866684599,,
2012-12-20,25.0,24.770000457763672,1.5322624185704392,,
2012-12-19,25.3799991607666,24.920000076293945,-0.9199981689453124,"Celgene, Sutro Join Forces - Analyst Blog",ACORDA THERAPT (ACOR): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. Another biopharma company Acorda Therapeutics Inc. ( ACOR ) carries a Zacks #2 Rank (Buy) in the short run. Celgene Corporation ( CELG ) recently collaborated with Sutro Biopharma for the development of novel antibody drug conjugates (ADCs) and bispecific antibodies for two undisclosed targets and for the manufacturing of a proprietary Celgene antibody.
2012-12-18,25.76000022888184,25.31999969482422,-1.8124472012739103,,
2012-12-17,25.299999237060547,25.65999984741211,-1.7080765921899985,,
2012-12-14,25.270000457763672,25.14999961853028,1.4229273565519236,,
2012-12-13,25.229999542236328,25.290000915527344,-0.4748747014625542,,
2012-12-12,25.8700008392334,25.26000022888184,0.23781757582107846,,
2012-12-11,25.549999237060547,25.75,-2.357945846783494,,
2012-12-10,25.040000915527344,25.3700008392334,0.7827818744094125,,
2012-12-07,25.170000076293945,25.059999465942383,1.3178910209281232,,
2012-12-06,25.15999984741211,25.09000015258789,-0.43703063177645846,,
2012-12-05,24.950000762939453,25.239999771118164,-0.2782181846134579,,
2012-12-04,24.489999771118164,24.790000915527344,1.1623206385206741,,
2012-12-03,24.1299991607666,24.420000076293945,1.2249944761656575,,
2012-11-30,25.459999084472656,25.209999084472656,1.2018272922232895,,
2012-11-29,25.100000381469727,25.36000061035156,-0.9819324783576604,,
2012-11-28,24.729999542236328,24.920000076293945,1.0358574698420309,,
2012-11-27,24.690000534057617,24.81999969482422,0.7682997880089548,,
2012-11-26,25.01000022888184,24.63999938964844,0.5265255486215138,,
2012-11-23,24.940000534057617,25.07999992370605,-1.479411578757673,,
2012-11-21,25.280000686645508,24.90999984741211,0.5613447740598614,,
2012-11-20,24.729999542236328,25.270000457763672,-1.463610874935048,,
2012-11-19,24.1299991607666,24.81999969482422,2.183586435596479,,
2012-11-16,23.07999992370605,23.850000381469727,2.8595132948844086,Alkermes Reverts to Neutral - Analyst Blog,"ACORDA THERAPT (ACOR): Free Stock Analysis Report ALKERMES INC (ALKS): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report To read this article on Zacks.com click here. For example, Risperdal Consta is marketed by Johnson & Johnson ( JNJ ), Ampyra/ Fampyra is marketed by Acorda Therapeutics, Inc. ( ACOR ) in the US and by Biogen Idec ( BIIB ) in the ex-US markets. Alkermes' revenues climbed 72% to $124 million in the second quarter of fiscal 2013 (ended September 30, 2012) due to the expanded product portfolio."
2012-11-15,23.65999984741211,23.239999771118164,3.3362238314948542,,
2012-11-14,24.170000076293945,23.61000061035156,-1.7751482629019721,,
2012-11-13,24.290000915527344,24.170000076293945,-2.316919586986831,,
2012-11-12,24.239999771118164,24.559999465942383,-0.49403390164834493,,
2012-11-09,23.950000762939453,24.07999992370605,1.320130766690422,,
2012-11-08,24.290000915527344,24.11000061035156,0.5427939733837521,,
2012-11-07,24.520000457763672,24.31999969482422,-0.7410469262712951,,
2012-11-06,24.959999084472656,24.81999969482422,-0.8156637814259406,,
2012-11-05,23.799999237060547,24.93000030517578,-0.5608950111521823,,
2012-11-02,24.040000915527344,23.729999542236328,4.747903799743133,,
2012-11-01,24.020000457763672,23.88999938964844,-1.2895231342973326,,
2012-10-31,23.350000381469727,23.950000762939453,-0.541220090082106,,
2012-10-26,23.290000915527344,22.479999542236328,2.5695947394753773,,
2012-10-25,22.979999542236328,23.350000381469727,-3.4778932651350445,,
2012-10-24,23.030000686645508,22.780000686645508,1.6100994195119611,,
2012-10-23,23.059999465942383,22.8799991607666,-1.0855405668527334,Acorda's Ampyra Patent Extended - Analyst Blog,"We note that in March 2010, Acorda had applied for the extension of the above-mentioned Ampyra patent based on the provisions of the Hatch Waxman Act that allow for up to five additional years of patent protection. Acorda Therapeutics Inc. ( ACOR ) recently announced that its patent no. The patent is related to Acorda's lead product Ampyra (dalfampridine, 10 mg)."
2012-10-22,23.170000076293945,23.14999961853028,-0.7805737612510619,,
2012-10-19,23.809999465942383,23.299999237060547,-0.08632049071129677,,
2012-10-18,24.420000076293945,24.01000022888184,-2.1419581701853283,Acorda Initiated at Neutral - Analyst Blog,"We are positive on Acorda's June 2009 agreement with Biogen Idec ( BIIB ) for the development and commercialization of Fampyra (ex-US trade name of Ampyra) in ex-US markets. We recently initiated coverage on commercial-stage biopharmaceutical company Acorda Therapeutics, Inc. ( ACOR ) with a Neutral recommendation and a target price of $25.00. Ardsley, New York based Acorda is focused on the development and commercialization of novel treatments that improve neurological function in people suffering from multiple sclerosis, spinal cord injury and other nervous system disorders."
2012-10-17,23.56999969482422,24.51000022888184,-1.6789510488581811,,
2012-10-16,23.600000381469727,23.459999084472656,3.988122809624123,,
2012-10-15,24.479999542236328,23.61000061035156,-0.5932258251444634,,
2012-10-12,24.450000762939453,24.459999084472656,-3.553917271868102,,
2012-10-11,24.39999961853028,24.5,0.04089292933012202,,
2012-10-10,24.13999938964844,24.3799991607666,0.4098376353816636,,
2012-10-09,25.8700008392334,24.13999938964844,0.9941995740939233,,
2012-10-08,26.6299991607666,25.809999465942383,-6.687287953084667,,
2012-10-05,27.0,26.65999984741211,-3.0792328977325183,,
2012-10-04,26.489999771118164,26.93000030517578,-1.259259824399595,"After Hours Most Active for Oct 4, 2012 : SUN, PETM, AMAT, QQQ, CAB, ACOR, NVDA, BAC, ORCL, A, NOK, HPQ","Acorda Therapeutics, Inc. ( ACOR ) is -0.04 at $26.89, with 1,888,352 shares traded. ACOR's current last sale is 86.05% of the target price of $31.25. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2012."
2012-10-03,26.84000015258789,26.459999084472656,1.6610061829345362,,
2012-10-02,26.59000015258789,26.670000076293945,-1.4158012889526566,,
2012-10-01,25.729999542236328,25.549999237060547,0.30086469818342076,,
2012-09-28,25.86000061035156,25.61000061035156,-0.6995736819983498,,
2012-09-27,25.520000457763672,25.959999084472656,-0.9667439833699266,,
2012-09-26,25.729999542236328,25.309999465942383,1.7241325188735581,,
2012-09-25,25.46999931335449,25.75,-1.6323361203505133,,
2012-09-24,25.61000061035156,25.32999992370605,1.0993352736319109,,
2012-09-21,25.780000686645508,25.71999931335449,-1.0933255758390399,,
2012-09-20,25.34000015258789,25.450000762939453,-0.23274387778469277,,
2012-09-19,25.549999237060547,25.39999961853028,0.43409869648453214,,
2012-09-18,25.1299991607666,25.36000061035156,-0.5870826732264254,Back to Neutral on Alkermes - Analyst Blog,"ACORDA THERAPT (ACOR): Free Stock Analysis Report ALKERMES INC (ALKS): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report To read this article on Zacks.com click here. For example, Risperdal Consta is marketed by Johnson & Johnson ( JNJ ), Ampyra/ Fampyra is marketed by Acorda Therapeutics, Inc. ( ACOR ) in the US and by Biogen Idec ( BIIB ) in ex-US markets. Interesting candidates include Zohydro (under review by the US Food and Drug Administration: target date - March 1, 2013) for pain, ALKS 9070 (phase III: data expected in mid-calendar 2013) for treating schizophrenia, three-month injectable version of schizophrenia drug Invega Sustenna (phase III), ALKS 5461 (a combination of ALKS 33 and buprenorphine) for cocaine dependence (phase Ib completed) and major depressive disorder (phase II, data expected in the first half of calendar 2013)."
2012-09-17,25.46999931335449,25.100000381469727,0.9152465470195467,,
2012-09-14,25.920000076293945,25.46999931335449,-1.452685284097214,,
2012-09-13,25.82999992370605,25.75,-1.7361140494402267,,
2012-09-12,26.0,25.670000076293945,-0.30971708843339735,,
2012-09-11,25.530000686645508,25.950000762939453,-1.2692304757925181,,
2012-09-10,25.25,25.549999237060547,1.645123638847543,,
2012-09-07,25.09000015258789,25.190000534057617,1.1881157903387995,,
2012-09-06,24.26000022888184,24.90999984741211,0.39856668338605844,,
2012-09-05,22.90999984741211,24.09000015258789,2.6793059043603678,,
2012-09-04,22.809999465942383,23.0,5.150590628699078,,
2012-08-31,23.170000076293945,22.850000381469727,0.8329703573264307,,
2012-08-30,23.07999992370605,23.030000686645508,-1.3810949234809105,,
2012-08-29,23.39999961853028,23.13999938964844,-0.21663447671500138,,
2012-08-28,23.1200008392334,23.34000015258789,-1.1111121073521186,,
2012-08-27,23.059999465942383,23.059999465942383,0.9515540889651058,,
2012-08-24,23.020000457763672,23.0,0.0,,
2012-08-23,23.280000686645508,23.1299991607666,-0.08688295988685164,,
2012-08-22,23.280000686645508,23.26000022888184,-0.6443364323651163,,
2012-08-21,23.65999984741211,23.229999542236328,-0.08591261672574398,,
2012-08-20,23.13999938964844,23.239999771118164,-1.8174146574342176,,
2012-08-17,23.14999961853028,23.26000022888184,0.4321537774735537,,
2012-08-16,22.959999084472656,23.15999984741211,0.4751646313786961,,
2012-08-15,22.770000457763672,23.0,0.8710834970142017,,
2012-08-14,22.64999961853028,22.739999771118164,1.010098979413535,Acorda Reports Data on Ampyra study - Analyst Blog,"Acorda Therapeutics Inc. ( ACOR ) recently announced results from a post-marketing commitment study evaluating a 5 mg dose of Ampyra (dalfampridine-ER) for improvement in walking in patients suffering from multiple sclerosis (MS). The drug is marketed outside the US under the trade name of Fampyra by Biogen Idec Inc. ( BIIB ) under a license agreement with Acorda. Meanwhile, Acorda reported Ampyra sales of $66.3 million in the second quarter of 2012."
2012-08-13,22.76000022888184,22.5,0.39735167374684255,,
2012-08-10,21.93000030517578,21.71999931335449,-1.1423560029314326,,
2012-08-09,21.81999969482422,21.96999931335449,-0.9575968486043729,,
2012-08-08,21.82999992370605,21.700000762939453,0.6874409744645886,,
2012-08-07,22.190000534057617,21.84000015258789,-0.595506922679495,,
2012-08-06,22.459999084472656,22.1299991607666,-1.5772887473911485,,
2012-08-03,22.89999961853028,22.420000076293945,-1.469278437923867,,
2012-08-02,22.68000030517578,22.63999938964844,-2.096067904944103,,
2012-08-01,24.049999237060547,22.790000915527344,-0.17637087737697968,"Acorda Misses on Earnings, Sales Up - Analyst Blog","Guidance for 2012 Acorda maintained its Ampyra revenue guidance of $255 million - $275 million. ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics Inc. ( ACOR ) reported second quarter earnings (including share-based compensation charges but excluding other special items) of 13 cents per share, above the year-ago earnings of 7 cents but below the Zacks Consensus Estimate of 16 cents per share."
2012-07-31,24.59000015258789,24.06999969482422,-5.239078426212887,,
2012-07-30,24.18000030517578,24.739999771118164,-2.114682613000904,"Pre-Market Earnings Report for July 31, 2012 : BP, ADM, AET, AMG, WTR, BRKR, AVX, AUXL, ACOR, ALLT, CPLP, ABFS","Acorda Therapeutics, Inc. ( ACOR ) is reporting for the quarter ending June 30, 2012. ACOR missed the consensus earnings per share in the 2nd calendar quarter by -41.67%. Zacks Investment Research reports that the 2012 Price to Earnings ratio for ACOR is 37.78 vs. an industry ratio of 10.70, implying that they will have a higher earnings growth than their competitors in the same industry."
2012-07-27,24.15999984741211,24.18000030517578,2.315961368381429,,
2012-07-26,24.25,23.940000534057617,0.0827833521936641,,
2012-07-25,24.38999938964844,23.89999961853028,-1.2783483131644653,,
2012-07-24,24.780000686645508,24.18000030517578,-2.0090192020510065,,
2012-07-23,24.81999969482422,24.780000686645508,-2.421308978385461,,
2012-07-20,25.18000030517578,25.020000457763672,-0.16115636047752263,,
2012-07-19,25.71999931335449,25.450000762939453,-0.6354243267392702,,
2012-07-18,25.51000022888184,25.670000076293945,-1.049761110510004,,
2012-07-17,25.68000030517578,25.540000915527344,0.6272044138633823,,
2012-07-16,25.309999465942383,25.65999984741211,-0.5451689563267674,,
2012-07-13,25.440000534057617,25.270000457763672,1.3828541637888763,,
2012-07-12,25.1200008392334,25.420000076293945,-0.6682392795800414,,
2012-07-11,25.88999938964844,25.350000381469727,1.194264438845067,,
2012-07-10,26.51000022888184,25.84000015258789,-2.0857436110818197,,
2012-07-09,26.14999961853028,26.350000381469727,-2.5273484364741883,,
2012-07-06,25.780000686645508,26.26000022888184,0.7648212843480215,,
2012-07-05,25.6200008392334,25.950000762939453,1.8619066309217744,,
2012-07-03,25.14999961853028,25.770000457763672,1.2880558661056192,,
2012-07-02,23.59000015258789,25.049999237060547,2.4652121218188037,,
2012-06-29,23.63999938964844,23.559999465942383,6.189059241326415,,
2012-06-28,23.170000076293945,23.15999984741211,-0.3384091614701516,,
2012-06-27,22.89999961853028,23.309999465942383,-0.04316024535566372,,
2012-06-26,22.63999938964844,22.81999969482422,1.790392376602214,,
2012-06-25,23.38999938964844,22.709999084472656,0.7950543729169809,,
2012-06-22,23.350000381469727,23.6200008392334,-2.9072266905518953,,
2012-06-21,23.600000381469727,23.290000915527344,1.156318858041394,,
2012-06-20,23.989999771118164,23.6200008392334,-1.3135570378455947,,
2012-06-19,24.020000457763672,23.959999084472656,-1.5423048579192216,,
2012-06-18,23.6299991607666,23.8799991607666,-0.2497975526541764,,
2012-06-15,22.809999465942383,23.700000762939453,1.057977185268294,,
2012-06-14,22.190000534057617,22.90999984741211,3.9018032346994636,,
2012-06-13,21.6200008392334,22.1299991607666,3.244701649508409,,
2012-06-12,22.1200008392334,21.6200008392334,2.3589190644605296,,
2012-06-11,22.940000534057617,21.84000015258789,-2.2603977442585315,,
2012-06-08,22.26000022888184,22.63999938964844,-4.795119249612148,,
2012-06-07,22.799999237060547,22.350000381469727,1.707094145819286,,
2012-06-06,22.3799991607666,22.440000534057617,-1.9736792572315704,,
2012-06-05,22.11000061035156,22.32999992370605,0.26810266104120956,,
2012-06-04,22.01000022888184,22.26000022888184,0.9950217425660853,,
2012-06-01,21.46999931335449,21.84000015258789,1.135847330305551,,
2012-05-31,21.950000762939453,21.989999771118164,1.723338849867866,,
2012-05-30,22.200000762939453,21.96999931335449,0.18222782135955806,,
2012-05-29,22.64999961853028,22.5,-1.0360425300927356,,
2012-05-25,22.540000915527344,22.540000915527344,-0.6622499825896853,,
2012-05-24,22.729999542236328,22.65999984741211,0.0,,
2012-05-23,22.170000076293945,22.65999984741211,-0.3079617080244416,,
2012-05-22,22.14999961853028,22.270000457763672,2.2101929157957634,,
2012-05-21,21.6200008392334,22.049999237060547,0.5417645205420268,,
2012-05-18,22.39999961853028,21.65999984741211,1.988891679628609,,
2012-05-17,23.34000015258789,22.90999984741211,-3.3035704630370186,,
2012-05-16,23.38999938964844,23.21999931335449,-1.8423320581174192,,
2012-05-15,23.6299991607666,23.36000061035156,-0.7268066726380004,,
2012-05-14,23.64999961853028,23.59000015258789,-1.1426092255785054,,
2012-05-11,23.6299991607666,23.920000076293945,-0.25369753450388666,,
2012-05-10,23.84000015258789,23.729999542236328,1.2272574093393898,,
2012-05-09,23.6200008392334,23.68000030517578,-0.4614119532193949,,
2012-05-08,24.01000022888184,23.96999931335449,0.25401974517597065,,
2012-05-07,23.5,24.26000022888184,-0.1666010626656863,,
2012-05-04,24.01000022888184,23.520000457763672,3.234043527156764,Revenues Climb at Acorda - Analyst Blog,"Guidance for 2012 Acorda maintained its Ampyra revenue guidance of $255 million - $275 million. Acorda Therapeutics Inc. ( ACOR ) reported first quarter earnings (including share-based compensation charges) of 26 cents per share, compared to a loss of 2 cents in the year-ago period. Acorda said that demand was affected by the switching of insurance plans, pharmacy benefit providers and specialty pharmacies by patients at the end of 2011."
2012-05-03,25.520000457763672,23.989999771118164,-2.0408153537988833,,
2012-05-02,24.440000534057617,25.520000457763672,-5.995300388719437,,
2012-05-01,25.200000762939453,24.96999931335449,4.418984861318042,,
2012-04-30,25.290000915527344,25.239999771118164,-0.9127041373872402,,
2012-04-27,25.059999465942383,25.290000915527344,-0.1977111213882179,,
2012-04-26,25.13999938964844,25.09000015258789,0.9178030905289635,,
2012-04-25,24.84000015258789,25.100000381469727,-0.19888320713777716,,
2012-04-24,24.530000686645508,24.38999938964844,1.046699787780591,,
2012-04-23,24.600000381469727,24.520000457763672,-0.570734990126949,,
2012-04-20,24.0,24.850000381469727,-0.32520293685164203,,
2012-04-19,24.309999465942383,24.309999465942383,3.541668256123861,,
2012-04-18,24.239999771118164,24.3799991607666,0.0,,
2012-04-17,24.43000030517578,24.32999992370605,0.5775552432770484,Zacks #1 Rank Additions for Tuesday - Tale of the Tape,"ACCO BRANDS CP ( ABD ): Free Stock Analysis Report ACI WORLDWIDE ( ACIW ): Free Stock Analysis Report ACORDA THERAPT ( ACOR ): Free Stock Analysis Report BARRETT BUS SVS ( BBSI ): Free Stock Analysis Report AMICUS THERAPT ( FOLD ): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Here are 5 stocks added to the Zacks #1 Rank (""strong buy"") List today: ACCO Brands Corp ( ABD ) ACI Worldwide Inc. ( ACIW ) Acorda Therapeutics Inc. ( ACOR ) Amicus Therapeutics, Inc. ( FOLD ) Barrett Business Services, Inc. ( BBSI ) View the entire Zacks #1 Rank List ."
2012-04-16,24.34000015258789,24.270000457763672,-0.4093343439236219,,
2012-04-13,24.549999237060547,24.25,-0.2875911848208275,Biogen's Fampyra Launched in Canada - Analyst Blog,"ABBOTT LABS ( ABT ): Free Stock Analysis Report ACORDA THERAPT ( ACOR ): Free Stock Analysis Report BAYER A G -ADR ( BAYRY ): Free Stock Analysis Report BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. Biogen has a licensing deal with Acorda Therapeutics, Inc. ( ACOR ) for the development and commercialization of Fampyra in ex-US markets. Fampyra is available in the US, under the trade name Ampyra, where it is being marketed by Acorda."
2012-04-12,24.59000015258789,24.63999938964844,-1.2219928569597251,,
2012-04-11,24.8700008392334,24.6200008392334,0.20333158499508358,,
2012-04-10,24.96999931335449,24.61000061035156,-1.0052271474217853,,
2012-04-09,25.86000061035156,24.979999542236328,-1.4417249215156955,,
2012-04-05,25.90999984741211,26.31999969482422,-3.402942951838033,,
2012-04-04,26.3700008392334,26.030000686645508,1.5824000379261298,,
2012-04-03,26.89999961853028,26.540000915527344,-1.2893444890681875,,
2012-04-02,26.38999938964844,27.0,-1.3382851602531207,,
2012-03-30,26.940000534057617,26.549999237060547,2.311483988100559,,
2012-03-29,27.40999984741211,26.71999931335449,-1.4476662556262005,,
2012-03-28,27.049999237060547,27.6200008392334,-2.517331404227521,,
2012-03-27,27.350000381469727,26.989999771118164,2.1072148548969505,,
2012-03-26,26.850000381469727,27.280000686645508,-1.3162727800013907,,
2012-03-23,26.71999931335449,26.540000915527344,1.601490871756344,,
2012-03-22,26.63999938964844,26.56999969482422,-0.6736467157661296,,
2012-03-21,26.8799991607666,26.950000762939453,-0.26276162322819807,,
2012-03-20,26.89999961853028,26.76000022888184,0.26042263526192444,,
2012-03-19,26.82999992370605,27.059999465942383,-0.5204438350698017,,
2012-03-16,26.450000762939453,26.850000381469727,0.8572476440192313,,
2012-03-15,25.84000015258789,26.350000381469727,1.5122858487427149,,
2012-03-14,25.5,25.520000457763672,1.9736850846371188,,
2012-03-13,25.64999961853028,25.489999771118164,0.07843316770067402,,
2012-03-12,25.82999992370605,25.38999938964844,-0.6237810908056627,,
2012-03-09,25.670000076293945,25.84000015258789,-1.703447678502662,,
2012-03-08,25.600000381469727,25.690000534057617,0.6622519508713953,,
2012-03-07,25.84000015258789,25.46999931335449,0.3515630908077495,,
2012-03-06,26.40999984741211,25.709999084472656,-1.4318917842434542,,
2012-03-05,26.61000061035156,26.540000915527344,-2.6505140741530355,,
2012-03-02,26.920000076293945,26.57999992370605,-0.26305784749581934,,
2012-03-01,26.40999984741211,27.06999969482422,-1.2630020491244431,,
2012-02-29,27.5,26.15999984741211,2.4990528255409363,,
2012-02-28,26.86000061035156,27.489999771118164,-4.87272782759233,,
2012-02-27,26.90999984741211,26.809999465942383,2.345491982318906,,
2012-02-24,26.209999084472656,27.049999237060547,-0.3716104869444785,,
2012-02-23,25.200000762939453,26.270000457763672,3.204884326323857,,
2012-02-22,24.959999084472656,25.06999969482422,4.246030406466578,,
2012-02-21,25.729999542236328,25.07999992370605,0.4407075896889463,Earnings Beat for Acorda - Analyst Blog,"Acorda Therapeutics Inc.'s ( ACOR ) fourth quarter earnings (including share-based compensation charges) of 32 cents per share were way above the Zacks Consensus Estimate of 17 cents and the year-ago earnings of 9 cents per share. Acorda expects SG&A expenses in the range of $145 million - $160 million, driven primarily by commercial and administrative costs related to the marketing of Ampyra. Acorda has a licensing agreement with Biogen Idec ( BIIB ) for the development and commercialization of Ampyra outside the US."
2012-02-17,26.200000762939453,25.729999542236328,-2.52623253048757,,
2012-02-16,27.6299991607666,27.1299991607666,-1.7938977367052344,,
2012-02-15,26.63999938964844,26.479999542236328,-1.809627271758945,,
2012-02-14,26.3700008392334,26.5,-0.6006000415836511,,
2012-02-13,25.71999931335449,26.459999084472656,0.49298125380863944,,
2012-02-10,25.6299991607666,25.440000534057617,2.877137600598382,,
2012-02-09,26.3799991607666,25.81999969482422,-0.7413134332045818,,
2012-02-08,26.440000534057617,26.40999984741211,-2.122818361477572,,
2012-02-07,27.25,26.440000534057617,-0.1134670425095629,,
2012-02-06,26.299999237060547,27.25,-2.9724751043757167,,
2012-02-03,26.770000457763672,26.43000030517578,3.612170306076523,,
2012-02-02,26.01000022888184,26.290000915527344,-1.270078994299329,,
2012-02-01,25.799999237060547,25.86000061035156,1.0765116654423859,,
2012-01-31,25.770000457763672,25.530000686645508,0.23256346924546717,,
2012-01-30,25.709999084472656,25.59000015258789,-0.9313145784049058,,
2012-01-27,25.600000381469727,26.290000915527344,-0.4667403195562072,,
2012-01-26,25.940000534057617,25.770000457763672,2.695314545999251,,
2012-01-25,25.64999961853028,25.690000534057617,-0.6553588002850875,,
2012-01-24,25.270000457763672,25.520000457763672,0.15594899072996032,,
2012-01-23,24.709999084472656,25.34000015258789,0.9893153758261717,,
2012-01-20,25.479999542236328,25.420000076293945,2.5495794878888374,,
2012-01-19,25.88999938964844,25.38999938964844,-0.23547671515035193,,
2012-01-18,26.07999992370605,25.850000381469727,-1.9312476314692932,,
2012-01-17,26.729999542236328,26.1299991607666,-0.881900087841875,,
2012-01-13,26.32999992370605,26.61000061035156,-2.244670376898661,,
2012-01-12,27.0,26.709999084472656,1.063428361021038,,
2012-01-11,26.700000762939453,27.0,-1.074077464916088,,
2012-01-10,27.06999969482422,26.989999771118164,1.1235926160607324,,
2012-01-09,26.940000534057617,26.540000915527344,-0.2955298286218698,,
2012-01-06,25.86000061035156,25.68000030517578,-1.4847795493715483,,
2012-01-05,24.81999969482422,25.8799991607666,-0.696056848133735,,
2012-01-04,24.39999961853028,24.850000381469727,4.270747296437023,,
2012-01-03,24.36000061035156,24.459999084472656,1.8442654507162304,,
2011-12-30,23.51000022888184,23.84000015258789,0.4105027570426409,,
2011-12-29,23.40999984741211,23.56999969482422,1.4036576796824058,,
2011-12-28,23.920000076293945,23.420000076293945,0.6834679558094776,,
2011-12-27,23.31999969482422,23.8799991607666,-2.09030099667737,,
2011-12-23,23.6200008392334,23.450000762939453,2.401369953991348,,
2011-12-22,23.190000534057617,23.600000381469727,-0.7197293406170038,,
2011-12-21,22.86000061035156,23.11000061035156,1.7680027510563003,,
2011-12-20,22.350000381469727,22.81999969482422,1.093613269138733,,
2011-12-19,21.799999237060547,21.93000030517578,2.1029051692731344,,
2011-12-16,21.8799991607666,21.71999931335449,0.5963351957106002,,
2011-12-15,21.96999931335449,21.709999084472656,-0.7312607566229316,,
2011-12-14,21.979999542236328,21.65999984741211,-1.1834330314420671,,
2011-12-13,22.63999938964844,22.040000915527344,-1.4558676136881337,,
2011-12-12,22.920000076293945,22.530000686645508,-2.650170010143336,,
2011-12-09,22.84000015258789,23.21999931335449,-1.7015680119993202,,
2011-12-08,22.34000015258789,22.700000762939453,1.6637441253411818,,
2011-12-07,22.15999984741211,22.489999771118164,1.6114619869859743,,
2011-12-06,22.63999938964844,22.350000381469727,1.4891693410575215,,
2011-12-05,22.850000381469727,22.670000076293945,-1.2809143816112871,,
2011-12-02,23.1200008392334,22.530000686645508,-0.7877474930886785,,
2011-12-01,23.1200008392334,23.18000030517578,-2.5519036815374685,,
2011-11-30,22.729999542236328,23.14999961853028,0.2595132515763881,,
2011-11-29,22.36000061035156,22.09000015258789,1.8477786394738749,,
2011-11-28,21.530000686645508,22.280000686645508,-1.2075154310982963,Big Potential? Takeover Targets With Solid Profitability,"Acorda Therapeutics, Inc. (ACOR): Acorda Therapeutics, Inc., a commercial stage biopharmaceutical company, involves in the identification, development, and commercialization of therapies for multiple sclerosis (MS), spinal cord injury, and other nervous system disorders. = (Net Profit/Equity) = (Net profit/Sales)*(Sales/Assets)*(Assets/Equity) = (Net Profit margin)*(Asset turnover)*(Leverage ratio) From this breakdown, we can focus on companies with the following characteristics: Increasing ROE along with, • Decreasing leverage, i.e. decreasing Asset/Equity ratio • Improving asset use efficiency (i.e. increasing Sales/Assets ratio) and improving net profit margin (i.e. increasing Net Income/Sales ratio) Companies passing all requirements are thus experiencing increasing profits due to operations and not to increased use of leverage. MRQ net profit margin at 20.28% vs. 19.55% y/y."
2011-11-25,21.5,20.89999961853028,3.483511268372626,,
2011-11-23,21.239999771118164,21.520000457763672,-2.7906994486963694,,
2011-11-22,21.520000457763672,21.450000762939453,1.3182706669622877,,
2011-11-21,21.809999465942383,21.5,-0.3252773853866963,,
2011-11-18,21.88999938964844,22.030000686645508,-1.4213639318353284,,
2011-11-17,22.549999237060547,21.920000076293945,0.6395673864809331,,
2011-11-16,23.0,22.6299991607666,-2.793787947146395,,
2011-11-15,22.64999961853028,23.020000457763672,-1.6086993010147759,,
2011-11-14,23.18000030517578,22.64999961853028,1.6335578166221623,,
2011-11-11,22.71999931335449,23.34000015258789,-2.2864567716470594,,
2011-11-10,23.0,22.459999084472656,2.7288770157179294,,
2011-11-09,22.6200008392334,22.709999084472656,-2.3478300675101904,,
2011-11-08,23.229999542236328,23.190000534057617,0.3978702117603807,,
2011-11-07,22.920000076293945,23.06999969482422,-0.17218686597899208,,
2011-11-04,21.89999961853028,23.07999992370605,0.6544485952485549,,
2011-11-03,20.8799991607666,20.450000762939453,5.388129341232203,,
2011-11-02,21.09000015258789,20.64999961853028,-2.059379382711437,,
2011-11-01,21.15999984741211,20.809999465942383,-2.086299340323233,,
2011-10-31,22.739999771118164,21.84000015258789,-1.6540660869264228,,
2011-10-28,23.239999771118164,23.07999992370605,-3.957782003469294,,
2011-10-27,22.520000457763672,23.26000022888184,-0.6884675085537435,,
2011-10-26,22.61000061035156,22.049999237060547,3.2859669452762197,,
2011-10-25,22.6299991607666,22.38999938964844,-2.4767861927196324,,
2011-10-24,22.059999465942383,22.729999542236328,-1.0605381353007104,,
2011-10-21,21.920000076293945,21.96999931335449,3.037171770236593,,
2011-10-20,21.239999771118164,21.420000076293945,0.22809870842389518,,
2011-10-19,21.65999984741211,21.32999992370605,0.8474590730483105,,
2011-10-18,21.43000030517578,21.75,-1.5235453648698245,,
2011-10-17,21.709999084472656,21.520000457763672,1.4932323390911586,,
2011-10-14,21.46999931335449,21.75,-0.8751664427516005,,
2011-10-13,20.950000762939453,21.299999237060547,1.3041485589212338,,
2011-10-12,21.93000030517578,21.01000022888184,1.6706370471367284,,
2011-10-11,21.780000686645508,21.729999542236328,-4.1951667281865435,,
2011-10-10,21.61000061035156,22.01000022888184,-0.22957365855290393,,
2011-10-07,21.920000076293945,21.26000022888184,1.8509930922383864,Top 10 list of unusual option activity,"Acorda Therapeutics (ACOR): Options volume 1,604 percent above average. ACOR fell 1.83 percent to $21.51. AMAG Pharmaceuticals (AMAG): Options volume 1,953 percent above average."
2011-10-06,20.39999961853028,21.90999984741211,-3.0109481985170374,,
2011-10-05,20.07999992370605,20.34000015258789,7.401962044696435,Brain Disorders: 3 Biotech Stocks at the Forefront,"Acorda Therapeutics, Inc. (ACOR): Involves in the identification, development, and commercialization of therapies for multiple sclerosis (MS), spinal cord injury, and other nervous system disorders. A new study by the European Brain Council (EBC) found that the cost of mental and neurological disorders in Europe is far outpacing other diseases, such as heart disease and cancer. The annual cost for treating brain disorders in Europe is now at 798 billion euros ($1 trillion) and rising, posing a “ticking bomb” to the European economy."
2011-10-04,18.57999992370605,19.209999084472656,1.2948218619009473,,
2011-10-03,19.75,18.709999084472656,3.390738231181557,,
2011-09-30,20.0,19.959999084472656,-5.265827420391614,,
2011-09-29,20.8700008392334,20.270000457763672,-0.20000457763671872,,
2011-09-28,21.950000762939453,20.559999465942383,-2.8749418176437693,,
2011-09-27,21.709999084472656,21.89999961853028,-6.3325797206529435,,
2011-09-26,21.540000915527344,21.34000015258789,0.875175228328387,,
2011-09-23,20.8799991607666,21.3700008392334,-0.9285086092790292,,
2011-09-22,21.0,20.940000534057617,2.346751427976622,,
2011-09-21,21.979999542236328,21.530000686645508,-0.2857117425827753,,
2011-09-20,22.93000030517578,21.96999931335449,-2.0473105776281364,,
2011-09-19,23.059999465942383,22.84000015258789,-4.1866593067798625,,
2011-09-16,23.229999542236328,23.450000762939453,-0.954030001949532,,
2011-09-15,23.18000030517578,23.07999992370605,0.9470565003805667,,
2011-09-14,23.290000915527344,23.040000915527344,-0.43140802481957424,,
2011-09-13,23.25,23.059999465942383,-1.0734220273616482,,
2011-09-12,23.14999961853028,23.170000076293945,-0.8172065980972784,,
2011-09-09,24.39999961853028,23.46999931335449,0.08639506735739003,,
2011-09-08,25.600000381469727,24.64999961853028,-3.8114767201451696,,
2011-09-07,24.350000381469727,25.76000022888184,-3.7109404249348894,,
2011-09-06,23.6299991607666,24.850000381469727,5.790553697424655,,
2011-09-02,24.600000381469727,24.299999237060547,5.1629338300134995,,
2011-09-01,25.96999931335449,25.01000022888184,-1.2195168282808624,,
2011-08-31,26.290000915527344,26.049999237060547,-3.696569541220555,,
2011-08-30,25.979999542236328,26.059999465942383,-0.9129009893835629,,
2011-08-29,26.309999465942383,26.0,0.3079288880509672,,
2011-08-26,25.11000061035156,26.020000457763672,-1.1782572110792673,,
2011-08-25,26.14999961853028,25.32999992370605,3.624053465920534,,
2011-08-24,25.229999542236328,25.979999542236328,-3.1357541368496435,,
2011-08-23,24.63999938964844,25.209999084472656,2.9726516591665453,,
2011-08-22,25.64999961853028,24.51000022888184,2.313310507076063,,
2011-08-19,24.479999542236328,25.14999961853028,-4.444442131004452,,
2011-08-18,25.39999961853028,24.88999938964844,2.7369284674126497,,
2011-08-17,26.68000030517578,25.940000534057617,-2.0078749470128914,,
2011-08-16,26.670000076293945,26.63999938964844,-2.7736123037997418,,
2011-08-15,26.75,26.940000534057617,-0.11248851353461693,,
2011-08-12,26.88999938964844,26.770000457763672,0.7102823703088493,,
2011-08-11,25.600000381469727,26.81999969482422,-0.4462585890982352,,
2011-08-10,24.90999984741211,25.559999465942383,4.7656222467776805,,
2011-08-09,23.420000076293945,25.530000686645508,2.6093923023359697,,
2011-08-08,23.780000686645508,22.86000061035156,9.009396257378047,,
2011-08-05,24.1299991607666,24.350000381469727,-3.8687975177839546,,
2011-08-04,25.5,23.88999938964844,0.9117332298163894,,
2011-08-03,26.68000030517578,26.09000015258789,-6.313727883731604,,
2011-08-02,27.14999961853028,26.520000457763672,-2.211394849472448,,
2011-08-01,28.920000076293945,27.290000915527344,-2.3204389304544404,,
2011-07-29,28.07999992370605,28.39999961853028,-5.636234980866167,,
2011-07-28,27.770000457763672,28.270000457763672,1.139600055889157,,
2011-07-27,28.479999542236328,27.709999084472656,1.8005041114798208,,
2011-07-26,28.979999542236328,28.68000030517578,-2.703653336165782,,
2011-07-25,29.709999084472656,28.96999931335449,-1.0351940710810534,,
2011-07-22,29.81999969482422,29.670000076293945,-2.4907431636539963,,
2011-07-21,29.299999237060547,29.850000381469727,-0.503016834558548,,
2011-07-20,29.559999465942383,29.299999237060547,1.8771370605139897,,
2011-07-19,29.11000061035156,29.64999961853028,-0.8795677725955164,,
2011-07-18,29.479999542236328,28.89999961853028,1.8550291887891517,,
2011-07-15,30.190000534057617,29.6299991607666,-1.9674353212762947,,
2011-07-14,31.21999931335449,30.13999938964844,-1.8549233633145286,,
2011-07-13,31.030000686645508,31.09000015258789,-3.459320779818445,,
2011-07-12,31.01000022888184,30.950000762939453,0.19335953791391633,,
2011-07-11,32.150001525878906,31.280000686645508,-0.19348424862797825,,
2011-07-08,32.08000183105469,32.45000076293945,-2.7060678007529724,,
2011-07-07,32.29999923706055,32.27000045776367,1.1533631881734878,,
2011-07-06,31.76000022888184,32.150001525878906,-0.09287547989306093,,
2011-07-05,32.33000183105469,31.61000061035156,1.2279637726274581,,
2011-07-01,32.36000061035156,32.220001220703125,-2.227037364444344,,
2011-06-30,32.5099983215332,32.310001373291016,-0.43263098580923215,,
2011-06-29,32.849998474121094,32.41999816894531,-0.6151859691414326,,
2011-06-28,32.4900016784668,32.849998474121094,-1.308981202889648,,
2011-06-27,32.34000015258789,32.41999816894531,1.108023321195732,,
2011-06-24,32.56999969482422,32.810001373291016,0.24736554106361167,,
2011-06-23,32.13999938964844,32.619998931884766,0.7368795846348631,,
2011-06-22,31.780000686645508,32.43000030517578,1.4934646899555482,,
2011-06-21,31.459999084472656,32.029998779296875,2.045310272140473,,
2011-06-20,30.51000022888184,31.3700008392334,1.811823621779909,,
2011-06-17,31.39999961853028,30.520000457763672,2.8187499308421904,,
2011-06-16,30.75,31.25,-2.802545132030158,,
2011-06-15,30.950000762939453,30.790000915527344,1.6260162601626018,,
2011-06-14,30.57999992370605,31.18000030517578,-0.5169623375379636,,
2011-06-13,30.81999969482422,30.25,1.9620679626117372,,
2011-06-10,30.82999992370605,30.549999237060547,-1.849447438248814,,
2011-06-09,31.290000915527344,30.959999084472656,-0.908208522018853,,
2011-06-08,31.030000686645508,31.18000030517578,-1.0546558689646042,,
2011-06-07,31.0,31.030000686645508,0.4834019181792326,,
2011-06-06,32.040000915527344,30.8799991607666,0.09677640853389617,,
2011-06-03,32.16999816894531,31.93000030517578,-3.6204797803191626,,
2011-06-02,32.279998779296875,32.52000045776367,-0.7460300821565123,,
2011-06-01,32.869998931884766,32.310001373291016,0.743499651619332,,
2011-05-31,33.209999084472656,32.849998474121094,-1.7036737961391828,,
2011-05-27,32.9900016784668,33.08000183105469,-1.0840127078470196,,
2011-05-26,32.650001525878906,32.9900016784668,0.27281039105443705,,
2011-05-25,31.459999084472656,32.79999923706055,1.041348045017398,,
2011-05-24,31.75,31.64999961853028,4.259377595625102,,
2011-05-23,30.0,31.670000076293945,-0.3149618314006912,,
2011-05-20,31.600000381469727,30.3799991607666,5.566666920979817,,
2011-05-19,26.59000015258789,26.709999084472656,-3.860763310048993,,
2011-05-18,26.420000076293945,26.40999984741211,0.45129346068501863,,
2011-05-17,25.93000030517578,26.39999961853028,-0.03785097976138506,,
2011-05-16,25.88999938964844,26.1200008392334,1.812569640659374,,
2011-05-13,25.39999961853028,26.049999237060547,0.8883795094909059,,
2011-05-12,24.959999084472656,25.270000457763672,2.5590536546940204,,
2011-05-11,25.13999938964844,25.030000686645508,1.2419927270104112,,
2011-05-10,25.450000762939453,25.290000915527344,-0.4375445730846991,,
2011-05-09,24.280000686645508,25.25,-0.6286830751105625,,
2011-05-06,24.549999237060547,24.420000076293945,3.995054719615438,,
2011-05-05,25.989999771118164,23.93000030517578,-0.5295281662182519,,
2011-05-04,27.96999931335449,27.15999984741211,-7.926123447802384,,
2011-05-03,28.0,27.90999984741211,-2.8959581187963734,,
2011-05-02,28.170000076293945,27.979999542236328,-0.3214291163853237,,
2011-04-29,28.75,28.040000915527344,-0.6744782873377035,,
2011-04-28,28.1200008392334,28.780000686645508,-2.4695620329483696,,
2011-04-27,27.850000381469727,28.280000686645508,2.347083313352071,,
2011-04-26,27.6200008392334,28.0,1.5439867119782382,,
2011-04-25,27.68000030517578,27.700000762939453,1.3758115467788978,,
2011-04-21,28.1200008392334,27.559999465942383,0.07225598823397435,,
2011-04-20,28.5,27.950000762939453,-1.9914699736057413,,
2011-04-19,28.540000915527344,27.989999771118164,-1.9298218844229715,,
2011-04-18,28.3799991607666,28.299999237060547,-1.927123779838243,Put sellers show confidence in Acorda,"If ACOR remains above the strike prices, investors will get to keep the credit. (See our Education section) The trades pushed overall option volume in ACOR to 30 times greater than average in the session. Acorda Therapeutics surged on a bullish analyst report last week, and investors appear confident that it will hold its ground."
2011-04-15,27.68000030517578,29.14999961853028,-0.28188839348751316,,
2011-04-14,21.25,27.1299991607666,5.310691102411692,,
2011-04-13,21.13999938964844,21.420000076293945,27.670584285960476,,
2011-04-12,21.18000030517578,21.100000381469727,1.3245065975858605,,
2011-04-11,21.93000030517578,21.299999237060547,-0.3777144596475998,,
2011-04-08,22.51000022888184,22.040000915527344,-2.872781848373005,,
2011-04-07,21.739999771118164,22.34000015258789,-2.08795783463145,,
2011-04-06,22.11000061035156,21.81999969482422,2.75989138816291,,
2011-04-05,22.200000762939453,22.07999992370605,-1.3116278042596086,,
2011-04-04,22.8700008392334,22.31999969482422,-0.5405443022944876,,
2011-04-01,23.299999237060547,22.90999984741211,-2.404902161025088,,
2011-03-31,22.84000015258789,23.200000762939453,-1.6738171777624427,,
2011-03-30,22.14999961853028,22.84000015258789,1.5761847983646906,,
2011-03-29,21.93000030517578,22.170000076293945,3.1151266182432273,,
2011-03-28,21.93000030517578,21.96999931335449,1.0943901859477896,,
2011-03-25,22.049999237060547,21.989999771118164,0.18239401560458285,,
2011-03-24,21.770000457763672,21.920000076293945,-0.2721064309224042,,
2011-03-23,22.170000076293945,21.6299991607666,0.6890198225824116,,
2011-03-22,22.5,22.239999771118164,-2.4357280724809685,,
2011-03-21,22.979999542236328,22.57999992370605,-1.1555565728081596,,
2011-03-18,22.96999931335449,22.8799991607666,-1.7406424129604248,,
2011-03-17,22.530000686645508,22.299999237060547,-0.39181608741086044,,
2011-03-16,22.209999084472656,22.280000686645508,-1.0208674770316035,,
2011-03-15,21.84000015258789,22.270000457763672,0.3151805720775141,,
2011-03-14,22.18000030517578,22.229999542236328,1.968865852433747,,
2011-03-11,22.290000915527344,22.39999961853028,0.22542487093149127,,
2011-03-10,22.290000915527344,22.270000457763672,0.4934890017268284,,
2011-03-09,22.46999931335449,22.57999992370605,-0.08972838466659479,,
2011-03-08,21.88999938964844,22.459999084472656,0.4895443422919304,,
2011-03-07,21.989999771118164,21.86000061035156,2.6039274130531145,,
2011-03-04,21.989999771118164,21.940000534057617,-0.5911739978158027,,
2011-03-03,22.450000762939453,22.059999465942383,-0.22737261291933372,,
2011-03-02,21.0,22.3799991607666,-1.7371994821527397,,
2011-03-01,21.049999237060547,21.0,6.571424575079055,,
2011-02-28,20.709999084472656,20.96999931335449,-0.2375260754048789,,
2011-02-25,20.700000762939453,20.65999984741211,1.2554333190519926,,
2011-02-24,20.600000381469727,20.600000381469727,-0.19324113069097065,,
2011-02-23,20.84000015258789,20.799999237060547,0.0,,
2011-02-22,21.280000686645508,20.86000061035156,-0.19194297137457783,,
2011-02-18,21.34000015258789,21.270000457763672,-1.9736845053652858,How To Play Biotech With ETFs,"That means it puts an equal amount of money into a $50 billion giant like Amgen ( AMGN ) as it does into an $800 million small-cap like Acorda Therapeutics ( ACOR ). I got my start in this industry as a biotech analyst for an actively managed mutual fund, and spent a number of fun years working at Genzyme, one of the largest biotech companies in the world. Choice 1:iShares Nasdaq Biotech ETF (NYSEArca:IBB): IBB is the oldest and largest biotech ETFs."
2011-02-17,22.600000381469727,21.989999771118164,-0.3280210605609107,,
2011-02-16,23.07999992370605,23.200000762939453,-2.6991176993594936,,
2011-02-15,23.479999542236328,22.989999771118164,0.5199343138218389,,
2011-02-14,23.09000015258789,23.59000015258789,-2.0868815190423744,,
2011-02-11,22.729999542236328,22.979999542236328,2.165439569925515,,
2011-02-10,22.18000030517578,22.82999992370605,1.099868037988545,,
2011-02-09,22.530000686645508,22.229999542236328,2.9305663191473905,,
2011-02-08,22.270000457763672,22.6200008392334,-1.33156296167804,,
2011-02-07,22.520000457763672,22.31999969482422,1.5716226954441348,,
2011-02-04,22.64999961853028,22.540000915527344,-0.8881028369184767,,
2011-02-03,22.8700008392334,22.6200008392334,-0.48564549605089313,,
2011-02-02,22.25,22.84000015258789,-1.093135071386294,,
2011-02-01,22.190000534057617,22.239999771118164,2.651686079046699,,
2011-01-31,22.09000015258789,21.950000762939453,0.22532328011352293,,
2011-01-28,22.6299991607666,21.950000762939453,-0.6337681696757991,,
2011-01-27,22.81999969482422,22.6200008392334,-3.004853835814783,,
2011-01-26,23.1200008392334,22.76000022888184,-0.8764191860886915,,
2011-01-25,23.40999984741211,22.989999771118164,-1.5570960090133616,,
2011-01-24,23.350000381469727,23.600000381469727,-1.7941054208950573,,
2011-01-21,23.89999961853028,23.96999931335449,1.0706637940716992,,
2011-01-20,26.850000381469727,27.82999992370605,0.2928857570773162,,
2011-01-19,27.63999938964844,26.84000015258789,3.6499051333819046,,
2011-01-18,26.5,27.799999237060547,-2.8943533094293814,,
2011-01-14,27.559999465942383,26.420000076293945,4.905657498341686,The Top 20 Most Undervalued Healthcare Stocks By Target Price,"Acorda Therapeutics, Inc. (ACOR): Biotechnology Industry. Price at time of writing $4.12 vs. target price of $6.75 (discount of 38.96%). China Medical Technologies Inc. (CMED): Medical Instruments & Supplies Industry."
2011-01-13,29.299999237060547,27.440000534057617,-4.136427473655092,,
2011-01-12,30.71999931335449,29.18000030517578,-6.348118605580994,,
2011-01-11,31.0,30.979999542236328,-5.013017716798075,,
2011-01-10,28.5,30.8700008392334,-0.06451760568926411,,
2011-01-07,27.950000762939453,27.670000076293945,8.3157924183628,,
2011-01-06,28.690000534057617,27.979999542236328,-1.0017913381125096,,
2011-01-05,28.38999938964844,28.6299991607666,-2.4747332819964707,,
2011-01-04,26.93000030517578,27.530000686645508,0.8453672993232582,,
2011-01-03,27.40999984741211,27.0,2.2279999059428532,,
2010-12-31,27.549999237060547,27.26000022888184,-1.495803902570321,,
2010-12-30,27.59000015258789,27.51000022888184,-1.0526280080204056,,
2010-12-29,27.549999237060547,27.59000015258789,-0.289959852350879,,
2010-12-28,27.479999542236328,27.59000015258789,0.14519388978252348,,
2010-12-27,26.39999961853028,27.32999992370605,0.4002933485588065,,
2010-12-23,25.790000915527344,26.530000686645508,3.5227284795981557,,
2010-12-22,25.920000076293945,25.850000381469727,2.8693282080212477,,
2010-12-21,26.06999969482422,25.920000076293945,-0.27006055022445563,,
2010-12-20,26.299999237060547,25.89999961853028,-0.5753725365790988,,
2010-12-17,26.38999938964844,26.34000015258789,-1.5209111411935266,,
2010-12-16,26.200000762939453,26.32999992370605,-0.18946282007176848,,
2010-12-15,26.5,26.190000534057617,0.49617998847727146,,
2010-12-14,26.040000915527344,26.5,-1.1698093054429541,,
2010-12-13,27.040000915527344,27.0,1.7665094788777993,,
2010-12-10,26.13999938964844,27.3799991607666,-0.14793237490008287,,
2010-12-09,26.700000762939453,26.020000457763672,4.743687069897966,,
2010-12-08,26.700000762939453,26.13999938964844,-2.5468175496071366,,
2010-12-07,26.8799991607666,26.57999992370605,-2.097383360633884,,
2010-12-06,26.3799991607666,26.700000762939453,-1.1160686251003389,,
2010-12-03,25.989999771118164,26.39999961853028,1.2130462939846143,,
2010-12-02,26.280000686645508,26.190000534057617,1.5775292459514982,,
2010-12-01,26.739999771118164,26.46999931335449,-0.34246632510030817,,
2010-11-30,26.59000015258789,26.420000076293945,-1.0097249815809741,,
2010-11-29,26.809999465942383,26.790000915527344,-0.6393383802872974,,
2010-11-26,26.68000030517578,26.8700008392334,-0.07459362481690412,,
2010-11-24,26.51000022888184,26.799999237060547,0.7121459216053985,,
2010-11-23,26.049999237060547,26.3700008392334,1.0939230693131503,,
2010-11-22,26.790000915527344,26.38999938964844,1.2284130961416495,,
2010-11-19,27.049999237060547,26.8799991607666,-1.4931000829009449,,
2010-11-18,27.190000534057617,27.040000915527344,-0.6284661038401522,,
2010-11-17,27.09000015258789,26.88999938964844,-0.5516719955278673,,
2010-11-16,27.43000030517578,26.989999771118164,-0.7382826202027305,,
2010-11-15,27.63999938964844,27.479999542236328,-1.6040850498080135,,
2010-11-12,27.43000030517578,27.520000457763672,-0.5788706618858865,,
2010-11-11,27.1200008392334,27.71999931335449,0.32810846367693425,,
2010-11-10,28.01000022888184,27.59000015258789,2.2123836856711923,,
2010-11-09,27.71999931335449,28.0,-1.4994647371008438,,
2010-11-08,27.09000015258789,27.700000762939453,1.0101035121982027,,
2010-11-05,26.670000076293945,27.040000915527344,2.251755654911982,,
2010-11-04,26.32999992370605,26.600000381469727,1.3873297269401945,,
2010-11-03,25.989999771118164,26.059999465942383,1.0254480005546152,,
2010-11-02,25.6299991607666,26.0,0.2693331875362582,,
2010-11-01,26.40999984741211,25.049999237060547,1.443624078614022,,
2010-10-29,26.559999465942383,27.040000915527344,-5.149566899693972,,
2010-10-28,27.39999961853028,26.75,1.8072344097764832,,
2010-10-27,26.440000534057617,27.170000076293945,-2.372261414524597,,
2010-10-26,26.549999237060547,26.64999961853028,2.7609664428561898,,
2010-10-25,26.0,26.65999984741211,0.3766492818958178,,
2010-10-22,25.729999542236328,25.84000015258789,2.5384609515850363,,
2010-10-21,26.11000061035156,25.729999542236328,0.42751889742941585,,
2010-10-20,26.989999771118164,26.51000022888184,-1.4553851368527957,,
2010-10-19,27.51000022888184,26.75,-1.7784347769797655,,
2010-10-18,28.89999961853028,27.56999969482422,-2.762632579275446,,
2010-10-15,29.600000381469727,28.93000030517578,-4.602075921320373,,
2010-10-14,28.51000022888184,29.239999771118164,-2.2635137420923166,,
2010-10-13,30.3700008392334,28.39999961853028,2.5605034597537606,,
2010-10-12,30.5,30.14999961853028,-6.486668311705074,,
2010-10-11,31.26000022888184,30.600000381469727,-1.147542234326949,,
2010-10-08,29.8700008392334,31.280000686645508,-2.1113238726157264,,
2010-10-07,30.39999961853028,29.950000762939453,4.720454662860654,,
2010-10-06,31.11000061035156,30.09000015258789,-1.480259411965687,,
2010-10-05,31.530000686645508,31.1299991607666,-3.278689931700846,,
2010-10-04,32.060001373291016,31.31999969482422,-1.268637859714118,,
2010-10-01,33.380001068115234,32.2400016784668,-2.3081773136893484,,
2010-09-30,33.20000076293945,33.02000045776367,-3.415216756051489,,
2010-09-29,34.150001525878906,33.09000015258789,-0.5421695814438422,,
2010-09-28,33.900001525878906,34.34000015258789,-3.103957030537013,,
2010-09-27,34.27000045776367,33.689998626708984,1.29793099381749,,
2010-09-24,33.720001220703125,34.16999816894531,-1.6924476898373995,,
2010-09-23,33.5,33.380001068115234,1.3345104743528364,,
2010-09-22,34.209999084472656,33.70000076293945,-0.3582057668201959,,
2010-09-21,35.220001220703125,34.790000915527344,-1.490787299566701,,
2010-09-20,35.72999954223633,35.34000015258789,-1.2208980416588322,,
2010-09-17,35.33000183105469,35.54999923706055,-1.0915180370697188,,
2010-09-16,34.7400016784668,34.9900016784668,0.6226928802830801,,
2010-09-15,34.439998626708984,34.88999938964844,0.7196315138780195,,
2010-09-14,34.04999923706055,34.459999084472656,1.306622476432004,,
2010-09-13,34.0,34.09000015258789,1.204111179438322,,
2010-09-10,32.630001068115234,33.849998474121094,0.2647063311408548,,
2010-09-09,33.349998474121094,32.439998626708984,3.7388825193695547,,
2010-09-08,32.810001373291016,33.2400016784668,-2.7286353494686075,,
2010-09-07,33.470001220703125,32.66999816894531,1.310576919164115,,
2010-09-03,32.290000915527344,32.650001525878906,-2.390209209980442,,
2010-09-02,31.0,31.90999984741211,1.1148981113173286,,
2010-09-01,30.450000762939453,31.0,2.93548337874874,,
2010-08-31,29.459999084472656,30.1200008392334,1.806237186469789,,
2010-08-30,30.09000015258789,29.56999969482422,2.2403318916211585,,
2010-08-27,29.89999961853028,30.290000915527344,-1.7281503992247378,,
2010-08-26,29.8700008392334,29.530000686645508,1.3043521805109426,,
2010-08-25,28.690000534057617,29.850000381469727,-1.1382662974060251,,
2010-08-24,29.950000762939453,28.8700008392334,4.043220027253345,,
2010-08-23,31.88999938964844,30.190000534057617,-3.6060096700981106,,
2010-08-20,31.61000061035156,31.6200008392334,-5.330821223353949,,
2010-08-19,32.43000030517578,31.75,0.03163628183722541,,
2010-08-18,32.86000061035156,32.619998931884766,-2.0968248497588027,,
2010-08-17,32.959999084472656,32.9900016784668,-0.7303763664301075,,
2010-08-16,32.2599983215332,32.59000015258789,0.09102729013203992,,
2010-08-13,32.790000915527344,32.29999923706055,1.0229443528346833,,
2010-08-12,32.7400016784668,32.970001220703125,-1.4943631131000121,,
2010-08-11,34.099998474121094,33.29999923706055,0.7025031473581126,,
2010-08-10,34.86000061035156,34.540000915527344,-2.3460389233380057,,
2010-08-09,35.349998474121094,35.0099983215332,-0.9179566529588524,,
2010-08-06,34.70000076293945,35.33000183105469,-0.9618109399263391,,
2010-08-05,36.5099983215332,35.02000045776367,1.8155649978777313,,
2010-08-04,35.349998474121094,36.77000045776367,-4.081068014979191,,
2010-08-03,35.86000061035156,35.290000915527344,4.01697891071234,,
2010-08-02,32.869998931884766,33.15999984741211,-1.58951390162464,,
2010-07-30,31.8700008392334,32.34000015258789,0.8822662760905514,,
2010-07-29,33.040000915527344,32.349998474121094,1.4747389425101678,,
2010-07-28,33.77000045776367,32.70000076293945,-2.0883850553465915,,
2010-07-27,34.04999923706055,33.939998626708984,-3.16849179840099,,
2010-07-26,31.64999961853028,33.72999954223633,-0.32305613161904606,,
2010-07-23,30.65999984741211,31.40999984741211,6.571879774962966,,
2010-07-22,30.940000534057617,30.8700008392334,2.4461839652073727,,
2010-07-21,31.40999984741211,30.559999465942383,-0.22624335363913667,,
2010-07-20,31.3799991607666,31.13999938964844,-2.7061457675866833,,
2010-07-19,32.5,31.75,-0.7648176467073475,,
2010-07-16,33.959999084472656,33.279998779296875,-2.307692307692308,,
2010-07-15,34.0099983215332,34.22999954223633,-2.002356665217621,,
2010-07-14,34.630001068115234,33.970001220703125,0.6468721892403997,,
2010-07-13,34.310001373291016,34.63999938964844,-1.9058614699835768,,
2010-07-12,33.459999084472656,33.869998931884766,0.9618128917194166,,
2010-07-09,31.920000076293945,33.459999084472656,1.225343271459839,,
2010-07-08,31.020000457763672,31.71999931335449,4.824558284767748,,
2010-07-07,29.88999938964844,30.690000534057617,2.2566049170241755,,
2010-07-06,30.270000457763672,29.670000076293945,2.67648431162643,,
2010-07-02,29.8799991607666,29.90999984741211,-1.9821617852530888,,
2010-07-01,30.979999542236328,29.809999465942383,0.10040390725612762,,
2010-06-30,30.86000061035156,31.11000061035156,-3.7766303859973767,,
2010-06-29,31.670000076293945,30.950000762939453,0.810110158961374,,
2010-06-28,32.75,32.189998626708984,-2.273442726933985,,
2010-06-25,32.09000015258789,32.7400016784668,-1.709927857377147,,
2010-06-24,32.290000915527344,32.040000915527344,2.0255578771833913,,
2010-06-23,32.29999923706055,32.52000045776367,-0.7742334868742048,,
2010-06-22,32.630001068115234,32.43000030517578,0.6811183464385312,,
2010-06-21,33.810001373291016,32.560001373291016,-0.6129352019387032,,
2010-06-18,32.68000030517578,33.400001525878906,-3.6971308761539006,,
2010-06-17,32.869998931884766,32.43000030517578,2.2031860892886614,,
2010-06-16,33.06999969482422,32.86000061035156,-1.3386024977389765,,
2010-06-15,33.11000061035156,33.369998931884766,-0.6350138687951762,,
2010-06-14,33.68000030517578,32.97999954223633,0.785256166536937,,
2010-06-11,32.02000045776367,33.560001373291016,-2.078387044527076,,
2010-06-10,32.040000915527344,32.349998474121094,4.809496856687115,,
2010-06-09,32.04999923706055,31.61000061035156,0.9675329267656727,,
2010-06-08,33.43000030517578,31.75,-1.372850662037464,,
2010-06-07,35.04999923706055,33.38999938964844,-5.025427130838752,,
2010-06-04,36.5099983215332,35.02000045776367,-4.73609096589334,,
2010-06-03,36.56999969482422,37.7400016784668,-4.081068014979191,,
2010-06-02,35.25,36.70000076293945,3.1993491752972845,,
2010-06-01,34.08000183105469,35.119998931884766,4.1134773416722075,,
2010-05-28,34.02000045776367,34.380001068115234,3.051634521575649,,
2010-05-27,33.470001220703125,34.189998626708984,1.0582028380584783,,
2010-05-26,33.68000030517578,33.04999923706055,2.151172332675326,,
2010-05-25,32.599998474121094,33.40999984741211,-1.8705494727041878,,
2010-05-24,34.40999984741211,33.45000076293945,2.4846669055338153,,
2010-05-21,33.79999923706055,34.59000015258789,-2.7898840125826254,,
2010-05-20,35.529998779296875,34.18000030517578,2.3372808679271646,,
2010-05-19,35.97999954223633,36.09999847412109,-3.7996018027102494,,
2010-05-18,36.93999862670898,36.11000061035156,0.3335156570635688,,
2010-05-17,37.29999923706055,36.63999938964844,-2.2468815571565717,,
2010-05-14,37.040000915527344,37.09000015258789,-1.769436624428524,,
2010-05-13,37.709999084472656,37.27000045776367,0.1349871377556769,,
2010-05-12,36.5,37.869998931884766,-1.1667956441032021,,
2010-05-11,35.75,36.290000915527344,3.7534217311911386,,
2010-05-10,35.22999954223633,36.02000045776367,1.5104920714051573,,
2010-05-07,35.939998626708984,34.459999084472656,2.2424096673070695,,
2010-05-06,38.0,36.15999984741211,-4.117973285442641,,
2010-05-05,37.84000015258789,38.290000915527344,-4.842105664704975,,
2010-05-04,38.720001220703125,38.77000045776367,1.1892197704145024,,
2010-05-03,39.02000045776367,39.70000076293945,0.1291302569324633,,
2010-04-30,39.369998931884766,38.75,1.7426968149624509,,
2010-04-29,39.95000076293945,39.56999969482422,-1.5748004793128003,,
2010-04-28,38.34999847412109,38.88999938964844,-0.9511916416976672,,
2010-04-27,38.59000015258789,38.290000915527344,1.4080858853012685,,
2010-04-26,38.45000076293945,38.58000183105469,-0.7774014922890032,,
2010-04-23,38.880001068115234,38.40999984741211,0.33810420165332644,,
2010-04-22,38.150001525878906,38.84000015258789,-1.208850843084375,,
2010-04-21,38.34999847412109,38.220001220703125,1.808646393476358,,
2010-04-20,37.22999954223633,38.369998931884766,-0.33897590245195164,,
2010-04-19,37.84000015258789,37.18999862670898,3.062045134744474,,
2010-04-16,38.560001373291016,37.84999847412109,-1.7177630107236126,,
2010-04-15,38.97999954223633,38.4900016784668,-1.8412937600715953,,
2010-04-14,35.459999084472656,37.900001525878906,-1.2570494343864722,,
2010-04-13,34.90999984741211,35.20000076293945,6.88099973041084,,
2010-04-12,35.33000183105469,35.0,0.8307101598249982,,
2010-04-09,35.84000015258789,35.33000183105469,-0.934055516421229,,
2010-04-08,36.0,35.7400016784668,-1.4229863821481534,,
2010-04-07,36.45000076293945,36.02000045776367,-0.7222175598144531,,
2010-04-06,36.11000061035156,36.56999969482422,-1.1796990292877694,,
2010-04-05,34.5,36.150001525878906,1.2738827934020844,,
2010-04-01,34.380001068115234,34.349998474121094,4.782613118489584,,
2010-03-31,35.0,34.20000076293945,-0.08726757726009987,,
2010-03-30,36.02000045776367,35.029998779296875,-2.285712105887277,,
2010-03-29,35.869998931884766,35.95000076293945,-2.7484776954060646,,
2010-03-26,36.0,35.900001525878906,0.2230327110034398,,
2010-03-25,35.5,35.93000030517578,-0.2777735392252604,,
2010-03-24,35.5,35.43000030517578,1.2112684652838908,,
2010-03-23,35.58000183105469,35.630001068115234,-0.19718223894146128,,
2010-03-22,34.72999954223633,35.58000183105469,0.14052623520920365,,
2010-03-19,34.84000015258789,34.84000015258789,2.4474583933830547,,
2010-03-18,35.849998474121094,35.290000915527344,0.0,,
2010-03-17,36.11000061035156,35.86000061035156,-1.5620574126327882,,
2010-03-16,35.63999938964844,36.11000061035156,-0.6923289830361652,,
2010-03-15,35.7400016784668,35.470001220703125,1.3187464330867409,,
2010-03-12,36.09999847412109,35.869998931884766,-0.7554573169657852,,
2010-03-11,34.5,36.2599983215332,-0.6371178724597459,,
2010-03-10,33.90999984741211,34.4900016784668,5.101444410241168,,
2010-03-09,33.31999969482422,33.810001373291016,1.7104153160264646,,
2010-03-08,32.83000183105469,33.209999084472656,1.4705932861785458,,
2010-03-05,32.11000061035156,33.029998779296875,1.157469485909441,,
2010-03-04,33.31999969482422,32.099998474121094,2.865145286383848,,
2010-03-03,32.400001525878906,33.27000045776367,-3.661468282944296,,
2010-03-02,32.279998779296875,32.27000045776367,2.685181762074517,,
2010-03-01,30.170000076293945,32.31999969482422,-0.030973735784697913,,
2010-02-26,30.3700008392334,30.18000030517578,7.126283106043589,,
2010-02-25,30.32999992370605,30.25,-0.6256191267935876,,
2010-02-24,30.770000457763672,30.670000076293945,-0.26376499804578923,,
2010-02-23,31.68000030517578,30.799999237060547,-0.3249931101138322,,
2010-02-22,31.75,31.770000457763672,-2.777781122595073,,
2010-02-19,31.93000030517578,31.709999084472656,0.06299356775959646,,
2010-02-18,31.209999084472656,31.940000534057617,-0.6890110197320083,,
2010-02-17,31.34000015258789,31.90999984741211,2.3389986254377857,,
2010-02-16,31.3700008392334,31.299999237060547,1.8187609829260043,,
2010-02-12,30.479999542236328,31.309999465942383,-0.2231482317504529,,
2010-02-11,29.799999237060547,30.57999992370605,2.7230969034494854,,
2010-02-10,29.920000076293945,29.76000022888184,2.617452035621069,,
2010-02-09,30.18000030517578,29.989999771118164,-0.5347588469388944,,
2010-02-08,30.51000022888184,29.920000076293945,-0.6295577605578508,,
2010-02-05,30.51000022888184,30.6200008392334,-1.9337926848960796,,
2010-02-04,30.51000022888184,30.6299991607666,0.36053952647115517,,
2010-02-03,30.51000022888184,31.0,0.39331016383004436,,
2010-02-02,29.729999542236328,30.420000076293945,1.6060300473361173,,
2010-02-01,28.059999465942383,29.09000015258789,2.3208898240222258,,
2010-01-29,27.25,27.979999542236328,3.6707081477163372,,
2010-01-28,28.26000022888184,27.559999465942383,2.6788974027021215,,
2010-01-27,27.440000534057617,28.31999969482422,-2.47700197193931,,
2010-01-26,27.790000915527344,27.479999542236328,3.206993963700459,,
2010-01-25,28.25,27.96999931335449,-1.1155140808858555,,
2010-01-22,25.709999084472656,28.1200008392334,-0.991152873081456,,
2010-01-21,25.530000686645508,25.6200008392334,9.373791678647873,,
2010-01-20,25.84000015258789,25.5,0.3525270276822547,,
2010-01-19,25.40999984741211,26.020000457763672,-1.3157900564247458,,
2010-01-15,26.06999969482422,25.26000022888184,2.400632089786054,,
2010-01-14,25.790000915527344,25.950000762939453,-3.107017550534117,,
2010-01-13,26.290000915527344,25.959999084472656,0.6203948884537593,,
2010-01-12,26.06999969482422,26.3700008392334,-1.2552370466437777,,
2010-01-11,26.40999984741211,26.239999771118164,1.1507523894169438,,
2010-01-08,25.690000534057617,26.270000457763672,-0.6436958624617465,,
2010-01-07,26.020000457763672,25.690000534057617,2.2576874723577376,,
2010-01-06,26.0,25.950000762939453,-1.26825487279187,,
2010-01-05,25.51000022888184,25.979999542236328,-0.1923047579251803,,
2010-01-04,25.440000534057617,25.450000762939453,1.842412031115414,,
2009-12-31,25.540000915527344,25.200000762939453,0.039309074968171494,,
2009-12-30,25.270000457763672,25.5,-1.3312456554423362,,
2009-12-29,25.61000061035156,25.39999961853028,0.9101683342695217,,
2009-12-28,25.89999961853028,25.5,-0.8199960437970315,,
2009-12-24,25.700000762939453,25.82999992370605,-1.544400094292275,,
2009-12-23,25.350000381469727,25.6299991607666,0.5058332953595184,,
2009-12-22,25.25,25.34000015258789,1.104531657133811,,
2009-12-21,25.100000381469727,25.200000762939453,0.3564362478728341,,
2009-12-18,24.5,25.059999465942383,0.39840788824669754,,
2009-12-17,24.200000762939453,24.290000915527344,2.285712105887277,,
2009-12-16,24.21999931335449,24.270000457763672,0.3719014452500321,,
2009-12-15,24.290000915527344,24.14999961853028,0.20644568879741246,,
2009-12-14,24.3799991607666,24.39999961853028,-0.5763741939901188,,
2009-12-11,24.190000534057617,24.21999931335449,0.08203633491450084,,
2009-12-10,23.8799991607666,24.190000534057617,0.12401314028346352,,
2009-12-09,24.01000022888184,23.790000915527344,1.2981632503586062,,
2009-12-08,24.15999984741211,23.93000030517578,-0.9162820127334137,,
2009-12-07,24.3799991607666,24.18000030517578,-0.951984866262176,,
2009-12-04,24.31999969482422,24.309999465942383,-0.8203398788982222,,
2009-12-03,24.82999992370605,24.01000022888184,-0.04111936269458172,,
2009-12-02,24.5,24.75,-3.3024554866845968,,
2009-12-01,24.239999771118164,24.600000381469727,1.0204081632653061,,
2009-11-30,24.1299991607666,24.07999992370605,1.485151046826747,,
2009-11-27,23.809999465942383,24.1299991607666,-0.20720778615626761,,
2009-11-25,24.290000915527344,24.3700008392334,1.3439718689701927,,
2009-11-24,24.270000457763672,24.299999237060547,0.32935331696473863,,
2009-11-23,24.14999961853028,24.26000022888184,0.1236043623034987,,
2009-11-20,23.479999542236328,23.89999961853028,0.455489076973548,,
2009-11-19,23.81999969482422,23.64999961853028,1.7887567482207452,,
2009-11-18,24.34000015258789,23.90999984741211,-0.7136863076067841,,
2009-11-17,23.76000022888184,24.280000686645508,-1.766640519638873,,
2009-11-16,23.600000381469727,23.89999961853028,2.1885540940844503,,
2009-11-13,23.559999465942383,23.420000076293945,1.2711831873363344,,
2009-11-12,23.96999931335449,23.540000915527344,-0.5942249270880348,,
2009-11-11,24.100000381469727,24.1200008392334,-1.793902420295767,,
2009-11-10,23.82999992370605,24.0,0.08298944998793463,,
2009-11-09,23.780000686645508,23.979999542236328,0.7133868100638684,,
2009-11-06,23.420000076293945,23.780000686645508,0.8410380564166117,,
2009-11-05,22.770000457763672,23.459999084472656,1.5371503380820233,,
2009-11-04,22.86000061035156,22.75,3.0302969382406055,,
2009-11-03,21.989999771118164,22.770000457763672,-0.4811925083752973,,
2009-11-02,21.93000030517578,21.989999771118164,3.5470700080223136,,
2009-10-30,22.32999992370605,21.729999542236328,0.27359537212693114,,
2009-10-29,21.989999771118164,22.549999237060547,-2.686969921718399,,
2009-10-28,22.61000061035156,21.959999084472656,2.5466096942751695,,
2009-10-27,22.770000457763672,22.700000762939453,-2.8748408152687617,,
2009-10-26,23.299999237060547,22.770000457763672,-0.3074207001183947,,
2009-10-23,23.790000915527344,23.299999237060547,-2.2746729470010827,,
2009-10-22,23.59000015258789,23.809999465942383,-2.0596959210160466,,
2009-10-21,23.700000762939453,23.68000030517578,0.9325956419307511,,
2009-10-20,24.450000762939453,23.670000076293945,-0.08439011442964724,,
2009-10-19,24.8799991607666,24.459999084472656,-3.190186757899036,,
2009-10-16,24.459999084472656,24.89999961853028,-1.6881032574801915,,
2009-10-15,25.06999969482422,24.64999961853028,1.798857524638826,,
2009-10-14,16.739999771118164,16.739999771118164,-1.6753094591407138,,
2009-10-13,17.239999771118164,16.739999771118164,0.0,,
2009-10-12,17.850000381469727,17.229999542236328,-2.9002320570655704,,
2009-10-09,20.200000762939453,17.520000457763672,-3.473393983100571,,
2009-10-08,23.1299991607666,22.280000686645508,-13.267327742347046,,
2009-10-07,22.920000076293945,22.950000762939453,-3.6748746431555084,,
2009-10-06,22.739999771118164,22.920000076293945,0.13089304775586535,,
2009-10-05,22.81999969482422,22.57999992370605,0.7915580782212572,,
2009-10-02,22.01000022888184,22.6299991607666,-1.05170803824595,,
2009-10-01,23.13999938964844,22.26000022888184,2.8168965262944,,
2009-09-30,23.6200008392334,23.280000686645508,-3.802935107942417,,
2009-09-29,23.790000915527344,23.600000381469727,-1.4394586812340076,,
2009-09-28,23.57999992370605,23.809999465942383,-0.7986571111630641,,
2009-09-25,23.64999961853028,23.559999465942383,0.975400945634027,,
2009-09-24,24.239999771118164,23.770000457763672,-0.38055033420542084,,
2009-09-23,24.34000015258789,24.239999771118164,-1.9389410800015519,,
2009-09-22,24.59000015258789,24.38999938964844,-0.41084790814635336,,
2009-09-21,24.68000030517578,24.479999542236328,-0.8133418531858008,,
2009-09-18,24.93000030517578,24.670000076293945,-0.8103758527811277,,
2009-09-17,25.040000915527344,25.049999237060547,-1.0429210818254848,,
2009-09-16,25.200000762939453,25.14999961853028,0.03992939763433934,,
2009-09-15,24.049999237060547,25.06999969482422,-0.19841723371178266,,
2009-09-14,23.440000534057617,24.200000762939453,4.2411662790902405,,
2009-09-11,22.89999961853028,23.489999771118164,3.2423217216978233,,
2009-09-10,21.75,22.809999465942383,2.5764199232146083,,
2009-09-09,21.670000076293945,21.65999984741211,4.873560762953484,,
2009-09-08,21.88999938964844,21.61000061035156,-0.046147802707097174,,
2009-09-04,21.59000015258789,21.700000762939453,-1.279117346295088,,
2009-09-03,21.57999992370605,21.520000457763672,0.5094979600469213,,
2009-09-02,22.0,21.40999984741211,-0.2780327439967628,,
2009-09-01,22.38999938964844,22.09000015258789,-2.681818875399503,,
2009-08-31,22.600000381469727,22.6200008392334,-1.339880505754944,,
2009-08-28,23.290000915527344,22.68000030517578,0.08849759923044391,,
2009-08-27,22.739999771118164,23.1200008392334,-2.619152367421668,,
2009-08-26,21.920000076293945,22.59000015258789,1.6710689179419858,,
2009-08-25,23.040000915527344,22.0,3.0565696804834293,,
2009-08-24,23.63999938964844,22.96999931335449,-4.513892683165894,,
2009-08-21,23.709999084472656,23.61000061035156,-2.834179752928988,,
2009-08-20,23.809999465942383,23.479999542236328,-0.4217565499046556,,
2009-08-19,23.299999237060547,23.920000076293945,-1.385971991213539,,
2009-08-18,23.290000915527344,23.600000381469727,2.6609478949992265,,
2009-08-17,23.270000457763672,23.1299991607666,1.3310410208516028,,
2009-08-14,24.059999465942383,23.6299991607666,-0.6016385657197574,,
2009-08-13,23.799999237060547,24.020000457763672,-1.78719997805677,,
2009-08-12,23.31999969482422,23.6299991607666,0.9243749065359069,,
2009-08-11,23.290000915527344,23.229999542236328,1.3293287735813561,,
2009-08-10,23.600000381469727,23.450000762939453,-0.25762718305010013,,
2009-08-07,23.299999237060547,23.790000915527344,-0.6355915936681522,,
2009-08-06,23.93000030517578,23.0,2.1030115644270464,,
2009-08-05,24.850000381469727,23.780000686645508,-3.8863363698939573,,
2009-08-04,23.440000534057617,24.01000022888184,-4.305833715890409,,
2009-08-03,25.670000076293945,25.850000381469727,2.431739256985211,,
2009-07-31,25.170000076293945,25.26000022888184,0.7012088221301184,,
2009-07-30,26.309999465942383,25.200000762939453,0.3575691391143845,,
2009-07-29,26.420000076293945,25.989999771118164,-4.218923320161197,,
2009-07-28,26.13999938964844,26.65999984741211,-1.6275560330584957,,
2009-07-27,25.959999084472656,26.350000381469727,1.989290244473345,,
2009-07-24,25.31999969482422,26.06999969482422,1.502316297192553,,
2009-07-23,24.09000015258789,25.479999542236328,2.9620853437581642,,
2009-07-22,23.84000015258789,23.93000030517578,5.770026487522108,,
2009-07-21,23.420000076293945,24.0,0.37751741615706697,,
2009-07-20,23.559999465942383,23.26000022888184,2.476515464631184,,
2009-07-17,23.89999961853028,23.39999961853028,-1.2733414425336174,,
2009-07-16,23.290000915527344,23.8700008392334,-2.092050242596394,,
2009-07-15,23.559999465942383,23.450000762939453,2.4903387758966176,,
2009-07-14,23.40999984741211,23.26000022888184,-0.46688754455169007,,
2009-07-13,23.420000076293945,23.489999771118164,-0.6407501901237808,,
2009-07-10,23.31999969482422,23.420000076293945,0.2988885337155632,,
2009-07-09,23.530000686645508,23.40999984741211,0.4288181079690204,,
2009-07-08,24.0,23.299999237060547,-0.5099908020891182,,
2009-07-07,24.239999771118164,24.100000381469727,-2.9166698455810547,,
2009-07-06,23.84000015258789,24.15999984741211,-0.5775552432770484,,
2009-07-02,24.89999961853028,23.739999771118164,1.342280590503612,,
2009-07-01,25.64999961853028,23.989999771118164,-4.65863399672046,,
2009-06-30,27.93000030517578,28.190000534057617,-6.471734394151358,,
2009-06-29,28.0,27.64999961853028,0.9308994845719877,,
2009-06-26,27.56999969482422,27.950000762939453,-1.250001362391855,,
2009-06-25,26.36000061035156,27.459999084472656,1.3783136464327668,,
2009-06-24,25.93000030517578,26.36000061035156,4.172983492607084,,
2009-06-23,25.65999984741211,25.850000381469727,1.6583119942730855,,
2009-06-22,26.0,25.450000762939453,0.7404541511592384,,
2009-06-19,26.280000686645508,26.049999237060547,-2.1153816810021033,,
2009-06-18,25.450000762939453,25.950000762939453,-0.8751957518092414,,
2009-06-17,25.5,25.450000762939453,1.964636483343863,,
2009-06-16,25.65999984741211,25.549999237060547,-0.196075439453125,,
2009-06-15,25.770000457763672,26.530000686645508,-0.4286851559067971,,
2009-06-12,25.39999961853028,25.530000686645508,2.9491665323307057,,
2009-06-11,24.989999771118164,25.46999931335449,0.5118152364868008,,
2009-06-10,25.6200008392334,24.8700008392334,1.920766493127692,,
2009-06-09,26.100000381469727,25.63999938964844,-2.9274003724913285,,
2009-06-08,25.690000534057617,26.01000022888184,-1.7624558816017237,,
2009-06-05,26.1299991607666,25.959999084472656,1.245619650338247,,
2009-06-04,25.959999084472656,26.040000915527344,-0.6505935007804947,,
2009-06-03,25.75,25.979999542236328,0.30817347409899815,,
2009-06-02,25.270000457763672,25.799999237060547,0.8932021057721481,,
2009-06-01,25.0,25.43000030517578,2.0973437661100007,,
2009-05-29,24.39999961853028,24.63999938964844,1.720001220703125,,
2009-05-28,24.56999969482422,24.280000686645508,0.9836056347144188,,
2009-05-27,24.82999992370605,24.56999969482422,-1.1802971582445747,,
2009-05-26,23.520000457763672,24.8700008392334,-1.0471213438611462,,
2009-05-22,23.90999984741211,23.75,5.7397974285502515,,
2009-05-21,23.38999938964844,23.32999992370605,-0.6691754430497284,,
2009-05-20,23.700000762939453,23.670000076293945,-0.2565176037111976,,
2009-05-19,23.64999961853028,23.63999938964844,-0.12658517164447086,,
2009-05-18,23.3700008392334,23.700000762939453,-0.04228426656719308,,
2009-05-15,22.559999465942383,23.229999542236328,1.4120663750771163,,
2009-05-14,22.450000762939453,22.520000457763672,2.9698585645155196,,
2009-05-13,22.530000686645508,22.309999465942383,0.31180263895480353,,
2009-05-12,23.1299991607666,22.739999771118164,-0.9764811983939667,,
2009-05-11,22.89999961853028,22.93000030517578,-1.686119341975418,,
2009-05-08,23.600000381469727,23.25,0.13100736744652464,,
2009-05-07,22.51000022888184,23.200000762939453,-1.4830524398827563,,
2009-05-06,24.020000457763672,22.809999465942383,3.0653066505627873,,
2009-05-05,19.3799991607666,19.5,-5.037472809165564,,
2009-05-04,20.0,19.459999084472656,0.6191994036631921,,
2009-05-01,19.89999961853028,19.770000457763672,-2.7000045776367188,,
2009-04-30,19.729999542236328,19.82999992370605,-0.6532621269276677,,
2009-04-29,20.440000534057617,20.739999771118164,0.5068443172319927,,
2009-04-28,20.71999931335449,20.350000381469727,1.467706600891135,,
2009-04-27,20.700000762939453,20.96999931335449,-1.7857091898950486,,
2009-04-24,21.93000030517578,21.68000030517578,1.3043407751869813,,
2009-04-23,22.0,21.88999938964844,-1.1399908642089558,,
2009-04-22,18.25,18.34000015258789,-0.500002774325268,,
2009-04-21,18.13999938964844,18.559999465942383,0.4931515210295377,,
2009-04-20,18.420000076293945,18.14999961853028,2.31532574655771,,
2009-04-17,18.76000022888184,18.84000015258789,-1.465800524676155,,
2009-04-16,18.440000534057617,18.700000762939453,0.426438820522442,,
2009-04-15,18.559999465942383,18.229999542236328,1.4099795084150377,,
2009-04-14,18.799999237060547,18.65999984741211,-1.778016881474619,,
2009-04-13,18.280000686645508,18.670000076293945,-0.7446776347333882,,
2009-04-09,18.600000381469727,18.450000762939453,2.133475793211279,,
2009-04-08,17.950000762939453,18.3700008392334,-0.8064495454511428,,
2009-04-07,18.64999961853028,18.09000015258789,2.3398331946653745,,
2009-04-06,19.46999931335449,18.850000381469727,-3.0026781629849753,,
2009-04-03,20.700000762939453,19.690000534057617,-3.1843808615827958,,
2009-04-02,20.850000381469727,20.780000686645508,-4.879227979015849,,
2009-04-01,19.76000022888184,20.440000534057617,-0.33572994505280884,,
2009-03-31,20.15999984741211,19.809999465942383,3.4412970511096845,,
2009-03-30,24.59000015258789,24.89999961853028,-1.7361130164624248,,
2009-03-27,25.959999084472656,25.11000061035156,1.26067289149555,,
2009-03-26,25.8700008392334,26.270000457763672,-3.2742623424416966,,
2009-03-25,26.09000015258789,25.81999969482422,1.546190976243225,,
2009-03-24,26.700000762939453,25.81999969482422,-1.0348810125893781,,
2009-03-23,26.75,26.96999931335449,-3.2958840560660474,,
2009-03-20,25.18000030517578,26.81999969482422,0.8224273396429482,,
2009-03-19,25.780000686645508,25.229999542236328,6.513103136505259,,
2009-03-18,25.36000061035156,25.68000030517578,-2.133441155003886,,
2009-03-17,24.959999084472656,25.38999938964844,1.2618284192532843,,
2009-03-16,25.93000030517578,24.89999961853028,1.7227576961061801,,
2009-03-13,26.200000762939453,25.84000015258789,-3.9722355361480908,,
2009-03-12,24.8700008392334,26.0,-1.374048091100792,,
2009-03-11,24.8700008392334,24.850000381469727,4.54362333186569,,
2009-03-10,23.440000534057617,24.65999984741211,-0.08042001241962313,,
2009-03-09,22.979999542236328,23.01000022888184,5.204775109035812,,
2009-03-06,21.290000915527344,23.440000534057617,0.13055129348619565,,
2009-03-05,21.32999992370605,21.13999938964844,10.098635632101939,,
2009-03-04,21.290000915527344,21.71999931335449,-0.8907666888758141,,
2009-03-03,20.850000381469727,20.940000534057617,2.0197199593051027,,
2009-03-02,21.790000915527344,20.59000015258789,0.4316554001978703,,
2009-02-27,23.3799991607666,22.0,-5.507116624691577,,
2009-02-26,24.14999961853028,23.81999969482422,-5.902477375116181,,
2009-02-25,25.38999938964844,24.190000534057617,-1.3664593329966475,,
2009-02-24,21.209999084472656,25.61000061035156,-4.72626579140473,,
2009-02-23,21.850000381469727,21.459999084472656,20.74493972562234,,
2009-02-20,22.18000030517578,21.6200008392334,-1.7849029299231396,,
2009-02-19,23.040000915527344,22.56999969482422,-2.524794671944639,,
2009-02-18,23.670000076293945,22.86000061035156,-2.0399357726864373,,
2009-02-17,23.709999084472656,23.530000686645508,-3.4220509646454107,,
2009-02-13,24.63999938964844,24.61000061035156,-0.7591666165226756,,
2009-02-12,23.920000076293945,24.63999938964844,-0.12174829561678055,,
2009-02-11,23.540000915527344,24.229999542236328,3.010030564623849,,
2009-02-10,24.14999961853028,23.489999771118164,2.931175020702105,,
2009-02-09,24.450000762939453,24.209999084472656,-2.7329186659932656,,
2009-02-06,23.979999542236328,24.61000061035156,-0.9816019262894417,,
2009-02-05,23.36000061035156,23.989999771118164,2.6271938287805243,,
2009-02-04,23.770000457763672,23.489999771118164,2.6969141451453233,,
2009-02-03,23.739999771118164,23.75,-1.1779582719951316,,
2009-02-02,24.170000076293945,23.63999938964844,0.04212396368260336,,
2009-01-30,24.84000015258789,24.530000686645508,-2.192803826944674,,
2009-01-29,24.979999542236328,24.549999237060547,-1.2479849598957684,,
2009-01-28,25.5,25.229999542236328,-1.721378354906429,,
2009-01-27,25.09000015258789,25.1200008392334,-1.0588253245634192,,
2009-01-26,24.63999938964844,25.07999992370605,0.11957228562397362,,
2009-01-23,23.46999931335449,24.68000030517578,1.7857164973894422,,
2009-01-22,23.209999084472656,24.309999465942383,5.155522058889874,,
2009-01-21,22.5,23.690000534057617,4.739338323393644,,
2009-01-20,23.36000061035156,22.1200008392334,5.288891262478298,,
2009-01-16,24.280000686645508,23.57999992370605,-5.3082180595863395,,
2009-01-15,24.479999542236328,24.1299991607666,-2.88303436220441,,
2009-01-14,22.559999465942383,24.46999931335449,-1.4297401471182907,,
2009-01-13,21.6299991607666,22.90999984741211,8.466311580793828,,
2009-01-12,22.81999969482422,21.709999084472656,5.917710292690287,,
2009-01-09,21.989999771118164,22.920000076293945,-4.864156990340892,,
2009-01-08,21.920000076293945,21.920000076293945,4.229196520489513,,
2009-01-07,21.489999771118164,22.209999084472656,0.0,,
2009-01-06,21.36000061035156,21.89999961853028,3.350392373303545,,
2009-01-05,20.530000686645508,21.09000015258789,2.5280851720436064,,
2009-01-02,20.520000457763672,20.440000534057617,2.7277128456535076,,
2008-12-31,20.450000762939453,20.51000022888184,-0.38986316725829795,,
2008-12-30,19.64999961853028,20.3700008392334,0.2933959105327785,,
2008-12-29,20.100000381469727,19.43000030517578,3.664128420766709,,
2008-12-26,19.549999237060547,20.15999984741211,-3.333333649643216,,
2008-12-24,19.549999237060547,19.5,3.120207847349663,,
2008-12-23,19.350000381469727,19.18000030517578,-0.25575058318040395,,
2008-12-22,20.049999237060547,19.32999992370605,-0.8785533485402082,,
2008-12-19,20.15999984741211,20.049999237060547,-3.591019155869315,,
2008-12-18,18.0,19.68000030517578,-0.5456379523022814,,
2008-12-17,16.84000015258789,17.610000610351562,9.33333502875434,,
2008-12-16,16.18000030517578,17.010000228881836,4.572449232699928,,
2008-12-15,16.280000686645508,15.859999656677246,5.1297892957427695,,
2008-12-12,15.880000114440918,16.270000457763672,-2.5798587976276237,,
2008-12-11,16.399999618530273,16.290000915527344,2.4559215397492116,,
2008-12-10,16.399999618530273,16.579999923706055,-0.6707238143996218,,
2008-12-09,16.34000015258789,16.200000762939453,1.097562861967386,,
2008-12-08,16.329999923706055,16.489999771118164,-0.8567894023321948,,
2008-12-05,15.289999961853027,15.960000038146973,0.9797908644190476,,
2008-12-04,16.1299991607666,15.539999961853027,4.381949496177413,,
2008-12-03,15.9399995803833,16.360000610351562,-3.657775757041848,,
2008-12-02,15.56999969482422,16.200000762939453,2.6348873339064554,,
2008-12-01,18.0,15.4399995803833,4.046249713958938,,
2008-11-28,17.81999969482422,18.1200008392334,-14.222224553426107,,
2008-11-26,16.510000228881836,18.020000457763672,1.6835081343818115,,
2008-11-25,16.270000457763672,16.739999771118164,9.145973397627886,,
2008-11-24,16.110000610351562,15.93000030517578,2.8887480032627733,,
2008-11-21,15.609999656677246,16.06999969482422,-1.11732028774799,,
2008-11-20,15.619999885559082,15.399999618530272,2.9468292649846766,,
2008-11-19,17.270000457763672,15.699999809265137,-1.4084524240759044,,
2008-11-18,18.15999984741211,17.309999465942383,-9.09091260500081,,
2008-11-17,17.920000076293945,18.14999961853028,-4.6806188800208375,,
2008-11-14,18.75,18.020000457763672,1.2834795829080248,,
2008-11-13,18.190000534057617,19.06999969482422,-3.8933308919270835,,
2008-11-12,18.280000686645508,18.1299991607666,4.837818223913495,,
2008-11-11,19.11000061035156,18.450000762939453,-0.8205772442256535,,
2008-11-10,20.56999969482422,19.170000076293945,-3.453688259196576,,
2008-11-07,20.200000762939453,20.14999961853028,-6.806026442880982,,
2008-11-06,20.64999961853028,19.979999542236328,-0.24753040851814573,,
2008-11-05,21.51000022888184,20.709999084472656,-3.244552487510594,,
2008-11-04,21.93000030517578,21.799999237060547,-3.7192056527038444,,
2008-11-03,21.1299991607666,21.420000076293945,-0.5928001199550934,,
2008-10-31,19.90999984741211,20.39999961853028,1.3724606107216828,,
2008-10-30,18.850000381469727,19.979999542236328,2.4610737060445587,,
2008-10-29,18.0,18.3799991607666,5.994690386730358,,
2008-10-28,16.170000076293945,17.850000381469727,2.111106448703342,,
2008-10-27,16.90999984741211,15.890000343322754,10.389612227885813,,
2008-10-24,16.399999618530273,17.170000076293945,-6.031930888783865,,
2008-10-23,18.0,17.639999389648438,4.6951248516716575,,
2008-10-22,18.06999969482422,18.049999237060547,-2.000003390842014,,
2008-10-21,19.309999465942383,18.3700008392334,-0.11068322136939823,,
2008-10-20,18.82999992370605,19.530000686645508,-4.867937093249991,,
2008-10-17,17.25,18.420000076293945,3.7174761857443763,,
2008-10-16,16.84000015258789,17.950000762939453,6.782609137935915,,
2008-10-15,18.270000457763672,16.770000457763672,6.591452495806438,,
2008-10-14,18.799999237060547,18.459999084472656,-8.210180418263691,,
2008-10-13,17.100000381469727,18.51000022888184,-1.8085115233283964,,
2008-10-10,16.790000915527344,16.40999984741211,8.245612958816348,,
2008-10-09,18.489999771118164,17.280000686645508,-2.263258173880208,,
2008-10-08,18.68000030517578,18.170000076293945,-6.544073009469176,,
2008-10-07,19.059999465942383,18.790000915527344,-2.730193900160307,,
2008-10-06,20.68000030517578,19.06999969482422,-1.416571657819244,,
2008-10-03,21.770000457763672,21.280000686645508,-7.785302643098184,,
2008-10-02,23.06999969482422,21.68000030517578,-2.2508027598291536,,
2008-10-01,23.65999984741211,23.290000915527344,-6.025138309647596,,
2008-09-30,24.63999938964844,23.850000381469727,-1.5638162902407433,,
2008-09-29,25.75,24.39999961853028,-3.206164885339253,,
2008-09-26,25.799999237060547,26.11000061035156,-5.2427199280377454,,
2008-09-25,25.770000457763672,26.100000381469727,1.2015557459618407,,
2008-09-24,26.530000686645508,25.57999992370605,1.2805584704855382,,
2008-09-23,26.81999969482422,26.440000534057617,-3.5808546488943804,,
2008-09-22,27.63999938964844,26.75,-1.4168499816945732,,
2008-09-19,29.420000076293945,28.11000061035156,-3.2199689193255123,,
2008-09-18,27.030000686645508,27.709999084472656,-4.45275140226107,,
2008-09-17,27.93000030517578,26.420000076293945,2.5157172791457225,,
2008-09-16,26.700000762939453,28.270000457763672,-5.406373835957366,,
2008-09-15,27.350000381469727,27.020000457763672,5.8801485017312585,,
2008-09-12,26.8799991607666,27.51000022888184,-1.2065810570505053,,
2008-09-11,28.0,27.030000686645508,2.34375404681847,,
2008-09-10,28.020000457763672,28.15999984741211,-3.464283261980329,,
2008-09-09,29.600000381469727,27.799999237060547,0.4996409256290609,,
2008-09-08,29.88999938964844,29.64999961853028,-6.081084868958385,,
2008-09-05,29.040000915527344,29.559999465942383,-0.8029433791198994,,
2008-09-04,30.299999237060547,29.030000686645508,1.7906285606795624,,
2008-09-03,28.14999961853028,30.43000030517578,-4.1914144633432135,,
2008-09-02,28.540000915527344,28.190000534057617,8.099469689316251,,
2008-08-29,28.1200008392334,28.14999961853028,-1.226350281156813,,
2008-08-28,27.739999771118164,28.14999961853028,0.10668128876805512,,
2008-08-27,27.600000381469727,27.729999542236328,1.4780095558580097,,
2008-08-26,27.8700008392334,27.559999465942383,0.4710114455428822,,
2008-08-25,28.479999542236328,27.75,-1.1123120342882007,,
2008-08-22,28.290000915527344,28.479999542236328,-2.5632006810734893,,
2008-08-21,28.01000022888184,28.200000762939453,0.6716105357377388,,
2008-08-20,28.51000022888184,28.14999961853028,0.6783310692789611,,
2008-08-19,27.96999931335449,28.459999084472656,-1.2627169675953318,,
2008-08-18,27.93000030517578,28.239999771118164,1.7518762357788602,,
2008-08-15,29.059999465942383,27.989999771118164,1.1099157270146396,,
2008-08-14,28.5,28.81999969482422,-3.6820361819972933,,
2008-08-13,29.190000534057617,28.770000457763672,1.1228059467516447,,
2008-08-12,27.84000015258789,28.940000534057617,-1.4388491559083993,,
2008-08-11,26.96999931335449,28.01000022888184,3.9511507738532647,,
2008-08-08,26.86000061035156,27.01000022888184,3.8561399406947077,,
2008-08-07,29.299999237060547,26.770000457763672,0.5584497956879133,,
2008-08-06,30.31999969482422,29.93000030517578,-8.634808345307968,,
2008-08-05,31.21999931335449,30.540000915527344,-1.2862776832910472,,
2008-08-04,33.790000915527344,31.479999542236328,-2.1780858833532153,,
2008-08-01,32.599998474121094,33.880001068115234,-6.83634599201657,,
2008-07-31,31.75,32.810001373291016,3.9263885089143393,,
2008-07-30,34.099998474121094,31.86000061035156,3.3385870024913875,,
2008-07-29,34.77000045776367,33.68000030517578,-6.568908985346426,,
2008-07-28,34.650001525878906,34.70000076293945,-3.1348867938956504,,
2008-07-25,33.959999084472656,34.68000030517578,0.1442979361002456,,
2008-07-24,34.72999954223633,33.59000015258789,2.120144994445324,,
2008-07-23,33.4900016784668,34.52000045776367,-3.2824630137470794,,
2008-07-22,31.979999542236328,33.36000061035156,3.075541139668373,,
2008-07-21,30.940000534057617,31.82999992370605,4.315200399839444,,
2008-07-18,32.650001525878906,30.700000762939453,2.876533207130217,,
2008-07-17,32.689998626708984,32.209999084472656,-5.972436973376102,,
2008-07-16,33.36000061035156,32.4900016784668,-1.468337602939359,,
2008-07-15,32.34000015258789,33.15999984741211,-2.607910419566378,,
2008-07-14,32.900001525878906,32.54999923706055,2.53555872280539,,
2008-07-11,32.63999938964844,32.86000061035156,-1.0638366947887528,,
2008-07-10,32.56999969482422,33.0,0.6740233603463147,,
2008-07-09,32.540000915527344,32.54999923706055,1.320234292922372,,
2008-07-08,31.690000534057617,32.599998474121094,0.03072624846925605,,
2008-07-07,32.59000015258789,31.799999237060547,2.8715617694152167,,
2008-07-03,32.4900016784668,32.33000183105469,-2.424059256914768,,
2008-07-02,33.380001068115234,32.47999954223633,-0.49245872313435896,,
2008-07-01,32.540000915527344,33.36000061035156,-2.696229769562808,,
2008-06-30,33.15999984741211,32.83000183105469,2.5199744061252733,,
2008-06-27,31.700000762939453,33.09000015258789,-0.9951689320745752,,
2008-06-26,31.38999938964844,31.6299991607666,4.384856013232306,,
2008-06-25,31.790000915527344,31.690000534057617,0.7645739910313787,,
2008-06-24,31.0,31.63999938964844,-0.31456551931359933,,
2008-06-23,30.299999237060547,31.15999984741211,2.0645141601562615,,
2008-06-20,30.729999542236328,31.850000381469727,2.838285914211107,,
2008-06-19,30.100000381469727,30.75,3.6446497101115547,,
2008-06-18,30.76000022888184,30.1200008392334,2.159467143829103,,
2008-06-17,30.64999961853028,30.600000381469727,-2.0806221875366537,,
2008-06-16,30.799999237060547,30.82999992370605,-0.16312964986246067,,
2008-06-13,30.90999984741211,30.96999931335449,0.09740482918390951,,
2008-06-12,31.450000762939453,30.559999465942383,0.19411021105974743,,
2008-06-11,30.700000762939453,31.43000030517578,-2.8298927675888774,,
2008-06-10,30.170000076293945,30.84000015258789,2.3778486126865896,,
2008-06-09,30.63999938964844,30.690000534057617,2.220749335762837,,
2008-06-06,31.32999992370605,30.729999542236328,0.16318911685771362,,
2008-06-05,29.600000381469727,31.690000534057617,-1.9150985730316865,,
2008-06-04,29.68000030517578,30.14999961853028,7.0608112353143015,,
2008-06-03,27.88999938964844,30.11000061035156,1.583555621704417,,
2008-06-02,26.1299991607666,28.290000915527344,7.959846788405043,,
2008-05-30,21.25,21.559999465942383,8.266367486164787,,
2008-05-29,21.209999084472656,21.049999237060547,1.4588210161994484,,
2008-05-28,21.479999542236328,21.229999542236328,-0.7543604635477873,,
2008-05-27,21.06999969482422,21.32999992370605,-1.1638733953807707,,
2008-05-23,20.549999237060547,21.01000022888184,1.2339830690443752,,
2008-05-22,20.26000022888184,20.61000061035156,2.2384477318700413,,
2008-05-21,20.76000022888184,20.15999984741211,1.7275438179451403,,
2008-05-20,19.549999237060547,20.670000076293945,-2.890175216062832,,
2008-05-19,19.61000061035156,19.59000015258789,5.728904772079146,,
2008-05-16,19.64999961853028,19.559999465942383,-0.10199111239757255,,
2008-05-15,19.5,19.559999465942383,-0.4580160525958793,,
2008-05-14,18.8700008392334,19.14999961853028,0.3076895689352965,,
2008-05-13,19.25,18.84000015258789,1.4838302429469163,,
2008-05-12,19.459999084472656,19.21999931335449,-2.1298693372057627,,
2008-05-09,19.18000030517578,19.38999938964844,-1.2332979568825675,,
2008-05-08,19.93000030517578,19.76000022888184,1.094885720184222,,
2008-05-07,20.729999542236328,19.89999961853028,-0.8529858188200482,,
2008-05-06,21.049999237060547,20.64999961853028,-4.003858861718567,,
2008-05-05,21.82999992370605,21.200000762939453,-1.9002357863558899,,
2008-05-02,21.700000762939453,21.76000022888184,-2.8859329499239132,,
2008-05-01,21.239999771118164,21.5,0.27649522503638346,,
2008-04-30,22.6299991607666,21.049999237060547,1.2241065521826435,,
2008-04-29,23.07999992370605,22.520000457763672,-6.981882378702357,,
2008-04-28,22.34000015258789,23.030000686645508,-2.426340848325522,,
2008-04-25,22.09000015258789,22.34000015258789,3.088632629117,,
2008-04-24,21.020000457763672,21.959999084472656,1.1317338083889148,,
2008-04-23,21.1200008392334,21.0,4.471924863169063,,
2008-04-22,20.82999992370605,20.809999465942383,-0.5681857692471293,,
2008-04-21,19.71999931335449,20.950000762939453,-0.09601756042690307,,
2008-04-18,20.57999992370605,20.059999465942383,6.237330083231803,,
2008-04-17,20.040000915527344,20.209999084472656,-2.5267272093848803,,
2008-04-16,20.1200008392334,20.170000076293945,0.8482942174598153,,
2008-04-15,19.34000015258789,19.89999961853028,0.2485051440109777,,
2008-04-14,19.26000022888184,19.290000915527344,2.8955504732374897,,
2008-04-11,18.920000076293945,19.200000762939453,0.15576680316190206,,
2008-04-10,18.57999992370605,18.86000061035156,1.4799190566406935,,
2008-04-09,18.950000762939453,18.6200008392334,1.507000472525608,,
2008-04-08,18.21999931335449,19.030000686645508,-1.7414243293933584,,
2008-04-07,18.3799991607666,18.39999961853028,4.445671810192234,,
2008-04-04,18.5,18.299999237060547,0.10881642370458515,,
2008-04-03,18.6200008392334,18.450000762939453,-1.081085205078125,,
2008-04-02,19.209999084472656,18.8700008392334,-0.9129971462500984,,
2008-04-01,17.90999984741211,19.18000030517578,-1.7699024541551212,,
2008-03-31,19.200000762939453,17.950000762939453,7.0910132249229445,,
2008-03-28,19.13999938964844,19.100000381469727,-6.510416407965962,,
2008-03-27,19.93000030517578,19.190000534057617,-0.20898124061773643,,
2008-03-26,20.5,19.81999969482422,-3.712994278911213,,
2008-03-25,20.479999542236328,20.64999961853028,-3.317074659394055,,
2008-03-24,18.90999984741211,20.38999938964844,0.8300785160827652,,
2008-03-20,18.809999465942383,18.8700008392334,7.826544443039084,,
2008-03-19,18.40999984741211,18.40999984741211,0.31898657626043453,,
2008-03-18,18.06999969482422,18.600000381469727,0.0,,
2008-03-17,18.18000030517578,17.459999084472656,2.9330420342913213,,
2008-03-14,20.309999465942383,18.770000457763672,-3.96040268766191,,
2008-03-13,18.61000061035156,20.21999931335449,-7.582467004792977,,
2008-03-12,18.270000457763672,18.790000915527344,8.65125550886543,,
2008-03-11,17.690000534057617,17.979999542236328,2.8461983838796368,,
2008-03-10,18.86000061035156,17.170000076293945,1.63933860612605,,
2008-03-07,19.26000022888184,18.709999084472656,-8.960766062383025,,
2008-03-06,19.71999931335449,19.5,-2.85566530567541,,
2008-03-05,19.940000534057617,19.809999465942383,-1.115615218127842,,
2008-03-04,20.239999771118164,19.700000762939453,-0.6519612067872913,,
2008-03-03,20.5,20.18000030517578,-2.667979319591062,,
2008-02-29,20.6200008392334,20.440000534057617,-1.56097412109375,,
2008-02-28,21.89999961853028,20.82999992370605,-0.8729403387476934,,
2008-02-27,21.88999938964844,21.959999084472656,-4.885843440466862,,
2008-02-26,21.96999931335449,22.030000686645508,0.3197793365737477,,
2008-02-25,22.46999931335449,22.059999465942383,0.2731059406749607,,
2008-02-22,23.51000022888184,22.43000030517578,-1.824654472367663,,
2008-02-21,24.61000061035156,23.38999938964844,-4.593789507408372,,
2008-02-20,23.850000381469727,24.700000762939453,-4.957339254148397,,
2008-02-19,23.8700008392334,24.1299991607666,3.563942842240518,,
2008-02-15,23.36000061035156,23.5,1.0892262773022723,,
2008-02-14,24.440000534057617,23.46999931335449,0.5993124400279463,,
2008-02-13,22.64999961853028,24.700000762939453,-3.9689083449544653,,
2008-02-12,22.040000915527344,21.549999237060547,9.050777831943265,,
2008-02-11,22.93000030517578,21.96999931335449,-2.22323801321436,,
2008-02-08,22.90999984741211,22.93000030517578,-4.1866593067798625,,
2008-02-07,23.739999771118164,22.8700008392334,0.08730012176726884,,
2008-02-06,25.540000915527344,23.43000030517578,-3.664696462816303,,
2008-02-05,26.25,26.32999992370605,-8.26155260264209,,
2008-02-04,26.84000015258789,26.739999771118164,0.30476161411829006,,
2008-02-01,25.559999465942383,26.86000061035156,-0.3725796605857493,,
2008-01-31,25.020000457763672,25.36000061035156,5.086076571094504,,
2008-01-30,25.88999938964844,25.479999542236328,1.3589134547053354,,
2008-01-29,27.0,26.049999237060547,-1.5836224684348297,,
2008-01-28,25.38999938964844,27.280000686645508,-3.518521344220197,,
2008-01-25,22.520000457763672,21.780000686645508,7.443880828794444,,
2008-01-24,23.0,22.309999465942383,-3.2859669452762037,,
2008-01-23,23.549999237060547,23.049999237060547,-3.00000232198964,,
2008-01-22,23.25,23.940000534057617,-2.123142319313335,,
2008-01-18,24.57999992370605,24.31999969482422,2.9677442325058805,,
2008-01-17,22.559999465942383,24.59000015258789,-1.0577714796128885,,
2008-01-16,22.739999771118164,22.440000534057617,8.998230207009051,,
2008-01-15,23.5,22.709999084472656,-1.3192578719441008,,
2008-01-14,25.030000686645508,23.850000381469727,-3.3617060235206115,,
2008-01-11,24.21999931335449,25.25,-4.714343878565525,,
2008-01-10,21.549999237060547,24.420000076293945,4.2526866880528225,,
2008-01-09,21.06999969482422,21.8700008392334,13.31786979508437,,
2008-01-08,20.88999938964844,21.209999084472656,3.796873070699178,,
2008-01-07,20.799999237060547,20.8700008392334,1.5318319970022771,,
2008-01-04,21.459999084472656,20.739999771118164,0.33654617663699576,,
2008-01-03,21.75,21.729999542236328,-3.3550761606296913,,
2008-01-02,21.76000022888184,21.739999771118164,-0.09195612764906609,,
2007-12-31,21.96999931335449,21.959999084472656,-0.09191386743245072,,
2007-12-28,22.43000030517578,22.11000061035156,-0.04551765677914125,,
2007-12-27,22.84000015258789,22.18000030517578,-1.426659342266623,,
2007-12-26,21.3700008392334,22.84000015258789,-2.889666563059668,,
2007-12-24,20.479999542236328,21.549999237060547,6.878798575691704,,
2007-12-21,20.739999771118164,20.39999961853028,5.22460800166297,,
2007-12-20,20.63999938964844,20.39999961853028,-1.6393450161043706,,
2007-12-19,19.739999771118164,20.38999938964844,-1.1627896231359742,,
2007-12-18,19.57999992370605,19.739999771118164,3.292804590004603,,
2007-12-17,19.25,19.3700008392334,0.8171595916014108,,
2007-12-14,18.950000762939453,19.43000030517578,0.6233809830306412,,
2007-12-13,18.780000686645508,19.170000076293945,2.5329790127241787,,
2007-12-12,19.14999961853028,18.700000762939453,2.0766739903570226,,
2007-12-11,20.07999992370605,18.71999931335449,-2.3498635224796094,,
2007-12-10,20.14999961853028,19.989999771118164,-6.7729114318669525,,
2007-12-07,20.770000457763672,20.38999938964844,-0.7940439227848815,,
2007-12-06,19.84000015258789,20.71999931335449,-1.829566970342503,,
2007-12-05,19.209999084472656,19.799999237060547,4.435479606847748,,
2007-12-04,18.6200008392334,18.86000061035156,3.071317963074682,,
2007-12-03,18.670000076293945,18.81999969482422,1.2889353399623236,,
2007-11-30,19.93000030517578,18.709999084472656,0.8034259127868673,,
2007-11-29,19.229999542236328,19.729999542236328,-6.121431018675364,,
2007-11-28,18.43000030517578,19.280000686645508,2.600104066054768,,
2007-11-27,17.360000610351562,18.200000762939453,4.612047571323247,,
2007-11-26,17.209999084472656,17.190000534057617,4.838710386260059,,
2007-11-23,17.59000015258789,17.209999084472656,-0.11620308819819936,,
2007-11-21,17.5,17.5,-2.1603244162526485,,
2007-11-20,17.989999771118164,17.799999237060547,0.0,,
2007-11-19,18.229999542236328,17.920000076293945,-1.0561452833515392,,
2007-11-16,18.15999984741211,18.1200008392334,-1.7004908048634775,,
2007-11-15,18.13999938964844,18.010000228881836,-0.22025885746034846,,
2007-11-14,18.739999771118164,18.239999771118164,-0.7166436887577234,,
2007-11-13,18.51000022888184,18.46999931335449,-2.6680896803990004,,
2007-11-12,18.59000015258789,18.3700008392334,-0.2161043491773487,,
2007-11-09,19.21999931335449,18.56999969482422,-1.1834282493207315,,
2007-11-08,18.8700008392334,19.520000457763672,-3.381891996627885,,
2007-11-07,20.11000061035156,18.959999084472656,3.444618916915109,,
2007-11-06,20.489999771118164,20.440000534057617,-5.718555400177079,,
2007-11-05,20.09000015258789,20.3799991607666,-0.24401775314328544,,
2007-11-02,20.0,20.31999969482422,1.4434992831065496,,
2007-11-01,20.030000686645508,19.700000762939453,1.5999984741210938,,
2007-10-31,20.14999961853028,20.270000457763672,-1.6475282695625353,,
2007-10-30,21.11000061035156,20.1200008392334,0.5955376749637084,,
2007-10-29,20.63999938964844,21.290000915527344,-4.689719291778236,,
2007-10-26,20.540000915527344,20.540000915527344,3.1492322921525733,,
2007-10-25,20.59000015258789,20.5,0.0,,
2007-10-24,20.26000022888184,20.540000915527344,-0.43710612880485483,,
2007-10-23,20.440000534057617,20.5,1.382036937227407,,
2007-10-22,18.89999961853028,20.25,0.2935394538880284,,
2007-10-19,19.8799991607666,18.940000534057617,7.14285930538394,,
2007-10-18,20.46999931335449,19.8799991607666,-4.72836351303315,,
2007-10-17,20.739999771118164,20.530000686645508,-2.882267573907416,,
2007-10-16,19.809999465942383,20.420000076293945,-1.012531758872505,,
2007-10-15,20.07999992370605,19.920000076293945,3.0792560666156694,,
2007-10-12,20.63999938964844,19.989999771118164,-0.7968119921315994,,
2007-10-11,21.5,20.690000534057617,-3.149223051122137,,
2007-10-10,21.450000762939453,21.520000457763672,-3.767439376476199,,
2007-10-09,21.420000076293945,21.40999984741211,0.3263388920021007,,
2007-10-08,21.38999938964844,21.39999961853028,-0.04668640917935123,,
2007-10-05,21.0,21.350000381469727,0.04675188951468152,,
2007-10-04,20.5,20.809999465942383,1.666668483189174,,
2007-10-03,19.76000022888184,20.440000534057617,1.5121925167921113,,
2007-10-02,19.200000762939453,19.88999938964844,3.4412970511096845,,
2007-10-01,18.299999237060547,19.25,3.5937427046401407,,
2007-09-28,18.690000534057617,18.350000381469727,5.191261216096355,,
2007-09-27,19.100000381469727,18.739999771118164,-1.8191553925765258,,
2007-09-26,18.32999992370605,18.979999542236328,-1.8848199118405504,,
2007-09-25,17.979999542236328,18.239999771118164,3.5460972244175375,,
2007-09-24,18.25,18.1299991607666,1.4460524777605055,,
2007-09-21,18.170000076293945,18.290000915527344,-0.657538845114512,,
2007-09-20,18.280000686645508,18.0,0.6604338950441793,,
2007-09-19,17.56999969482422,18.26000022888184,-1.5317323639383826,,
2007-09-18,16.770000457763672,17.510000228881836,3.9271516564731734,,
2007-09-17,17.239999771118164,16.65999984741211,4.412640136664881,,
2007-09-14,16.469999313354492,17.299999237060547,-3.36426874365577,,
2007-09-13,16.010000228881836,16.610000610351562,5.039465442072361,,
2007-09-12,15.960000038146973,15.979999542236328,3.747660043048179,,
2007-09-11,16.010000228881836,15.989999771118164,0.12531017569895633,,
2007-09-10,16.760000228881836,16.040000915527344,-0.12492478124760613,,
2007-09-07,17.200000762939453,16.6299991607666,-4.295938565166284,,
2007-09-06,17.549999237060547,17.31999969482422,-3.313962656333273,,
2007-09-05,17.989999771118164,17.3799991607666,-1.3105387591734778,,
2007-09-04,18.059999465942383,18.13999938964844,-3.390776087339817,,
2007-08-31,18.280000686645508,17.989999771118164,0.4429674754803975,,
2007-08-30,18.57999992370605,17.979999542236328,-1.5864382091582991,,
2007-08-29,18.14999961853028,18.790000915527344,-3.2292808607829326,,
2007-08-28,18.86000061035156,18.020000457763672,3.5261780189992544,,
2007-08-27,19.270000457763672,19.06999969482422,-4.4538712905811995,,
2007-08-24,18.989999771118164,19.440000534057617,-1.0378866538058384,,
2007-08-23,19.38999938964844,19.1299991607666,2.369672292591904,,
2007-08-22,19.520000457763672,19.39999961853028,-1.3408985923983237,,
2007-08-21,18.600000381469727,19.290000915527344,-0.6147583832953422,,
2007-08-20,17.719999313354492,18.64999961853028,3.7096802145500547,,
2007-08-17,17.479999542236328,17.68000030517578,5.248308923324299,,
2007-08-16,17.0,16.969999313354492,1.1441691543309145,,
2007-08-15,17.299999237060547,16.959999084472656,-0.17647462732651656,,
2007-08-14,16.610000610351562,17.389999389648438,-1.96531888775771,,
2007-08-13,17.510000228881836,16.489999771118164,4.695958763606366,,
2007-08-10,17.299999237060547,17.15999984741211,-5.8252452566004775,,
2007-08-09,17.559999465942383,17.520000457763672,-0.8092450625577304,,
2007-08-08,18.21999931335449,18.200000762939453,-0.227784791544493,,
2007-08-07,17.649999618530273,18.030000686645508,-0.10976153221025325,,
2007-08-06,17.149999618530273,18.209999084472656,2.1529806024260827,,
2007-08-03,16.84000015258789,17.100000381469727,6.180755040933482,,
2007-08-02,16.729999542236328,16.719999313354492,1.5439443380401654,,
2007-08-01,16.770000457763672,16.68000030517578,-0.05977423284794179,,
2007-07-31,17.709999084472656,16.780000686645508,-0.5366735249325831,,
2007-07-30,18.15999984741211,17.770000457763672,-5.2512616934155005,,
2007-07-27,17.829999923706055,18.15999984741211,-2.147573749589069,,
2007-07-26,17.950000762939453,17.809999465942383,1.8508128161419675,,
2007-07-25,18.57999992370605,18.11000061035156,-0.7799514821532744,,
2007-07-24,19.040000915527344,18.40999984741211,-2.5295980370528657,,
2007-07-23,20.0,19.190000534057617,-3.3088289801575645,,
2007-07-20,20.959999084472656,20.020000457763672,-4.049997329711914,,
2007-07-19,20.780000686645508,21.01000022888184,-4.484726468358213,,
2007-07-18,21.229999542236328,20.84000015258789,1.1068312542652772,,
2007-07-17,20.520000457763672,21.309999465942383,-1.837020245207955,,
2007-07-16,20.57999992370605,20.39999961853028,3.8498976147918045,,
2007-07-13,19.5,20.700000762939453,-0.8746370546310288,,
2007-07-12,18.440000534057617,19.6299991607666,6.153850066356171,,
2007-07-11,18.739999771118164,18.32999992370605,6.453354621715578,,
2007-07-10,18.989999771118164,18.739999771118164,-2.1878327236908466,,
2007-07-09,19.540000915527344,19.14999961853028,-1.3164823750036283,,
2007-07-06,19.239999771118164,19.520000457763672,-1.9959123783210833,,
2007-07-05,18.690000534057617,19.280000686645508,1.4553050414575712,,
2007-07-03,18.46999931335449,18.690000534057617,3.1567690515191282,,
2007-07-02,17.15999984741211,18.3799991607666,1.191127389723613,,
2007-06-29,17.540000915527344,17.059999465942383,7.109553171345043,,
2007-06-28,17.450000762939453,17.440000534057617,-2.7366101740624087,,
2007-06-27,16.760000228881836,17.520000457763672,-0.05730789939605366,,
2007-06-26,17.0,16.90999984741211,4.534607508967441,,
2007-06-25,17.360000610351562,16.979999542236328,-0.5294126622817096,,
2007-06-22,17.65999984741211,17.459999084472656,-2.1889461679433597,,
2007-06-21,18.43000030517578,17.68000030517578,-1.132507161197746,,
2007-06-20,18.71999931335449,18.299999237060547,-4.069451913082031,,
2007-06-19,19.239999771118164,18.6200008392334,-2.243590233437251,,
2007-06-18,18.56999969482422,18.440000534057617,-3.222447709253447,,
2007-06-15,18.6299991607666,18.420000076293945,-0.7000493425039451,,
2007-06-14,18.18000030517578,18.5,-1.1272093072065121,,
2007-06-13,17.860000610351562,18.450000762939453,1.7601743094202038,,
2007-06-12,18.14999961853028,17.6299991607666,3.303472186030776,,
2007-06-11,18.459999084472656,18.229999542236328,-2.865016356434429,,
2007-06-08,18.56999969482422,18.38999938964844,-1.2459347434626293,,
2007-06-07,20.200000762939453,18.950000762939453,-0.9693069904893261,,
2007-06-06,19.61000061035156,20.14999961853028,-6.188118578160406,,
2007-06-05,19.0,19.790000915527344,2.7536919498802646,,
2007-06-04,19.75,19.13999938964844,4.157899555407072,,
2007-06-01,20.229999542236328,19.700000762939453,-3.088610685324349,,
2007-05-31,20.31999969482422,19.89999961853028,-2.619865503161975,,
2007-05-30,20.600000381469727,20.32999992370605,-2.0669295403627292,,
2007-05-29,20.920000076293945,20.5,-1.3106818095331123,,
2007-05-25,21.700000762939453,20.950000762939453,-2.0076485409284466,,
2007-05-24,23.600000381469727,22.25,-3.4562210766411328,,
2007-05-23,24.280000686645508,23.700000762939453,-5.720340506984574,,
2007-05-22,24.0,24.3799991607666,-2.3887969823043145,,
2007-05-21,22.229999542236328,24.1200008392334,1.5833298365275066,,
2007-05-18,22.21999931335449,22.670000076293945,8.502030301017887,,
2007-05-17,22.57999992370605,22.020000457763672,2.0252060164061336,,
2007-05-16,22.200000762939453,22.56999969482422,-2.480068502367234,,
2007-05-15,22.8700008392334,22.239999771118164,1.6666617980592127,,
2007-05-14,24.030000686645508,22.8799991607666,-2.7547050502703523,,
2007-05-11,24.61000061035156,23.96999931335449,-4.7856907741080965,,
2007-05-10,25.200000762939453,23.709999084472656,-2.6005740801480126,,
2007-05-09,25.299999237060547,25.11000061035156,-5.912704894271581,,
2007-05-08,25.40999984741211,25.290000915527344,-0.7509827369111918,,
2007-05-07,25.280000686645508,25.56999969482422,-0.4722508170222873,,
2007-05-04,25.65999984741211,25.1299991607666,1.147147944232085,,
2007-05-03,25.100000381469727,25.200000762939453,-2.065474239271907,,
2007-05-02,24.940000534057617,24.989999771118164,0.39840788824669754,,
2007-05-01,24.700000762939453,24.989999771118164,0.20047809137882258,,
2007-04-30,24.56999969482422,24.780000686645508,1.1740850170896888,,
2007-04-27,24.600000381469727,24.56999969482422,0.8547049020335427,,
2007-04-26,24.25,24.82999992370605,-0.12195400886296824,,
2007-04-25,24.030000686645508,24.229999542236328,2.3917522627053653,,
2007-04-24,23.850000381469727,23.959999084472656,0.832288180923641,,
2007-04-23,23.51000022888184,23.920000076293945,0.4612104873943451,,
2007-04-20,23.600000381469727,23.700000762939453,1.7439380834561813,,
2007-04-19,23.39999961853028,23.56999969482422,0.423730423107302,,
2007-04-18,23.6299991607666,23.440000534057617,0.726496064381627,,
2007-04-17,23.6200008392334,23.770000457763672,-0.8040568491616504,,
2007-04-16,23.670000076293945,23.81999969482422,0.6350534005109788,,
2007-04-13,23.65999984741211,23.540000915527344,0.6337119478106868,,
2007-04-12,20.989999771118164,23.739999771118164,-0.5071806114060093,,
2007-04-11,21.3700008392334,21.190000534057617,13.10147703662173,,
2007-04-10,22.600000381469727,20.6299991607666,-0.8423036879124352,,
2007-04-09,21.61000061035156,22.489999771118164,-8.716819413500433,,
2007-04-05,21.09000015258789,21.440000534057617,4.0721848029243946,,
2007-04-04,20.01000022888184,20.76000022888184,1.6595560878968467,,
2007-04-03,19.549999237060547,20.0,3.748125894159023,,
2007-04-02,19.299999237060547,19.26000022888184,2.301794273661124,,
2007-03-30,19.39999961853028,19.420000076293945,-0.20724875523259018,,
2007-03-29,18.950000762939453,18.8799991607666,0.10309514513887387,,
2007-03-28,18.84000015258789,18.690000534057617,-0.3694015797073413,,
2007-03-27,19.38999938964844,19.020000457763672,-0.7961763127144629,,
2007-03-26,19.63999938964844,19.40999984741211,-1.9081946546233366,,
2007-03-23,19.700000762939453,19.780000686645508,-1.1710771353565135,,
2007-03-22,19.68000030517578,19.700000762939453,0.4060909675524187,,
2007-03-21,19.040000915527344,19.600000381469727,0.10162834071914022,,
2007-03-20,19.200000762939453,19.040000915527344,2.9411735242391543,,
2007-03-19,17.860000610351562,18.920000076293945,-0.8333325054910776,,
2007-03-16,17.5,17.43000030517578,5.9350471988674665,,
2007-03-15,17.969999313354492,17.469999313354492,-0.3999982561383929,,
2007-03-14,18.3799991607666,17.739999771118164,-2.7824152426562563,,
2007-03-13,19.31999969482422,18.32999992370605,-3.4820425401028374,,
2007-03-12,19.549999237060547,19.43000030517578,-5.124222498737338,,
2007-03-09,19.82999992370605,19.770000457763672,-0.6138053021367184,,
2007-03-08,20.09000015258789,19.8799991607666,-0.3025691688009139,,
2007-03-07,19.049999237060547,19.82999992370605,-1.0453010961985374,,
2007-03-06,19.239999771118164,19.190000534057617,4.094491957396319,,
2007-03-05,19.15999984741211,18.89999961853028,-0.25987129758495364,,
2007-03-02,20.770000457763672,19.270000457763672,-1.3569949423404948,,
2007-03-01,21.170000076293945,20.780000686645508,-7.221954583247547,,
2007-02-28,21.950000762939453,21.709999084472656,-1.8422266804106289,,
2007-02-27,23.799999237060547,21.93000030517578,-1.093401686217786,,
2007-02-26,23.989999771118164,24.0,-7.857138621134354,,
2007-02-23,23.0,24.170000076293945,0.041684989484140504,,
2007-02-22,22.36000061035156,22.549999237060547,5.0869568534519365,,
2007-02-21,23.700000762939453,22.61000061035156,0.8497254987597276,,
2007-02-20,23.549999237060547,24.81999969482422,-4.599156613920312,,
2007-02-16,22.1200008392334,24.030000686645508,5.392783434850719,,
2007-02-15,22.1299991607666,22.13999938964844,8.634718693248942,,
2007-02-14,21.989999771118164,22.1299991607666,0.04518856421634439,,
2007-02-13,22.68000030517578,22.030000686645508,0.6366502551414929,,
2007-02-12,21.75,22.64999961853028,-2.8659594787656935,,
2007-02-09,21.65999984741211,21.770000457763672,4.137929280598991,,
2007-02-08,20.0,21.440000534057617,0.5078513902423002,,
2007-02-07,19.1200008392334,20.190000534057617,7.200002670288086,,
2007-02-06,19.030000686645508,19.1299991607666,5.596232467880579,,
2007-02-05,18.84000015258789,18.809999465942383,0.5254780373774167,,
2007-02-02,17.829999923706055,18.81999969482422,-0.15923931211532857,,
2007-02-01,17.299999237060547,17.850000381469727,5.552438448425902,,
2007-01-31,17.1200008392334,17.290000915527344,3.1791975067313976,,
2007-01-30,17.06999969482422,17.34000015258789,0.9929910511707521,,
2007-01-29,16.770000457763672,16.8799991607666,1.5817250298225751,,
2007-01-26,17.25,16.93000030517578,0.655925462136799,,
2007-01-25,17.420000076293945,17.200000762939453,-1.855070694633152,,
2007-01-24,17.489999771118164,17.540000915527344,-1.2629122410503248,,
2007-01-23,17.3799991607666,17.5,0.28588419132942633,,
2007-01-22,17.700000762939453,17.440000534057617,0.6904536537854782,,
2007-01-19,17.5,17.540000915527344,-1.4689277834734822,,
2007-01-18,17.850000381469727,17.56999969482422,0.22857666015625003,,
2007-01-17,17.700000762939453,17.899999618530273,-1.5686312642109492,,
2007-01-16,16.989999771118164,17.520000457763672,1.129936988531555,,
2007-01-12,16.200000762939453,16.940000534057617,3.119486131756592,,
2007-01-11,16.110000610351562,16.170000076293945,4.567899606591702,,
2007-01-10,15.84000015258789,16.170000076293945,0.3724361494054187,,
2007-01-09,15.59000015258789,15.90999984741211,2.0833328316107393,,
2007-01-08,15.31999969482422,15.600000381469728,2.0525958415151124,,
2007-01-05,15.06999969482422,15.449999809265137,1.8276807586367287,,
2007-01-04,15.630000114440918,15.350000381469728,2.5215668356743692,,
2007-01-03,15.84000015258789,15.609999656677246,-1.7914250218878207,,
2006-12-29,16.040000915527344,15.84000015258789,-1.4520233187817726,,
2006-12-28,16.350000381469727,16.09000015258789,-1.2468874783282875,,
2006-12-27,15.699999809265137,16.229999542236328,-1.59021543006511,,
2006-12-26,15.34000015258789,15.649999618530272,3.375794518535086,,
2006-12-22,15.619999885559082,15.390000343322754,2.0208569938643937,,
2006-12-21,15.649999618530272,15.489999771118164,-1.4724682709438819,,
2006-12-20,15.699999809265137,15.729999542236328,-1.0223632671700573,,
2006-12-19,15.6899995803833,15.81999969482422,0.19108110404872414,,
2006-12-18,16.389999389648438,16.489999771118164,0.8285539701572374,,
2006-12-15,16.360000610351562,16.360000610351562,0.6101304770815587,,
2006-12-14,16.059999465942383,16.5,0.0,,
2006-12-13,15.960000038146973,16.360000610351562,2.7397294438938418,,
2006-12-12,16.75,15.960000038146973,2.5062692434118046,,
2006-12-11,17.31999969482422,16.649999618530273,-4.71641768270464,,
2006-12-08,16.729999542236328,17.1299991607666,-3.8683607857924107,,
2006-12-07,18.489999771118164,17.780000686645508,2.390912310071736,,
2006-12-06,18.39999961853028,18.36000061035156,-3.839908562798861,,
2006-12-05,18.13999938964844,18.1200008392334,-0.217385918521647,,
2006-12-04,18.64999961853028,18.14999961853028,-0.11024559585407016,,
2006-12-01,19.690000534057617,18.64999961853028,-2.680965202289922,,
2006-11-30,19.5,19.36000061035156,-5.281873475465155,,
2006-11-29,19.020000457763672,19.6299991607666,-0.7179455879407233,,
2006-11-28,19.11000061035156,18.8799991607666,3.207143471723407,,
2006-11-27,20.13999938964844,19.229999542236328,-1.203565893453554,,
2006-11-24,19.90999984741211,20.0,-4.51837077949384,,
2006-11-22,20.020000457763672,20.09000015258789,0.45203492354415464,,
2006-11-21,19.350000381469727,19.940000534057617,0.3496488173009665,,
2006-11-20,18.15999984741211,19.36000061035156,3.049096335692564,,
2006-11-17,16.0,17.549999237060547,6.607933772149539,,
2006-11-16,15.25,16.020000457763672,9.687495231628418,,
2006-11-15,14.56999969482422,15.350000381469728,5.049183329597849,,
2006-11-14,14.869999885559082,14.619999885559082,5.353470850947181,,
2006-11-13,14.869999885559082,14.920000076293944,-1.6812374036585305,,
2006-11-10,15.0,15.25,0.33624876341403953,,
2006-11-09,15.1899995803833,14.829999923706056,1.6666666666666667,,
2006-11-08,15.5,15.029999732971191,-2.369978055444819,,
2006-11-07,16.149999618530273,15.199999809265137,-3.032259787282636,,
2006-11-06,16.219999313354492,16.190000534057617,-5.882351899099247,,
2006-11-03,16.84000015258789,16.440000534057617,-0.18494932531948974,,
2006-11-02,17.43000030517578,16.809999465942383,-2.375294625331719,,
2006-11-01,17.5,17.229999542236328,-3.557090237395413,,
2006-10-31,18.0,17.790000915527344,-1.5428597586495534,,
2006-10-30,18.059999465942383,17.989999771118164,-1.166661580403646,,
2006-10-27,17.100000381469727,17.829999923706055,-0.38759522089812043,,
2006-10-26,17.229999542236328,17.420000076293945,4.269003075739028,,
2006-10-25,17.0,17.25,1.1027309292252976,,
2006-10-24,17.1299991607666,16.979999542236328,1.4705882352941175,,
2006-10-23,17.0,16.420000076293945,-0.875654558546754,,
2006-10-20,17.100000381469727,17.030000686645508,-3.4117642570944393,,
2006-10-19,17.399999618530273,17.149999618530273,-0.4093549313605474,,
2006-10-18,17.059999465942383,17.350000381469727,-1.436781640694753,,
2006-10-17,16.309999465942383,16.950000762939453,1.6998881864345023,,
2006-10-16,16.600000381469727,16.350000381469727,3.923981103331639,,
2006-10-13,17.260000228881836,16.780000686645508,-1.5060240617769525,,
2006-10-12,16.5,17.1200008392334,-2.7809938347111145,,
2006-10-11,15.65999984741211,16.360000610351562,3.7575808438387788,,
2006-10-10,16.3700008392334,16.15999984741211,4.4699921440620685,,
2006-10-09,14.920000076293944,15.5,-1.2828404462752816,,
2006-10-06,12.90999984741211,14.899999618530272,3.8873989325751106,,
2006-10-05,11.06999969482422,13.56999969482422,15.414405845380937,,
2006-10-04,11.300000190734863,10.5,22.58355979150456,,
2006-10-03,8.699999809265137,11.5,-7.079647586119532,,
2006-10-02,8.880000114440918,8.699999809265137,32.18391094391726,,
2006-09-29,9.739999771118164,9.149999618530272,-2.0270304375678942,,
2006-09-28,9.229999542236328,8.649999618530273,-6.057496575486671,,
2006-09-27,10.369999885559082,9.0,-6.283856473144819,,
2006-09-26,10.100000381469728,11.0,-13.21118515600852,,
2006-09-25,5.980000019073486,8.5,8.910886975623121,,
2006-09-22,2.289999961853028,2.220000028610229,42.14046777406116,,
2006-09-21,2.3299999237060547,2.240000009536743,-3.056765694710144,,
2006-09-20,2.490000009536743,2.3499999046325684,-3.8626573869650316,,
2006-09-19,2.450000047683716,2.450000047683716,-5.622494151324176,,
2006-09-18,2.4100000858306885,2.319999933242798,0.0,,
2006-09-15,2.2799999713897705,2.390000104904175,-3.7344460324726096,,
2006-09-14,2.390000104904175,2.240000009536743,4.824567319944038,,
2006-09-13,2.490000009536743,2.369999885559082,-6.276154342405177,,
2006-09-12,2.569999933242798,2.440000057220459,-4.819282068998336,,
2006-09-11,2.8299999237060547,2.539999961853028,-5.058361066115143,,
2006-09-08,2.890000104904175,2.799999952316284,-10.247348751630161,,
2006-09-07,3.039999961853028,2.9100000858306885,-3.1141920180267535,,
2006-09-06,3.049999952316284,3.0,-4.276311764921801,,
2006-09-05,2.819999933242798,2.7699999809265137,-1.639342724524056,,
2006-09-01,2.9200000762939453,2.869999885559082,-1.773047996451114,,
2006-08-31,2.9200000762939453,2.9200000762939453,-1.7123352543991492,,
2006-08-30,2.900000095367432,2.900000095367432,0.0,,
2006-08-29,3.220000028610229,2.789999961853028,0.0,,
2006-08-28,3.190000057220459,2.650000095367432,-13.354039221632922,,
2006-08-25,3.200000047683716,3.0999999046325684,-16.927898187047205,,
2006-08-24,3.299999952316284,3.3299999237060547,-3.1250044237821637,,
2006-08-23,3.3399999141693115,3.240000009536743,0.9090900552502553,,
2006-08-22,3.3499999046325684,3.190000057220459,-2.994009197675062,,
2006-08-21,3.5199999809265137,3.289999961853028,-4.776114984088585,,
2006-08-18,3.2799999713897705,3.430000066757202,-6.5340914863569575,,
2006-08-17,3.75,3.400000095367432,4.573173679141071,,
2006-08-16,3.400000095367432,3.359999895095825,-9.333330790201812,,
2006-08-15,3.5,3.400000095367432,-1.1764764455773975,,
2006-08-14,3.509999990463257,3.400000095367432,-2.8571401323590835,,
2006-08-11,3.5,3.380000114440918,-3.1339001536950644,,
2006-08-10,3.7200000286102295,3.5199999809265137,-3.428568158830915,,
2006-08-09,3.7200000286102295,3.740000009536743,-5.376345326492771,,
2006-08-08,4.090000152587891,3.799999952316284,0.5376338917391232,,
2006-08-07,4.050000190734863,3.9600000381469727,-7.0904691797655035,,
2006-08-04,3.1600000858306885,3.400000095367432,-2.2222258851686694,,
2006-08-03,3.1600000858306885,3.069999933242798,7.59493680436573,,
2006-08-02,3.0899999141693115,2.940000057220459,-2.8481060171943553,,
2006-08-01,3.25,3.0,-4.854364437391164,,
2006-07-31,3.3499999046325684,3.200000047683716,-7.6923076923076925,,
2006-07-28,3.5999999046325684,3.440000057220459,-4.4776077975830475,,
2006-07-27,3.569999933242798,3.4100000858306885,-4.444440323629388,,
2006-07-26,3.450000047683716,3.450000047683716,-4.481788526723418,,
2006-07-25,3.660000085830689,3.5,0.0,,
2006-07-24,4.050000190734863,3.549999952316284,-4.371586942036222,,
2006-07-21,3.839999914169312,3.950000047683716,-12.345684317803828,,
2006-07-20,3.7100000381469727,3.700000047683716,2.8645868742994396,,
2006-07-19,3.819999933242798,3.700000047683716,-0.26954151914918884,,
2006-07-18,3.7100000381469727,3.75,-3.141358315606412,,
2006-07-17,3.859999895095825,3.75,1.0781660765967553,,
2006-07-14,3.910000085830689,3.759999990463257,-2.8497382923657937,,
2006-07-13,4.050000190734863,3.9600000381469727,-3.8363194904013467,,
2006-07-12,4.139999866485596,3.859999895095825,-2.2222258851686694,,
2006-07-11,3.9600000381469727,4.130000114440918,-6.763284551201197,,
2006-07-10,4.159999847412109,4.050000190734863,4.29293117818995,,
2006-07-07,4.110000133514404,4.110000133514404,-2.6442226132694615,,
2006-07-06,3.9600000381469727,4.0,0.0,,
2006-07-05,4.360000133514404,3.900000095367432,1.0101000370632516,,
2006-07-03,4.119999885559082,4.25,-10.55045926744471,,
2006-06-30,3.940000057220459,4.170000076293945,3.155342671163133,,
2006-06-29,4.239999771118164,3.75,5.837563851096586,,
2006-06-28,4.190000057220459,4.139999866485596,-11.5565989992717,,
2006-06-27,3.9700000286102295,4.070000171661377,-1.1933219582825534,,
2006-06-26,3.690000057220459,3.799999952316284,2.518895272808205,,
2006-06-23,3.829999923706055,3.569999933242798,2.9810269211400517,,
2006-06-22,3.7799999713897705,3.7300000190734863,-6.788511635573906,,
2006-06-21,3.869999885559082,3.7100000381469727,-1.3227500712890479,,
2006-06-20,3.9700000286102295,3.759999990463257,-4.134363104483526,,
2006-06-19,3.819999933242798,3.75,-5.28967346684093,,
2006-06-16,3.9600000381469727,3.859999895095825,-1.8324590174370738,,
2006-06-15,3.740000009536743,3.890000104904175,-2.5252561133292604,,
2006-06-14,3.3299999237060547,3.7899999618530273,4.010697726870099,,
2006-06-13,3.7200000286102295,3.3399999141693115,13.813815275858177,,
2006-06-12,3.940000057220459,3.7100000381469727,-10.21505676124642,,
2006-06-09,3.900000095367432,3.890000104904175,-5.837563851096586,,
2006-06-08,3.849999904632568,3.849999904632568,-0.25641000560834976,,
2006-06-07,3.950000047683716,3.799999952316284,0.0,,
2006-06-06,3.900000095367432,3.75,-3.7974707229533293,,
2006-06-05,4.010000228881836,3.859999895095825,-3.8461561974218377,,
2006-06-02,3.950000047683716,3.859999895095825,-3.7406564893847256,,
2006-06-01,4.090000152587891,3.900000095367432,-2.278484848137326,,
2006-05-31,3.950000047683716,3.849999904632568,-4.645477998337938,,
2006-05-30,3.900000095367432,3.900000095367432,-2.531649160606671,,
2006-05-26,4.150000095367432,3.849999904632568,0.0,,
2006-05-25,3.940000057220459,3.849999904632568,-7.22892009255008,,
2006-05-24,3.690000057220459,3.7799999713897705,-2.284267799005648,,
2006-05-23,3.809999942779541,3.7100000381469727,2.439022026387315,,
2006-05-22,3.609999895095825,3.75,-2.6246694523468834,,
2006-05-19,3.930000066757202,3.559999942779541,3.8781193621186683,,
2006-05-18,4.210000038146973,3.9600000381469727,-9.41476126444351,,
2006-05-17,4.170000076293945,3.920000076293945,-5.938242226478393,,
2006-05-16,4.619999885559082,4.21999979019165,-5.995203727242758,,
2006-05-15,4.929999828338623,4.619999885559082,-8.658010936704304,,
2006-05-12,5.010000228881836,4.880000114440918,-6.288031512650355,,
2006-05-11,5.010000228881836,4.900000095367432,-2.5948125449473727,,
2006-05-10,5.21999979019165,5.110000133514404,-2.195611347086801,,
2006-05-09,5.050000190734863,5.28000020980835,-2.10727320112033,,
2006-05-08,5.099999904632568,5.019999980926514,4.554455651218843,,
2006-05-05,4.900000095367432,5.099999904632568,-1.568625984353196,,
2006-05-04,4.699999809265137,5.059999942779541,4.081628681073312,,
2006-05-03,4.980000019073486,4.699999809265137,7.659577619657217,,
2006-05-02,4.760000228881836,4.53000020980835,-5.622494151324176,,
2006-05-01,4.949999809265137,4.610000133514404,-4.831932941472048,,
2006-04-28,5.099999904632568,4.900000095367432,-6.868680582862645,,
2006-04-27,4.699999809265137,4.96999979019165,-3.92156496088299,,
2006-04-26,4.989999771118164,4.619999885559082,5.744680678374947,,
2006-04-25,5.0,4.909999847412109,-7.414827706017552,,
2006-04-24,4.989999771118164,4.869999885559082,-1.8000030517578127,,
2006-04-21,4.840000152587891,4.849999904632568,-2.404807436137263,,
2006-04-20,5.050000190734863,4.809999942779541,0.20660644069052325,,
2006-04-19,5.139999866485596,5.079999923706055,-4.752479978033388,,
2006-04-18,5.139999866485596,5.139999866485596,-1.1673140921804177,,
2006-04-17,5.329999923706055,5.099999904632568,0.0,,
2006-04-13,5.289999961853027,5.170000076293945,-4.315197417743352,,
2006-04-12,5.400000095367432,5.119999885559082,-2.26842885490395,,
2006-04-11,5.210000038146973,5.239999771118164,-5.18518897895126,,
2006-04-10,5.449999809265137,5.300000190734863,0.5758106094344931,,
2006-04-07,5.440000057220459,5.389999866485596,-2.752286674859517,,
2006-04-06,5.5,5.489999771118164,-0.9191211435466534,,
2006-04-05,5.079999923706055,5.25,-0.18182234330610794,,
2006-04-04,5.099999904632568,5.099999904632568,3.3464582450214637,,
2006-04-03,5.400000095367432,5.199999809265137,0.0,,
2006-03-31,5.429999828338623,5.21999979019165,-3.703708936484497,,
2006-03-30,5.710000038146973,5.369999885559082,-3.867404139701876,,
2006-03-29,5.75,5.760000228881836,-5.954468481899145,,
2006-03-28,5.789999961853027,5.659999847412109,0.17391702403192935,,
2006-03-27,5.980000019073486,5.849999904632568,-2.245252423098684,,
2006-03-24,6.0,5.900000095367432,-2.173914950272184,,
2006-03-23,6.050000190734863,6.0,-1.6666650772094727,,
2006-03-22,5.809999942779541,6.0,-0.8264494075791097,,
2006-03-21,5.949999809265137,5.829999923706055,3.2702247692202513,,
2006-03-20,5.769999980926514,5.980000019073486,-2.016804863963564,,
2006-03-17,6.0,5.849999904632568,3.639515404526086,,
2006-03-16,5.820000171661377,5.900000095367432,-2.5000015894571943,,
2006-03-15,5.989999771118164,5.820000171661377,1.374569095299836,,
2006-03-14,6.400000095367432,6.150000095367432,-2.838056860644136,,
2006-03-13,6.230000019073486,6.170000076293945,-3.90624994179234,,
2006-03-10,6.050000190734863,6.050000190734863,-0.9630809405433051,,
2006-03-09,6.400000095367432,6.070000171661377,0.0,,
2006-03-08,6.150000095367432,6.099999904632568,-5.156248731073012,,
2006-03-07,6.650000095367432,6.150000095367432,-0.8130112188539084,,
2006-03-06,6.5,6.550000190734863,-7.5187968846543844,,
2006-03-03,6.150000095367432,6.46999979019165,0.7692337036132812,,
2006-03-02,6.369999885559082,6.119999885559082,5.2032469896262725,,
2006-03-01,6.300000190734863,6.25,-3.9246468522983022,,
2006-02-28,6.190000057220459,6.199999809265137,-0.7936537971601397,,
2006-02-27,6.349999904632568,6.25,0.1615468812962822,,
2006-02-24,6.349999904632568,6.159999847412109,-1.57480167140813,,
2006-02-23,6.5,6.340000152587891,-2.992126930298797,,
2006-02-22,6.5,6.329999923706055,-2.4615361140324516,,
2006-02-21,6.619999885559082,6.210000038146973,-2.61538578913762,,
2006-02-17,6.489999771118164,6.21999979019165,-6.1933512764325895,,
2006-02-16,6.099999904632568,6.28000020980835,-4.160246385956271,,
2006-02-15,6.099999904632568,6.039999961853027,2.950824721146016,,
2006-02-14,6.039999961853027,6.0,-0.9836056347144335,,
2006-02-13,6.760000228881836,6.0,-0.6622510282393388,,
2006-02-10,6.170000076293945,6.71999979019165,-11.24260655546674,,